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Abstract 
 
Nuclear receptor (NR) liver receptor homologue-1 (LRH-1) is a potential target for the treatment of 
breast cancers as a consequence of its regulation of aromatase and the estrogen receptor (ER). 
Development of modulators of NRs historically focuses on production of high affinity small molecules 
that compete for binding with natural ligands at the ligand-binding pocket (LBP) of the NR ligand-
binding domain (LBD). Ligand-bound NRs induce transcriptional activity by subsequent recruitment of 
coactivator proteins. 
 
The majority of this thesis describes approaches towards the development of the first antagonists of 
LRH-1. 
 
In the first instance, small molecules that bind at the LBP of the receptor were developed through use 
of ligand-based virtual screening (VS) programs Cresset and SHop.  Secondly, small molecules that 
directly disrupt the binding of cofactor proteins to the NR activation function-2 (AF-2) were developed 
through use of rational design and further Cresset VS. 
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Chapter 1 – Introduction 
 
1.0 LRH-1 – A New Target for the Treatment of Breast Cancer 
Liver receptor homolog-1 (LRH-1) is an orphan nuclear receptor (NR) in the NR superfamily of 
transcription factors.  Since its discovery in 1996, LRH-1 has been shown to control a range of 
fundamental human physiology.1 Of significant interest is the impact that LRH-1 has on the regulation 
of estrogen biosynthesis and the growth and invasion of breast carcinomas.2,3 
 
Due to the fundamental control the NR superfamily exhibits in human biology, they have received 
substantial investigation as targets in drug discovery.4 The development of small molecule 
modulators of LRH-1, however, is limited to one example of agonists with application to 
cardiovascular disease.5 
 
The work in this thesis is concerned with the identification and development of small molecule 
antagonists of LRH-1 as potential therapies for breast cancer.  Consequently, the following sections 
serve as an introduction to the aspects of drug discovery and nuclear receptor function relating to 
work carried out in this research. 
 
1.1 Introduction to Drug Discovery 
Early records of pain relief treatments by Hippocrates between 460 and 370 B.C consequently 
resulted in patenting of the first marketed tablet drug, Aspirin, by Bayer in 1900 A.D. This process 
heralded the beginning of a modern era of western pharmacology in which pure organic chemicals, 
not plant or animal extracts, became the standard drugs. In the proceeding century tremendous 
advances in science and technology streamlined drug discovery resulting in more than 1400 small 
molecule drugs being brought to market.6 
 
Early drug discovery efforts, in the first half of the 20th century, combined intrigue in the biological 
action of natural extracts with the basic synthetic organic chemistry available at the time.  This 
combination mostly limited these endeavours to synthesis of natural product analogues with 
biological activity being gauged in whole animal systems. 
 
It was with the emergence of the field of molecular biology in the 1950s7 that drug discovery began to 
change. Knowledge about the structure of DNA8, the expression of proteins from genes and the link 
between mutated genes and disease grew rapidly. Techniques became available to modify, prepare 
and purify genes and proteins allowing for drugs to be designed based on their protein target 
(structure based drug design, SBDD). Progression in computing and robotics gave the ability to 
screen thousands of compounds in weeks rather than years.9 Chemistry advanced alongside these 
discoveries with huge additions to a synthetic chemists toolbox and combinatorial chemistry enabled 
synthesis of dozens of compounds simultaneously. 
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This 100 year period changed the face of drug discovery projects putting a huge range of approaches 
at the hands of a medicinal chemist.10 
 
1.2 Modern Drug Design Strategies 
1.2.1 High Throughput Screening 
The use of high throughput screens (HTSs) to identify chemical start points in drug discovery 
boomed at the end of the 1980s creating a huge demand for new chemical entities (NCEs). Large 
libraries of over 100,000 NCEs were created by consolidation of a company’s legacy library and the 
purchase of compounds from newly formed companies devoted to NCE production.  This approach 
represents an extremely effective hit discovery technique as even with a hit percentage of 0.01%, an 
HTS of 100,000 compounds could identify 10 new chemical leads. 
 
The shift to in vitro based HTS technology resulted in the seminal publication of the ‘Lipinski 
Guidelines’ by Lipinski in 1997.11 This work highlighted the pharmacological inefficiencies of the new 
drug discovery paradigm and proposed a guideline through which medicinal chemists should operate 
to avoid producing molecules with a poor physiochemical profile.  His scepticism about the shift to in 
vitro HTS proved well-founded when at the turn of the century the large numbers of clinical 
candidates developed from HTS in the late 80s began to filter through to clinical trials.   
 
Despite the ability of HTS to identify hit compounds for new biological targets the attrition rate in late 
stage clinical trials has been growing, suggesting that the quality of chemical leads this technique 
affords is not optimal for successful drug discovery.12,13 To ensure identification of high-quality hits, 
recent utilisation of this approach has paid particular attention to the selection of compound libraries.  
In addition, parameters such as ligand efficiency (LE, the potency of a molecule divided by its 
number of heavy atoms) complement the physiochemical guidelines initially suggested by Lipinski in 
an attempt to reduce late-stage attrition. 
 
As a result of the lessons learnt from a decade of this type of medicinal chemistry practice, 
alternatives to HTS hit identification have emerged.  
 
1.2.2 Fragment Based Drug Design 
In the early 2000s fragment based drug design (FBDD) emerged as a natural continuation to the 
proposition of key drug design parameters such as LE.14 FBDD, capable of identifying low molecular 
weight ligands (~150 Da) of a biological target of interest, is most successfully used in combination 
with X-ray crystallography, utilising the knowledge gained from SBDD approaches developed in the 
1980s. 
 
Due to their small size, the chemical space explored in a fragment-based screen is inherently higher 
and, despite the weak binding affinity of hits obtained from a fragment screen15, the quality of the 
interaction is much higher as there is less room for ‘spectator’ atoms in the interaction. In contrast to 
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the extremely large HTS screening libraries, FBDD libraries often contain only 1000 fragments and 
have been shown to achieve 10-1000 times higher hit rates than HTS assays.16 
 
The weak interactions of fragment molecules have required the development of alternative assay 
technologies. Fluorescence-based thermal shift, NMR spectroscopy and isothermal titration 
calorimetry (ITC) have all been used successfully to screen fragment-based libraries.17  Due to the 
weakness of the interaction, high concentrations (~ 0.1M) of fragment molecules solutions are 
required. This requirement prevents the screening of fragments with low inherent solubility therefore 
decreasing the likelihood of final compounds exhibiting unfavourable physiochemical properties. 
 
The success of lead compounds identified by FBDD in clinical trials is only just emerging but current 
signs are positive.14 This approach has been enthusiastically taken up by universities, large pharma 
and biotech companies alike and all early signs suggest that a shift towards smaller is better is well 
on its way. 
 
1.2.3 Computation 
As computing power grew in the 1970s and 80s, development of computational approaches which 
enable ‘in silico’ drug discovery have emerged.  These techniques endeavoured, and continue to 
provide virtual alternatives to the expensive physical medicinal chemistry practices available.  
Generally termed “virtual screening” (VS) or “in silico screening” they can be separated into two 
distinct approaches depending on being target-based or ligand-based. 
 
1.2.3.1 Target-Based Approaches 
The explosion of X-ray crystallography of biological molecules has resulted in public access to 65052 
solved structures.18  From these, target-based VS has grown, with the ‘docking’ of small molecules 
into structures of bio molecules becoming the predominant computational approach in this branch of 
VS. 
 
1.2.3.1.1 Docking:  
Docking is the process of predicting and scoring the conformation and orientation of small molecule 
binding to a bio molecular site of interest. This approach can be broken down into 3 steps. Firstly, 
selection and construction of a computational library of potential small molecule queries is required. 
Secondly, the library is passed through a sequence of parameters to approximate the conformation, 
orientation and position of the molecules at a selected site on a biomolecule.  Finally a more 
sophisticated “scoring function” is used to predict the rank of the binding affinity of the screened 
molecules.19,20 
 
Pioneered in the 1980s21, there are now many companies providing software suites for this purpose. 
Schrodinger provides one of the leading suites for target-based drug design.22 The suite, operated 
through its user interface Maestro, contains its docking software, Glide23,24, which can be utilised to 
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generate binding modes for each ligand for both HTS VSs or high accuracy/lower throughput screens 
depending on the requirement. Refinement and scoring of the ligand and receptor binding and strain 
energy within Glide generated binding modes can then be achieved using Prime to access a more 
accurate MM-GBSA docking algorithm.25 
 
Each software package provides its own unique compilation of a user interface, docking parameters 
and scoring functions. Despite the variety of available software, reproduction of the experimentally 
observed binding modes is extremely difficult and the ranking or affinity prediction of generated 
binding modes is variable with no one package suiting multiple biological targets.20 Application of this 
approach to guide lead discovery/optimisation should always be considered with uncertainty, yet the 
insight gained into the gross binding interactions of computationally available small molecules can be 
invaluable. 
 
1.2.3.1.2 Hot-Spot Mapping: 
Protein-protein and protein-ligand interactions have been shown to occur through a small number of 
regions at the binding interface termed ‘hot-spots’.26,27 NMR28 and X-ray crystallography29 have both 
been used to identify hot-spots on protein surfaces.  As a result of the time intensive manner of these 
physical methods, many computational methods to identify hot-spots have recently been described.30 
 
Vajda et al. at Boston University have created an algorithm, FTMAP, which virtually mimics the 
physical NMR and crystallography based approaches by docking 16 small molecule solvent probes 
to a rigid protein crystal structure.31 Clustering and ranking the binding modes of the probe molecules 
then generates a map of the solvent hot spots on a submitted biomolecule.  This approach has been 
made available on an open access web server32 or can be downloaded as shareware. 
 
Despite the advantages of identifying hot spots computationally, the drawback of rigid protein docking 
(in both hot-spot mapping and docking) to allow reduced computational expense generates debate 
about the validity of such methods.33  This limitation will no doubt be overcome in time as processing 
power reduces the expense of flexible-protein calculations.  In the meantime, as with HTS library 
selection, effort in structure-based VS should be placed on educated selection of small molecules to 
reduce screening library size. 
 
1.2.3.2 Ligand-Based Approaches 
Ligand-based approaches often circumvent the discussed limitations around structure-based VS.  
They offer an alternative to structure-based VS by using a known (natural/generated) ligand to a 
target of interest as a query to identify novel small molecules capable of exerting a desired action.  
Ligand-based approaches can be utilised in any project where a ligand is known but most importantly 
they enable virtual drug discovery of the many drug targets that are too flexible or otherwise 
inaccessible to structural determination by X-ray crystallography. 
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Analogous to the computational approximations required in structure-based VS, ligand-based 
approaches utilise algorithms to approximate molecular structure.  Extended from early molecular 
similarity concepts developed by Hansch et al. in the development of quantitative structure-activity 
relationship (QSAR) analysis, a plethora of methods to evaluate and screen small molecules based 
on molecules similarity have emerged.34  
 
1.2.3.2.1 3D VS Approaches: 
Of use in this research are 3D VS approaches, which provide a particularly powerful method of 
identifying novel chemical structures at early stages of drug discovery projects with a high success 
rate relative to that of structure-based approaches.35,36 
 
An early example of such an approach was CAVEAT37, which allowed the user to identify novel core 
structures (scaffolds) based on the similarity of the vectors and locations of desired bonds in a query 
small molecule (Figure 1). 
 
 
Figure 1 – The concept of CAVEAT 3D VS.37 
 
CAVEAT made the first step towards automating molecular similarity analysis based on the 
geometric features of a molecule that are necessary for recognition by a biomolecule (geometric 
pharmacophores). A significant step away from geometry-based models of pharmacophores 
occurred with the description of molecular interaction fields (MIFs).38 MIFs, calculated using complex 
algorithms, represent the approximate quantum properties of atoms within a molecule.  These fields 
can be used to create a 3D quantum property map of a molecule, which describe pharmacophores 
without the use of physical structure. 
 
MIFs were first powerfully used in the early 90s in a programme called GRID.39 Its ability to generate 
MIFs was incorporated into many other programmes including ROCS40 (OpenEye, Santa Fe) and 
SHop41 (MolDiscovery, Perugia). SHop, Scaffold Hopping, combines the principles of CAVEAT and 
MIFs to identify novel scaffolds that match both the bond vectors projecting off a query scaffold and 
its molecular field based pharmacophores (Figure 2). 
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Figure 2 – The integration of 3D structure and GRID calculated MIFs in SHop VS. SHop descriptors (illustrated 
by arrows) calculated for two ‘anchor points’ (shown in purple).  The distance of a point from the GRID surface 
(beige net) illustrated by dashed green and orange arrows, while distances between two points is shown by the 
purple arrows.  Black dashed line represents the dihedral angle. (Taken from Bergmann et al. 41). 
  
From early efforts in the area of molecular fields, significant research into the production of 
algorithms that generate the most accurate MIFs has been undertaken.42 The work of Vinter et al. 
describes the use of a novel ‘XED’ (extended electron distributions) force-field, which utilises a more 
complex approximation of quantum properties that better displays the MIF of loan pairs of atoms and 
aromatic systems.43 The XED force-field is used to generate a 3D pharmacophore map of ‘field 
points’ that represent the van der Waals extrema, areas of positive and negative electron density and 
the hydrophobicity of a structure (Figure 3). 
 
 
Figure 3 – The 3 steps of field point generation using Cresset; (a) Structure of a candidate drug in its active 
conformation. (b) The molecular electrostatic potential map at the 0.5 kcal/mol contour showing the XED 
constructs on the electronegative and π atoms as mauve dummy atoms. (c) Distilled field point extrema for 
positive, negative, surface, and hydrophobic points superimposed onto (b). (d) The final field point pattern for the 
conformation of the drug shown in (a). All 4 field types are included:  electrophilic (red), nucleophilic (blue), van 
der Waals attractive (yellow), and hydrophobic (orange).43 
 
The XED force-field has been successfully commercialised in the formation of Cresset44, which 
provides a powerful method of identifying novel lead molecules. 
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The two approaches above are most commonly used in the absence of knowledge of either a natural 
ligand or the 3D biomolecule structure.  Methods combining the abilities of both have been devised to 
allow virtual replication of the initial hit to lead stages of drug discovery. 
 
1.2.3.3 De Novo Drug Design 
Computer-based de novo drug design draws on knowledge of both target structure and natural 
ligands to design novel small molecules.45 The approach utilises docking in combination with rounds 
of virtual synthesis and can guide physical combinatorial synthesis and screening library selection. A 
recent example, described by Domling et al., highlights its power by using virtual multi component 
reactions (MCRs) based around a key tryptophan residue at the protein-protein interface to identify 
new inhibitors of the p53/Hdm2 interaction.46 
 
Despite the huge advances in computational screening software, most virtual approaches to drug 
discovery have been limited to the identification of small molecule-protein interactions.  Due to the 
increased size and complexity of protein secondary structure, application of VS to protein-protein 
interfaces is less investigated. 
 
1.2.4 Peptidomimetics 
The abundant use of protein-protein interactions (PPIs) to control therapeutically relevant biological 
systems has resulted in significant investment into the design of drugs capable of disrupting such 
interactions.47-49 Despite the significant challenges associated with disrupting such PPIs, small 
molecules capable of achieving this have been discovered.50 Alongside more conventional drug 
discovery approaches (described above), de novo rational design of ‘mimetics’ that reproduce the 
structure and function of natural protein interfaces (α-helices, β-strands51 and β-turns52) have been 
subject to thorough investigation.53 
 
Of all protein secondary structure the α-helix is the most predominant.  Generation of small 
molecules that mimic this structure is of great benefit to the study of PPIs and the creation of 
therapeutic drugs of targets with α-helix based proteins interfaces. Hamilton et al. first described such 
non-peptidic synthetic molecules capable of mimicking the general α-helix structure in 2000 (Figure 
5).54 
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Figure 5 – Hamilton’s α-helix mimetic rational design strategy: (A) Schematic representation of an α-helical 12-
mer peptide with i, i + 3, and i + 7 substituents, side view; (B) top view; (C) 3,2‘,2"-trisubstituted terphenyl, top 
view; (D) side view; (E) X-ray crystal structure.54 
 
This mimetic design was based on the analysis that the critical interactions in PPIs formed at α-
helical interfaces are often located on one face of the α-helix  (Figure 5 A,B).55 The 3 substituents 
projected off the terphenyl structure mimic one face of a α-helix by representing the i, i+3 and i+7 
(IUPAC nomenclature for numbering amino acids in a peptide sequence standardised to i) residues 
(Figure 5 C). 
 
This mimetic strategy has been applied to multiple PPIs53 and has been developed by many other 
research groups who have progressed its application either through number of side chains,56 ease of 
synthesis57 or enhanced conformational rigidity58.   
 
1.3 Breadth of Therapeutic Targets 
Application of the array of drug design strategies available in a drug discovery project has resulted in 
the development of 1400 approved small molecule drugs that target ~324 molecular targets.59 Of 
these, nuclear receptors represent the second largest class of biomolecules targeted by currently 
approved small molecule drugs (FDA, 2005). 
 
1.4 Nuclear Receptors 
1.4.1 Biological Function 
In living organisms, hormones and growth factors manipulate expression of key proteins within 
cellular pathways through interaction with transcription factors (TFs).60 Nuclear receptors (NRs) are a 
class of TFs, which selectively bind small molecule ligands resulting in direct binding to DNA and 
expression of adjacent genes.61,62 This intricate small molecule control, combined with direct DNA 
binding result in their status as master ‘switches’ for regulation of genes responsible for virtually all 
aspects of development, reproduction and metabolism.63 
 
In the first half of the 20th century lipophilic small molecule steroids, retinoids and thyroid hormones 
were first isolated from living organisms.  In the 1980s, the control on mammalian physiology these 
molecules commanded was finally linked to their role as ligands of NRs.  In 1985, the first primary 
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structure of cDNA encoding the human glucocorticoid receptor (GR) was published.64 A year later the 
sequence for and expression of the human estrogen receptor (ER) was published65 and in the 
following decade a further 30 NRs were identified.66 
 
Controlled expression of NR proteins enabled investigation into the mode of action of this TF 
subfamily. Transcriptional activation was found to be elicited through interaction with specific DNA 
sequences, called response elements (REs)67, which are located in the vicinity of receptor sensitive 
target genes.68 Consequent investigation into the relationship between individual NRs, their REs and 
the resulting biological effects have been thoroughly documented over the past 2 decades.69 
Recently, individual NRs have been identified to control tissue specific expression of other NRs 
indicating a complex in vivo regulatory network that extends beyond ligand control.70,71 
 
Based on ligand binding, DNA binding and dimerization behaviour, 3 classes have been established 
among the NR superfamily (Figure 6). 
 
 
Figure 6 – Cartoon schematics of the cellular action of the 3 NR classes. (Taken from Glass et al.)72 
 
Class 1 - bind small molecule ligands in the cytosol resulting in dissociation of their intracellular heat-
shock protein chaperone (Figure 6a). The NRs then homodimerise before translocation to the 
nucleus where they then bind to two REs, the 2nd of which is an inverted repeat of the 1st. This class 
of NRs are generally referred to as the ‘hormone receptors’ due to their binding of naturally occurring 
small molecule hormones. 
 
Class 2 – are contained within the nucleus where they bind small molecule ligands and then bind to 
direct repeat REs as a heterodimer - typically with retinoid X receptor (RXR) (Figure 6b). This class 
includes almost all other ligand dependent receptors outside of nuclear hormone receptors. 
 
Class 3 – predominantly bind to DNA as a monomer although some bind as homodimers to direct 
repeat REs (Figure 6c).  This final class generally represents nuclear receptors that do not have a 
natural ligand and are therefore termed ‘orphan’ NRs.73,74 Over time, some of these receptors have 
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been ‘adopted’ by discovery of a natural ligand for the receptor whereas some are believed to bind to 
DNA in the absence of any ligand due to innate constitutive activity.75 
 
The classification of NRs within these 3 classes broadly relates the biological mechanism through 
which each NR induces its function.  Analysis of the structural biology of NRs can allow for 
elucidation of these mechanisms and also the evolutionary selection of these receptors as master 
switches. 
 
1.4.2 Structural Biology 
Analysis of the primary structures published in the 1980s identified a modular organisation conserved 
across all NRs (Figure 7).76  
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Structural biology schematic with ribbon format representation of DBD (PDB:1QKM, green) and LBD 
(PDB:1GWR, cyan) of estrogen receptor-α (ER-α). 
 
Their structure is divided into six distinct domains termed A-F. Domain C and E, the DNA binding 
domain (DBD) and ligand binding domain (LBD), constitute the most highly conserved regions of the 
NR amino acid sequence (Figure 7).77  
 
The superfamily, containing 48 distinct NRs, is divided into six subfamilies according to primary 
amino acid sequence homology.78 The largest family, the ‘thyroid hormone receptor (TR) like’ 
subfamily, contains 19 distinct human nuclear receptors whereas the smallest, the ‘germ cell nuclear 
factor (GCNF) like’ subfamily contains only one. 
  
A/B      C    D        E       F 
N-terminal Domain                 Hinge Region           C-terminal domain 
         DNA binding domain        Ligand binding domain 
   (DBD)                         (LBD)                      
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1.4.2.1 DNA Binding Domain (DBD) 
The NR DBD is the portion of the receptor responsible for binding to REs.  The domain is a highly 
conserved 66 amino acid sequence, which contains 8 highly conserved cysteine’s that coordinate 
two Zn2+ ions creating two zinc fingers motifs (Figure 8). 
 
 
Figure 8 – X-ray crystal structure of ER DBD bound to DNA (PDB:1QKM). 
 
The N-terminal helix of the DBD forms the interaction between the NR and the major groove of the 
DNA. Variation in a portion of this helix, called the ‘p-box’, generates selectivity for various REs 
present on DNA.  REs consist of a recognition motif derived from an archetypal hexameric AGGTCA 
base pair sequence called a ‘half-site’.  The dimerization behaviours of class 1 and 2 NRs have 
evolved to enable selectivity between the highly similar RE half-sites.  Variation in the orientation 
(direct or inverted repeats) and spacing between REs enhances the ability of dimers to achieve 
specificity for the RE target gene.  For class 3 NRs, which bind as monomers, extra RE specificity is 
gained through a DNA binding motif C-terminal to the DBD and 5’ extended half-site motifs.79 
 
Despite the critical role of the DBD for generating the final expression of a target gene, initial 
activation of this function is controlled by small molecule ligand activation of an NR at the LBD. 
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1.4.2.2 Ligand Binding Domain (LBD) 
The NR LBD, formed of approximately 250 amino acids, is the site of the ligand-mediated activation 
of the receptor.  The first high-resolution structure of a NR LBD, that of RXR-α, was determined by X-
ray crystallography in 1995.80 This structure was the first of 25 further NR LBD structures to be 
determined (Figure 9). 
 
   
Figure 9 – Ribbon diagrams of 3 NR LBD X-ray crystal structures (a) RXR-α with bound natural ligand 9-cis 
retinoic acid and coactivator peptide GRIP1 (PDB:3OAP). (b) ER-α with 17-β estradiol and coactivator peptide 
SRC2 (PDB:1GWR). (c) LRH-1 with phospholipid and coactivator peptide TIF2 (PDB:1YUC). 
 
The LBD was shown to be a globular domain consisting of approximately 12 α-helices and 3 β-
sheets.  These 12 α-helices (H1 to H12) form a ‘sandwich’ of 3 perpendicular layers containing 
distinct structural features critical for natural ligand-mediated activation of this portion of the receptor. 
 
1.4.2.3 Natural Ligands 
Successful isolation of the majority of the NR superfamily by the end of the 20th century allowed 
pairing of the receptors with the lipophilic small molecules identified at the start of the century.  These 
natural ligands include steroid hormones, vitamins, eicosanoids, oxysterols and bile acids (Figure 
10).81 
e 
Helix 12   Coactivator peptide           Ligand 
a b c 
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Figure 10 – Structures of known natural ligands with NR in bold below. 
 
The small lipophilic nature of the natural ligands enables them to move effectively between tissues 
and within cells making them perfect for control of the ligand-mediated activity of NRs.  
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1.4.2.4 Ligand Binding Pocket (LBP) 
The LBP is the region of the LBD responsible for the binding of small molecule ligands. It is at the 
core of the LBD completely hidden from the external environment. Formed by the inner layers of the 
α-helical sandwich and the 2 or 3 β-sheets, ligand recognition is achieved through hydrophobic 
interactions, hydrogen bonding networks and the steric size of the pocket.  The large amount of 
structural data produced around the steroid receptor class of NRs has also shown that the 
hydrophobic regions of the LBP are very flexible and closely contour the shape of the ligand.82,83  
 
Despite the highly conserved tertiary structure of LBDs, the LBP volume varies significantly from 280 
Å3 in ER-β to 1400 Å3 in PPARs.  This variation in size has been linked to receptor function84 with 
class 1 NRs containing small LBPs with extensive polar residues that facilitate high affinity 
recognition of a small number of natural ligands.  In contrast, class 3 orphan and adopted receptors 
have large LBPs with very few polar residues thereby allowing promiscuous recognition of diverse 
metabolites with low affinity. 
 
The recognition and binding of small molecule ligands at the LBP results in significant conformational 
stabilisation of the entire LBD.  This increased stability is required for the 2nd step in NR activation, 
which occurs at the ligand-dependent activation function-2 (AF-2) site present on the LBD. 
 
1.4.2.5 Activation Function-2 (AF-2) 
Early analysis of apo- (non ligand bound) and holo-LBD (ligand bound) structures revealed significant 
flexibility in the C-terminal H12 portion of NR LBDs.80 This conformational change, along with other 
structural movement (bending of H11 and H3), creates distinct surfaces on the apo- and holo-LBD 
(Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Different conformations of H12 in RXR LBD (LBD, green; H12, blue; coactivator, purple). (a) holo-
LBD in the presence of a ligand forming AF-2 for coactivator binding. (b) apo-LBD conformation with H12 swung 
away from AF2 site (PDB:1LBD).80 (c) apo-LBD with corepressor binding (PDB:3R29).85
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With a bound small molecule ligand (Figure 11a), the conformation of the receptor is stabilised 
resulting in H12 forming a hydrophobic cleft, known as the AF-2, with the surfaces of H3 and H4.  In 
the absence of small molecule binding, the H12 can adopt a number of conformations (Figure 11b 
and c).  In these apo conformations H12 can rotate away, destroying the previously formed AF-2 and 
creating an elongated hydrophobic surface now situated between H3, H4, and H11.   
 
The ligand-controlled variation of these hydrophobic surfaces enables selective recruitment of 
cofactor proteins that ultimately initiate or suppress NR transcriptional activity.  The intricate binding 
interaction of the cofactor proteins family to these interfaces has long been investigated to try to 
understand this final step of NR activation. 
 
1.4.2.6 Coactivation vs Corepression 
The understanding that NR controlled transcription was not directly induced by holo-NRs was first 
deciphered when transcriptional interference (‘squelching’) between different steroid receptors was 
observed.86  
 
Since this time, over 200 coactivator proteins, which contain the further molecular machinery required 
for transcription, have been published.87 These proteins were identified to interact with the NR AF-2 
through a conserved α-helical LXXLL (L= leucine and X= any amino acid) sequence, present on all 
coactivators, termed the ‘NR-box’.88,89 To validate this it was identified that significantly truncated 
coactivator proteins were capable of binding to holo-NRs and that NR-box containing peptides were 
capable of disrupting NR transcriptional activation in vivo.90 
 
In the last 15 years, most NR LBD crystal structures have been obtained in the presence of LXXLL 
containing peptides.  These illustrate that the NR-coactivator interaction dominated by the leucine 
residues of the NR-box packing into the hydrophobic cleft of the AF-2.  Also, 2 conserved residues 
present on the AF-2 (typically a lysine on H3 and a glutamic acid on H12) form hydrogen bonds to 2 
main chain carbonyl functional groups, producing a ‘charge-clamp’ (Figure 12). 
 
 
Figure 12 – Close up of RXRα-coactivator binding interaction with coactivator NR box (pink ribbon) and residues 
(pink sticks) at the AF-2 interface; H-bonds with charge clamp residues yellow dashed lines (PDB:3OAP). 
a b 
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Despite the local NR-box residues being responsible for the majority of the binding energy, selectivity 
between coactivators and NRs is affected by the residues immediately flanking the NR-box.91 Also, 
the effect of the LBP contortion around specific small molecule ligands creates conformational 
changes to the LBD that has been shown to effect NR-box selectivity.92  This has been most 
noticeably observed with ER for which numerable small molecule ligands have been developed.93 
 
It was only in the mid-1990s that corepressors, the second family of cofactors, were identified to 
mediate transcriptional silencing through binding to the elongated AF-2 hydrophobic groove present 
in apo-NR LBDs (Fig. 12).94 These corepressors silence NR transcriptional activity by recruiting 
complexes with histone deacetylase enzymes, which maintain DNA in a condensed state.95 The 
corepressor proteins were identified to interact with the elongated AF-2 using a consensus sequence, 
LXXIIXXIL, analogous to the NR-box of coactivators.  Called the ‘CoRNR’-box, peptides containing 
this motif are capable of disrupting NR transcriptional repression in vivo.96 
 
Finally, it was also shown that mutation of AF-2 residues involved in coactivator protein binding can 
disrupt corepressor protein binding.97  This led to the proposition of a coactivator-corepressor 
exchange mechanism that was enabled by ligand-mediated repositioning of H12.  This succinct 
mechanistic proposition is consistent with the structural changes discussed above and highlights the 
power small molecule ligands have in controlling NR gene transcription.   
 
1.4.3 Orphan Nuclear Receptors 
As discussed above, class 3 NRs are mainly populated by orphan and adopted NRs.  Many of these 
NRs are thought to be constitutively active, achieving transcriptional activation in the absence of a 
natural ligand. 
 
Some of these receptors, called ‘true’ orphan receptors, are missing key structural features required 
for the conventional activation paradigm discussed above.  For example NGFIBβ has been shown by 
crystallography to be devoid of a LBP, with the volume of this area being occupied by bulky amino 
acid residues.98 Loss of key structural features such as a LBP or AF-2 site suggests the potential of 
alternative mechanisms of modulation such as post-translational modification (such as 
phosphorylation).99 
 
The adopted NRs (e.g. RXRs and PPARs, the FXRs, LXRs, CAR, and PXR), initially discovered 
without knowledge of a natural ligand have been identified to display structural homology to the 
steroid receptor families.62 Adoption of such NRs, explored by both in vivo and in vitro assays and 
crystallography, proved difficult due to the low binding affinity and promiscuous behaviour of 
endogenous ligands.75  Following this, a ‘reverse endocrinology’ approach has been taken with many 
adopted NRs in which the identified natural ligand is used to elucidate their true in vivo biological 
function.100 Through this method, many adopted NRs have been shown to be involved in lipid 
sensing, providing a regulatory system to diet controlled metabolic systems.101 
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The unique structural features and diverse biological functions of orphan NRs illustrate the 
importance of the NR superfamily as a whole. The effort to adopt orphan NRs has expanded the 
continuum of biologically relevant molecules that control NR function resulting in an expansive array 
of understood NR controlled physiology.  
 
Given the role of NRs as a ‘master-switch’ for human physiology, mutations of NR genes have been 
identified in most human disease.62,101 Drug discovery programmes targeting NRs have been a 
significant focus of the pharmaceutical industry over the last century and the continuing elucidation of 
novel biological roles of NRs will ensure this focus in the future. 
 
1.5 Nuclear Receptor Drug Design 
1.5.1 Early History 
As with the early history of drug-discovery strategies outlined in section 1.1 and 1.2, small molecules 
capable of modulating NR activity were first identified in natural extracts. This applies most notably in 
the class 1 steroid NRs for which the steroidal natural ligands are abundant in animal species. 
 
The first steps into the vast area of ER pharmacology and drug design were taken as early as 1915 
when knowledge that ovariectomy reduced the incidence of mammary cancer from between 60-90% 
to 9% in high-incidence strains of mice.102 This effect, later identified to be due to the absence of 
estrogen in the mice, led to an explosion of research into its biological effects. Discovery of ER in the 
1950s and association to a variety of cell-growth related disease states raised the potential of anti-
estrogen drugs for the treatment of cancer.   
 
Screening for anti-estrogenic molecules by Imperial Chemical Industries (ICI) in the 1960s identified 
the first reported ER antagonists ICI,46,474 (Figure 13). 
 
 
Figure 13 – Structure of ICI,46,474 (Tamoxifen). 
 
Initially pursued for use as a contraceptive, clinical candidate, ICI,46,474 was finally approved for the 
treatment of breast cancer in 1973.103 To date, it underlines the power of NRs as pharmaceutical 
targets by remaining to be the most prescribed drug for endocrine treatment of breast cancers. 
 
Isolation and characterisation of many other small molecules capable of modulating endocrine 
systems resulted in early drug discovery efforts aimed at modulating other steroid NRs (AR, PR, 
O
N
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etc.).  Due to an absence of advanced computational techniques, early drug development, was 
focused on alteration of the natural steroidal core (Figure 14). 
 
 
Figure 14 – Natural steroid NR ligands and their developed steroidal modulators. 
 
This technique, known as the ‘extension hypothesis’, resulted in the creation of many of the most 
potent NR modulators on the market today. Spironolactone and Mifepristone were developed by 
small modification and extension of the natural ligands aldosterone and progesterone respectively.   
These two modulators, synthesised in 1972 104 and 1981 105 respectively, still represent the two most 
widely used drugs for their NR targets. 
 
1.5.2 Current Directions 
With the advent of modern drug discovery practice, NR modulator identification was streamlined 
through use of a variety of HTS platforms.106,107 Progression away from steroidal modulators was 
sought in order to improve physiochemical properties inline with the guidelines set out by Lipinski.11 
By the late 1990s VS techniques were being used to identify non-steroidal NR modulators. Many of 
these approaches were taken using ligand-based VS techniques, as the large volumes of NR LBPs 
are not conducive to structure-based docking studies. 
 
One such approach utilised a 3D similarity search, analogous to SHop, using known antagonists as 
queries (Figure 15).108 
 
 
Figure 15 – Development of novel GR antagonist 1 from RU-43033 using VS. 
 
The similarity search VS identified small molecule GR antagonist 1 from use of steroidal antagonist 
RU-43044 as a query.  Pyrimidinedione 1 displayed a greatly reduced cLogP of 3.8, compared to that 
of 5.8 for RU-43044, and a comparable IC50 of 9 nM. 
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Approaches such as FBDD have seen little application to NR drug discovery due to the difficulty in 
generating crystallographic information of low affinity of fragments with highly flexible NR LBDs. 
Despite this, Bunsveld et al. have just described the first application of FBDD to the development of a 
novel ER agonist.109   
 
1.5.3 Structural Basis of NR Modulation 
The first NR LBD small molecule co-crystal structures were published in 1997 giving the first insights 
into the structural basis of NR modulation.82,110 These first co-crystal structures were obtained of the 
ER LBD in the presence of the endogenous ligand 17β-estradiol, non-steroidal agonist 
diethylstilbestrol (DES) and the selective ER antagonists raloxifene and 4-hydroxytamoxifen (Figure 
16).111 
 
Figure 16 – ER modulators 
 
1.5.3.1 Agonist Action 
As discussed above, natural ligands elicit their agonistic action on NRs through binding to the flexible 
LBD at the LBP through a combination of hydrophobic and electrostatic hydrogen bonding 
interactions that stabilise the H12 conformation resulting in recruitment of coactivator peptides and 
expression of gene transcription.  The co-crystal structures of 17β-estradiol and DES confirmed that 
unnatural small molecule agonists act as endogenous ligand mimics by binding at the LBP in a 
similar fashion (Figure 17). 
 
 
Figure 17 – Ribbon diagrams of (a) 17β-estradiol (pink stick) (from PDB:1GWR), and (b) DES (blue stick) (from 
PDB:3ERD) binding to the ER LBP respectively (H-Bond interactions shown by yellow dashed lines). 
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Both 17β-estradiol and its non-steroidal mimic, DES, occupy the same region of the LBP with the 
diphenol moieties of DES forming H-bond interactions with the same three hydrophilic amino acids 
(Glu353, Arg394 and His524) as the two hydroxy residues of 17β-estradiol. 
 
1.5.3.2 Antagonist Action 
Although knowledge regarding the structural mode of action of agonists was important, 
understanding the unnatural mode of action of antagonists was desired to observe if a paradigm 
through which agonists could rationally be transformed into antagonists existed.  The co-crystal of 4-
hydroxytamoxifen, a direct analogue of the tetra-substituted trans-stilbene DES, with ER was the 
perfect structure to analyse this (Figure 18). 
 
  
Figure 18 – Binding of 4-hydroxytamoxifen in the ER LBP (LBP surface in transparent pink, H-bonds shown as 
yellow dashed lines) (PDB:3ERT). 
 
4-Hydroxytamoxifen was observed to bind in the same orientation as both 17β-estradiol and DES 
agonists with the conserved phenol moiety of the trans-stilbene interacting with both Glu353, Arg394. 
However, the additional phenyl substituent now projects directly towards the flexible H12. The tertiary 
amine substituent of this phenyl group was observed to occupy the region of the active LBD 
conventionally occupied by H12 (Figure 19 and 11a).  This steric clash forces a shift in the H12 
conformation, analogous to that observed in apo-LBD structures, forcing it to fill the position occupied 
by coactivator peptides in holo-LBD structures (Figure 19). 
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Figure 19 – Ribbon structures depicting antagonist induced H12 shift. (a) Structure of 4-hydroxytamoxifen 
(green stick) clashing with holo-ER H12 (pale blue) from side (PDB:3ERT). (b) Observed shift of holo-ER H12 to 
occupy AF-2 in apo-ER structure (dark blue, from PDB:1GWR). 
 
This forced structural shift was the first observation of the structural basis of NR antagonism.  
Subsequently described as the ‘H12-folding inhibition’ hypothesis, it has been observed in many NR 
LBD-antagonist structures (Figure 20).112 
 
 
Figure 20 – Structures of NR antagonists (NR in brackets below compound identifier) with region of molecule 
that disrupts H12 (as shown by co-crystal structures) in shaded box. (Adapted from Pearce et al.)113 
 
Since its initial articulation this hypothesis has been utilised in the rational development of many NR 
antagonists. 
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1.5.3.3 Complexities of Small Molecule Modulation 
Despite the apparently simple structural mechanism of agonist and antagonist action observed in 
NR-modulator complexes, evidence of varied in vivo activity of tamoxifen provided the first sign of a 
more complex mechanism than initially inferred from the solid state structures presented.103 Initially 
identified in Rats, tamoxifen was shown to reduce bone density, which indicated an agonistic mode of 
action, suggesting tissue dependent activity of the compound.114 Furthermore, in the absence of 
endogenous estrogen, tamoxifen is observed to be weakly agonistic where as in the presence of 
estradiol it exhibits antagonistic behaviour. 
 
Variable activity of small molecule ligands has been observed in many other NRs and significant 
effort has been devoted to understanding the structural mechanism for this.115 The crystal structures 
of ERβ and RXRα, with agonist’s genistien and oleic acid respectively, highlighted the disparity 
between in vitro and in vivo behaviour with both molecules exhibiting H12-folding inhibition but 
agonistic in vivo activity.116,117 This led to the description of many NR modulators exhibiting this 
variable activity as ‘partial’ agonists or antagonists.  
 
ER antagonist ICI,164,384 (trade name faslodex, Figure 20), however, does not display this variable 
activity maintaining its antagonistic activity in all physiological environments.118 Termed a ‘pure’ 
antagonist, faslodex exhibits it activity through a distinct structural mechanism.  A co-crystal structure 
of ERβ with faslodex reveals that the long side chain off the steroid B-ring fully occupies the 
hydrophobic groove into which H12 is displaced in structures of partial antagonists tamoxifen and 
raloxifene (Figure 21).119 
 
     
Figure 21 – (a) Binding mode of pure antagonist Faslodex (pink stick) in ERβ LBD (dark blue ribbon) 
(PDB:1HJ1). (b) Overlay of ERα LBD (PDB:1GWR, green ribbon) with H12 (purple ribbon) and coactivator (red 
ribbon) highlighted.  4-Hydroxytamoxifen present in LBP (cyan stick) for comparison (from PDB:3ERT). 
  
As can be seen from the crystal structure, occupation of the AF-2 by faslodex disrupts H12 so 
significantly that the side chain is not present in the X-ray crystal structure (Figure 21a).  Overlay of 
the structure with that of ERα in the active conformation illustrates the extent to which faslodex 
a b 
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occupies the space usually filled by H12 and a coactivator.  Comparison of the binding mode of 
partial antagonist 4-hydroxytamoxifen (Figure 21b) with faslodex indicates that the extent of H12 
displacement elicited by partial antagonists does not completely disrupt coactivator binding at the AF-
2.   
 
Based on the knowledge that small molecules were capable of eliciting selective recruitment of 
cofactors based on their concentrations in specific tissues the search for Selective Nuclear Receptor 
Modulators, SNuRMs, began.  Despite the unintentional development of many SNuRMs from prior 
drug discovery efforts, the ability to base lead selection criteria on this variable in vivo activity proved 
difficult.120 Burris et al. confirmed the ability of small molecules to selectively control NR cofactor 
recruitment by screening a large range of cofactor peptides in vitro (Figure 22). 
 
 
Figure 22 – Four synthetic LXR ligands (T901317, GW3965, PX009667 and PX00118) induce differential 
recruitment patterns. Each bar represents an LXRβ–cofactor interaction signal as fold induction of the liganded 
over the unliganded state. Taken from Kremoser et al..120 
 
Selection of ligands based on in vitro cofactor screens carried out in this way, however does not give 
data that correlate with in vivo performance.  This confirms that the picture presented of antagonist 
action in solid-state structural data is indeed simplistic, with a myriad of potential factors being 
responsible for the lack in correlation between such in vitro/in vivo studies. 
 
In an effort to bridge this gap Katzenellenbogen et al. recently suggested a more accurate gauge of 
small molecule ‘efficacy’ against NRs in vitro.121 Acknowledging that in conventional EC and IC50 
measurements of small molecule potency there is no gauge of the cofactor affinity to ligand-NR 
complexes, they suggest ‘relative recruitment potency’ (RRP) as a more representative gauge of in 
vitro efficacy that better correlates to that in vivo (Figure 23). 
 
both in the core sequence, as well as in amino-terminal and
carboxy-terminal sequences surrounding the LXXLL interaction
box [50]. Peptides representing these binding motifs for nuclear
receptors have been used to identify differences in the cofactor
interaction profile of nuclear receptors using standard biochemical
binding assays, such as HTR-FRET [30,51,43], fluorescence polar-
isation [52] or bead-based multiplexed measurements coupled to
flow cytometry [53,54]. In addition to peptides derived from
natural NR-binding sequences, artificial peptides selected from
phage display libraries that bind to ligand-free or ligand-bound
NRs have been used in such experiments [55].
The advantages of these cell-free cofactor profiles are their high
throughput and the fact that they are based on fully defined
reaction conditions. This allows titration of the peptide in the
binding reaction at fixed ligand concentrations, as opposed to
titration of the ligand concentration done in usual dose response
experiments [30]. The resulting EC50 value is a direct measure of
the cofactor peptide’s affinity in dependence of the ligand-induced
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FIGURE 2
Cofactor profiling using the yeast two-hybrid system. (a) Cofactor profiles are nuclear receptor specific. Members of the steroid receptor superfamily estrog n
receptor alpha (ERa), androgen receptor (AR, NR3C4) and mineralocorticoid receptor (MR, NR3C2) were tested for ligand-dependent cofactor recruitment. Each
bar represents a nuclear receptor–cofactor interaction signal in the presence of the natural ligand of the respective receptor as fold induction over the non-ligand
bound state. (b) Cofactor profiles are ligand specific. Four synthetic liver X receptor (LXRa and b, NR1H3 and NR1H2) ligands (T901317, GW3965, PX009667 and
PX00118) induce differential cofactor recruitment patterns. Each bar represents an LXRbeta–cofactor interaction signal as fold induction of the liganded over the
unliganded state.
proteins recruit protein complexes of overlapping composition, such as the NuRD and Sin3A complexes, to induce transcriptional repression. In many cases, these
complexes contain enzymes such as histone de-acetylases that counteract the activities of the co-activating complexes. Together, these activities lead to
repression of transcription. (b) Full Agonists and SERMs differ in the relative position of the LBD’s Helix 12. (i) Crystal structure of the human ER(-LBD in complex
with 17-(-estradiol; (ii) ER(-LBD in complex with Raloxifene (data from pdb structures 1ERE and 1ERR after [12]). The natural (full agonist) ligand 17-(-estradiol
induces a conformation that ‘locks’ the helix 12 (in green) in a position that results in the formation of a co-activator recruitment patch (termed AF-2), together with
other structural elements of the LBD. Raloxifene, a selective ER modulator (SERM) protudes from the binding pocket towards the solvent and hence displaces the
Helix 12 (in green) from its fully agonistic and co-activator recruiting position.
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both in the core sequence, as well as in amino-terminal and
c rboxy-terminal sequenc s sur ounding the LXXLL i teraction
box [50]. Peptides representing these binding motifs for nuclear
receptors have been used to identify differences in the cofactor
interaction profile of nuclear receptors using standard biochemical
binding assays, such as HTR-FRET [30,51,43], fluorescence polar-
isation [52] r bead- ased multiplexed measurements coupled to
flow cytometry [53,54]. In addition to peptides derived from
natural NR-binding sequences, artificial peptides selected from
phage display libraries that bind to ligand-free or ligand-bound
NR have been used in such experiments [55].
The advantages of these cell-free cofactor profiles are their high
throughput and the fact that they are based on fully defined
reaction conditions. This allows titration of the peptide in the
binding reaction at fixed ligand concentrations, as opposed to
titration of he ligand concentration done in sual dose response
experiments [30]. The resulting EC50 value is a direct measure of
the cofactor peptide’s affinity in dependence of the ligand-induced
Drug Discovery Today ! Volume 12, Numbers 19/20 !October 2007 REVIEWS
FIGURE 2
Cofactor profiling using the yeast two-hybrid system. (a) Cofactor profiles are nuclear receptor specific. Members of the steroid receptor superfamily estrogen
receptor alpha (ERa), androgen receptor (AR, NR3C4) and mineralocorticoid receptor (MR, NR3C2) were tested for ligand-dependent cofactor recruitment. Each
bar represents a nuclear receptor–cofactor interaction signal in the presence of the natural ligand of the respective receptor as fold induction over the non-ligand
bound state. (b) Cofactor profiles are ligand specific. Four synthetic liver X receptor (LXRa and b, NR1H3 and NR1H2) ligands (T901317, GW3965, PX009667 and
PX00118) induce differential cofactor recruitment patterns. Each bar represents an LXRbeta–cofactor interaction signal as fold induction of the liganded over the
unliganded state.
proteins recruit protein complexes of overlapping composition, such as the NuRD and Sin3A complexes, to induce transcriptional repression. In many cases, these
complexes contain enzymes such as histone de-acetylases that counteract the activities of the co-activating complexes. Together, these activities lead to
repression of transcription. (b) Full Agonists and SERMs differ in the relative position of the LBD’s Helix 12. (i) Crystal structure of the human ER(-LBD in complex
with 17-(-estradiol; (ii) ER(-LBD in complex with Raloxifene (data from pdb structures 1ERE and 1ERR after [12]). The natural (full agonist) ligand 17-(-estradiol
induces a conformation that ‘locks’ the helix 12 (in green) in a position that results in the formation of a co-activator recruitment patch (termed AF-2), together with
other structural elements of the LBD. Raloxifene, a selective ER modulator (SERM) protudes from the binding pocket towards the solvent and hence displaces the
Helix 12 (in green) from its fully agonistic and co-activator recruiting position.
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Figure 23- Functionally relevant interactions of estrogen’s with the ERs and SRCs.  (A) Interactions in a cellular 
context.  (B) In vitro systems for analysis of RLA, RCA, and RRP.121 
 
RRP seeks to incorporate the cellular context of small molecule action in an in vitro environment. 
 
Before such approaches can be rationally applied, more investigation into in vivo systems must be 
carried out to improve the understanding of NR-cofactor interactions in relevant biological systems. 
 
1.5.4 Assay Technology for NR Drug Discovery 
In drug discovery, screening technology represents a key factor for the identification and progression 
of novel, drug like small molecules.  As discussed above, historically, characterisation of small 
molecules began using full animal models.  Advances and refinement in biotechnology led to the 
ability to culture cells that displayed specific disease phenotypes while expressing the receptor of 
interest within such tissue.  In most recent years, fluorescent HTS technology, which enables high-
throughput testing of molecules in an in vitro setting, has become the assay technology of choice. 
 
The use of both in vivo and in vitro screening technologies have been exploited in NR drug discovery 
although inherent complexities in in vivo NR biology generate uncertainty around data from either. 
 
1.5.4.1  Cell-Based Assay Technology 
Within biology, ‘reporter’ genes have been extensively used to study eukaryotic gene expression and 
regulation.122 In such systems, reporter genes can be attached to a sequence of DNA that is 
regulated by a protein of interest (POI).  Expression of the reporter gene is then activated on binding 
of the POI to its regulatory sequence.  To allow facile detection of reporter gene activation, genes 
that are not endogenously expressed in the cell of interest must be selected.  
of SRC3 labeled directly with fluorescein (fluoresce t accep-
tor). Human ER! LBD (amino acids 256–505) containing only
one reactive cysteine at position 369, generated as described
previously (17), was similarly labeled with SA-Tb. Excitation of
Tb at 340 nm results in emission at 495 nm. If the fluorescein-
labeled SRC3 and the SA-Tb-labeled ER are close to one
another, as would be the case after recruitment by agonist-
bound ER, the energy from the excited state of the Tb complex
is transferred to fluorescein, which emits at 520 nm (15, 19). By
monitoring the degree of FRETas the ratio of acceptor emission
intensity (A, at 520 nm) to donor emission intensity (D, at 495
nm), expressed asA/D! 1000,we couldmeasure quantitatively
the ligand-dep ndent binding of S C3 to the LBD of ER" or
ER!. A notable aspect of our coactivator assays is that we have
used a "200-amino acid segment of SRC3 encompassing all
three of the LXXLL motifs that constitute the NRID of the
coactivator rather than smaller peptides containing only one
LXXLLmotif, as have typically been used in coactivator peptide
recruitment assays (21–23).
Determination of RCA for Various ER!Ligand Complexes;
tr-FRET SRC3 Titration Assay
We measured the affinity with which the SRC3 NRID frag-
ment bound to conformations of ER" and ER! stabilized by the
FIGURE 1. Functionally relevant interactions of estrogenswith the ERs and SRCs. A, interactions in a cellular context. B, in vitro systems for analysis of RLA,
RCA, and RRP.
FIGURE 2. Structures of the four classes of estrogens used in this study.
Exploration of Dimensions of Estrogen Potency
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This technology has been successfully utilised for in vivo assays of NR activation by small molecules.  
In such assays, reporter genes are used that code for a family of enzymes called luciferases.  These 
enzymes, isolated from naturally bioluminescent species, catalyse the oxidation of a broad range of 
luciferin substrates to yield light (Figure 24). 
 
 
Figure 24 – Top – oxidative catalysis of Firefly luciferase substrate beetle luciferin. Bottom – oxidative catalysis 
of Renilla luciferase substrate coelentrazine. 
 
Due to the differing substrates in this family of enzymes the light emitted is in a variety of 
wavelengths.  Following addition of the luciferase substrate, detection of the emitted light can be 
directly correlated to the increased activation of the POI.  For the purpose of NR analysis, the 
reporter gene construct is linked to the RE of the NR under investigation. 
 
In many cases a ‘dual-reporter’ system is utilised in which two reporter genes constructs (typically 
Firefly and Renilla luciferase) are transferred into the cell (transfected).  One construct contains the 
sequence for expression of the NR of interest (in combination with Firefly luciferase reporter gene) 
and a second simply contains the Renilla reporter gene.  This use of a second reporter gene allows 
for the efficiency of transfection to be monitored thereby allowing experiment-to-experiment (and 
indeed well-to-well) variability to be normalised. 
 
The ability to create customised construct to incorporate any POI has resulted in bioluminescent 
dual-reporter assays becoming the predominant assay of choice for NR cell biology. 
 
1.5.4.2  In Vitro Assay Technology 
In vitro assays allow the analysis of a specific binding interaction without interference from the huge 
expanse biomolecules present in vivo.  In such settings detection of successful interaction at an 
interface of interest requires labelling of one member of the interaction. 
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AlphaScreenTM (Amplified Luminescent Proximity Homogeneous Assay) is one technology, 
developed by PerkinElmer, for highly sensitive detection of biomolecular interactions.123 This 
technology utilises ‘donor’ beads and ‘acceptor’ beads to generate detectable chemiluminescence 
when in close proximity to each other (Figure 25). 
 
 
Figure 25 – (a) Laser excitation of donor bead results in generation of singlet oxygen. (b) On binding of bio 
molecules A and B, singlet oxygen triggers emission of luminescence in 520-620 nm region from acceptor 
bead.123 
 
The short lifetime (~ 4 µsec) of singlet oxygen, generated by the phthalocyanine photosensitiser, 
diffuses over 200 nM resulting in a highly sensitive luminescent gauge for the interaction being 
investigated.  Binding of the donor and acceptor beads to the POIs is facilitated through coating of 
the beads with streptavidin.  Labelling of the POI with biotin enables facile attachment of the beads 
for use. 
 
To gauge the agonist/antagonist action of a small molecule on NRs in vitro the AF-2/Cofactor binding 
interaction is most commonly used.  Typically, a small peptide containing a coactivator NR-box is 
labelled with a fluorescent/luminescent moiety, which alters its output on binding. Many research 
groups have successfully described use of AlphaScreenTM technology for analysis of small molecule 
NR modulators.124 
 
Despite advances in understanding and analysis the mode of action of small molecule NR 
modulators, significant progress in the understanding of in vivo NR modulation must occur before 
discovery of modulators can be considered more sophisticated than working in a ‘black-box’. 
 
1.5.5 Coactivator Binding Inhibition 
Early work investigating the role of cofactors in NR activation identified that it was possible to negate 
such activation by using small NR-box containing peptides to disrupt coactivator recruitment.90  Given 
the complex nature of the indirect antagonist action elicited through binding at the LBP, direct 
disruption of the NR-coactivator interaction represents an approach, which could provide superior 
results.  Development of such coactivator binding inhibitors (CBIs) is being investigated by a growing 
number of academic groups. 
 
2
Introduction
AlphaScreen is a bead-based, non-radioactive Amplified Luminescent Proximity Homogeneous Assay. When a
biological interaction brings the beads together, a cascade of chemical reactions acts to produce a greatly amplified
signal. On laser excitation, a photosensitizer in the “Donor” bead converts ambient oxygen to a more excited singlet
state. The singlet state oxygen molecules diffuse across to react with a thioxene derivative in the Acceptor bead
generating chemiluminescence at 370 nm that further activates fluorophores contained in the same bead. The
fluorophores subsequently emit light at 520-620 nm (Figure 1).
In the absence of a specific biological interaction, the singlet state oxygen molecules produced by the Donor bead
go undetected without the close proximity of the Acceptor bead. As a result, only a very low background signal is
produced (Figure 2).
AlphaScreen provides a highly versatile, sensitive, homogeneous and miniaturizable means to efficiently perform
assay development and HTS resulting in higher throughput at lower costs.
Figure 2: When the Donor and Acceptor beads are not in close proximity, the reactive oxygen decays and there is no detectable
signal generated.
Figure 1: When biological interactions bring the Donor and Acceptor beads into close proximity, a highly amplified signal with
output in the 520-620 nm range is generated.
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1.5.5.1 Rational Design 
The first steps towards the development of CBIs were based on the rational design of small 
molecules that mimicked the location of residues on the α−helical coactivator NR-box motifs. 
Katenellenbogen et al. published the first non-peptidic CBIs in 2004.125 This paper disclosed the 
structures of a range of small molecules capable of inhibiting the ERα-coactivator interaction (Figure 
26). 
 
 
Figure 26 – 4 designed CBIs with pendent isobutyl leucine side chain mimics. 
 
Design of the tri-substituted 6-membered cyclic cores was based on the distances between Cα of the 
3 leucines of the α-helical LXXLL NR-box.  All CBIs disclosed mimicked the 3 leucines using pendant 
isobutyl groups situated at appropriate positions.  The CBIs displayed greatly varied binding affinities, 
with the substituted pyrimidine core producing the best inhibition with a Ki of 29 µM.  Analysis, carried 
out by docking using FlexiDock, suggested that the pyrimidine core generated the best inhibition by 
allowing the isobutyl residues to bury deeper into the AF-2 binding cleft (Figure 27a). 
 
 
Figure 27 – (a) Docking pose of 2 in ERα AF-2; (b) structure of best pyrimidine analogue 2; (c) electrostatic 
render of 2 docked onto ERα AF-2. 
 
Synthesis of a larger library of trisubstituted pyridimines identified 2 (Fig. 27b) as a more potent CBI, 
displaying a 10 fold more potent Ki of 2.5 µM.126  Docking analysis suggested this is achieved 
through increased hydrophobic interactions generated by the large naphthyl substituent on the shelf 
adjacent to the AF-2 binding cleft (Figure 27c). 
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Katzenellenbogen and others described a series of further small molecules capable of disrupting a 
variety of NR-coactivator interactions (Figure 28). 
 
 
Figure 28 – Images of other designed CBIs 3127, 4128, 5129 and 6130. Portions of molecule designed to create 
interaction with AF-2 shown in shaded regions. 
 
Bicyclo[2.2.2]octane 3 was designed to represent the i-1 isoleucine, i leucine, i+3 leucine and i+4 
leucine residues.127 The molecule was capable of disrupting coactivator binding although its relatively 
low efficacy (Ki = 7.1 µM) suggests that the highly flexible side chain generates a significant entropic 
penalty in generating the required orientation for binding.  Despite its simplicity, guanylhydrazone 4 
represents the best CBI to date with a Ki of 2.1 µM.128 Docking indicates that the hydrazine moiety is 
responsible for the majority of the binding efficiency by generating a strong hydrogen bond to the 
glutamic acid side chain of the AF-2 charge-clamp.   
 
Following this, Hamilton adapted the principles outlined in his pioneering α-helix mimetic design 
strategy to develop 5, which represents the 3 leucines of the NR-box.129  The molecule displayed a Ki 
of 4.2 µM although overlay images indicate the Cα overlay is not optimal for representing the isobutyl 
groups to the AF-2 interface.  Finally, Hanson designed biphenyl mimic 6 that represents only 2 of 
the leucine residues but attempts to interact with both charge-clamp residues with tertiary amine and 
carboxylic acid moieties at opposing ends of the structure.130  However, the molecule only displayed 
week affinity with a Ki of 33 µM. 
 
The above examples highlight the success of de novo design approaches in creating proof-of-
principle CBIs.  However, the difficulty of rational design (highlighted in discussion above) has limited 
the efficacy of the created molecules to low µM binding affinities. 
 
1.5.5.2 HTS Approach 
In search of sub-µM affinities, and more biologically useful molecules, Katzenellenbogen et al. have 
taken a HTS approach to identifying CBIs of ERα.131 This approach utilises a custom developed time-
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resolved fluorescence resonance energy transfer (TR-FRET) assay to identify molecules, in HTS 
format, that are acting directly as CBIs and not as indirect antagonists acting at the LBP.132 The 
screen of an 86,000-member library of small molecules identified 4 distinct CBI scaffolds of which 2 
were taken forward yielded lead compounds 7-8 (Figure 29). 
 
 
Figure 29 – Lead CBIs from TR-FRET HTS. 
 
From initial screening hit compounds displaying IC50 values of 14.8 µM and 20 µM, the 2 lead 
compounds, 7 and 8, were refined to 2.3 and 5.8 µM respectively. Despite extensive analogue 
synthesis Katzenellenbogen et al. were unable to generate a molecule with the desired nM potency.  
In an effort to understand the low potency of the identified inhibitors the molecules were docked onto 
the ERα AF-2 (Figure 29). 
 
 
 
Figure 29 – Images of (a) 7 and (b) 8 docked onto ERα AF-2 (H-bonds displayed as dashed yellow lines). 
 
Analysis of the docking poses suggested that, due to their linear nature, the molecules were 
occupying the core hydrophobic groove of the AF-2 but no part of the molecule was occupying the 
adjacent hydrophobic shelf on which the i-1 isoleucine and i+4 leucine of the coactivator NR-box are 
situated.  Calculations indicated that the entropy lost by not occupying this portion of the AF-2 
resulted in the diminished activity of these molecules.  It was postulated that an absence of branched 
molecules in the HTS library resulted in identification of ligands with limited potential to disrupt 
coactivator binding. 
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tivity in both TR-FRET and cell-based assays; thus, they were
examined further.
The benzothiazole scaffold 4 contains two a-thioamides,
each of which can be diversely functionalized with different
amines and thiols. R1 was functionalized with different alkyl
amines, and there is no clear preference for any of them. R2
was functionalized with a number of arenethiols. Some com-
pounds containing substituents at the ortho- and meta-posi-
tions on the benzene ring showed increased activity over the
resynthesized hit (4b ; Table 2); however, those compounds
containing a para-oriented substituent, particularly hydropho-
bic ones, were among the most consistently potent com-
pounds assayed in this series. For instance, the CF3-substituted
compounds showed consistently lower IC50 values when this
substituent was in the para-position, as opposed to the ortho-
or meta-position (4ee–4gg ; Table 2). Surprisingly, the CF3-con-
taining compounds were much more potent than the CH3-con-
taining compounds. In fact, all compounds with ortho- or para-
methyl groups experienced complete loss of activity.
Introduction of halogens (Cl and Br) at the para-position
gave compounds showing moderate activity, but placing a
chloro substituent in the meta-position of the ring also led to
good-to-moderate binders (4n, IC50=20–50 mm ; 4o, IC50=
6.3 mm ; Table 2). Other potent compounds incorporated a 2-
naphthyl ring, rather th n a substituted phenyl, at R2, and all
of these derivatives showed IC50 values of 9–12 mm (4kk–
4mm ; Table 2). Replacing the naphthyl group with the bioiso-
steric 3,4-dichlorophenyl compound gave a marked reduction
in activity (4nn–oo ; Table 2). Since there are neither p–p nor
p–cation interactions in the binding model for benzothiazoles
(see model in Figure 8), the origin of the difference may arise
from selective desolvation (see below).
The binding site seems to be tolerant of various alkyl groups
introduced at the R1 position, as changing the alkyl substituent
in the best compounds did little to change activities. In gener-
al, however, the c-Pr substituent at R1 tends to increase the po-
tency of the compounds, sometimes by twofold, relative to iBu
and iPr (4b vs 4k and 4p ; 4ee vs 4 ff and 4gg ; Table 2). While
R1 is most likely deep in the hydrophobic CBI binding cleft, R2
may be outside of it. This has unexpected consequences for
the observed SAR that is noted below in the context of bind-
ing site water displacement.
Induced-fit molecular modeling to identify binding poses
for CBIs
To identify the putative binding poses of the compounds in
the phenyl piperazine and benzothiazole series, we employed
the crystal structure of the human estrogen receptor a com-
plexed by both diethylstilbestrol (DES; ligand binding pocket)
and a peptide from the NR-box II region of the coactivator
GRIP1 (CBI site; PDB: 3ERD). The peptide was deleted, and
docking of the ligands to the coactivator site was performed
with the Prime induced-fit docking method.[15] This procedure
allows for flexibility of both ligand molecule and protein side
chains within the target coactivator binding groove. The ener-
getically favored pose is subsequently derived with MM-
GBSA,[14] a method that provides ligand binding energies with
reasonable accuracy;[16] the same method was used to evaluate
the interaction of compound 1g with the ERa ligand binding
pocket (Figure 6). For additional details, see the Molecular
Modeling subsection in the Experimental Section.
Phenyl piperazine scaffold
All active compounds in Table 1, with the exception of 1e and
1 f (both of which bear a hydroxy hydrogen donor), exhibit
similar docked poses at the coactivator binding groove. These
show good alignment with the X-ray structure of the bound
ERa coactivator peptide and simultaneously form productive
hydrophobic contacts and hydrogen bonds with Gln375,
Lys362 or Val368 (Figure 7). In addition, as a result of the in-
duced-fit docking, each is accompanied by side-chain move-
ments of Glu380, Glu542, Met543, Ile358 and/or Leu372, in
order to better match dipoles of the functional groups on the
phenyl ring associated with the piperazine ring or hydrophobic
contacts with the benzene center of the quinazolinone ring.
Notably, the center of mass of 1b does not fall along the axis
of the peptide helix, but below it and deeper into the groove
(Figure 7b). The docking has provided an intuitively reasonable
Figure 8. a) Docked pose of 4o showing three hydrogen-bond anchors and
side chain movement upon docking (!) in parentheses; b) Alignment of 4o
(stick) and coactivator peptide (purple ribbon).
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By molecular modeling : As a prelude to our induced-fit dock-
ing studies by molecular modeling, described below, we per-
formed an additional probe of the site of action of our active
molecules by modeling. To test the possibility that these com-
pounds might be competing with estradiol and functioning as
conventional antagonists, we examined their fit into the ligand
binding pocket of the X-ray structure of ERa complexed with
the classical antiestrogen, 4-hydroxytamoxifen (HT). HT occu-
pies the ER ligand binding site and stabilizes an antagonist
conformation of the LBD in which helix 12 is repositioned into
the coactivator site, blocking coactivator binding (PDB: 3ERT).[3]
Since HT and the high-potency test compound 1g have very
similar molecular volumes, in principle, both could separately
occupy the expansive ligand binding pocket in ER. Glide dock-
ing of 1g into the emptied HT site suggests that the phenyl
piperazine-quinazolinone scaffold is able to penetrate the site,
but the best binding pose is quite different from that of HT.
The predicted molecular orientation occupies the pocket only
partially, while much of the structure resides in solvent avoid-
ing contact with the receptor (Figure 6).
In addition, MM-GBSA calculations[14] were carried out to
compare estimated binding free energies (DGbinding=
Ecomplex(minimized)!Eligand(minimized)!Ereceptor) for HT and 1g.
The latter complex, as pictured in Figure 6, is posited to be
much less stable than that for HT (DDGbinding ~17 kcalmol!1).
These calculations are in qualitative agreement with conclu-
sions from the mechanistic studies in the reporter gene assays,
described above. This consistency between biology and mod-
eling offers a measure of confidence that the CBI docking re-
sults, reported later, might be useful for guiding future design
strategies.
Structure–activity relationships from cell-based reporter
gene assays
Quinazolinone Series 1: The key structural features of hit 1 are
the phenyl quinazolinone and the substituted phenyl piper-
azine m ietie connected by a carbon chain linker (Figure 1b
and Figure 7). Hit optimization focused on these two hetero-
cyclic units. A number of hydrophobic and hydrophilic sub-
stituents at various positions of the aromatic ring (sector A)
were introduced, and compounds with variable carbon chain
linkers (s ctor C) were also examined (Table 1).
Most of the compounds in this series showed activities in
the low-micromolar range (~5–10 mm). Alth ugh hit 1 with 3-
chloroph nyl substitutio an the analogue with a five-carbon
linker (1v) both show d only weak activity, the analogue with
a seven-carbon linker (1y) had good activity with an IC50 value
of 4.2 mm. Repositioning of the chloro group from the meta-
(1) to the para-position (1a) increased activity, with compound
Figure 6. Alignment of 1g (blue) and 4-hydroxytamoxifen (HT) (maroon) in
PDB: 3ERT (hERa–HT complex) as determined by Glide docking. Much of 1g
is predicted to bind well outside the ligand binding site.
Figure 7. a) Induced-fit docked p se for 1b at the coactivator binding site of
the ERa receptor (X-ray structur PDB: 3ERD). Displacements of Glu542 and
Ile358 side chains resulting from docking and hydrogen bond distances (!)
are indicated in parentheses; brown = hydrophobic; green = neutral ; blue
= polar; b) Alignment of 1b (stick) and the coactivator peptide (purple
ribbon; PDB: 3ERD). Hydrophobic residues Leu690 and Leu694 are matched
by ligand hydrophobes.
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As discussed above, PPIs are extremely challenging interactions to inhibit and the NR-coactivator 
interaction is no different.  The work discussed highlights that in order to compete with the large 
binding interface coactivators generate at the AF-2 site, a small molecule (designed de novo or 
identified using other methods) must be capable of occupying a significant proportion of the same 
interface.  This work described has made great steps towards achieving this although obvious 
limitations are still evident. 
 
1.5.6 Drug Discovery and Orphan Nuclear Receptors 
As discussed above, adoption of NRs has significantly expanded the therapeutically accessible range 
of human physiology.  Due to their role in dietary lipid regulation many of the adopted NRs have been 
exploited for control of metabolic disorders such a diabetes, obesity and cholesterol-related 
diseases.133  
 
Structurally, the receptors have much larger LBPs than those of class 1 steroid NRs and constitutive 
activity is observed due to a variety of evolved structural novelties.  Despite this, significant effort has 
been taken to develop drugs to access the therapeutic area of human physiology these receptors 
control. 
 
Of all the adopted NRs the peroxisome proliferator-activated receptor family (PPAR; PPARα,β and γ) 
have been the subject of the most significant drug discovery efforts.134  The first PPAR, PPARγ, was 
identified in 1990 and was shown to play a central role in the storage and catabolism of dietary 
fats.135 PPARγ was adopted in 1995 by the discovery that a prostaglandin, J2 metabolite 15-deoxy-
Δ12,14-PGJ2 9, promoted adipocyte differentiation through PPAR modulation.136 Although proposed to 
also have natural ligands, it was not until 2006 that significant mass-spectrometry analysis adopted 
the remaining PPARs, PPARβ and δ, revealing their ability to bind a variety of endogenous single 
chain fatty acids (Figure 30).137 
 
 
Figure 30 – Natural ligand of the PPARγ, 9, and proposed major PPARβ ligand vaccenic acid. 
 
Structurally, the PPAR family has the largest LBP of all NRs with an average volume of ~1300 A3. 
The majority of the LBP is hydrophobic with the entrance of the pocket containing 4 hydrophilic 
residues that form H-bond interactions with fatty acid carboxylate head groups.  Structures of the 
apo-LBD display H12 in an active conformation, suggesting that the receptor can demonstrate 
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constitutive activity.138 Structures obtained in the presence of agonists indicate that like steroid NRs 
they also stabilise the active H12 conformation. 
 
Due to the therapeutic potential of regulating dietary lipids, development of synthetic ligands capable 
of modulating the PPARs were identified before their adoption in the mid 1990s.  The first agonists, 
thiazalindiones (TZDs, e.g. rosiglitazone 10), were developed as antidiabetic agents over 15 years 
through screening in insulin resistant rodent models.  Together with many other novel agonists 
further agonists based on this TZD head group have been developed since.134 
 
Only one antagonistic ligand has been created for any of the PPARs.  This small molecule, GW0072 
(11), is a partial antagonist of PPARγ acting by altering the conformation of H12 in such a way as to 
disrupt coactivator recruitment (Figure 31).139 
 
  
Figure 31 – On left - PPARγ agonist TZD rosiglitazone (10) and partial antagonist GW0072, 11. On Right – 
Image of GW0072 induced conformation of PPARγ, LBD (green) and shifted H12 (red) (PDB:4PRG).  Active 
conformation H12 (blue) and coactivator peptide (purple).  
 
Despite the partial antagonist nature of GW0072, it was identified to be an inhibitor of adipocyte 
differentiation in cell culture and displayed an IC50 of 150 nM. 
 
The abundance of research into PPARs and drug discovery efforts surrounding them have shown 
that despite the promiscuous nature of fatty acid ligand binding and their extremely large hydrophilic 
LBPs, creating modulators of adopted NRs for treatment of metabolic disease is still possible.   
 
The observations and knowledge gained from drug discovery efforts toward the whole NR 
superfamily have greatly increased the knowledge of structure and function of these receptors.  
Application of these learning’s to new, novel NR targets can only expand the understanding of this 
pivotal family of transcription factors. 
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1.6 Liver Receptor Homolog-1 
1.6.1  Genealogy 
The focus of my PhD research, Liver receptor homolog-1 (LRH-1, NR5A2) is a member of the 
steroidogenic factor like subfamily of NRs.  The NR5 family is a two-member subfamily of orphan 
nuclear receptors consisting of LRH-1 and steroidogenic factor-1 (SF-1; NR5A1). 
 
1.6.2  Biological Function 
Human LRH-1 was first identified in 1996 due to its homology to the previously identified family 
member, Drosophila Fushitarazu factor 1 (Ftz-F1, NR5A3), present in drosophila.140 Alongside its 
family member steroidogenic factor-1 (SF-1), it has extensive roles in both adult and developmental 
biology.141 
 
In developmental biology LRH-1 is required for early embryonic differentiation where it effects 
formation of the endoderm.142 This control has been extended to show that LRH-1 can control stem 
cell differentiation to any adult cell through replacement of Oct4, a transcription factor involved in the 
renewal of stem cells, function.143  
 
Resulting from its role in embryonic development of the endoderm, LRH-1 is expressed in tissues 
derived from endoderm (e.g. intestine, liver, pancreas as well as the ovary).  Like PPARs and other 
adopted NRs, LRH-1 has been mainly investigated for its control of metabolism.62 This control 
includes regulation of bile acid and cholesterol homeostasis as well as steroidogenesis.1 Most 
recently LRH-1 has been implicated in intestinal cell renewal and as an essential transcriptional 
regulator of gut function.144 
 
Through its role in cholesterol homeostasis and as a regulator of gut function LRH-1 is a potential 
therapeutic target for the treatment of cardiovascular disease and gut-associated common diseases, 
such as colorectal cancer.  Of most significant importance to this project, and related to a growing 
body of research, is the role of LRH-1 in breast cancer.70 
 
1.6.3 Role in Cancer 
The first indication of the therapeutic potential of LRH-1 as a target for breast cancer came in 2002 
with the discovery that LRH-1 regulates aromatase production in breast adipose tissue.2 Up 
regulation of LRH-1 was shown to be evident in a number of breast cancer cells lines, indicating a 
direct role in breast cancer development. At the same time LRH-1 stimulation of aromatase 
production was limited to the stromal tissue surrounding tumours.145 
 
Aromatase is the enzyme responsible for estrogen biosynthesis from androgens.  In postmenopausal 
women aromatase activity is the major source of estrogens in adipose tissue and as a consequence 
it indirectly regulates ER function.  Creation of aromatase inhibitors, as alternatives to the well 
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established ER inhibitors (tamoxifen, raloxifene etc.), for the treatment of breast cancer has been 
very successfully exploited although approved therapeutics exhibit significant side effects.146 
 
The role of LRH-1 in breast cancer was significantly expanded with the recent discovery that LRH-1 
also directly regulates ER expression in breast cancer cells.70 This regulation was compounded by 
the observation that it also promotes breast cancer motility and invasion in an estrogen-independent 
fashion.71  The ability of LRH-1 to regulate both of the current leading therapeutic targets in the 
treatment of breast cancer, aromatase and ER, highlights the therapeutic value of a small molecule 
capable of antagonising this receptor. 
 
1.6.4  Structural Biology 
1.6.4.1  DNA Binding Domain (DBD) 
Sharing >90% primary sequence homology, the NR5A (or Ftz-f1) subfamily of NRs are grouped 
based on the presence of a highly conserved C-terminal extension of the DBD termed the Ftz-F1 
box.1 This Ftz-F1 extension to the ‘P-box’ DBD recognition surface results in recognition of a 5’-YCA 
extension to the RE half site sequence.  This extended DNA binding interface enables the NR5A 
subfamily to bind to DNA as a monomer rendering it a class 3 NR. 
 
1.6.4.2 Ligand Binding Domain (LBD) 
LRH-1 and SF-1 share 65% primary sequence homology across the LBD with the N-terminal H1, H2 
and H3 sharing the most prominent homology.  In this N-terminal region, the H2 is extended forming 
a rigid additional fourth layer to the traditional 3-layer sandwich, which is distinct from other NR 
subfamilies (Figure 32). 
 
Figure 32 – Overlay images of LRH-1 (PDB:1YUC, dark blue) and ERα (PDB:1GWR, purple) ribbon form LBDs.  
Rigid extension of LRH-1 H2 (green) relative to disordered ERα H2 (cyan). Views from 2 perpendicular angles, 
left and right, are shown. 
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The extended H2 confers increased stability to the LBD, in particular to H3, H4 and H12 around the 
AF-2.  This increased stability results in the NR5A NRs displaying constitutive activity with H12 
adopting an active conformation in the absence of bound ligands.147 
 
1.6.4.3 Natural Ligands 
The constitutive activity created by the novel H2 structure has created much debate around the 
ligand-independent nature of LRH-1 activation.  The first crystal structure of LRH-1, obtained from 
murine LRH-1, presented LRH-1 in the absence of ligand in the LBP.147 The study displayed that 
filling the LBP with bulky side chains (installed by creation of a LBP mutant LRH-1) did not diminish 
the basal activity of the receptor.  Although this displayed a ligand-independent mechanism it did not 
unequivocally label LRH-1 as a ‘true’ orphan receptor. 
 
Subsequent structures of LRH-1, obtained using human LRH-1, displayed the potential for ligand-
activation of the NR5As.148-150  These structures displayed the presence of natural phospholipids in 
the LBP of LRH-1 and SF-1.  As with the mLRH-1 study, LBP mutants of hLRH-1 were created and 
their ability to bind phospholipid was compared to in vivo receptor activity. Mass spectrometric 
analysis indicated the major phospholipids present were phosphatidyl ethanolamine (PE) and 
phosphatidyl glycerol (PG) and that a diminished ability to bind these correlated with a diminished 
receptor activity (Figure 33).149 
 
 
Figure 33 – Right - Structures of major PE and PG isoforms found in LRH-1. Left – Activity of wild type and LBP 
mutants in MCF7 breast cancer cells. 
 
The presence of PE and PG phospholipids in the LRH-1 LBP and their ability to modulate activity has 
confirmed the ability of natural ligands to modulate the activity of the receptor.  However, it is not 
completely clear whether these particular phospholipids are natural ligands or whether they occupied 
the LBP as an artefact of bacterial expression of the protein for crystallographic experiments.  For 
this reason the exact structure of the correct endogenous ligands has not yet been deciphered 
although this initial work has gone a long way to understanding the potential lipid sensing nature of 
this family of receptors. 
 
 
 
 
P
O
OO
HO
H2N O
O
O
O
PE
16:1/18:1
P
O
OO
HO
O
O
O
O
OH
HOPG
16:1/18:1
 35 
1.6.4.4 Ligand Binding Pocket (LBP) 
The LBP of LRH-1 is the second largest in NR family with a volume of 1200 A3.  It is mainly 
hydrophobic with a small cluster of hydrophilic residues present in the back of the pocket.  With direct 
analogy to the lipid sensing PPARs, LRH-1 and SF-1 also have a collection of hydrophilic residues at 
the entrance to the pocket to which phospholipid head groups form H-bond interactions (Figure 34). 
 
     
Figure 34 – Phospholipid (pink stick) present in LRH-1 LBP with hydrophilic residues shown as sticks (green) 
(PDB:1YUC).  Views from two different angles, (a) and (b), are shown. 
 
The hydrophilic residues in the LBP, H390 and Q394, and at the entrance to the pocket, Y516 and 
K520, are conserved across the NR5A family suggesting similar binding modes of natural 
phospholipids.  Despite this similarity, the LBP of the two receptors have been observed to be 
markedly different varying from 1200 A3 in LRH-1 to only 750 A3 in SF-1.  Despite the conserved 
nature of the hydrophilic residues, significant variation in the LBD primary sequence indicates the 
potential for variable ligand binding between the two receptors. 
 
1.6.4.5 Activation Function-2 (AF-2) 
The largely hydrophobic nature of the ligand and the unusual conformational rigidity of the LBD as a 
whole probably explains why an inactive conformation of H12 has never been observed.  However, 
despite H12 rigidity, selectivity for cofactor binding is observed in LRH-1.124 
 
The AF-2 region of the NR5A family, as with all other NRs, contains 2 charge clamp residues on H3 
and H12 that form H-bond interactions with the backbone dipole of cofactor helices.  In LRH-1 and 
SF-1 however, the charge clamp residue present on H3 is an arginine (R361 in LRH-1 and R282 in 
SF-1) as opposed to a lysine in other NRs.  The bulkier guanadinium group of the arginine causes 
the NR5A receptors to have a shortened, shallower binding groove. 
 
a b 
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A molecular dynamics study by Burendahl et al. also highlights a unique structural feature of the 
LRH-1 AF-2.  The dynamics study, carried out on several structures over a 10 ns time frame, 
revealed the formation of a third charge clamp H-bond from an aspartate residue on H5 of the AF-2.  
The D372 residue was identified to form H-bonds to side chain residues of cofactor peptides for 
significant time frames during the dynamics experiments.  The identification of this novel feature of 
the LRH-1 AF-2 suggests a triangular charge clamp unique among NRs (Figure 35). 
 
 
Figure 35 – 2 Views of LRH-1 AF-2 with transparent surface and SHP cofactor bound (Pink) (PDB:1YUC). (a) 
Birdseye view of AF-2 with novel D372 residue to north, H3 R361 (east), unique F354 (south) and H12 E534 
(west). (b) View of AF-2 from the south with charge clamp H-bonds shown with dashed yellow line. 
 
Structural analysis of the LRH-1 AF-2 reveals one final unique feature.  The residue that forms the 
southern wall of the AF-2 groove is a phenylalanine residue (F354) as opposed to an isoleucine or 
leucine residue in other NRs. 
 
1.6.4.6 Coactivation vs Corepression 
As described above, the unique structural features of the LRH-1 AF-2 result in an ability to selectively 
recruit cofactor proteins.  The conformational rigidity of H12 however results in an inability of LRH-1 
to bind to conventional corepressors through a double LXXLL CoRNR-box motif as for many other 
NRs.  Instead, LRH-1 binds to unique corepressor proteins SHP and Dax-1.  These proteins have 
physiological relevance in tissues which also express LRH-1 suggesting evolutionary development of 
this unique AF-2 surface.151 
 
Along with selective recruitment of corepressors, LRH-1 has been identified to bind to a variety of 
coactivator proteins including SRC-1, TIF-2 and PGC1α.124 Of most significance to this research is 
the selective interaction of LRH-1 with tissue-specific coactivator PGC1α.  This coactivator, 
preferentially expressed in adipose tissue, is a critical regulator of aromatase expression and in 
breast carcinoma tissue its selective interaction with LRH-1 has been highlighted as a cause of 
tumour progression.152 
a b 
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The physiological role of LRH-1 in human disease stands it out as important target for the 
development of novel therapies to compliment or replace existing NR modulators.  However, 
publication of efforts to modulate LRH-1 and the NR5A receptors is limited to 2 recent disclosures, 
which are discussed below. 
 
1.6.5 LRH-1 In Drug Discovery 
In 2006 Whitby et al. published the first series of small molecules capable of modulating LRH-1.  The 
lead compound 5a (10), identified using a HTS FRET-based screen, displayed an EC50 of 430 nM 
(Figure 36).5 
 
 
Figure 36 – Structure of identified LRH-1 agonist, 5a.5 
 
A library of 23 analogues were synthesized based around the 1-arylamino-cis-bicyclo[3.3.0]oct-2-
enes core achieving a minimum EC50 of 12 nM in an in vitro FRET assay.  Selectivity against SF-1 
could also be achieved with total loss of activity in SF-1 being observed in some cases. 
 
It wasn’t until 2011 that a co-crystal of 5a (10) with the LRH-1 LBD was published.153 The structure 
confirmed that the agonistic mode of action was indeed elicited through binding at the LBP with 5a 
occupying the rear of the pocket.  The smaller volume of 5a, relative to phospholipids, resulted in 
significant contraction of the LBP at flexible regions around the entrance to the pocket (Figure 37). 
 
 
        Figure 37 – (a) Co-crystal structure of LRH-1 LBD (bright blue) with 5a (pink stick) (PDB:3PLZ); 
phospholipid (green stick) from 1YUC has been overlaid for reference with H12 (dark blue) and H12 (pink). (b) 
Overlay of 1YUC LRH-1 LBD (dark blue) with 5a co-crystal structure (light blue).153 
H
NH
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The contraction of H3, and the β-sheet/H6 regions of the ligand-binding pocket indicate that the LBD 
does contain flexible regions despite the conformational rigidity conferred by H2.  It is also observed 
that the aniline nitrogen does not generate any polar interactions indicating only hydrophobic forces 
dictate small molecule binding. 
 
The co-crystal facilitated rational modification of the 5a structure to improve the agonist potency.  
Synthesis of 24-exo was carried out in which substitution of the aniline nitrogen sought to improve 
the hydrophobic nature of the molecule while installation of a hydroxyl group at the 6 position of the 
bicycle[3.3.0]octene core potentially facilitated hydrogen bonding with the polar H390 and Q394 
residues (Figure 38). 
 
 
Figure 38 – Whitby 2nd generation LRH-1 agonist 24-exo.  
 
This molecule was the most potent of the range of analogues synthesised, displaying an EC50 of 250 
nM (although preferred binding to SF-1 was observed displaying an EC50 of 3 nM). 
 
In 2008, Madoux et al. published the only disclosed molecule capable of antagonising a member of 
the NR5A subfamily.154  The lead SF-1 antagonist, SID7970631, was one of many identified using a 
cell-based HTS of 65,000 compounds.  Synthesis and exploration of analogue potency was explored 
in a publication in the same year (Figure 39).155 
 
 
Figure 39 – HTS Hit antagonist SID7970631 and optimised antagonist analogue 12.155 
 
Optimisation of initial isoquinolinone-based antagonist, SID7970631 (IC50 = 255 nM), was achieved 
generating 12, which displayed an improved IC50 of 200 nM and greater selectivity against LRH-1 (no 
inhibition observed) and other NRs. 
H
HO
11
24-exo
N
O
OO
O
N
H
O
O
O
N
O
OO
O
N
H
O
O
CF3
12
IC50 = 200 nM
SID7970631
IC50 = 255 nM
 39 
Although no co-crystal structures of these antagonists with SF-1 have been disclosed, this was the 
first proof-of-principle example of small molecule mediated antagonism of the NR5A family.  Given 
the gross structural similarity of SF-1 and LRH-1, this study augurs well for the ability to disrupt the 
induced rigid conformation of H12 in the development of a small molecule antagonist. 
 
The particular control of ER regulation and aromatase production in stromal tissue elicited by LRH-1 
highlights it as an extraordinary target for the treatment of breast cancer in post-menopausal women.  
The unique structural features combined with the recent discovery of natural ligands and small 
molecule modulators make the development of antagonists for use as therapeutics a compelling 
challenge. 
 
1.6 Project Aims and Objectives 
The aim of this project is to utilise multiple design approaches to generate molecules capable of 
antagonising the transcriptional activity of orphan NR LRH-1 by action at either its LBP or AF-2 sites 
(Figure 40).  
 
 
Figure 40 – Parallel design approaches for development of LRH-1 antagonists. 
 
Building upon the wealth of knowledge gained around the structure and function of NRs, the plan is 
to develop antagonists that act at either the conventionally targeted LBP or the less well-explored AF-
2 site. 
 
(i) Ligand Binding Pocket (LBP): With one of the described Whitby agonists as a query, Cresset and 
SHop ligand-based VS software’s will be used to access novel small molecule agonists.  These 
structures will then be explored to generate antagonism through the H-12 extension hypothesis 
described above. 
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(ii) Activation Function – 2 (AF-2): Using the coordinates of NR-box peptides, co-crystallised with 
LRH-1, rational design of an α-helix mimetic that represents the required amino acid residues will be 
undertaken.  Secondly, a section of a cofactor peptide will be used as a query in a Cresset VS to 
identify novel small molecule CBIs of the cofactor-LRH-1 PPI. 
 
Run in parallel, these approaches will provide opportunity to identify novel chemical structures 
capable of antagonising LRH-1.  To evaluate their activity, all small molecules will be tested either in 
a dual-reporter cell-based assay or an AlphaScreenTM in vitro assay by our collaborator Simak Ali 
(Department of Oncology, Imperial College Medical School). 
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Chapter 2 – Results and Discussion 
 
2.1  Ligand Binding Pocket 
2.1.1 Approach 
As discussed above the LBP of LRH-1, one of the largest in the NR superfamily, is mainly 
hydrophobic and displays significant flexibility of its 3D structure.  To add to such drug discovery 
challenges, structural data of the known inhibitors bound to LRH-1 was not available at the start of 
this research (disclosed by Whitby et al. in 2011153).  Given this combination of factors, application of 
ligand-based virtual screening approaches using the only known LRH-1 modulators to formulate the 
query was undertaken.   
 
First, however, to validate the cell-based assay used by our collaborators (the lab of Professor Simak 
Ali, Imperial College London, Department of Oncology) and to select the most potent agoinst 
published by Whitby et al. for formulating a query, synthesis of a variety of the 1-amino-cis-
bicyclo[3.3.0]oct-2-ene molecules was carried out. 
 
2.1.2 Evaluation of Whitby Analogues 
The selection of compounds for synthesis followed analysis of the data provided in the initial 
published SAR table (Table 1).  
      LRH-1 SF-1 
Thesis 
# 
Whitby
cmpd 
# 
yield 
(%) R
1 R2 R3 EC50 (µM) ±SD 
REa 
(%) 
EC50 
(µM) ±SD 
REa 
(%) 
10 5a 53 Ph (E)-4-oct-4-enyl Ph 0.43 0.07 100 0.054 0.008 50 
17 5b 61 Me (E)-4-oct-4-enyl Ph 0.09 0.04 15 >10 - - 
- 5c 68 n-C4H9 (E)-4-oct-4-enyl Ph 0.022 0.007 50 0.03 0.001 95 
- 5d 53 c-C6H11 (E)-4-oct-4-enyl Ph 0.012 0.002 50 0.01 0.002 90 
- 5e 19 4-Br-C6H4 (E)-4-oct-4-enyl Ph 0.16 0.01 70 0.17 0.07 35 
- 5f 27 3-MeO-C6H4 (E)-4-oct-4-enyl Ph 0.1 0.01 115 0.14 0.01 45 
- 5g 35 2-naphthyl (E)-4-oct-4-enyl Ph 0.06 0.01 55 0.13 0.05 30 
- 5h 34 Ph (E)-3-hex-3-enyl Ph 1.4 0.2 50 0.8 0.1 80 
18 5i 49 Ph (E)-6-dodec-6-enyl Ph >10 - - 0.014 0.003 30 
- 5j 7 Ph CH(Me)C4H9 Ph 0.07 0.01 45 0.13 0.05 90 
- 5k 42 Ph CH(Me)C8H17 Ph 0.32 0.05 25 0.13 0.04 95 
24 5l 58 Ph Me Ph 2.1 0.7 20 >10 - - 
- 5m 29 Ph n-C6H13 Ph 0.034 0.003 45 0.043 0.008 100 
- 5n 27 Ph c-C6H11 Ph 0.23 0.02 25 0.18 0.07 65 
25 5o 39 Ph n-C12H25 Ph >10 - - >10 - - 
- 5p 34 Ph Ph Ph 0.15 0.02 35 0.12 0.02 55 
- 5q 29 Ph n-C6H13 3-F-C6H4 0.33 0.004 45 0.56 0.02 70 
- 5r 20 Ph n-C6H13 4-Cl-C6H4 1 0.7 15 0.7 0.3 25 
- 5s 13 Ph n-C6H13 2,3-diMe-C6H4 0.03 0.01 30 0.011 0.008 20 
26 5t 30 Ph n-C6H13 4-OCF3-C6H4 >10 - - >10 - - 
27 5u 16 Ph n-C6H13 4-tert-Bu-C6H4 >10 - - >10 - - 
28 5v 28 Ph n-C6H13 4-I-C6H4 >10 - - >10 - - 
29 5w 14 Ph n-C6H13 1-naphthyl 1.2 0.3 45 >10 - - 
 
Table 1 – SAR table from 2006 publication. a RE, relative efficacy normalised to 5a for LRH-1 and 5m for SF-1.5 
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Initially 4 compounds [10 (5a), 17 (5b), 24 (5l) and 29 (5w)] were selected based on their ability to 
agonise LRH-1 and their selectivity against SF-1.  In order to confirm the inactive compounds as 
being inactive in vivo 4 further compounds [25 (5o), 26 (5t), 27 (5u), 28 (5v)] were selected that 
displayed no activity against SF1 or LRH-1.  Finally, as the only small molecule that displayed no 
activity against LRH-1 but an EC50 of 14 nM against SF-1, 18 (5i) was selected for synthesis (Table 
1).  
 
2.1.2.1 Synthesis of Analogues 
Synthesis of the 1-amino-cis-bicyclo[3.3.0]oct-2-ene compounds were achieved by one of two 
synthetic routes described by Whitby et al. in their 2006 publication.5 
 
Firstly, those analogues containing an octenyl substituent in the R2 position (10, 17 and 18) were 
synthesised by a one-pot zirconium-mediated cyclisation (scheme 1).156  
 
 
Scheme 1 – Zirconium-mediated synthesis of 1-amino-cis-bicyclo[3.3.0]oct-2-ene LRH-1 agonists. Reagents 
and conditions: (i) Bromopentene, n-BuLi (1.1 equiv), DMPU (1.1 equiv), TBAI (0.1 equiv), THF, -78 °C to RT, 8h. 
(ii) Cp2ZrBu2, THF, -78 °C to RT Then 20 °C, 2h. (iii) Phenylisonitrile, -35 °C to RT. (iv) (a) 4 Octyne, RT, 1.5h 
then 60 °C, 2h. (b) MeOH/H2O.  (v) Spontaneous or silica chromatography induced 1,3-rearrangement. 
 
To begin the one-pot synthesis, firstly phenylisonitrile and enynes 12 and 13 were required. 
Generation of phenylisonitrile was achieved via POCl3 mediated dehydration of formanilide in the 
presence of DIPA.  Although synthesised in 55% yield, instability to ambient conditions requires this 
isonitrile to be freshly distilled prior to addition.  Synthesis of methyl and phenyl enynes 12 and 13 
was achieved by deprotonation of propyne and phenyl acetylene respectively followed by alkylation 
with 5-iodo pent-1-ene; formed in situ from the corresponding bromide using TBAI.  In the formation 
of enyne 12, full deprotonation of propyne required addition of DMPU to increase the kinetic bascisity 
of the n-BuLi butyl anion.  This allowed generation of enyne 12 in 55% yield while less volatile enyne 
13 was synthesised in 87%. 
 
R1
R1
ZrCp2
R1
H
R1
H
NPh
ZrCp2
R1
H
NHPh
R2
R1
H
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NH
Ph
(i) (ii) (iii)
(iv)
(v)
12 R1 = Me, 55%
13 R1 = Ph, 87%
10 - R1 = Ph; R2 = (E)-4-oct-4-enyl, 49%
17 - R1 =  Me; R2 = (E)-4-oct-4-enyl, 42%
18 - R1 =  Ph; R2 = (E)-6-dodec-6-enyl, 30%
14 15
16
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Synthesis of compounds 10, 17 and 18 was subsequently achieved in a three step, one pot, 
zirconecene cyclisation described by Whitby et al. in 1994.156  Initially, zirconecene Cp2ZrBu2, 
generated in situ from the corresponding chloride (Cp2ZrCl2) using n-BuLi, reacts with the required 
enyne to generate the corresponding zirconacyle 14.  Phenylisonitrile is then added, which 
coordinates to zirconium before inserting to give the reactive zirconecene η2-imine intermediate 15.  
4-Octyne then inserts into the Zr-C bond and protonolysis, by addition of Methanol/H2O, gives the 
resulting bicyclic amine 16.  The unsaturated ring junction generates instability in these bicyclic 
systems resulting in a spontaneous 1,3-amine shift during the reaction or on purification on silica to 
generate the final 1-amino-cis-bicyclo[3.3.0]oct-2-ene compounds.  To avoid partial reversal of this 
1,3 amino shift under acidic conditions, purification requires neutralised silica or basic alumina.  
Using this one-pot procedure, bicyclooctanes 10, 17 and 18 were synthesised with an isolated yields 
of 49, 42 and 30% respectively. 
 
For those analogues containing a saturated R2 substituent, an alternative synthetic strategy utilising a 
Pauson-Khand cyclisation was deployed (Scheme 2).5  
 
 
Scheme 2 – Pauson-Khand mediated synthesis of 1-amino-cis-bicyclo[3.3.0]oct-2-ene LRH-1 agonists.5 
Reagents and conditions: (i) Co2(CO)8, DMSO (6 equiv), THF, 50 °C, 4.5 h. (ii) R2MgBr (5 equiv), CeCl3, THF, 
0 °C, 30 min. (iii) Aniline (10 equiv), camphor sulfonic acid (0.1 equiv), THF, 65 °C, 6h. 
 
As with the one-pot zirconium mediated synthesis described above, this synthetic pathway begins 
with enyne 13. The Pauson-Khand intramolecular cycloaddition was carried out using Co2(CO)8 as a 
catalyst generating bicyclo[3.3.0]octenone 20 in 60% yield.  Insertion of the R2-substituent was 
achieved by Grignard reagent addition to the ketone functionality of enone 20.  Presumably, due to 
protonation of the alcohol and consequent elimination of water, tertiary alcohols 21, 22 and 23 were 
observed to be unstable under acidic conditions.  As a result the alcohols were not purified and the 
crude reaction mixtures were used in the final acid catalysed hydroxyl elimination to achieve the 6 
desired bicyclo[3.3.0]oct-2-ene analogues in between 20 and 68% yields. 
 
These compounds were initially synthesised on a small scale (10’s of mg) to test the synthetic route 
and for evaluation in in vivo assays designed by our collaborators.  Later, these compounds were re-
synthesised on a larger scale (up to 1g) and stored for use as controls in cell-based screens over an 
extended period of time. 
Ph
O
Ph
H
(i)
Ph
H
(ii) R2
OH
13 20
60%
Ph
H
NH
R3
R2
21 R2 = Me 
22 R2 = C12H25
23 R2 = C6H13
(iii)
24 - R2 =  Me; R3 = Ph, 68%
25 - R2 =  n-C12H25; R
3 = Ph, 23%
26 - R2 =  n-C6H13; R
3 = 4-OCF3C6H4, 20%
27 - R2 =  n-C6H13; R
3 = 4-t-Bu-C6H4, 25%
28 - R2 =  n-C6H13; R
3 = 4-i-C6H4, 30%
29 - R2 =  n-C6H13; R
3 = 1-naphthyl, 24%
yield over 2 steps
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2.1.2.2 Cell-Based Testing of Analogues 
Initially, analysis of the selected agonist analogues [10 (5a), 17 (5b), 24 (5l) and 29 (5w)] was carried 
out in a cell-based dual reporter assay developed by our collaborators (Figure 41). 
 
 
 10 17 24 29 
EC50 (µM) 9.2 22.1 21.5 - 
Efficacy 0.203 0.369 0.887 - 
Erel 100% 182% 437% - 
 
Figure 41 – Normalised data from in vivo reporter assay of selected agonist analogues. 
 
As can be observed from the graph, the activity of the analogues in this cell-based assay varied 
greatly from the in vitro data published by Whitby et al. The compounds exhibited greatly reduced 
EC50 values in our cell-based assay, with 5a displaying an EC50 of 9.2 µM in cells compared to 430 
nM reported by Whitby using their in vitro FRET assay.  
 
Moreover, although 17 (5b) and 18 (5l) displayed lower efficacy than 10 (5a), EC50 values of 22 and 
21 µM respectively, they both displayed a greater ability to agonise LRH-1 displaying relative 
efficacies (Erel, relative to 5a) of 182 and 437% respectively.  On the other hand, 5w displayed no 
agonistic activity, with minimal increase above the constitutive LRH-1 activity even at 50 µM. 
 
This significant difference in both the observed EC50 and Erel values probably indicates there is a 
significant difference between cofactor peptide recruitment in vitro and LRH-1 activation in cells.  This 
observation underscores the complexities of in vivo NR coregulation discussed earlier and although 
the data generated from the cell-based dual reporter assay differs from that in vitro, the cellular 
environment can be considered to be much closer to real human models. 
 
10        17      24       29      DMSO 
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Given the efficacy of the 17 (5b) and 24 (5l) analogues, which contain methyl substituents at R1 and 
R2 respectively, synthesis of an analogue 32, which we called 5x (not described by Whitby), 
containing methyl substituents at both the R1 and R2 positions was undertaken (Scheme 3). 
 
 
Scheme 3 – Synthesis of analogue 32 (5x). Reagents and conditions: (i) Co2(CO)8, DMSO (6 equiv), THF, 50 °C, 
4.5 h. (ii) MeMgBr (5 equiv), CeCl3, THF, 0 °C, 30 min. (iii) Aniline (10 equiv), camphor sulfonic acid (0.1 equiv), 
THF, 65 °C, 6h. 
 
Due to the saturated nature of the methyl R2 substituent, synthesis proceeded through the Pauson-
Khand route. Initial cyclisation of methyl enyne 12 proceeded in 48% yield; a 12% reduction 
compared to that of phenyl enyne 20.  Methyl Grignard reagent addition to the ketone proceeded in 
near quantitative yield (by analysis of the 1H NMR spectrum of the crude product).  Final acid 
catalysed dehydration occurred efficiently resulting in a 79% yield over the two steps resulting in a 
38% overall yield from methyl enyne 12. 
 
Analysis in the cell-based assay revealed this analogue displayed very low potency (Figure 42). 
 
 
Figure 42 – Cell-Based analysis of analogue 5x (32). 
 
Compound 32 (5x) displayed an EC50 of 16 µM but an Erel of only 13%.  This indicated that either the 
R2 octenyl chain of 5b or the R1 phenyl substituent of 5l is required for increased efficacy. 
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Finally, testing of the analogues that were reported by Whitby as displaying no agonism for LRH-1 
[18 (5i), 25 (5o), 26 (5t), 27 (5u) and 28 (5v)] was carried out (Figure 43). 
 
 
 10 18 25 26 27 28 
EC50 (µM) 9.2 42 - 12.3 11.1 12.5 
Efficacy 0.203 0.183 0.279 0.171 0.375 0.237 
Erel 100% 91% 137% 84% 182% 117% 
 
Figure 43 – Cell-based analysis of 18, 25, 26, 27 and 28. 
 
As can be immediately recognised, all compounds displayed agonistic activity in the cell-based 
assay.  The activity of 5o at the concentrations tested displayed a flat profile with no EC50 reading 
being detected.  This would suggest that this analogue has an EC50 somewhere below 1 µM although 
testing at these concentrations was not attempted.  Compound 18, the R2 dodecenyl analogue of 10, 
displayed significantly reduced activity indicating the extended alkyl chains at this position were not 
tolerated in the LBP.  The series of R3 analogues 26, 27 and 28 all displayed EC50’s of ~11 µM.  
However, the Erel values varied significantly among the series with the tert-butyl group of 27 
generating the highest efficacy. 
 
The screening of the 10 synthesised analogues discussed above primarily allowed calibration of the 
cell-based assay developed by our collaborators.  Additionally however, it facilitated selection of the 
most potent analogue in this assay for use as a query in ligand-based VS.  For this purpose, 
compound 5l was selected as, although it did not display the lowest EC50, it displayed high efficacy in 
so far as it appeared to generate greater activation of LRH-1 at 10 µM than any other compound 
even at 50 µM. 
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2.1.3 Generation of VS Query 
In order to create a valid entry point to ligand-based VS software, the bioactive 3D structure of 
compound 24 (5l) was required.  Due to the association of GSK with the research published by 
Whitby et al., no crystallographic data had been disclosed at this point in the investigation and 
therefore no definite active conformation of the described agonists was available.  However, 
discussion with Richard Whitby revealed the (3aS,6aR) enantiomer of the bicycle[3.3.0]octene core 
was the most active enantiomer displaying EC50 values 3 times greater than the opposing 
enantiomer. 
 
Using this enantiomer, a global energy minimisation of compound 24 in the gas phase was carried 
out by Dr Caroline Low (computational chemist, Imperial College, Drug Discovery Centre) using 
Cresset fieldpoint software (Figure 44).   
  
Figure 44 – Left - Energy minimisation of compound 24 to give 3D structure, 33. Right – Structure of compound 
5a from now known LRH-1 X-ray co-crystal. 
 
As the binding energy of small molecules to protein receptors is quite low, compared to that of 
enzyme binding, this conformation was assumed to be close to that of the active conformation.157 
Comparing the generated structure, 33, to that of the now known x-ray structure of 10 (5a) it can be 
observed that the gas phase energy minimisation was close to accurate.  The generated structure, 
33, could now be used as the query for generation of alternative series of agonist structures using a 2 
different ligand-based VS programmes. 
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2.1.4  Cresset Approach 
2.1.4.1 Cresset VS 
As described above, Cresset software processes the physical structure and properties of query 
compound to generate 3D MIF descriptors termed ‘field points’.43 These field points represent 
extremes of eletrostatic, steric and hydrophobic fields on a given chemical structure.  The Cresset VS 
then aligns the generated field point structure of a query compound with a database of commercially 
available ‘drug-like’ compounds.  To run the VS, the 3D field-point map of the energy-minimised 5l 
structure, 33, was first generated by Caroline Low (Figure 45). 
     
Figure 45 – Generation of 3D field-point map 35 from energy minimised structure 33 (carried out by Caroline 
Low). 
 
The field point structure 35 was generated using Cresset FieldViewTM software.  The aniline 
hydrogen generates the most significant positive field point while electron density present in π orbitals 
above and below the phenyl rings generates the only negative field points.  The yellow field points 
throughout 35 represent the Van der Waals extremity of structure 33.  Finally, a large number of 
golden field points indicate the dominant nature of hydrophobic forces present in the 24 (5l) structure. 
 
Caroline Low then submitted field-point structure 35 to the Cresset VS which generated rank-ordered 
200 hits (see electronic supporting information) for processing and procurement.  These hits 
contained a diverse range of compound structures (Figure 46). 
  
33 34 35 
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Figure 46 – Top – Overlay of hit field-point map (spherical field points) and structure (green sticks) onto 5l 
energy minimised structure 33 (grey sticks) with generated field-point map (rhomboidal field-points).  Bottom – 
structures of Cresset VS hits 1 (36), 3 (37), 7 (38) and 10 (39). 
 
As illustrated in the overlay images (Figure 46, top) the majority of the top scoring hits displayed a 
large positive field point generated by the presence of an aniline nitrogen; be it primary, substituted or 
cyclic.  Influenced by the uneven 3D nature of 33, a large proportion of the top VS hits also contained 
individual or multiple stereocentres. 
 
I then applied a selection process to the top 200 hits to remove unsuitable compounds and minimise 
the cost of procurement.  The top 200 were initially reduced to 178 by visually removing compounds 
containing phosphine, organometallic, nitro and nitroso groups and also entirely hydrocarbon-based 
structures.  Compounds were then removed by visual analysis of their field point similarity.  Many 
compounds did not produce a positive field point to match that produced by the aniline moiety of 34 
while many also had large field-point maps, representing structures that greatly exceeded the size of 
query 35.  Removing these structures reduced the hit list to 143 compounds.   
 
Finally, these 143 compounds were condensed to a final list for procurement based on the structural 
similarity of hit compounds within the list.  Of the 143 compounds, 60 contained aniline groups, which 
were refined by removing metabolically unstable primary anilines and then removing remaining 
aniline containing compounds with a high structural and field point similarity to a compound with a 
higher score.  This left a list of 110 compounds of which 100 could be procured for in vivo 
assessment. 
 
2.1.4.2 Cell-Based Analysis 
The 100 procured compounds were analysed for their ability to modulate LRH-1 by the lab of Simak 
Ali using the cell-based assay developed in his lab (Full data and qualitative analysis present in 
electronic supporting information). 
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Cell-based analysis identified 3 molecules (VS hits 66, 88 and 98) that displayed significant agonistic 
efficacy.  These hits (AB_WC066, 40, AB_WC088, 41, and AB_WC098, 42) were labelled to identify 
their origin as Andrew Bayly using Whitby compound as a query in a Cresset VS (Figure 47). 
 
  
Figure 47 – Left – Graphs of cell-based efficacy of selected compounds. Right – Structures and compound 
identifiers for selected compounds. 
 
The agonism observed in the cell-based assay was most potent at the higher concentrations of 10 
and 25 µM.   
 
2.1.4.3 Initial Lead Development 
From the 3 hit compounds, synthesis of small library of 3-phenylsulfenyl-indole analogues was 
carried out due to the structural similarity of AB_WC066, 40, and AB_WC088, 41 (Scheme 4).  
 
 
Entry R1 R2 R3 Yield (%) Compound AB_WC ID 
1 - - - 36 41 088 
2 - - 4-Cl 36 43 103 
3 - - 4-OMe - 44 104 
4 - - 3,4-DiCl 20 45 105 
5 - - 4-Me 31 46 106 
6 Me - - 40 40 066 
7 Me - 4-Cl 31 47 107 
8 Me - 3,4-DiCl 24 48 108 
9 Me - 4-OMe 47 49 109 
10 Me - 4-Me 22 50 110 
11 Ph - - 23 51 111 
12 - 2-Br - 9 52 112 
 
Scheme 4 – Synthesis of 3-sulfanylindole analogues. 
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Selection of analogues was based on the series outlined by Topliss in 1977 to investigate substituent 
effects on aryl rings by synthesis of the least possible analogues.158 Synthesis of the analogues was 
achieved by ferric chloride mediated oxidative sulfenylation of indoles at the C-3 position as 
described by Yadav et al.159 Yields varied though synthesis of greater than 20 mg of each analogue 
was achieved for in vivo testing (Figure 47).  
 
 
Figure 47 – Normalised cell-based data for 3-sulfenylindole analogues. Analogues of AB_WC088 on left and 
AB_WC066 on right. 
 
Analysis revealed the compounds displayed a range of levels of agonism. However, this testing also 
revealed significant variation in the activity of the LRH-1 luciferase and control renilla reporters,  
which resulted in significantly skewed normalised data.  This was observed in the gross firefly 
luciferase readout (indicative of LRH-1 activation) relative to renilla luciferase (indicative of 
transfection efficiency) (Figure 48). 
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Figure 48 – Firefly and renilla luciferase activation generated in cell-based dual reporter assay. 
  
A significant drop-off in renilla activity was observed at higher concentration (Figure 48, bottom), 
which resulted in exaggerated normalisation of the raw firefly activity of LRH-1.  This observed drop-
off in renilla activity corresponded to a visible deterioration in cell viability on exposure to high 
concentrations of these compounds.  The analogue specific variation and drop-off of the renilla profile 
had been observed to a small degree in data obtained from the Whitby 5 series analogues tested but 
the severity exhibited in this 3-sulfenylindole class resulted in the decision to drop this compound 
from development. 
 
2.1.4.4 Hit Re-Selection 
Taking into consideration the potential exaggeration of normalised data, careful re-analysis of initial in 
vivo data was undertaken.  4 Further hit compounds were identified (AB_WC057, AB_WC061, 
AB_WC063 and AB_WC079) which displayed no drop-off in renilla profile (see electronic supporting 
information) and also exhibited greater agonism of LRH-1 than 5a (Figure 49). 
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ID (AB_WC) 057 061 063 079 5l 
EC50 (µM) 0.37 1.6 3.5 1.8 21 
Erel (%)a 92 95 91 97 428 
a – relative to 5a 
 Figure 49 – Structures and activity of selected agonists AB_WC057, 061, 063 and 079. 
 
Quantitative evaluation revealed all compounds displayed EC50 values less than 5 µM and relative 
efficacies of greater than 90% of 5a.  Compound AB_WC057 (53) displayed the first sub µM EC50 of 
370 nM and the peak of its efficacy was observed between 10 and 25 µM indicating its maximal 
agonism was in the region.  Also, compound AB_WC063 (55) validated the series of 2-
sulfenylbenzimidazoles as it exhibited moderate potency. 
 
2.1.4.5 Secondary Lead Development 
Given the apparent potency of AB_WC057, this compound was selected for synthesis and lead 
development.  Firstly, synthesis of AB_WC057 was carried out starting from benzenediamine 57 
(Figure 50). 
 
 
Figure 50 – Synthesis of 2-sulfenylbenzamidazole AB_WC057. Reagents and conditions: (i) CS2, 8M KOH, 
ETOH, Δ, 3h. (ii) Benzyl bromide, Na, MeOH, DMF, RT, 8h. 
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Intermediate benzimidazole-2-thiol, 58, was synthesised by refluxing benzenediamine in ethanol in 
the presence of base and carbon disulfide.  Synthesis of the final agonists, AB_WC057 (53), was 
then achieved by alkylation with 2-methylbenzyl bromide in the presence of sodium methoxide in 
32% yield. 
 
2.1.4.5.1 Docking Study: 
At this point in my research I went on placement to carry out docking studies in the laboratory of Jim 
Snyder (Emory University, Atlanta, GA).  Docking studies were carried out using Schrodinger Glide 
docking software available through the MaestroTM interface.  
 
Given the large hydrophobic nature of the LRH-1 LBP and the rigid docking method utilised, docking 
of AB_WC057 (53) was carried out to reveal if any gross modifications could be made to increase 
potency significantly.  Glide docking followed by MM-GBSA scoring of AB_WC057 (53) revealed a 
conserved binding mode predicting the molecule to occupy the top portion of the LBP near to H12 
(Figure 51). 
 
 
Figure 51 – Top pose in MM-GBSA refinement of Glide docked AB_WC057 (53). 
 
In the most conserved pose, the benzimidaole N-H bond projected towards L531 of H12 with the 3-
methyl indole substituent pointing towards the mouth of the LBP and the 2-methyl group of the phenyl 
thiol projecting towards the hydrophilic region of the LBP (Figure 51, left).   
 
As a gross measure of the antagonistic potential of small molecules, docking was carried out on a 
structure of the LBD with the H12 removed.  Molecules that occupy this new vacant entrance to the 
LBP are highlighted as potential antagonists.  Despite the crude nature of this method, docking of a 
number of ER antagonists to ER structures with H12 removed validated this approach.  In silico 
generated N-substituted benzimidazole analogues were not however capable of occupying this 
region.  Instead, substitution at this position generated significant disorder in generated docking 
poses. 
 
Effort was then focused on structural changes to improve the agonistic potency of the ligand.  
Extension of the thiophenol methyl substituent was investigated in effort to generate electrostatic 
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interactions with the hydrophilic residues, H390 and Q394.  A 4-carbon tether to a pendant methyl 
ester group was optimal to act as a H-bond acceptor to the protonated imidazole and primary amide 
moieties of H390 and Q394 respectively (Figure 52). 
 
  
 
Figure 52 – Left – Structure of designed AB_WC057 analogue 59. Right – Top docking pose of 59 in LBP. 
 
This designed analogue 59 was calculated to decrease the ΔGbind of AB_WC057 from -31.329 to -
42.693 kCalmol-1 indicating a vast improvement in binding efficiency (Figure 52, right).  Installation of 
the H-bond accepting side chain was envisaged through Sonogashira coupling of the appropriate 
alkynyl ester with the halide substituted AB_WC057 analogue (Scheme 5). 
 
 
Scheme 5 – Proposed synthesis of unsaturated tethered analogue 62. Reagents and conditions: (i) Na, MeOH, 
DMF, RT, 8h. (ii) (PPh3)2PdCl2 10 mol%, CuI (20 mol%), Et3N, DMF, RT → 50 °C 16h. 
 
Synthesis of the Sonogashira palladium catalysed halide substrates 60 and 61 was achieved in 71 
and 58% yields respectively utilising the S-benzylation conditions previously described.  However, 
attempts to affect the desired Sonogashira cross coupling were unsuccessful with quantitative 
recovery of halide starting material observed in both cases.  2.5 Equivalents of triphenylphosphine 
were used to try and ensure ligand coordination to palladium and to avoid potential poisoning by the 
electron rich sulfur present in compounds 60 and 61, however, no reaction was observed again. 
 
In order to circumvent the observed poisoning, cross-coupling of the required alkyne was undertaken 
on the benzyl halide prior to S-benzylation (Scheme 6). 
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Scheme 6 – Successful synthesis of H-bond tethered analogue 62. Reagents and conditions: (i) (PPh3)2PdCl2 
(10 mol%), CuI (20 mol%), Et3N, RT, 2h. (ii) 32, Na, MeOH, DMF, RT, 8h. 
 
The absence of the electron rich thio-guanidine moiety in compound 63 allowed the Sonogashira 
cross-coupling of 2-iodobenzyl chloride to proceed in 99% isolated yield.  S-Benzylation using benzyl 
chloride 63 resulted in isolation of the desired substituted AB_WC057 analogue AB_WC113 (62) in 
75% yield. 
 
Following synthesis of compound 62, reduction of the alkyne to give the corresponding saturated 
alkane of 59 was required (Scheme 7). 
 
 
Scheme 7 – Attempted hydrogenation of alkyne 62 and hydrogenation of alkyne 63. Reagents and conditions: 
(i) Pd/C (10 mol %), H2, EtOH, RT, 24h 
 
As previously, an attempt to hydrogenate 62 fully using palladium on charcoal under a hydrogen 
atmosphere was unsuccessful. Hydrogenation of benzyl chloride 63 prior to benzylation did result in 
alkyne hydrogentation, however, reduction of the benzyl chloride to a tolyl-containing compound 64 
also occurred in an isolated yield of 76 %.  To avoid this, non-palladium mediated reduction 
conditions were explored (Scheme 8). 
 
 
Scheme 8 – Reduction of alkyne 62 to alkenes 65 and 66. Reagents and conditions: (i) trans selective; (a) 
(EtO)3SiH, Cp*Ru(MeCN)3PF6, CH2Cl2, 0 °C → RT, 30 min (b) CuI, TBAF, THF, RT, 20h. (ii) cis selective; 
Adams catalyst, H2 (1atm), EtOAc, RT, 72h. 
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Use of Trost’s chemo selective reduction by ruthenium catalysed hydro silylation followed by 
protodesilylation successfully generated trans-alkene analogue AB_WC114 (66) in 25% yield.160 The 
low yield was attributed to very slow initial hydro silylation, in spite of documented completion in 30 
min. In any case, 5-10 mg of material was isolated for testing.  Cis-selective reduction was achieved 
by use of Adams catalyst to generate AB_WC115 (66) over 3 days in a yield of 20%.  Reduction of 
the alkyne and alkene to the fully saturated alkane was not attempted. 
 
Due to the variability of the transfection efficiency in the dual reporter assay described above these 
analogues were not tested in the cell-based assay.  Alternatively, all new compounds were screened 
in a AlphaScreenTM in vitro assay developed by Fiona Kyle in the group of Simak Ali (Figure 52). 
 
 
Figure 52 – Cartoon schematics describing (i) the Whitby described FRET assay and (ii) the AlphaScreenTM 
assay developed by Simak Ali. LRH-1 shown by blue circle; coactivator peptide green ‘LXXLL’ oval; yellow 
square inside pink pentagon represents biotin and streptavidin complex and orange circle represents his tag for 
conjugation of assay technology to LRH-1. 
 
The AlphaScreenTM assay (Figure 52 (ii)) functions in a similar way to that of the FRET assay (Figure 
52 (i)) utilised by Whitby for analysis of the ‘5 series’ LRH-1 agonists.  The assays utilise LRH-1 and 
cofactor peptides labelled with components that, depending on proximity, produce light which can be 
detected to quantify the binding interaction of LRH-1 and the cofactor peptide.  An increase in light 
emission correlates to binding of an antagonist due to the increased stability of the AF-2 site and 
subsequent coactivator recruitment.  Conversely, antagonists would decrease peptide recruitment 
therefore supressing emission of light.    
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Selection of the AlphaScreenTM technology for use in this project was based on the commercial 
nature of all components of the assay.  Combined with this, detection of singlet oxygen, created by 
the ‘donor bead’ technology, by the acceptor bead is very sensitive due to a low decay time of singlet 
oxygen. 
 
Using this assay, all previous compounds were re-screened (electronic supporting information).  
Despite the benefits of the assay, it was optimised to detect antagonists and could not effectively 
measure the agonist activity these molecules displayed in the cell-based dual reporter assay.  For 
this reason, testing of AB_WC112, 114 and 115 revealed no agonist behaviour (Figure 53). 
 
 
Figure 53 – AlphaScreen in vitro activity of AB_WC057 analogues at 10 µM. 
 
2.1.4.6 Future Work 
Melanie Mueller, in the Spivey group is currently optimising the assay for detection of agonists 
allowing for successful progression of the identified agonist series in the future.  Synthesis of 
AB_WC057 and its analogues was also handed over to Melanie for future investigation. 
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2.1.5 SHop Approach 
2.1.5.1 SHop VS 
To complement the Cresset VS described above a VS using geometry-based SHop software was 
investigated.161 Two consecutive Masters project students, Luca Laraia162 and Fleur Ferguson172, 
under my supervision in the Spivey group, carried out the initial SHop VS and hit molecule synthesis.  
To generate a query structure for the VS, anchor points on the energy-minimised structure of 5l (33) 
had to be defined (Figure 54). 
 
  
Figure 54 – Selected anchor points from Whitby’s 5l structure 33 to generate SHop query 67 (selected anchor 
points highlighted in red).  
 
In order to isolate the bicyclo[3.3.0]octene central structure as the scaffold for variation in the VS the 
three Cα atoms of the three exo cyclic substituents were selected.  The query structure 67 was 
passed through two databases created for use with SHop software.  Firstly a database of all 
compounds published in the Journal of Combinatorial Chemistry between 2000 and 2005 was 
screened.163-168 Secondly, a database containing a collection of 250 monocyclic heterocycles was 
also screened.  The hits, 68-76, from these databases were combined and representative scaffolds 
selected based on perceived synthetic tractability and expected metabolic stability (Figure 55). 
 
 
Figure 55 – Top 9 hits from SHop VS. 
 
Of the 9 hits, 68-76, the top 3 were pyran derivatives (68-70).  Of these hits, tetrahydropyran 70 was 
selected for synthesis.   
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2.1.5.2 VS Hit Synthesis 
Luca Laraia,162 investigated the synthesis of hit THP 70 through a 4-step synthetic sequence based 
on a Prins cyclisation as the key step (Scheme 9). 
 
 
Scheme 9 – Planned synthesis of SHop VS hit 70. Reagents and conditions: (i) LiAlH4, Et2O, 0 °C → RT, 1h. 
(ii) SnBr4, acetaldehyde, CH2Cl2, -78 °C, 5h. (iii) NaI, acetone. (iv) PhNH2, Δ. 
 
Synthesis began by reduction of styrenyl acid 77 to generate homoallylic alcohol 78 in 90% yield.  
Stereoselective Prins cyclisation using homoallylic alcohol 78 in the presence of tin(IV) bromide and 
formaldehyde was envisaged to generate 4-bromo THP 79 before Finklestein inversion to 4-iodo 
THP 80 and final displacement with aniline to generate tri-substituted THP 70.  However, cyclisation 
was not observed to proceed through the desired 6-membered transition state required to generate 
bromo-THP 70 but instead occurred through a 5-membered transition state generating THF 81 
(Scheme 10). 
 
 
Scheme 10 – LHS – desired 6-membered transition state TSA-trans. RHS – Observed 5-membered transition 
states TSB-trans to generate THF 56. Reagents and conditions: (i) Acetaldehyde, SnBr4, TMSBr, CH2Cl2, -78 °C. 
 
THF 81 was isolated in 55% yield with a diastereomeric ratio of 2:1 at the bromine stereocentre.  
Preference for TSB-trans was predicted to be due to the increased stability of the C1’ benzyllic cation 
relative to the non-benzyllic cation in TSA-trans.  Given the novel nature of this cyclisation, it was 
decided to examine the scope of this process.169 
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2.1.5.3 Oxonia-Prins Synthesis of THFs 
Luca utilised the described conditions to determine the stereoselectivity in 7 further THF analogues 
by variation of the aldehyde component of the cyclisation (Table 2).162 
 
 
Product R Yield (%) dr (a:b:c/d)a 
81 Me 55 67:33:0 
82 iPr 47 52:37:11 
83 Ph 47 77:12:11 
84 o-BrC6H4- 71 72:28:0 
85 o-NO2C6H4- 68 100:0:0 
86 o-OMeC6H4- 23 53:37:10 
87 p-BrC6H4- 48 65:19:16 
88 2-Nap- 36 52:30:18 
 
Table 2 – Luca’s exploration of the novel Prins-based THF ring formation. a – Ratios of minor C1’ 2,3-trans 
isomers c and d could not be determined so were combined. Reagents and conditions: SnBr4, TMSBr, 
CH2Cl2, -78 °C, 2-5h. 
 
Moderate yields of 23-71% were achieved for the range of analogues synthesised, with ratios of 
products assigned from the ratios of 1H-NMR integrals in isolated mixtures of each analogue.  In 
some cases 3 stereo-isomers were observed and assignment of these was based on analysis of 1’-H 
and 2-H J-couplings and the structure of 85 determined by single crystal X-ray crystallography 
(Figure 56). 
 
 
Figure 56 – Molecular structure of 85 as determined by a single crystal X-ray experiment. 
 
This structure suggested that the major product obtained displayed a trans relationship between the 
C2-C3 substituents. However, Luca also observed that use of 2-hydroxybenzaldehyde generated the 
2,3-cis-THF ring system of fungicidal polyphenol, cordigol (90) (Scheme 11). 
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Scheme 11 – Intramolecular trapping of intermediate cation to generate 89. Structure of natural product 
coridigol, 90, with ring system of 89 highlighted in red. Reagents and conditions: (i) SnCl4, CH2Cl2, -78 °C, 2h. 
 
At this point Luca finished his project and I carried out the remaining work. In order to confirm that the 
major stereoisomers observed in the pure mixtures of 81-88 were indeed those of 2,3-trans-1’ 
bromine THPs, selective de-bromination of the C1’ bromine was explored.  Firstly, In order to carry 
out analysis studies and to generate NMR spectra of a suitable standard for publication, re-synthesis 
of the majority of THF analogues was undertaken (Table 3). 
 
 
Entry R Yield (%) dr (a:b:c:d)a Product 
1 Me 55 60:40:0:0 81 
2 iPr 92b 80:12:8:0 82 
3 Ph 60b 11:0:77:12 83 
4 o-BrC6H4 71c 72:0:28:0 84 
5 o-NO2C6H4 83b 100:0:0:0 85 
6 o-OMeC6H4 58b 0:0:87:13 86 
7 p-BrC6H4 55b 65:19:16 87 
8 2-Nap 48b 12:0:68:20 88 
 
a – a-d labelled as in table 2 (above). b – My improved yields. c – Comprising 59a, 51%, 59c, 20%, separable. 
Table 3 – Resynthesis of bromo-THPs 81-88. Reagents and conditions: (i) SnBr4, TMSBr,CH2Cl2, -78 °C, 2-5h. 
 
Apart from bromo-THPs 81 (entry 1) and 84 (entry 4) re-synthesis of all bromo-THFs was achieved 
with an improved yield.  An improved diastereomeric ratio was also observed for all of the reaction 
products. 
 
Analysis of the NOESY NMR spectra of these analogues was undertaken to try and elucidate the 
cis/trans relation of the 2,3-substituents.  Initial analysis of the sole 2,3-cis isomer of 85, as confirmed 
by X-ray crystallography, displayed no nOe between the two C1’ and C2 benzyllic protons. The two 
separable isomers of 84 displayed distinct NOESY patterns: compound 84a displayed no C1’-C2 
nOe but compound 84c displayed a clear nOe for its pair of protons (Figure 57). 
 
O
HO
O
H
H O
H
O H
H O
H
HO
OH
HO
O
HO
HO
OH
Cordigol
90
78 89
88%
Ph
OH
(i)
(i)
81-88a-d
O R
Br
H
Ph
OH
RCHO
 63 
 
Figure 57 – NOESY expansions. Left top – 85a expansion. Right top – 84a expansion. Bottom – 84c expansion. 
   
This evidence suggested that 84a was C2,C3-cis by analogy to 85a and that the proximity of the C2 
and C1’ protons in C2,C3-trans systems was sufficient to generate a nOe, as observed in 84c.  This 
evidence was contrary to the 3J2-3 analysis used to assign isomers by Luca.  Debromination was 
sought to observe if the isomeric peaks would coalesce in the absence of bromine, indicating they 
are not a result of the C2,C3 geometry but due to the C1’ stereocentres.  
 
With material in hand selective debromination was attempted using Indium hydride based methods 
described by Baba et al. (Scheme 12).170,171 
 
 
Scheme 12 – Attempted de-bromination of THF 84. Reagents and conditions: (i) InCl3, Bu3SnH, THF, RT, 2h. 
(ii) InCl3, NaBH4, MeCN, RT, 16h. 
 
Both procedures utilised indium(III) chloride in combination with a hydride source to generate indium 
hydride species capable of radical de-bromination of alkyl bromides.  Very poor reactivity led to the 
use of an alternative reduction system employing NiCl4/NaBH4 as described by Khurana et al. (Table 
4).172 
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R S.M.a Yield (%) dr (a:b) Product 
Me 81a and b 18 n/ac 92 
iPr 82a,b and c 47 88:12 93 
Ph 83a,b and c 57 16:84 94a and b 
o-BrC6H4- 84a 84c 
10b 
13b n/a
c 94a 94b 
p-BrC6H4- 87a,b and c 0 - - 
 
a – Reactions run using mixture of starting material unless otherwise stated.  b – Yield of di-debrominated product c – Only one 
2,3-isomer observed.  
Table 4 – Debromination of THPs to aid stereochemical assignment. Reagents and conditions – (i) NiCl2, NaBH4, 
MeOH, RT, 15 min. 
 
De-bromination was achieved for the majority of the analogues, although yields were extremely 
variable.  Di-debromination of both alkyl and aryl bromides was observed in the case of ortho-bromo 
analogue 84, of which the two isomers isolated corresponded to the mixture of products isolated from 
mono-debrominated compound 83.  The retention of shifted isomeric signals in both of these 
reactions indicated the isomers were related to the C2,C3 bond geometry and not the C1’ bromine. 
 
Analysis of the C1’,C3 proton NOESY spectra of di-debrominated compounds 84a and 84c and 
mono-debrominated compound 83 revealed retention of the nOe observed in their parent THF 
analogues.  This indicated that analysis of NOESY spectra was a reliable method for assigning the 
C2,C3 bond geometry (Figure 58). 
 
 
Figure 58 – Diagnostic nOe correlations for assigning C2,C3 bond stereochemistry. 
 
This method analysis was used to assign the cis/trans configuration of all the synthesised THF 
analogues.  The assignments revealed that the major product was not always the cis-isomer, as 
previously thought, but that the major isomer was substrate dependent.  No trend could be identified 
for the cis/trans selectivity suggesting that the respective transition states for ring closure, TSB-cis and 
TSB-trans, are close in energy (Figure 59). 
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Figure 59 – transition states for formation of 2,3-cis and 2,3-trans THFs. 
 
Despite the lack of trend in the selectivity of the novel oxonia-Prins reaction this work constituted the 
first examples of this cyclisation where the γ,δ-unsaturated alkene is that of a styrene. 
 
2.1.5.4 Alternative THP Structure 
Following the observation that THF formation is preferred over THP formation for the type of Prins 
reaction originally envisaged, it was considered that no such problem would be encountered in the 
synthesis of THP analogue 95 (Figure 60). 
 
 
Figure 60 – New THP analogue 95 with corresponding Whitby analogue 5y (96). 
 
This analogue features inverted C2 and C3 substituents, which corresponds to use of a γ,δ-
unsaturated alkene with a methyl substituent that was expected to favour THP formation as opposed 
to THF formation.  The analogous bicycle[3.3.0]octene, as described by Whitby, is that of 96 which 
was not described in the original publication.5 
 
In order to evaluate its activity, synthesis of analogue 96, which we called 5y, was undertaken prior to 
synthesis of THP analogue 95 (Scheme 13). 
 
 
Scheme 13 – Synthesis of 5y from Pauson-Khand product 30. Reagents and conditions: (i) PhMgBr (1.1 equiv), 
CeCl3 (1.1 equiv), THF, -78 °C, 30 min. (ii) Aniline (5 equiv), CSA (0.1 equiv), THF, Δ, 5h. 
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The synthesis was started by addition of phenyl Grignard reagent to Pauson-Khand cyclisation 
product 30 to generate allylic alcohol 97.  Elimination of water by refluxing with camphor sulfonic acid 
in the presence of aniline generated 5y (96) in 36% yield over the 2 steps. 
 
As had been hoped, evaluation of compound 5y in the cell-based assay revealed comparable 
agonism to that of 5l (Figure 61). 
 
 5l 5y 
EC50 21.5 23.2 
RE 100% 97% 
 
Figure 61 – Cell-based activity of 5l and 5y. 
 
Analysis revealed 5y displayed comparable activity to that of 5l with an EC50 value of 23.2 µM 
compared to 21.5 µM.   
 
Work to synthesise the first inverted THP analogue was carried out by Luca Laraia and Fleur 
Ferguson (Scheme 14).162,172  
 
Scheme 14 – Synthesis of THP 77 by Luca and Fleur. Reagents and conditions: (i) LiAlH4, Et2O, 0 °C → RT, 1h. 
(ii) SnBr4, TMSBr, benzaldehyde, CH2Cl2, -78 °C, 5h. (iii) NaI, acetone, 85 °C, 48h. (iv) p-toluidine, Et3N, tBuOH, 
Δ, 3 days. 
 
Reduction of carboxylic acid 98 gave homoallylic alcohol 99 in 61% yield.  This homoallylic alcohol 
was utilised in Prins cyclisation and successfully generated 4-bromo THP, 100, in 85% yield.  
Finklestein inversion to 4-iodo THP 101 was achieved in 38% yield although significant amounts of 
elimination product 102 (24% yield) were formed.  Finally, displacement of the iodide with p-toluidine 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
5l 5y DMSO 
N
or
m
al
is
ed
 L
uc
ife
ra
se
 
ac
tiv
ity
 
1mM 
10mM 
20mM 
50mM 
DMSO 
O
Br
OH
Ph
Me
O
I
Ph
Me
O
HN
Ph
Me
Me
OH
Me
O
99
61%
100
85%
98
101
38%
103
43%
O Ph
Me
102
24%
(i) (ii) (ii) (iv)
 67 
gave 5y analogue 103 in 43% yield (p-Toluidine was used rather than aniline in order to monitor 
introduction of the group using 1H NMR due to the diagnostic 4-methyl substituent). 
 
THP 78 was analysed for agonism of LRH-1 in the cell-based assay (Figure 62). 
 
Figure 62 – Cell-based analysis of THP 103. 
 
The THP core of analogue 103, although not a direct analogue of 5l, displayed slightly improved 
potency to the bicycle[3.3.0]octene core of 5l.  This indicated that the SHop VS was very capable of 
identifying novel scaffolds with retention of activity. 
 
Following synthesis of THP 103 both Luca and Fleur completed their projects and I undertook all 
further synthetic work on this lead. 
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2.1.5.5 THP Analogue Synthesis  
For direct comparison to the 5 series analogues described by Whitby et al., a library of THP 
analogues varied at C2, C3 and the N-aryl C4 position was desired.  To ensure isolation of the 
maximum amount of material for testing, optimisation of the conditions identified by Luca and Fleur 
was undertaken.161,172 
 
2.1.5.5.1 Synthesis Optimisation: 
The Finklestein inversion and final nucleophilic displacement with aniline required optimisation to 
avoid excessive formation of the elimination product.  Firstly, optimisation of the Finklestein reaction 
to generate the iodo-THP 101 was carried out (Table 5). 
 
 
Entry Time (h) % Ratio of 100:101:102:104 Isolated Yield of 101 (%) 
1 42 0: 6 : 72 : 22 n/a 
2 16 0 : 45 : 55 : 0 n/a 
3 1 58 : 42 : trace : 0 n/a 
4 2 30 : 61 : 9 : 0 n/a 
5 3 8 : 77 : 15 : 0 n/a 
6 5 0 : 75 : 25 51 
7 6 trace : 99 : trace : 0 71 
 
Table 5 – Optimisation of Finklestein reaction. Reagents and conditions: (i) NaI (20 eq.), acetone, 85 °C. 
 
Using the exact reaction conditions described by Fleur and Luca (entry 1), a mixture of the desired 
product, 101, together with a mixture of the two possible elimination products 102 and 104 was 
generated. The 3 products were isolated in yields of 3, 37 and 10 % respectively indicating 
elimination of HX was occurring significantly during the reaction period.  To observe if this was due to 
the long duration of reaction, the reaction was repeated over a truncated period of 16 h (entry 2).  
Analysis of the crude reaction mixture revealed a 44:55 mix of desired product 101 to elimination 
product 102.  To try and understand how the elimination product was formed, the reaction was 
carried out in d6-acetone and 1H NMR spectra taken at regular intervals (entries 3-6).  Over the first 
hour, 42% conversion of 100 to 101 was observed with trace formation of the elimination product 
(entry 3). Over the following 2 h, slow formation of elimination product 102 was observed although 
formation of substitution product 101 was faster.  After 5 h complete consumption of starting material 
was observed (entry 6) and formation of products 101:102 in a ratio of 3:1 (1H NMR).  The desired 
iodo-THP 101 was isolated in 51% yield. 
 
The reaction was then carried out on a 2 g scale using this optimised protocol (entry 7).  Within 6 h 
the reaction was complete, without formation of the elimination product (possibly due to leaking of 
pressure from a only partially sealed reaction vessel), and isolation of iodo-THP 101 was achieved in 
71% yield. 
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Following optimisation of the Finklestein reaction, optimisation of the iodine displacement reaction 
was carried out (Table 5). 
 
 
Entry Et3N Eq. Time (h) Concentration (M) Conv (%) Isolated Yield (%) 
1 1.1 72 0.033 15 10 
2a 1.1 1 “ - n/a 
3a 10 1 “ - n/a 
4b “ 18 “ 17 n/a 
5 2 24 3.5 100 75c 
 
a – Reaction carried out in microwave at 140 °C; b – 1 equivalent of AgCO3 added; c – Isolatation of 77 from column due to 
elimination catalysed by acidic silica. 
Table 5 – Optimisation of aniline displacement reaction. Reagents and conditions: (i) p-toluidine, t-BuOH, Et3N, 
Δ. 
 
Despite Fleur reporting an isolated yield of 42 %, repetition of the exact reaction conditions only 
achieved a yield of 10 % (entry 1).  Analysis of the 1H NMR spectrum of the crude reaction mixture 
revealed an extremely low conversion of only 12% from starting iodo-THP 101.  
 
In an attempt to increase the reaction rate, the use of elevated temperature in the microwave was 
investigated (entries 2-4).  An increased temperate of 140 ºC was utilised although after 1h no 
formation of product was observed (entry 2).  Also, increasing the amount of base to 10 equivalents 
(following an experimental error reported in Fleur’s lab book) did not affect the outcome of the 
reaction (entry 3). The addition of silver carbonate was tested due to its known acceleration of 
halogen displacement reactions, such as the Koenigs-Knorr reaction (entry 4).173 Although increased 
conversion was observed, 17% over 18 h, it was unclear if this was due to the presence of silver 
carbonate or simply an increased reaction time.  Finally, increasing the reaction concentration 100 
fold from 0.033M to 3.5M resulted in complete conversion to desired THP analogue THP_001 103 in 
an isolated yield of 75% (entry 5). 
 
With optimised reaction conditions in hand, synthesis of a library of THP analogues was undertaken. 
 
2.1.5.5.2 C1 and C2 THP Analogues: 
Synthesis of an array of 6 THP analogues 104-109 including 5y (95) was carried out using the 
optimised reaction conditions (Table 7). 
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Entry  R1 R2 Prinns Yield 
(%) 
Inversion Yield 
(%)a 
Displacement Yield 
(%) 
Product THP ID 
1 Me - 82 69 48 95 THP_002 
2 Me 4-
OMe 
68 56 78 104 THP_014 
3 Me 4-Me 83 51 32 105 THP_015 
4 Me 4-Cl 90 59 44 106 THP_016 
5 Me 3,4-
Cl2 
94 43 51 107 THP_017 
6 Pr - 58 72 35 108 THP_018 
7 Pent - 50 68 46 109 THP_019 
 
a – isolation of mixture of elimination product and product due to co-elution by chromatography. 
Table 7 – Synthesis of C2 and C3 analogues. Reagents and conditions: (i) SnBr4, CH2Cl2, -78°C, 5h. (ii) NaI, 
acetone, 85°C, 6h. (iii) Aniline, Et3N, Δ, 24h. 
 
The initial Prins cyclisation reactions proceeded with moderate to high yield.  Benzadehyde 
analogues containing electron-withdrawing substituents generated higher yields than those without.  
Finklestien inversion proceeded in moderate yield although separation of the elimination product 
(described above) from the iodo-THP product was not possible without significant loss of product. 
The mixture of products was then taken through to the aniline displacement reaction, which 
proceeded with 100 % conversion (as determined by analysis of the 1H NMR spectra of the crude 
material) although isolation resulted in some loss of product due to the slightly acidic nature of silica. 
 
Definitive stereochemical assignment of the bromo-, iodo- and also the N-phenyl THP compounds 
was possible following single crystal X-ray structure determination on all three (Figure 63). 
 
       
 
Figure 63 – Molecular structures of bromo-, iodo- and arylamino-THPs obtained from single crystal X-ray 
structure determination. 
 
The crystal structures confirm the trans relationship of C2, C3 and C4 substituents formed during the 
Prins cyclisation.  However, the Finklestein exchange of bromine for iodine occurs with retention of 
stereochemistry.  This contrasts to the SN2 mechanism observed in many other reaction systems and 
is possibly due to the bulky C2 and C3 substituents creating a chiral environment for iodine attack 
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during a SN1 type mechanism.  Finally, displacement of iodine with various anilines also occurs with 
retention of stereochemistry indicating a congruent reaction mechanism. 
 
In view of these unusual stereochemical results, Finklestein exchange of bromine for the more 
reactive iodine in this reaction sequence would appear to be unnecessary from a stereochemistry 
perspective.  Unfortunately, however, direct nucleophilic displacement of the bromo-THP with 
anilines yielded no displacement product. 
 
2.1.5.5.3 C4 Analogues: 
Due to the poor reactivity of 4-bromo THPs synthesis of a library of substituted 4-amino THP 
analogues was therefore carried out in parallel utilising iodo-THP 76 (Table 8). 
 
 
Entry R Yield (%) Product THP ID 
1 3-F 4 110 THP_003 
2 4-F 17 111 THP_004 
3 3,4-F2 9 112 THP_005 
4 2,4-Cl2 - - - 
5 2-Br - - - 
6 4-I 8 113 THP_006 
7 2,3-Me2 26 114 THP_007 
8 4-tBu 50 115 THP_008 
9 4-CF3 - - THP_009 
10 4-CH2COCH3 28 116 THP_010 
11 4-NO2 - - - 
12 4-NN-Me2 73 117 THP_011 
13 3,4-Cl2 12a 118 THP_012 
 
a – Reaction carried out in microwave at 160 °C for 2h. 
Table 8 – Synthesis of C4 N-arylamino THP analogues. Reagents and conditions: (i) t-BuOH, Et3N, Δ, 24h. 
 
The success of these substitution reactons was controlled by the electronics of the aniline 
substituents.  Neutral and electron rich anilines were isolated in low to moderate yields whereas 
electron deficient anilines either did not react or were isolated in very low yield (<10%).  In order to 
overcome this limitation, 3,4-dichloroaniline was heated at 160 °C in the microwave with the iodo-
THP 101 (entry 13). Purification of the crude reaction mixture yielded 12% of the desired product 118 
indicating that harsher conditions can achieve iodine displacement for these poorly nucleophilic 
anilines albeit still in poor yield. 
 
To investigate the requirement for an N-aryl substituent at the C4 position, synthesis of an array of N-
alkyl substituted THP’s was desired.  To investigate initial reactivity, iodo-THP 101 was reacted with 
hexylamine (Scheme 15). 
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Scheme 15 - Attempted synthesis of N-hexyl THP 119. Reagents and conditions: (i) c-hexylamine, Et3N, tBuOH, 
Δ, 24h. 
 
After 24h however, no production of N-hexyl THP 119 was observed; elimination product 102 was 
isolated in quantitative yield.  The reaction was repeated at a range of temperatures to investigate if 
at lower temperature substitution would occur in preference to elimination.  At temperatures below 
60ºC however no reaction was observed and once heated at 65ºC elimination occurred exclusively. 
 
In order to circumvent the problem of elimination, installation of an N-alkyl substituent was 
investigated by azidation, reduction to the primary amine and reductive amination in the presence of 
alkyl aldehydes (Scheme 16). 
 
 
Scheme 16 – Revised synthesis of N-hexyl THP 94. Reagents and conditions: (i) NaN3, DMF, 50 °C, 4h. (ii) 
PPh3, H2O, THF, RT, 2h. (iii) benzaldehyde, Na(CN)BH3, MeOH, RT, 16h. 
 
Firstly a small amount of I-THP 101 was converted to aza-THP 120 by displacement with sodium 
azide in 40% yield.  Poor mass recovery after silica column chromatography was thought to have 
caused the low yield as analysis of the 1H NMR spectra of the crude material suggested near 
quantitative production of the azide 120.  Reduction to the amine was carried out using Staudinger 
conditions to give the required amino THP 121 in 45% yield.  The remaining material was carried 
through the 2 steps without purification of aza-THP 120, achieving synthesis of 121 in 63% yield over 
the 2-steps. 
 
Reductive amination utilising sodium cyanoborohydride was successfully applied to generate 4 N-
alkyl analogues 94-99 in yields of 17-37%.  These low isolated yields were attributed to increased 
O
HN
Hex
O
I
O
101
102
(i)
119
O
I
101
O
N3
120
40%
O
NH2
121
45%
63% (over 2 steps)
O
HN
R
(i) (ii) (iii)
R = c-Hex (94, THP_023) 17%
    = Et (97, THP_024) 37%
    = i-Pr (98, THP_025) 26%
    = Ph (99, THP_026) 25%
 73 
acidic instability of the 4-alkylamino group resulting in elimination of RNH2 during silica column 
chromatography. 
 
2.1.5.5.4 C4 Thio Analogues: 
Attempted one-pot synthesis of 4-amino THP analogues via direct trapping of the Prins cation by an 
aniline (cf. bromide) results simply in formation of the immine of the initially employed aldehyde.174  
However, I found that the reduced nucleophilicity of thiophenols enabled one-pot synthesis of 4-thio 
THP analogues via the utilised oxonia-Prins cyclisation.  This approach, described by Yadav et al., 
was utilised in the synthesis of two such 4-arylthio THP analogues 125 and 126 (Scheme 17).175 
 
 
Scheme 17 – One-pot synthesis of 4-thioaryl THP analogues 125 and 126. Reagents and conditions: (i) TFA (10 
equiv.), CH2Cl2, RT, 2h. 
 
Both analogues were synthesised using trifluoroacetic acid mediated Prins cyclisation.  5y analogous 
thio-THP 125 and the 4-chloro THP 126 were isolated in 20 and 38% yields respectively. 
 
Having synthesised a number of analogues exploring the C2, C3 and C4 positions of the THP core, 
the development of chemistry to vary C5 and C6 was explored next. 
 
2.1.5.5.5 C5 and C6 Analogues: 
Prins-cyclisation enabled facile access to C2, C3 and C4 analogues through variation of the 
benzaldehyde, aniline and the terminal substituent of the homoallylic alcohol.  Access to C5 and C6 
analogues could be envisaged through the use of a 2,3-disubstituted homoallylic alcohol (Figure 64).  
 
 
Figure 64 – Retrosynthetic analysis for penta substituted THP analogues. 
 
Such 2,3-disubstituted homoallylic alcohols would also allow access and generate the key 
stereochemistry of the previously described fungicidal polyphenol, Cordigol (Figure 65).  
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Figure 65 – Potential disconnection of cordigol to 2,3-disubstituted homoallylic alcohol. 
 
Synthesis of such substrates was initiated with synthesis of 3-alkyl homoallylic alcohols 129 and 130 
(Scheme 17). 
 
 
Scheme 17 –Synthesis of 3-alkyl homoallylic alcohols 129 and 130. Reagents and conditions: (i) LDA, THF, -78 
ºC → RT, 30 min. (ii) LiAlH4, THF, 0 ºC, 1h. 
 
Installation of the desired C3 substituent was achieved by quenching of the lithium enolate of penten-
3-oic acid with the required alkyl halide.  Reduction of the α-alkyl carboxylic acids, 127 and 128, to 
the desired β-alkyl homoallylic alcohols 129 and 130 was achieved in 69 and 84% yields respectively. 
 
For potential application to the synthesis of cordigol, and also to allow stereoselective synthesis of 
α,β-disubstituted homoallylic alcohols, chiral auxiliary oxazolidinone 131 was installed as an acyl 
substituent in penten-3-oic acid (Scheme 18). 
 
 
Scheme 18 – Formation of β,δ-unsaturated acyl oxazolidinone 132. Reagents and conditions: (i) Acid, pivCl, 
Et3N, CH2Cl2, -78 °C → RT, 2h. (ii) Oxazolidinone, n-BuLi, CH2Cl2, -78 °C, 45 min. 
 
Formation of compound 132 was achieved in 88% yield by reaction of the pivaloyl chloride derived 
mixed anydride with the lithium salt of chiral oxazolidinone 131.  Subsequent generation of the 
required α,β-disubstituted homoallylic alcohols was envisaged through aldol condensation with the 
desired aldehydes (Scheme 19)  
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Scheme 19 – Aldol condensation to generate α,β-disubstituted homoallylic alcohols 133-135. Reagents and 
conditions: (i) Bu2BOTf (1 eq.), DIPEA (1.1 eq.), CH2Cl2, -78 °C, 2h. (ii) Benzaldehyde (1.15 eq.), -78 → 0 °C, 2h. 
 
Synthesis of the desired syn-disubstituted homoallylic alcohol product was achieved through boron 
enolate aldol condensation of acyl oxazolidinone 132 with a range of aldehydes.  Complete 
diastereoselectivity was induced by the isopropyl oxazolidinone auxiliary and the resultant products 
133-135 were isolated in 58-94% yields. 
 
Having generated these 1,2-disubstituted homoallylic alcohols they were submitted to the previously 
utilised Prins cyclisation conditions (Table 8). 
 
 
Entry R1 R2 Yield (%) Ratio of product Product 
1 Me - 85 1:0.15 136 
2 Bn - 74 1:0.10 137 
3 (S)-iPr-oxazolidinone  Ph 36 n/a 138 
4 “ nHex 91 n/a 139 
5 “ nEt 56 n/a 140 
 
Table 8 – Prins cyclisation of disubstituted homoallylic alcohols. Reagents and conditions: (i) SnBr4, TMSBr, 
CH2Cl2, -78 °C, 5h. 
 
The previously identified conditions allowed successful synthesis of all 5 bromo-THP products 136-
140 (entries 1-5) in yields of 36-91%.  Formation of two cyclisation products was observed in the first 
two cases in which formation of the substituted homoallylic alcohols was not stereo-controlled.  In 
these cases, 9% and 13% of the minor products was observed through the alternative transition state 
respectively (Figure 66). 
 
 
Figure 66 – Prins cyclisation transition states. 
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Following successful synthesis of the bromo-THP analogues, the compounds were taken through a 
Finklestein iodination step followed by iodine displacement to give the desired aniline substituted 
THP’s 22-26 (Table 9). 
 
 
Entry R1 R2 Yield (% 2 steps) Product THP ID 
1 Me - 10 141 THP_026 
2 Bn - 5 142 THP_027 
3 (S)-iPr-oxazolidinone  Ph 17 143 THP_028 
4 “ nHex 12 144 THP_029 
5 “ nEt 43 145 THP_030 
 
Table 9 – Synthesis of penta-substituted THP analogues 116-120. Reagents and conditions: (i) NaI (20 eq.), 
acetone, 70 °C, 6h. (ii) Aniline (2 eq.), Et3N (1.5 eq.), tBuOH [5M], 80 °C, 16h. 
 
Due to risk of forming elimination products the two-step procedure was carried out without purification 
of the intermediate iodo-THPs.  Isolation of the final pentasubstituted THPs 141-145 was achieved in 
yields from 5-43% (over 2 steps).   
 
2.1.5.6 Analysis of THP Analogues 
In the period of time between the synthesis of the first THP analogue 103, a switch from the original 
cell-based assay to the previously described in vitro AlphaScreenTM assay was made.  Consequently, 
analysis of synthesised compounds was carried out using this method. 
 
First, analysis of the original THP analogue 103 was repeated using the AlphaScreenTM assay 
(Figure 67). 
 
Figure 67 – AlphaScreenTM analysis of THP 103 at 10 µM. 
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This data, along with the data for all consequently synthesised analogues no longer displayed 
agonistic activity.  To the contrary, at 10 µM THP 103 displayed 60% antagonism although at lower 
concentrations no antagonism was observed. 
 
The disparity between the cell-based and the in vitro data cannot currently be explained.  Analysis of 
these analogues in the previously described cell-based assay is underway to elucidate cell-based 
activity in an effort to correlate the two data sets.   
 
2.1.5.7 Future Work 
In order to progress the agonistic ability identified in initial THP analogue 103 evaluation in a reliable 
assay is first required.  Collaboration with the group of Eric Ortlund (Department of Biochemistry, 
Emory Universitry, GA) is currently investigation co-crystallisation conditions to give structural insight 
into the binding mode of these compounds.  With such information, extension of one of the 5 
synthetically accessible positions could be envisaged to generate the desired antagonistic activity. 
 
Also, application of the chemistry described for the synthesis of α,β-disubstituted homoallylic alcohols 
is currently being utilised in the synthesis of natural product cordigol, 90, by a project student under 
my supervision. 
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2.2 Activation Function-2 (AF-2) 
2.2.1 Approach 
Due to the constitutive activity conferred from the extended H2, the AF-2 of LRH-1 is assumed to be 
one of the most rigid among the NR superfamily.  Due to this rigidity the ability to develop antagonists 
of LRH-1 that act at the LBP through the previously discussed H12-displacement approach is 
currently unproven.  However, the efforts of Katzenellenbogen et al. towards small molecule CBIs, 
through both rational design and HTS, have displayed the AF-2 of NRs as a new drugable interface. 
 
Inspired by this work, modulation of the AF-2 was initially approached through development of a 
novel α-helix mimetic scaffold.  Later, a Cresset VS was utilised to identify more drug-like small 
molecule CBIs using the coordinates of a published LRH-1/cofactor co-crystal structure to build the 
query ligand. 
 
2.2.2 α-Helix Mimetic 
2.2.2.1 Mimetic Design  
As discussed above, LRH-1 is selectively corepressed by atypical orphan NR small heterodimer 
partner (SHP).124 It is known the SHP contains two NR box motifs that interact with LRH-1, SF-1 and 
other NRs (Figure 68). 
 
i-4 i-3 i-2 i-1 i+1 i+2 i+3 i+4 i+5 i+6 i+7 i+8 i+9  
R P A I L Y A L L S S S L SHP NR Box 1 
V P S I L K K I L L E E P SHP NR Box 2 
 
Figure 68 - SHP NR box motifs (Core LXXLL in red). 
 
Analysis of the binding of SHP NR box peptides by Xu et al. identified the residues required for the 
interaction (Figure 69).124 
 
 
Figure 69 – (a) the effects of alanine scanning mutations of SHP-1 and SHP-2 motifs on their binding to LRH-1 
according to Xu et al.124 (b) Schematic of interactions between SHP motifs and LRH-1.124 
 
From alanine scanning mutations of the SHP-1 and -2 motifs, the importance of the three leucine 
residues can be seen.  Surprisingly the i-1 isoleucine residue affects binding more significantly than 
the SHP-bound LRH-1 also contains a large binding pocket with a
cavity volume of !800 Å3, but the pocket is empty. Despite the
empty pocket, the C-terminal AF-2 is positioned in the active
conformation as in the apo structure. The rms deviation (rmsd) of
C! atoms between the apo- and the SHP-bound LRH-1 structures
is 0.45 Å (Fig. 3A). The major difference is the stability of the
extended helix H2, which is partially disordered toward its C
terminus in both LRH-1!SHP complexes in our crystals.
The docking mode of the SHP ID1 is well defined in the
LRH-1!SHP interface. The ILYTLL sequence of the SHP ID1
adopts a two-turn amphipathic !-helix with L21 and L25 oriented
inward toward the LRH-1 surface, and I20 and L24 partially
exposed to solvent (Fig. 3E). Like other nuclear receptor-
coactivator interactions, LRH-1 uses two ‘‘charge clamp’’ residues
(E553 from the AF2 and R380 from helix 3) to mediate a series of
hydrogen bonds with the backbone dipole of the SHP ID1 helix.
The charge clamp residue from helix 3, which is normally a lysine
in other receptors, is an arginine in LRH-1. The larger side chain
of R380 pushes the SHP helix outward by 1.0–1.6 Å. The docking
of the SHP ID1 helix is further stabilized by interactions of several
other residues with LRH-1, which are summarized in Fig. 2E.
Structural Model of the LRH-1!SHP ID2 Complex. We were unable to
crystallize the LRH-1!SHP ID2 complex despite numerous at-
tempts. Because the SHP ID2 motif interacts with other nuclear
receptors, although with lower affinity (Fig. 1D), we crystallized
SHP ID2 bound to the PPAR" LBD in the presence of the agonist
rosiglitazone. The structure of the PPAR"!SHP ID2 complex was
determined and refined at 1.8 Å, a resolution that permits the
unambiguous determination of the docking mode of the SHP ID2
motif (Fig. 2C). Like the coactivator LXXLL motif, the core
ILKKIL motif of the SHP ID2 peptide adopts a two-turn !-helix
with L121 and L125 directed toward the center interface of
receptor, and residues I120 and I124 oriented at a 90-degree angle
to the center interface. Overall, the interactions of the SHP ID2
peptide with PPAR" are analogous to those observed in the
SRC-1-bound PPAR" structure (20, 28), and there is not a signif-
icant conformational difference between these two structures.
The availability of both the LRH-1!SHP ID1 and the PPAR"!
SHP ID2 complexes provides an accurate template for modeling
the interactions between the SHP ID2 motif and LRH-1. Super-
position of the PPAR"!SHP ID2 complex with the LRH-1!SHP
ID1 complex indicates that the SHP ID2 helix would fit snuggly into
the SHP ID1-binding site of the LRH-1 without any additional
movement of the LRH-1 residues (Fig. 2D). In this model, the
interactions of the SHP ID2 with LRH-1 resemble those mediated
by the SHP ID1. Residues L121 and L125 of the SHP ID2 motif
mimic L21 and L25 of the SHP ID1 motif and mediate the core
interactions with LRH-1 (Fig. 2E). Residue K122 is extended to
form a unique hydrogen bond with LRH-1 D391, which is analo-
gous to the R " 2 charge clamp interaction of the third TIF2
LXXLL motif in the GR and CAR cocrystal structures (24, 29).
LRH-1 Conformational Changes Induced by SHP Binding. Although
there is no major rearrangement in the overall backbone structure
or the ligand-binding pocket of LRH-1 (Fig. 3A), the binding of the
SHP ID1 peptide induces a series of conformational changes in the
LRH-1 side chains that contact SHP. These conformational
changes are apparent when the LRH!SHP complex is overlaid on
the apo structure (Fig. 3B–D). Themost dramatic change is the side
Fig. 2. Structure of LRH-1 bo nd to the SHP LXXLL motifs. (A and B) Two
90-degree views of the LRH-1!SHP ID1 complex in ribbon representation.
LRH-1 is colored in gold with its charged clamp residues colored in red (AF-2)
and blue (end of H3). The SHP ID1 peptide is in yellow, and the LRH-1
ligand-binding pocket is represented by a pink surface. (C) The overall struc-
ture of the PPAR"!rosiglitazone!SHP ID2 ternary complex. PPAR" is colored in
goldwith its charged clamp residues colored in red (AF-2) andblue (endofH3).
The SHP is in yellow, and rosiglitazone is shown in space filling. (D) Docking of
the SHP ID2 motif (green) on the LRH-1 coactivator-binding site is shown in
surface representation. (E) A schematic representation depicting the inter-
molecular interactions of the SHP ID1 and ID2 motifs with LRH-1.
Fig. 3. Conformational changes
of LRH-1 induced by SHP binding.
(A) Superposition of the apo-LRH-1
(blue) with the LRH-1!SHP com-
plex, where LRH-1 is colored in red
and SHP in yellow. (B–D) Conforma-
tional changes of the side chain in
the LRH-1 residues involved inbind-
ing of the SHP ID1 motif. The apo-
LRH-1 is shown in green, the SHP-
bound LRH-1 is in blue, and the SHP
is in yellow. The electron density is
shown in purple at 1# contoured
level. (E) Docking mode of the SHP
ID1 motif on to the surface of the
LRH-1 coactivator-binding site. (F)
Surface topology of the cofactor-
binding site of the LRH-1!SHP com-
plex as distorted by the side chains
of the apo-LRH-1 (green).
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chain conformation of R380 (Fig. 3B). In the apo structure, the
extended R380 side chain traces along the coactivator-binding site
into the space that is normally occupied by L ! 5 (L25) of the
LXXLL motif. In response to SHP binding, the side chain of R380
ismoved 5–8.0Å to open up the pocket for the L! 5 of the LXXLL
motif. Side chains of residues F373,M394, andN549 are alsomoved
4–5 Å away from their corresponding positions in the apo structure
to accommodate the binding of L! 4, L! 1, and I" 1 of the SHP
LXXLL motif (Fig. 3C andD). In addition to these major changes
in the side chain conformations, the LRH-1 AF-2 helix is also
shifted 0.5 Å, which extends the length of the charge clamp pocket
to accommodate the binding of the SHP helix. These conforma-
tional changes dramatically alter the surface topology of the LRH-1
coactivator-binding site (Fig. 3F) and thus allow the receptor to
interact with SHP with high affinity.
Determinants of the SHP Binding to LRH-1. To determine the role of
each residue of the SHP ID1 and ID2 peptides in binding to LRH-1,
we performed peptide competition experiments with alanine scan
mutants (Fig. 4A). Replacement of the two core interface residues
(L ! 1 and L ! 5) resulted in #150-fold decrease in the binding
affinity of both SHPmotifs to LRH-1, in agreementwith the central
role of these two SHP residues in the binding to LRH-1. Mutations
in I " 1 and L ! 4, which comprise the peripheral interface, also
moderately decrease SHP binding. Interestingly, mutations in the
!3 and !7 residues increase SHP binding to LRH-1 by 5- to
10-fold. These residues do not contact LRH-1 directly, but the
alanine mutations can increase the helical propensity of the SHP
sequence (30), and thus stabilize the docking of the SHP helix.
To assess the importance of these two SHP motifs in the
repression of LRH-1, we mutated either motif in the context of the
full-length SHP and performed cell-based assays by using an
LRH-1!SF-1 reporter. Fig. 4B shows that wild-type SHP can
repress LRH-1 activity to baseline levels, andmutations in the SHP
ID1motif have little effect on SHP repression function. In contrast,
mutations in the SHP ID2motif abolish the ability of SHP to repress
LRH-1,which demonstrates that the functional interaction between
SHP and LRH-1 is mediated through the SHP ID2 motif despite
the finding that both SHPmotifs bind toLRH-1with approximately
the same affinity.
The transcriptional activity of SF-1, a receptor closely related to
LRH-1, is not inhibited by SHP but is repressed by Dax-1, a
tissue-specific repressor of SF-1 (Fig. 4C). The SHP ID1 and ID2
peptides interacted with purified SF-1 LBD with IC50 values of 11
!M and 33 !M, respectively (Fig. 4D). This binding affinity is
roughly 20- to 80-fold weaker than the binding of the SHP motifs
to LRH-1 or the binding of the second and third motifs of Dax-1
to SF-1 (Fig. 4D). In fact, the biotinylated SHP ID2 peptide showed
no interaction with SF-1 in conditions in which both TIF2 and SHP
ID1 interacted with SF-1 (Fig. 4E). Importantly, a mutated mouse
SHP in which the SHP ID2 motif is replaced with the third Dax-1
motif (SF-1 ! SWAP in Fig. 4C) represses SF-1 activation as
efficiently asDax-1. These data suggest that the insensitivity of SF-1
to SHP repression can be attributed in part to its poor binding to
the SHP ID2 motif. The transcriptional activity of LRH-1 is also
severely inhibited by Dax-1 as well as by the SHP swapmutant (Fig.
4C), consistent with the finding that all three Dax-1 motifs interact
well with LRH-1 (Fig. 5E). The higher affinity of the three Dax-1
motifs for LRH-1 compared with SF-1 is surprising but consistent
with a previous report (31) showing that all three Dax-1 motifs
interact strongly with LRH-1 and that Dax-1 mediates stronger
repression on LRH-1 than on SF-1. The coexpression of LRH-1
with SF-1 andDax-1 in steroidogenic tissues (32, 33) and the strong
interactions between LRH-1 and Dax-1 suggest that LRH-1 is also
a physiological target for Dax-1.
Basis of the SHP Selectivity Between LRH-1 and SF-1. To understand
the basis for the selective interaction between SHP and LRH-1, we
performed structural comparison of theLRH-1!SHP complexwith
our recent structure of the SF-1!SHP!phospholipid complex (PDB
code 1YP0) (34, 39). Although the C" atoms comprising the
coactivator-binding site overlap exceedingly well between LRH-1
and SF-1 (rmsd$ 0.5 Å), there are three major differences in their
coactivator binding sites (Fig. 5A). The first and most pronounced
difference is the change in LRH-1 residues L372 and F373, which
form part of the pockets for I" 1, L! 1, and L! 4 of the LXXLL
motif, to F274 and I275 in SF-1. The second difference is the
Fig. 4. Determinants and functional correlation of the LRH-1!SHP interac-
tions. (A) Effects of alanine scanning mutations of the SHP ID1 and ID2 motifs
on their binding to LRH-1 as determined by AlphaScreen. IC50 ratios are
determined between the values of mutated peptides and the IC50 values for
the wild-type SHP ID1 and ID2 motifs. (B) Effects of the mutations of the SHP
ID1 and ID2 motifs on repression of LRH-1 in cell-based rep rter assays. Th
amount of the expressing plasmids of SHP and LRH-1 is 2 ng and 40 ng,
respectively (1:20 ratio). The luciferaseactivity for the transfectionsperformed
withLRH-1alonewasnormalized to100%. (C)Direct comparisonof repression
of LRH-1 and SF-1 by SHP and Dax-1 in cell-based reporter assays. The amount
of themouse SHP, mouse Dax-1, and the SHP SWAP expression vector is either
40 ng (1:1 ratio to LRH-1 or SF-1) or 2 ng in the repression assays (1:20 ratio to
LRH-1 or SF-1). SWAP represents the SHP mutant containing K122Y!K123S!
I124L!E126T!E127S!P128S that replace the SHP ID2motifwith theDax-1 third
motif. The luciferase activities for the transfections performedwith LRH-1 and
SF-1 alone were normalized to 100%. (D) Binding affinity of the SHP motifs
and the Dax-1 motifs to SF-1 as determined by peptide competition experi-
ments by using AlphaScreen. The IC50 of the second and the third motifs of
Dax-1 is%500 nM vs. 10–40 !M for the two SHP motifs. (E) No binding of the
biotinylated SHP ID2 motifs to SF-1 as compared with the binding of the TIF2
and SHP ID1 motif to SF-1.
9508 " www.pnas.org!cgi!doi!10.1073!pnas.0501204102 Li et al.
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the conserved i+3 leucine residue with binding of i-1 isoleucine in the more selective SHP-2 giving a 
6-fold greater decrease in binding on mutation to the alanine residue.  As proposed in the molecular 
dynamics simulation discussed above176, the polar i+2 residues of the tyrosine (Y) and lysine (K) of 
the SHP-1 and -2 peptides respectively also play a role in the NR box motif interaction.   
 
To create a more sophisticated α-helix mimetic than that of the ter-phenyl type i+1, i+4 and i+7 
mimics of Hamilton and others, or the pyrimidine CBI i+1, i+4 and i+5 mimics of Katzenellenbogen, 
design of a small molecule capable of representing the 5 residues discussed here for LRH-1 was 
desired.  
 
Design of such a novel, comprehensive, NR coactivator mimetic scaffold was initially based around 
the geometry between the Cα’s of the amino acid side chains in the selective coactivator peptide 
SHP-2.  Analysis of the SHP-1 motif from LRH-1 crystal structure 1YUC149 revealed distances of ~3.2 
and 5.5 Å between the Cα of the i+1/i+2 and i+1/i+3 amino acid sign chains respectively.  Taking into 
account these distances and the desire to project the Cα−Cβ bonds with approximately the correct 
vectors the design was quickly constrained to bicyclic systems.   
 
Visual investigation into a variety of bicyclic structures identified that substituted bicyclo[2.2.2]octane 
scaffolds I, II and III allowed representation of the desired consecutive i-1, i+1 and i+2 residues 
(Figure 70). 
 
 
Figure 70 – Left – Potential mimetic bicylo[2.2.2]octane scaffolds. Right – Overlay image of scaffold III (pink) on 
SHP-2 peptide from 1YUC (blue). 
 
These scaffolds all matched the geometric constraints identified in analysis of the SHP-2 α-helix.  
Overlay of scaffold III onto the peptide reveals the near perfect representation of the Cα by the 
substituted bicyclo[2.2.2]octane (Figure 70, right). 
 
The remaining vectors of the bicyclic scaffolds were analysed for the ability to extend the scaffold for 
representation of the final two i+4 and i+5 leucines.  Scaffold III provided the best opportunity for 
completion of the mimetic with representation of the final two leucines being accommodated by 
appending a disubstituted aryl amide (Figure 71, IV). 
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Figure 71 – Left - Structures of complete designed mimetic scaffold IV, aza-modified scaffold V and fully 
appended mimetic 146. Right – overlay of 146 (grey) onto SHP-2 peptide (green).  
 
Following selection of the complete mimetic scaffold IV, placement of nitrogen at the internally 
situated i+1 anchor point was anticipated to allow facile variation of desired residues at this position 
and decrease the lipophilicity of the target molecules.  Substituting the designed scaffold anchor 
points for the amino acid side chains of LRH-1 coactivator NR-box in SHP-1 generates the target 
azabicyclo[2.2.2]octane structure 146. 
 
2.2.2.2 Synthetic Plan 
Retrosynthetic analysis for construction of the critical azabicyclo[2.2.2]octane leads to the 
precedented use of substituted N-alkylcarbonyl-1,2-dihyrdopyridines VI as dienophiles in hetero 
Diels-Alder reactions as described by the groups of Fowler 177 and Krow 178 (Scheme 20). 
 
 
Scheme 20 – Retrosynthesis of α-helix mimetic scaffold V. 
 
To explore the feasibility of this route, model system 148 containing methyl residues in place of the 
required amino acid side chains, was selected for synthesis (Scheme 21). 
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Scheme 21 – Forward synthetic plan for synthesis of model scaffold 148. 
 
It was envisaged that the initial hetero Diels-Alder reaction could be effected under either thermal or 
Lewis acid catalysed conditions from the α,β-unsaturated carbonyl containing compound XI and N-
alkoxydihydropyridine X.  The resulting azabicyclo[2.2.2]octene XII contains undesired unsaturation 
which it was envisaged could be removed by hydrogenation to the stereochemically desired system 
XIII.  Under hydrogenation conditions, removal of a benzyl carbamate protecting group could also be 
achieved in a global reduction to give the free amine required for subsequent N-alkylation generating 
the complete upper ring system XIV. 
 
Depending on the carboxyl functionality represented by X, conversion to the carboxylic acid 147 
would then by required to allow amide coupling. Amide coupling of the resulting carboxylic acid with 
commercially available 2,5-dimethylaniline should then generate the complete model α-helix mimetic 
scaffold 148. 
 
2.2.2.3 Model Synthesis 
2.2.2.3.1 1,2-Dihydropyridines: 
Synthesis of N-alkylcarbonyl-1,2-dihyrdopyridines (1,2-DHPs) was developed by Fowler in 1972.177 
This initial work by Fowler identified a facile synthesis of unsubstituted 1,2-dihydropyridine 149 by 
reaction of pyridine with chloroformate esters in the presence of sodium borohydride (Scheme 22).    
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Scheme 22 - Folwer’s synthesis of dihydropyridines (1972).177 Reagents and conditions: (i) NaBH4, benzyl 
chloroformate, THF, 0 → -10 °C. 
 
During the synthesis of dihydropyridine 149 by this method, a mixture of reduction products was 
observed with a significant amount of 1,4-dihydropyridine 150 generated due to addition of hydride at 
the 4-position.  However, regioselective formation of 1,2-DHP 149 was shown to occur when the 
reaction was carried out below -70 °C. 
 
For initial test reactions, synthesis of 4-methyl substituted 1,2-dihydropyridine 152 was undertaken 
utilising the reaction protocol described by Fowler (Scheme 23). 
 
 
Scheme 23 – Synthesis of N-benzylalkoxy-4-methyl-1,2-dihydropyridine 152. Reagents and conditions: (i) 
NaBH4, benzyl chloroformate, THF, -78 °C, 2 h. 
 
Hydride addition to the 4-position was not observed in this reaction and the desired 4-methyl 
substituted 1,2-dihydropyridine 152 was obtained in 75% yield.   
 
For access to the desired model system, use of 5-substituted 1,2-DHPs was required.  Synthesis of 
5-substituted 1,2-DHPs cannot, however, be accessed by the simple acylation, reduction process 
utilised above.  Access to such 1,2-DHPs requires selective hydride addition at C-6 and Fowler 
documented that 3-alkyl pyridines are selectively reduced at the C-2 position, generating the 
corresponding 3-alkyl-1,2-dihydropyridines.179  
 
Sundberg et al. investigated the regioselectivity elicited by a variety of reducing agents on various 3-
substituted pyridines.180 Selective hydride addition to the C-6 of 3-trimethylsilyl pyridine was achieved 
with use of the bulky hydride reagent N-Selectride, however, selective synthesis of 5-alky 1,2-DHPs 
was not so easily achieved with the best ratio of 1,2-:1,4-:1,6- reduction products being 60:20:20. 
 
To access the desired 5-methyl-1,2-DHP 160 a synthetic pathway described by Raucher et al. was 
utilised (Scheme 24).181  
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Scheme 24 - Synthesis of 5-methyl-benzyloxy-1,2-dihydropyridine 160.181 Reagents and conditions: (i) BnBr, 7 
Days, rt. (ii) NaBH4 (4 equiv.), EtOH, 0 °C → RT, 16 h. (iii) R chloroformate, Tol, 85 °C, 5 h. (iv) Br2, -78 °C, 1 h. 
(v) DBU (4 equiv.), 100 °C, 90 min. 
 
The route proceeded via reduction of the generated pyridinium bromide 154 to give 
tetrahydropyridine 155 in 93% yield over two steps.  Conversion of the N-benzyl protecting group to 
either methyl or benzyl carbamate was achieved by refluxing in toluene in the presence of the 
required alkyl chloroformate generating compounds 156 and 157 in 70 and 55% yields respectively. 
Finally, bromination and double dehydrobromination by heating in the presence of excess DBU 
allowed generation of 5-subsituted DHP 160 with an overall yield of 30% over 5 steps. 
 
2.2.2.3.2 Diels-Alder Chemistry: 
In 2007 Krow et al. extensively documented the stereoselectivity of Diels-Alder reactions of N-
alkoxycarbonyl-1,2-DHPs with various enones and enoates.178 Accordingly, some reactions of 4-
methyl-1,2-DHP 152 with methyl crotonate were carried out in an attempt to access the methyl 
substituted test structure 161 (Table 10). 
 
 
Entry Solvent Temp (°C) Time (hours) Yield (%) 
1b Neat 120 48 5 
2b Toluene 120 48 trace 
3b Neat a 170 1 - 
  a Microwave irradiation. b 5 equiv. of methyl crotonate. 
Table 10 – Thermal Diels-Alder reactions to form azabicyclo[2.2.2]octanes. 
 
Following various conditions described in the paper, the maximum yield obtained in these reactions 
was 5% with extensive degradation of the 1,2-DHP starting material 152 observed in all cases.  In an 
effort to increase reactivity, to reduce the reaction time and to reduce decomposition of 152 the 
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reaction was carried out in a microwave reactor at 170 ºC (entry 3).  However, no reaction was 
observed and alternative reaction conditions were sought to increase the yield of desired product.  
The small amount of Diels-Alder product isolated (entry 1) was assigned to be adduct 161 as a 70:30 
mix of diastereomers (assignment of the major diastereomer was confirmed by structural 
determination by single crystal x-ray crystallography on the final model system 148). 
 
2.2.2.3.3 Lewis Acid Catalysis: 
Due to the low yielding production of the desired Diels-Alder adduct in these thermal reactions, an 
investigation of catalysed Diels-Alder protocols was initiated. 
 
(i) Cu(II) Lewis Acids 
The use of copper(II) salts as Lewis acidic catalysts has been well documented for use in both 
conjugate addition and Diels-Alder reactions.182 Extensive work by Evans et al. suggested that C2-
symmetric chiral bis(oxazoline) ligands are particularly efficient promoters of enantioselective Diels-
Alder reactions (Scheme 26).183 
 
 
Scheme 26 – Evans’ enantioselective Diels-Alder protocol (1999).183 Reagents and conditions: (i) Cu(OTf)2, 
BOX, CH2Cl2. 
 
α,β-Unsaturated amides containing a copper coordinating heteroatom in the amidic position are 
utilised as the dienophiles.  Coordination to the Cu(II) salt pre-complexed with the chiral BOX ligand 
167 generates a square planar catalyst 68 which controls facial attack of the dienophile to give the 
Diels-Alder adducts enantioselectively.  Heteroatoms for complexation are presented in the form of a 
carbonyl oxygen or aromatic nitrogen as contained in oxazolidinone and pyrrole acyl substituents 
respectively (Scheme 27). 
 
 
Scheme 27 – Formation of active CuIIPhBOX complex 169/170.182 
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Synthesis of α,β-unsaturated N-acyl oxazolidinone 163 and pyrazole 164 dienophiles was achieved 
by reaction of the parent oxazolidinone and 3,5-dimethyl pyrazole with crotonyl chloride in the 
presence of a suitable base (Scheme 28).   
 
 
Figure 28 – Synthesis of dienophiles 163 and 164. Reagents and conditions: (i) n-BuLi (1.1 equiv), CH2Cl2, -
78 °C, 3h. (ii) Pyridine (2 equiv), DMAP (0.1 equiv), CH2Cl2, 0 °C, 3h. 
 
This chemistry proceeded without fault, generating the desired dienophiles 163 and 164 in 78 and 
89% yields respectively. 
 
There is also precedent for the use of propargyl amides as dienophiles in this type of Diels-Alder 
reaction.184 Due to the generated unsaturated system, control of exo/endo selectivity is negated and 
generation of the required stereochemistry can be controlled later. Synthesis of N-propiol pyrazole 
171 was achieved by DCC amide coupling between propargylic acid and 3,5-dimethylpyrazole 
(Scheme 29). 
 
 
Figure 29 – Synthesis of alkynyl dienophile 171 Reagents and conditions: (i) DCC (1.2 equiv), CH2Cl2, -78 °C, 
4h. 
 
Dienophiles 163, 164 and 171 were investigated in a series of potentially enantioselective Lewis acid 
catalysed Diels-Alder reactions with a variety of dienes XVI (Table 11). 
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Entry Diene [eq] Dienophile Lewis Acid [eq] Ligand Temp (°C) Solvent Time (h) Yield (%) 
1 152 [4] 163 Cu(OTf)2 [0.1] 167 0 CH2Cl2 20 0a 
2 “ “ “ “ 20 DCE 50 0a 
3 “ “ “ “ 70 “ “ 0b 
4 162 [10] 164 “ “ 20 CH2Cl2 40 0a 
5 162 [1] “ “ “ “ “ “ 0a 
6 152 [10] “ “ “ “ “ “ 0a 
7 “ [1] “ “ “ “ “ “ 0a 
8 162 [10] 171 “ “ -20 “ 48 0a,c 
9 152 [10] “ “ “ -20 “ “ 0a.c 
10 “ “ “ “ 20 “ “ 0a.c 
11 162 [10] 163 “ “ “ “ 40 0a.c 
12 “ “ Cu(SbF6)2 [0.2] “ “ “ 24 0a.c 
13 “ “ “ “ “ “ 40 0a,c 
14 152 [10] “ “ “ “ “ 30 0a 
15 162 [10] 174 Cu(SbF6)2 [0.1] “ “ “ 0.5 98 
16 152 [10] “ “ “ 40 “ 24 0a 
17 162 [25] 163 Et2AlCl [1.4] “ “ “ 3 49 
18 152 [25] “ “ “ “ “ 48 0a 
19 “ 171 “ “ “ “ 30 0a 
 
a – Only starting material recovered. b – Polymerisation of DHP observed. c – 4Å MS used. 
Table 11 – Lewis acid catalysed Diels-Alder reactions. 
 
The investigation started with use of Lewis acid catalyst Cu(OTf)2 to access the desired 
azabicyclo[2.2.2]octane model system 148 (entry 1). A range of temperatures was investigated 
although no reaction was observed after extended periods of time (entries 2 and 3).  Use of the 
pyrrole heterocycle of dienophile 164, for coordination to the CuPhBOX catalyst 167 did not affect the 
reactivity of the dienophile with both 1,2-DHP 152 and 1,3-cyclohexadiene (162) failing to react 
(entries 4-7).  Propargyl dienophile 171 was observed to be similarly unreactive towards 1,2-DHP 
152 and 1,3-cyclohexadiene (162) (entries 8-10). 
 
The lack of reactivity observed in these reactions suggested that the orbital energy gap between the 
crotonyl/propargyl dienophiles and the 1,2-DHP/1,3-cyclohexadiene was too large.  To combat this, 
synthesis of the more reactive hexafluoroantimonate Cu(II)-based catalyst described by Evans et al. 
was undertaken (Scheme 30).185 
 
 
Scheme 30 – Synthesis of Cu(SbF6)2 173 according to the method of Evans et al.185 
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Synthesis was carried out by displacement of the chloride counter ions of in situ generated Cu(II) 
BOX catalysts 172 with two hexafluoroantiminate anions from silver hexafluoroantimonate.  This 
generated the desired catalyst 173 as a bright blue solid. 
 
The enhanced reactivity of this catalyst was firstly explored for the reaction between 1,3-
cyclohexadiene (162) and crotonyl oxazolidinone 162 (entries 12 and 13).  Over these extended 
reaction times, however, no reaction was observed indicating that the enhancement in reactivity 
generated by the change in counter ion was not significant enough to produce the desired 
cycloaddition. 
 
Despite not containing the desired methyl substituent for the i+2 residue of the model system, 
preparation of acrylate dienophile 148 was undertaken as they are known to be more reactive than 
either the crotonyl or propargyl dieonphile’s (Scheme 31).182 
 
 
Scheme 31 – Synthesis of acrylyl oxazolidinone 174. Reagents and conditions: (i) DCC (2 equiv), DMAP (0.1 
equiv), CH2Cl2, RT, 18h. 
 
Synthesis of acrylate 174 was achieved by amide coupling between 2-oxazolidinone and acrylic acid 
in moderate yield.  This dienophile proved much more reactive with observed consumption of all 
starting material in the reaction with 1,3-cyclohexadiene observed within 30 minutes (entry 15).  
Application of the successful reaction conditions was investigated with 1,2-DHP 152, however after 
24 hours no production of the Diels-Alder adduct was observed (entry 16). 
 
Due to the inability of the Cu(II)-based Lewis acid catalysts to facilitate the desired Diels-Alder 
reaction with the required 1,2-DHP diene 52 the use of stronger Lewis Acids was investigated. 
 
(ii) Aluminium Lewis Acids 
Predating the work Evans carried out with chiral Cu(II) BOX complexes as asymmetric Lewis acid 
catalysts was work describing the use of dialkylaluminium chlorides for highly efficient Diels-Alder 
reactions of crotonate dienophiles at low temperature.186 Inspired by the increased reactivity of the 
aluminium Lewis Acids, investigation of their cycloaddition capabilities was undertaken (Table 12). 
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Entry Diene [eq] Dienophile Lewis Acid [eq] Ligand Temp (°C) Solvent Time (h) Yield (%) 
1 162 [25] 163 Et2AlCl [1.4] “ “ “ 3 49 
2 152 [25] “ “ “ “ “ 48 0a 
3 “ 174 “ “ “ “ 30 0a 
 
a – Only starting material recovered. 
Table 12 – Dialkylaluminium catalysed Diels-Alder reactions. 
 
The increased Lewis acidity of the diethylaluminium chloride enabled the reaction of crotonyl 
dienophile 163 with cyclohexadiene 162 resulting in an isolated yield of 49% (entry 1).  This 
increased reactivity, however, did not enable the successful reaction of the same crotonyl dienophile 
(163) or even of acryloyl dienophile 174 with 1,2-DHP 152 (entries 2 and 3). 
 
(iii) Group IV Lewis Acids 
Within the same 1988 publication, Evans discusses the high reactivity of the Group IV Lewis acids 
TiCl4 and ZrCl4.186 This high reactivity of these Lewis acids was utilised by Mutsuyama et al. in two 
publications in 2008 187 and 2010 188 for the Diels-Alder reaction of 1,2-DHP 175 with N-acryloyl-2,10-
camphorsultams (Scheme 31). 
 
 
Scheme 31 – Matsuyama’s Asymmetric Diels-Alder of 1,2-DHPs using Group IV Lewis Acids. Reagents and 
Conditions: (i) Lewis acid, CH2Cl2, 4A MS, -78 ºC/RT, 24h.  
 
Although only describing use of N-acryloyl dienophiles and selective isolation of endo adducts 
(undesired for α-helix mimetic 148), this work was considered promising for achieving a highly 
reactive system for application to synthesis of α-helix mimetic 148.  To this end synthesis of the 
described camphor sultam dienophiles was undertaken (Scheme 32). 
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Scheme 32 – Synthesis of N-acyl camphor sultams 178 and 179. Reagents and conditions: (i) NaH (1.5 equiv), 
toluene, rt, 90 min. (ii) NaH (1.5 equiv), CuCl (5 mol%), toluene, rt, 90 min. 
 
Synthesis was achieved using sodium hydride to deprotonate camphor sultam 177 followed by 
addition of the required acyl chloride with or without catalytic cuprous chloride.  Isolation of the 
crotonyl 178 and acryloyl 179 camphor sultams was achieved in 77 and 46% yields respectively. 
 
To allow for an analogous investigation to that described by Matsuyama, synthesis of 
phenoxycarbonyl-1,2-DHP 175 was completed (Scheme 33). 
 
 
Scheme 33 – Synthesis of phenoxycarbonyl-1,2-DHP 175. Reagents and conditions: (i) NaBH4 (1 equiv), MeOH, 
Et2O, -78 °C, 2h. 
 
This 1,2-DHP was synthesised using the conditions described by Fowler and isolated in 73% yield.  
These substrates were then used to investigate the previously discussed group IV Lewis acid 
catalysed Diels-Alder reaction (Table 13). 
 
 
Entry Diene R1 Diene R2 Dienophile R3 LA Temp (ºC) Time (h) Yield 
1 Me Bn CH3 TiCl4 -78 16 -a 
2 “ “ H “ “ “ -a 
3 “ “ Methyl acrylate “ “ “ -a 
4 “ “ Methyl crotonate “ “ “ -a 
5 “ “ - “ “ 2 -a 
6 “ “ - “ “ 2 -a 
7 Me “ CH3 HfCl4 RT 48 -a 
8 “ “ Methyl acrylate “ “ “ -a 
9 “ “ Methyl crotonate “ “ “ -a 
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10b “ “ H “ “ “ -a 
11b “ “ CH3 “ “ “ -a 
12 1,3-CHD “ H “ “ 3 50 % b 
13 H Ph “ “ “ 25 -a 
14 “ Ph CH3 “ “ “ -a 
 
a- Decompostion of 1,2-DHP observed. b - Both reagent solutions were stirred in 4Å MS before adding LA and combining. b- 
yield by conversion of dienophile in NMR of crude material.  
Table 13 – Group IV catalysis of Diels-Alder reaction. 
 
Preliminarily investigations were carried out using Ti(IV) chloride as this Lewis acid was observed to 
be the most reactive in the work by Matsuyama.187  Initial reactions were attempted between the 
desired 4-methyl-1,2-DHP 152 and the N-acryloyl and –crotonyl camphor sultams 178 and 179 
(entries 1 and 2).  Neither reaction however resulted in formation of product and decomposition of the 
1,2-DHP 152 starting material was observed in the 1H NMR spectrum of the crude material.  The 
reactions were repeated with previously used methyl acrylate and crotonate; unfortunately, no 
reaction was again observed with only decomposition of 1,2-DHP 152 (entries 3 and 4). 
 
To confirm decomposition was occurring as a result of the presence of TiCl4, the reaction was carried 
out in the absence of any dienophile (entries 5 and 6).  In these reactions consumption of 1,2-DHP 
was observed within 2 hours at -78 ºC identifying a previously unappreciated instability. 
 
To continue the investigation the least reactive group IV Lewis acid, HfCl4, was utilised. This 
compound is a solid and was described to react at ambient reaction temperatures.  Initially, the 
reactions previously carried out with TiCl4 were repeated with HfCl4 to see if the new reaction 
conditions would allow for a successful reaction (entries 7-9). Unfortunately, after 48 hours no 
reaction was observed with methyl acrylate, crotonate or the crotonyl sultam dienophile 178.  As 
observed then using TiCl4, broadening of the 1H NMR signals in spectra of crude material occurred. 
 
Complete removal of water from the reaction solution was investigated by addition of 3Å molecular 
sieves to both substrate solutions prior to reaction.  This new protocol was tested when employing 
acryloyl sultam dienophile 179 in parallel with the crotonyl sultam 178 (entries 10 and 11).  No 
successful reaction was observed. To test that the Lewis acid was active, the reaction was attempted 
with 1,3-cyclohexadiene (152, entry 12). This reaction was successful and after 3 hours 50% 
conversion of acryloyl cultam dienphile 179 was observed. 
 
Finally, in order to alleviate concerns that the 4-methyl substitutuent was accelerating the observed 
decomposition, the unsubstituted 1,2-DHP 175 used in the original paper was synthesised (Scheme 
33).  This diene was used in the reaction with acryloyl 179 and crotonyl sultam 178 dienophiles 
(entries 13 and 14).  After 25 hours no reaction was seen in either reaction and broad peaks in the 1H 
NMR spectra, possibly corresponding to decomposed 1,2-DHP 175, were again observed.  
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Despite the published ability of the investigated group IV Lewis acids to catalyse the Diels-Alder 
reaction of such N-alkoxycarbonyl-1,2-DHPs, in my hands, their increased acidity resulted in 
decomposition of the DHP starting material.  Discussion of practical considerations with a student in 
the group of Matsuyama did not result in an improved reaction. 
 
(iv) Boronic Acid Catlysis: 
In 2008, Hall et al. published a sequential, one pot cycloaddition/amidation of carboxylic acids with 
both steps being catalysed by ortho-halo arylboronic acids (Scheme 34).189 
 
 
Scheme 34 – Hall’s ortho-halo arylboronic acid catalysed direct cycloaddition/amidation.189 Reagents and 
conditions: (i) CH2Cl2, 4Å MS, rt. (ii) benzylamine (0.9 equiv.), 4Å MS, rt, 3 days. 
 
With the tantalising possibility of being able to generate the complete mimetic scaffold in one step 
from 1,2-DHP 152 this represented a very interesting procedure to us.  An investigation into the 
capabilities of this procedure, particularly the reactivity of 1,2-DHP dienes, was started using 
commercially available ortho-bromophenylboronic acid despite the fact this was reported to be 
slightly less active than the corresponding iodide (Table 14). 
 
 
Entry Diene Dienophile Solvent Temp (°C) Time  (h) Yield (Conversion b)  
1 180a 182 CH2Cl2 rt 72 16 
2 181a “ “ “ “ 25 (100) c 
3 162a “ “ “ “ - 
4 180 “ “ “ 48 24 (80) 
5 181 “ “ “ 24 40 (100) c 
6 162 “ “ “ 48 - 
7 151 “ “ “ “ - 
8 162 “ ClCH2CH2Cl 80 120 (80) d 
9 152 “ “ “ “ (70) d 
10 162 183 “ “ 144 - 
11 151 “ “ “ 144 - 
 
a – Reactions carried through to amide coupling step; b – ratio of product to dieonphile 1H NMR peaks; c – loss of product 
during chromatography; d – products not isolated  
Table 14 – Boronic acid catalysed direct cycloaddition/amidation. 
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Initially, the reactivity of dienes 180, 181 and 162 with acrylic acid (182) was investigated using the 
literature conditions (entries 1-3).  After the 6 days required for the full procedure, analysis of 1H-NMR 
spectra indicated no amide coupling had occurred.  The absence of amide coupling could perhaps be 
attributed to addition of only 5% of the described mass of 4Å molecular sieves due to a calculation 
error.  The initial Diels-Alder reactions did proceed although isolation proved difficult with only a 25% 
mass recovery observed in the reaction of cyclopentadiene (181, entry 2).   
 
To test the efficiency of cycloaddition, the 3 reactions were repeated and stopped prior to amine 
addition.  As described in the literature procedure, the reaction of cyclopentadiene (181) with acrylic 
acid (entry 5) was complete within 24 h (by 1H NMR) although isolation by silica gel chromatography 
yielded only 40% of the resulting cycloadduct.  Acyclic diene butadiene (180) reacted considerably 
slower with only 80% conversion after 48 hours (entry 4). Despite these successful reactions the 
reaction of cyclohexadiene 162 or 1,2-dihydropyridine 152 with acrylic acid 182 did not proceed 
(entries 6 and 7). 
 
To try and affect the cycloaddition of these less reactive dienes, increasing the reaction temperature 
to 80 ºC was investigated (entries 8-11).  At 80 ºC the reaction of cyclohexadiene (162) did proceed 
with steady conversion to the desired cycloadduct.  After 5 days 80% conversion of the starting 
acrylic acid was observed (entry 8).  In the case of the 1,2-dihydropyridine 152, 70% conversion was 
observed over the same period (entry 9).  After these encouraging results the reactivity of required 
crotonic acid dienophile 183 was investigated.  Unfortunately, the lack of reactivity observed in 
previous reaction systems was echoed, with no reaction occurring after 6 d heating at 80 °C.  
 
Having failed to facilitate the desired Diels-Alder reaction with use of the described catalytic systems, 
reinvestigation of thermal conditions with alternative dienophiles was undertaken. 
 
2.2.2.3.4 Thermal Conditions: 
Despite the availability of methods for the interconversion of the investigated α,β-unsaturated esters, 
sulfonamides, oxazolidinones and pyrroles to the desired carboxylic acid functionality their low 
reactivity suggested that use of a more reactive dienophile would be required.  The more reactive 
dienophiles 3-penten-2-one 184 and tert-butyl thioester 185 were selected for investigation. 
 
α,β-Unsaturated thioesters are known to undergo conjugate addition with similar efficacy to methyl 
ketones.  Synthesis of crotonyl-tert-butyl-thioester was carried out to allow for its use in the thermal 
Diels-Alder investigation (Scheme 34). 
 
 
Scheme 34 – Synthesis of thioester dienophile 185. Reagents and conditions: (i) Et3N, ZnCl, Tol, 60 ºC, 4h. 
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Synthesis was achieved in 45% yield by addition of the tert-butyl thiol to crotonyl chloride in the 
presence of triethylamine as base and ZnCl2 as a catalyst.  The low yield is attributed to loss of 
material during purification by distillation.  Thioester 185 and commercially available 3-penten-2-one 
184 were investigated for Diels-Alder reactivity using the previously identified thermal conditions 
(Table 15). 
 
 
Entry Dienophile Yield (%) Endo/Exo 
1 184 42 2.5:1 
2 185 36 2:1 
 
Table 15 – Thermal Diels-Alder reaction using dienophiles 184 and 185. Reagents and conditions: (i) Neat, 
120 °C, 48h. 
 
Gratifyingly, both dienophiles were observed to generate the desired cycloaddition product.  
Pentenone (184) generated a 2.5:1 mixture of endo and exo Diels-Alder adducts, respectively, in a 
combined yield of 42%.  Thioester 185 generated a 2:1 mixture of endo and exo products in 36% 
yield.  It was decided to progress the pentenone derived product. 
 
2.2.2.3.5 Hydrogenation/Alkylation 
Generation of the desired geometry for the i-1 methyl substituent requires hydrogenation of the 
alkene resulting from the Diels-Alder cycloaddition.  Under standard hydrogenation conditions (Pd/C, 
H2) the Cbz nitrogen protecting group was expected to decompose to reveal the internal bicyclic 
secondary amine.  Alkylation of this nitrogen would install the desired i+2 substituent. 
 
This hydrogenation/alkyation pathway was initially tested on the methyl ketone Diels-Alder product 
(Scheme 35). 
 
Scheme 35 – Hydrogenation/alkylation procedure. Reagents and conditions: (i) Pd/C (10 % by mass), H2 (1 
atm), EtOAc, rt, 16h. 60% (ii) Pd/C (10 % by mass), H2 (1 atm), EtOH, 1h. 94% (iii) MeI (1 equiv), DMF (0.05M), 
rt, 1h. 
 
Hydrogenation with 10% palladium on charcoal under an atmosphere of hydrogen resulted in 
isolation of saturated secondary amine 187 in 60% yield after 16 h. On a larger scale, use of protic 
solvent ethanol allowed complete hydrogenation of starting material in 1 h with an isolated yield of 
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94%.  N-Methylation was attempted using 1 equivalent of methyl iodide and a low concentration 
(0.05M) of amine substrate 187. No reaction occurred and it was suspected that formation of the 
quaternary ammonium species occurred due to negligible mass recover after aqueous workup 
 
To avoid quaternisation, a one-pot hydrogenation/reductive amination procedure was explored in 
which formaldehyde would generate methyl imminium species 189 in situ, which would also be 
reduced under the hydrogenation conditions (Scheme 36). 
 
 
Scheme 36 – One-pot hydrogenation/reductive amination. Reagents and conditions: (i) Pd/C (10 % by mass), 
H2 (1 atm), CH2O (37% weight in H2O; 3 equiv),MeOH, rt, 24h. 
 
Addition of formaldehyde to the previous conditions resulted in formation of the desired methylated 
amine in an isolated yield of 96%.  The stereochemistry of the resulting i-1 methyl substituent could 
not be elucidated from 1H NMR coupling constant analysis due to crowded regions in the 1H NMR 
between δ 0.5 and 2.0 ppm.  However, a crystal structure obtained of the complete model system 
retrospectively revealed the major product to contain the desired geometry (as shown).  Having these 
conditions in hand, application of these conditions to the bicyclic thioester system 190 was attempted 
(Scheme 37). 
 
 
Scheme 37 – Hydrogenation/reductive amination of bicyclic thioester 190. Reagents and conditions: (i) Pd/C 
(10 % by mass), H2 (1 atm), CH2O (37% weight in H2O; 3 equiv),MeOH, rt, 24 h. 
 
Successful formation of hydrogenated N-methyl thioester was achieved in 98% yield using the 
conditions described above.  With both fully functionalised top ring systems in hand, interconversion 
of the acyl functionality to a carboxylic acid for amide coupling was investigated. 
 
2.2.2.3.6 Functional Group Interconversion: 
(i) Bromoform Reaction – Conversion of methyl ketone 188 to the required carboxylic acid was first 
attempted using the bromoform reaction (Scheme 38). 
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Scheme 38 – Attempted bromoform mediated formation of carboxylic acid 147. Reagents and conditions: (i) 2M 
NaOH, Br2 (3 equiv), dioxane, -5 °C → RT, 45 min. 
 
Traditional bromoform reaction conditions were selected however no reaction was observed.189  In 
order to observe if this lack of reactivity was due to the presence of the tertiary amine, synthesis of a 
model system 192 comprising an all carbon framework was undertaken (Scheme 39).  
 
 
Scheme 39 – Investigation of the bromoform reaction on fully carbon model bicycle 168. Reagents and 
conditions: (i) Et2AlCl (1.2 equiv), CH2Cl2, RT, 3h. (ii) Pd/C, H2, MeOH, RT, 16h. (iii) 2M NaOH, Br2 (3 equiv), 
dioxane, -5 °C → RT, 45 min. 
 
Synthesis of fully carbon model bicycle 193 was achieved through Et2AlCl catalysed Diels-Alder 
cycloaddition followed by hydrogenation in a 95% yield over two steps.  Despite the absence of the 
cyclic tertiary amine, no reaction was observed on exposure of compound 193 to the bromoform 
reaction conditions.   
 
(ii) Oxidative Cleavage – Given the lack of reactivity observed in application of the bromoform 
reaction, an alternative synthetic strategy for this FGI was required.  For this reason, application of 
the widely utilised ruthenium chloride-sodium periodate protocol for oxidative cleavage of silyl enol 
ethers developed by Sharpless et al. was investigated.190 Initial attempts were focused on the 
isolation of the intermediate silyl enol ether using the full carbon biclo[2.2.2]octane model 193 
(Scheme 40).  
 
 
Scheme 40 – Ruthenium catalysed oxidative cleavage of silyl enol ether 196. Reagents and conditions: (i) (a) 
diisopropylamine (1.2 equiv), n-BuLi (1.2 equiv), THF, -78→20 °C, 10 min. (b) R3SiCl (5 equiv), -78 °C, 30 min. 
(ii) RuCl3 (5 mol %), NaIO4 (4 equiv), ClCH2CH2Cl:H2O (3:2), rt, 16h. 
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These initial attempts were made using TMSCl to form the trimethylsilyl protected enol ether 195.  
Isolation of this compound using silica gel chromatography was unsuccessful due to the instability of 
the trimethylsilyl enol ether functionality to mildly acidic conditions. Attempts to affect the oxidation of 
the crude silyl enol ether product also proved unsuccessful with quantitative recovery of starting 
methyl ketone 193 observed. 
 
In an effort to achieve formation of carboxylic acid 194, successful synthesis and isolation of the 
corresponding bulky tert-butyldimethylsilyl enol ether 196 was prepared (96% yield).  Oxidative 
cleavage using ruthenium and sodium hypochlorite oxidant was then successfully affected in 70% 
yield after 16 h.  Application of this successful reaction sequence was then applied to the desired 
azabicyclic system 199 (Scheme 41). 
 
 
Scheme 41 – Attempted oxidative FGI of desired azabicycle 188. Reagents and conditions: (i) Et3N (5 equiv), 
TBDMSOTf (4 equiv), CH2Cl2, rt, 3 h. (ii) RuCl3 (5 mol %), NaIO4 (4 equiv), ClCH2CH2Cl:H2O (3:2), rt, 16 h. 
 
Formation of the aza-silylenol ether 197 was achieved in 74% yield but the oxidative cleavage 
conditions simply resulted in consumption of starting material, no product formation and no mass 
recovery after work up. 
 
Due to the challenges encountered with the FGI of methyl ketone 188 into the required carboxylic 
acid, and given the prospect that saponification of a thioester would be more facile, investigation into 
this conversion was suspended in search of conditions to facilitate FGI of thioester 191. 
 
2.2.2.3.7 Thioester Reactivity: 
As a result of poor orbital overlap between the lone pairs on sulphur with the carbonyl π* molecular 
orbital, the carbonyl carbon in thioesters displays similar electrophilicity to ketones.  Due to this 
reactivity, examples of direct thioester amide coupling have been described.191-193  Investigation of 
such direct amidation protocols was investigated using initial Diels-Alder product 190 (Scheme 42). 
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Scheme 42 – Attempted amide coupling of thioester 190. Reagents and conditions: (i) either – AgOCOCF3 (2 
equiv.), THF, Et3N, RT, 5 h; or - iPrMgCl (3 equiv.), Et2O, 0 ºC → RT, 3 h. 
 
Initial attempts to affect amide coupling between thioester 190 and 2,5-dimethyl aniline were made 
using the mild and rapid protocol described by Ley et al.192  This procedure utilises silver(I) 
trifluoroacetate to activate the tert-butyl thioester moiety for nucleophilic attack by a desired amine.  
However, despite its reported success, no consumption of thioester 164 was observed.  Secondly, 
use of iso-propyl magnesium chloride as a base to enable amidation of thioesters has been 
described by Takahashi et al.193  Use of this protocol, also resulted in no product formation with 
complete recovery of starting thioester 190. 
 
The failure of the discussed direct amide coupling reactions led to the investigation of a simpler 
hydrolysis/amide coupling based procedure.  Hydrolysis of thioester 190 to generate carboxylic acid 
199 was undertaken first (Table 16). 
 
 
Entry 190  (exo:endo) Temp (ºC) Time (h) 
Yield 
(recovered SM) 
174  
(exo:endo) 
Recovered 164 
(exo:endo) 
1 1:2.2 20 3 5 (75) 1:5 1:2 
2 “ 80 16 10 (0) 1:1.5 - 
3 “ 40 1.5 45 (30) 1:3 2:1 
4 “ 35 3 60 (38) 1:2.5 1.7:1 
5a “ 35 3 66 (32) 1:2.5 2:1 
6 2:1 45 3 72 (0) 1.8:1 - 
7 1:2.2 45 3 78 (0) 1:2.8 - 
 
a – Reaction carried out on large scale (250 mg).  
Table 16 – Hydrolysis of thioester 190.  
 
An initial attempt to effect hydrolysis was carried out by exposure of thioester 190 to a 2M basic 
ethanolic solution at room temperature for 3 h (entry 1).  Over this time, a little consumption of 
thioester 164 was observed by TLC and isolation of 5% of acid 199 was achieved with the majority of 
the starting material recovered.  The isolated material was observed to consist mainly of the endo 
Diels-Alder adduct, displaying a 1:5 ratio of exo:endo product (by 1H NMR).  This result suggests that 
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hydrolysis of the endo thioester proceeds at a greater rate than the exo isomer potentially due to a 
disfavoured attack of the hydroxyl ion to the carbonyl carbon in the latter. 
 
In an attempt to force hydrolysis the reaction was refluxed overnight (entry 2). Over 16 h at this 
elevated temperature complete consumption of thioester 190 was observed, however, only 10% was 
isolated as hydrolysis product 199 with the rest degrading to unknown products.  In this case the 
product ratio was observed to be 1:1.5 endo:exo indicating that at 80 ºC both diastereomers are 
hydrolysed.  The reaction was therefore heated at 40 ºC (entry 3).  After 90 minutes 50% of thioester 
190 had been hydrolysed although the selectivity of hydrolysis was reduced: isolated acid 199 
contained a 1:3 (exo:endo) mixture of products in a yield of 45%.  
 
A slight reduction of the temperature to 35 ºC was not found to improve the selectivity of hydrolysis, 
generating a 1:2.5 mixture, but gave an improved isolated yield (60%) of the enriched material (entry 
4).  To bring through more material, these conditions were applied on a large scale resulting in 
isolation of a 1:2.5 mixture of the disfavoured acid product endo-199 (entry 5). 
 
Having selectively hydrolysed the undesired thioester, endo-190, hydrolysis of an enriched sample of 
the desired thioester exo-190 was sought to generate material for amide coupling.  Hydrolysis of the 
exo-enriched thioester 190 was carried out at 45 ºC over 3 h, generating a 72% isolated yield of a 
1.8:1 (exo:endo) mixture of acid 199 (entry 6).  This procedure was also applied on a large scale to 
the isolated Diels-Alder product to give a 1:2.8  (exo:endo) mixture of acid 199 in a yield of 78%. 
 
2.2.2.3.8 Amide Coupling: 
Having successfully affected hydrolysis of thioester 190, amide coupling of generated acid 199 was 
investigated (Table 17). 
 
 
Entry 174 exo:endo Time (min) Yield (%) 173 exo:endo 
1 1:3 5 59 a 
2 1.8:1 60 63 1.6:1b 
 
a – only endo product observed. b – partial separation of products possible to achieve 8:1 (exo:endo) ratio of amide 198.  
Table 17 – Amide coupling to generate desired amide 198. Reagents and conditions: (i) oxalyl chloride, DMF, 
2,5-dimethyl aniline, AgCN, CH2Cl2, 0 ºC→RT. 
 
Previously used amide coupling conditions were selected in which an intermediate acyl chloride 
species is formed to provide high reactivity for amide bond formation in the presence of the relatively 
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non-nucleophilic aniline.  Silver(I) cyanide was also utilised to accelerate amide coupling by 
precipitation of silver(I) chloride.  Application of the conditions to the previously isolated 1:3 
(exo:endo) mixture of 199 generated the desired amide 198 in 59% yield (entry 1).  None of the 
desired amide, exo-198, was isolated. 
 
In order to generate the desired amide, exo-198, the generated 1.8:1 (exo:endo) mixture of 199 was 
utilised resulting in 63% yield of a 1.6:1 (exo:endo) mixture of amide 198.  This mixture was partially 
separated by silica gel chromatography to isolate an enriched 8:1 (exo:endo) mixture in favour of 
exo-199 in a yield of 27%. 
2.2.2.3.9 Hydrogenation/Alkylation: 
With amounts of both exo and endo amide 198 in hand, the hydrogenation/alkylation conditions 
described above were applied (Table 18). 
 
 
Entry 173 Yield (%) 
1 endo 82 
2 exo 58 
 
Table 18 – Synthesis of complete helix mimetic 148. Reagents and conditions: (i) formaldehyde, H2, MeOH, RT, 
16 h. 
 
Successful hydrogenation and N-methylation was achieved using both amide diastereomers, 
resulting in synthesis of complete α-helix models endo-148 and exo-148 in 82 and 58% yields 
respectively (entries 1 and 2).  In both cases, no splitting of the 1H NMR signal for the generated alkyl 
i-1 methyl was observed indicating complete facial selectivity for molecular hydrogen approach. 
 
To elucidate the geometry of two isomeric products and the i-1 methyl orientation, formation of a 
crystal for single crystal X-ray structure determination was attempted.  Formation of crystals of 
undesired product endo-148 was achieved although repeated efforts to generate a crystal of exo-
148 for analysis was unsuccessful.  The generated structure of endo-148 confirmed the major Diels-
Alder adduct to be that of the endo product (Figure 72). 
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Figure 72 – Structure of endo-148 generated from single crystal X-ray analysis. 
 
Complete synthesis of the model system and confirmation of the stereochemical outcome of the 
Diels-Alder and hydrogenation reactions successfully served to aid the synthesis of the complete α-
helix mimetic. 
 
2.2.2.4 Complete Mimetic Synthesis 
Having developed the core chemistry for construction of the complete mimetic 146, design of the 
synthetic strategy for installation of the correct side chain residues was required (Scheme 43). 
 
 
Scheme 43 – Retrosynthetic analysis of full α-helix mimetic scaffold V. 
 
Installation of the i-1 residue was envisaged through palladium catalysed cross coupling using an 
installed reactive group, X, on the alkene of the generated Diels-Alder adduct.  Elaboration of the 
one-pot hydrogenation/alkylation procedure to include any aldehyde was anticipated to allow 
installation of the i+1 residue.  Metathesis with the required alkene would then generate the desired 
substituted α,β-unsaturated thioester XVIII for use in the described Diels-Alder reaction.  Finally 
installation of the final i+4 and i+5 aniline substituents would be achieved through alkylation of an 
aniline or analogous aromatic system. 
 
2.2.2.4.1 Palladium Cross-Coupling: 
The investigation Krow et al. carried out into thermal Diels-Alder reactions of 1,2-DHPs identified that 
the presence of bulky substituents on 1,2-DHPs resulted in preferential formation of exo Diels-Alder 
adducts (as required for mimetic scaffold V).178 The investigation described synthesis and 
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cycloaddition of 5-trimethylsilyl 1,2-DHP with methyl acrylate to generate a 7:3 (exo:endo) mixture of 
Diels-Alder adducts.  Hoping to benefit from this preferential formation of exo products, it was 
decided to deploy a palladium cross-coupling protocol for our approach. 
 
5-Benzyldimethylsilyl-1,6-DHP 200 was therefore selected as Diels-Alder diene so as to allow 
subsequent Denmark modified Hiyama cross-coupling to install the i-1 side chain (Scheme 44). 
 
 
Scheme 44 – Proposed Diels-Alder and Hiyama-Denmark Coupling. 
 
Initially, a concerted effort was made to generate the 3-pyridyl Grignard reagent using a protocol 
described by Knochel et al.194-196 Use of all methods described by Knochel proved unsuccessful, 
even when the described procedures were conducted at elevated temperatures.  However, 
successful synthesis of 3-silylpyridine 201 was achieved by following the work of Wanner et al., 
which described effective formation of sterically demanding 3-silylpyridines (Scheme 45).197 
 
 
Scheme 45 – Synthesis of 3-silylpyridine 201. Reagents and conditions: (a) n-BuLi (1.1 equiv.), Et2O, -78°C, 30 
min. (b) BnMe2SiCl (1.1 equiv.), THF, -78°C→RT, 1h. 
 
Initial bromine-lithium exchange was conducted in diethylether at -78 °C. The decreased polarity of 
ether, as compared to THF, encourages the 3-lithiopyridine intermediate to precipitate out of solution 
on formation.  This insolubility gives no opportunity for the lithiopyridine species to react and 
polymerise with unreacted bromopyridine starting material (as observed when using THF).  After 
complete formation of the intermediate, addition of the silyl chloride electrophile in THF allows the 
nucleophilic lithiopyridine to dissolve generating controlled formation of the desired substituted 
pyridine. Using this method synthesis of the 3-benzyldimethylsilylpyridine 201 was achieved in 97% 
yield. 
 
Following synthesis of 3-substituted pyridine 201, reduction and N-acylation to give the 
corresponding 1,6-DHP 200 was required for use as a diene in the Diels-Alder reaction (Scheme 46).   
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Scheme 46 – Reduction of 3-silylpyridine 201. Reagents and conditions: (a) benzylchloroformate (1.1 equiv.), 
THF, -78 °C, 1 h. (b) N-selectride, -78 °C, 1h. (c) H2O2, NaOH, RT, 16 h. 
 
Following conditions described by Sundberg et al.,180 reduction was achieved using N-selectride as 
the hydride source. Formation of a small amount of undesired 1,4-DHP 202 was observed although 
separation of the two products by silica gel chromatography allowed isolation of 1,6-DHP 200 in 69% 
yield. 
 
On obtaining 1,6-DHP 200, Diels-Alder cycloaddition to give bicyclo[2.2.2]octanes was investigated 
(table 19). 
 
 
Entry Conditions X R Yield (%) [Adduct ratio] 
1 Neat, 120 °C, 48h StBu Me 12 [2:1] 
2 “ Me H 42 [2:1] 
3 MW, 180 °C, 4h StBu Me 22 [2:1] 
4 “ Me H 75 [2:1] 
 
Table 19 – Diels-Alder reaction of silyldihydropyridine 200. 
 
Following the conditions identified from studies on the model system, the Diels-Alder cycloaddition 
with the crotyl thioester gave a 12% mixture of both exo and endo products (entry 1).  On reacting 
1,2-DHP 200 with the more reactive dienophile, methylvinylketone (MVK), the same ratio of products 
was formed in 42% yield (entry 2).  The reaction was then carried out at an elevated temperature 
under microwave irradiation to observe if harsher thermal conditions improved the yield and favoured 
exo product formation (entries 3 and 4). At 180 °C the reaction was more successful with both 
dienophiles: the thioester and ketone generated the Diels-Alder products in 22% and 75% yields 
respectively. 
 
Despite the higher reactivity of MVK, the yields obtained were deemed too low to continue with this 
synthetic pathway. 
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2.2.2.5 Strategy Redesign 
Having investigated a range of dienophiles and reaction conditions to achieve formation of the 
desired azabicyclo[2.2.2]octane core, a re-investigation of the structural requirements of substituents 
off the bicyclic core was undertaken. 
 
Analysis of the core revealed the potential to alter the i+1 substituent stereochemistry while 
maintaining the gross mimetic ability of the scaffold (Figure 73). 
 
 
Figure 73 – Re-analysis and redesign of new mimetic scaffold 203 (new sections shown in red). 
 
The ability to alter the i+1 geometry enables modification of the previously explored synthetic 
strategy.  Due to the modified geometry of the i+1 substituent of redesigned mimetic 203, use of a cis 
substituted acyclic or cyclic dienophile is required.  Cyclic dienophiles can display significantly 
increased reactivity in cycloaddition reactions.   The synthetic utility of maleimides as dienophiles in 
Diels-Alder chemistry has been well explored and consequently, a synthetic strategy based on the 
utility of N-aryl maleimides was designed (Scheme 47).  
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Scheme 47 – Re-designed synthetic strategy for preparation of mimetic 209. 
 
Utilisation of the increased reactivity of ortho- disubstituted N-arylmaleimide would yield 
azabicyclo[2.2.2]octane 205 with i+4 and i+5 residues already present.  Alkenyl Hiyama cross 
coupling with the desired vinyl halide would install the desired i-1 while generating diene 206.  Use of 
the previously described hydrogenation/alkylation procedure would then enable installation of the 
required i+1 N-alkyl group at the same time as generating the desired alkyl stereochemistry.  Finally, 
regioselective reduction of the generated succinyl imide 207 would present the disubstituted 
arylamide in the correct position while presenting a primary alcohol for concluding Mitsonobu 
etherification to give complete α-helix mimetic 209. 
 
2.2.2.5.1 Diels-Alder Reactivity of N-Aryl Maleimides: 
To begin exploration of the new synthetic strategy, investigation of the Diels-Alder reactivity of 
commercially available N-phenyl maleimide 210 was undertaken (Table 20). 
 
 
Entry Diene Temperature (ºC) Time (hr) Yield (%) Endo:Exoa 
1 136 60 0.33 83 1.12:1 
2 200 60 5 75 1.07:1 
3 “ 20 16 Trace n/a 
4 “ 80 3 79 1.08:1 
 
a – endo assumed major product due to previous model system assignment. 
Table 20 – Use of N-phenyl maleimide as a dienophile in Diels-Alder reactions with 1,2-DHPs 200 and 152. 
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As opposed to previously conducted reactions, in which the liquid crotonyl thioester dienophiles were 
employed as solvents, solid dienophile maleimide 210 was dissolved in toluene.  Use of model 1,2-
dihydropyridine 152 was initially attempted with the reaction proceeding to completion in 20 minutes 
resulting in an isolated yield of 83% (entry 1).  Repetition of the conditions with benzyldimethylsilyl 
dihydropyridine 200 resulted in a 75% isolated yield although a longer reaction time of 5 h was 
required (entry 2).  No improvement to the diastereoselectivity of the cycloaddition was observed in 
the presence of the bulkier silyl group despite previous reported improvements with larger groups.178  
The effect of temperature on the diastereoselectivity was investigated although no reaction was 
observed at 20 ºC and at 80 ºC no change in d.e. was observed although the reaction was complete 
in a shorter time of 3 h (entries 3 and 4).   
 
Having achieved a greatly increased cycloaddition yield through use of the more reactive N-aryl 
maleimide synthesis of the required di-substituted N-arylmaleimide was undertaken. 
 
2.2.2.5.2 Disubstituted N-Aryl Maleimide Synthesis: 
The re-designed synthetic strategy requires installation of the i+4 and i+5 residues prior to Diels-
Alder cyclisation.  These residues are represented by 2 distinct aryl substituents and require 
synthesis of a novel di-substituted N-aryl maleimide 204.  To gauge the feasibility of this synthetic 
approach synthesis of hindered N-aryl maleimide 213 was carried out using commercially available 
2,6-diisopropyl aniline (Scheme 48). 
 
 
Scheme 48 – Synthesis of hindered N-aryl maleimide 213. Reagents and conditions: (i) Et2O, RT, 1 h. (ii) Neat, 
120 °C, 1 h. (iii) acetic anhydride, sodium acetate, 100 °C, 2 h. (iv) Conc. H2SO4, Tol:DMSO 4:1, 135 °C, 16 h. 
 
An initial attempt to synthesise hindered maleimide 213 was made through synthesis of an activated 
anhydride intermediate [Scheme 48, (iii)].  Intermediate acid 214 was isolated although generation of 
the mixed acetic anhydride to enable cyclisation failed.  Therefore a simpler reaction using sulphuric 
acid to catalyse the condensation reaction was carried out.  Use of Dean and Stark apparatus 
successfully removed the generated water and gave the desired product 213 in 88% yield. 
 
Having discovered conditions for synthesis of the highly hindered N-aryl meleimide 213 from 
hindered 2,6-diisopropyl aniline, synthesis of the required disubstituted aniline 215 was initiated.  
Installation of the two alkyl groups was envisaged through two successive ortho-directed lithiation 
reactions followed by electrophile quench using commercial N-boc aniline 216 (Scheme 49). 
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Scheme 49 – Attempted synthesis of required disubstituted aniline 215. Reagents and conditions: (i) (a) t-BuLi, 
THF, -78 °C → -15 °C, 2 h. (b) 2-methyl propyl bromide, -78 → RT. (ii) (a) t-BuLi, THF, -78 °C → -15 °C, 2 h. (b) 
2-methyl butyl bromide, -78 → RT. (iii) TFA, CH2Cl2, RT. (iv) maleic anhydride, H2SO4, Δ, 16 h. 
 
Initial ortho-directed lithiation was achieved although isolation of the 2-methyl propyl bromide 
quenched product 217 was achieved in a yield of only 20%.  Attempts to affect the second ortho 
directed lithiation with the required alkyl bromide electrophile, however, generated none of desired 
disubstituted product 215. 
 
Given the low reactivity of the required alkyl bromide, use of an allylic bromide was investigated to 
test whether the increase in electrophilicity would allow for generation of the product (Scheme 50). 
 
 
Scheme 50 – Use of allylic bromide quench in ortho directed lithiation. Reagents and conditions: (ii) (a) t-BuLi, 
THF, -78 °C → -15 °C, 2 h. (b) allylic bromide, -78 → RT. 
 
The increased electrophilicity of the allylic bromide allowed formation of the desired unsaturated 
product 218 in 78% yield.  Despite the improved yield of the second directed lithiation step, a yield of 
16% over two steps was unsatisfactory.  An alternative route using commercially available 2-hydroxy-
N-Boc aniline 219 was investigated in search of an improved yield (Scheme 51). 
 
 
Scheme 51 – Synthesis of alternative disubtituted aniline 223. Reagents and conditions: (i) 2-methylpropyl 
bromide, Cs2CO3, DMF, 60 °C, 16 h. (ii) (a) t-BuLi, THF, -78 °C → -15 °C, 2 h. (b) electrophile, -78 → RT. (iii) 
Pd/C, H2, MeOH, RT, 1 h. (iv) TFA, CH2Cl2, RT, 5 min. 
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Initial O-alkylation of 219 proceeded in a moderate yield to give ortho-directed lithiation precursor 220 
in 65% (4 g scale).  Both 1-bromo-2-methylbutane and 1-bromo-2-methylbutene reacted to yield the 
desired product, however 1-Bomo-2-methylbutane gave 221 in only trace amounts.  As above, use of 
the allylic bromide generated the alkenyl analogue 222 in an improved yield of 74% giving a yield of 
49% over two steps.   
 
This aryl ether analogue was selected for progression as together with an increased yield it presents 
opportunity for late stage installation of the required i+5 (through protection with a suitable protecting 
group).  Hydrogenation of the installed alkene and TFA cleavage of the N-Boc protecting group was 
therefore carried out with both proceeding in near quantitative yield generating the desired 
disubstituted aniline 223 in 98% yield over the two steps. 
 
Final incorporation of the desired aniline into maleic anhydride was undertaken to allow exploration of 
the utility of the resulting N-aryl maleimide in the required Diels-Alder cycloaddition (Scheme 52). 
 
 
Scheme 52 – Synthesis of required maleimide 224. Reagents and conditions: (i) (a) Neat, 120 °C, 1 h. (b) Conc. 
H2SO4, Tol:DMSO 4:1, 135 °C, 16 h. 
 
Synthesis and isolation of the desired N-aryl maleimide 224 was achieved in 93% yield. 
 
2.2.2.5.3 Diels-Alder Investigation: 
Having the desired disubstituted N-aryl maleimide 224 and 2,6-diisoproply N-aryl maleimide 213 
analogues in hand, an investigation into the Diels-Alder reactivity was started (Table 21). 
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Entry Dienophile 
Equiv. 
of 
DHP 
Equiv. 
of 1 
Conc. 
(M) Solvent 
Temp. 
(ºC) 
Time 
(hr) 
Yield 
(%) Product 
Adduct 
Ratioa 
1 210 1 5 0.75 Toluene 60 5 78 211 1.08:1 
2 213 “ “ “ “ 120b 16 61 225 1:1 
3 224 “ “ “ “ 120c “ 60 226 1:1 
4 “ “ “ “ “ “ 8 59 “ 1:1 
5 “ “ “ “ “ 140d 1.5 55 “ 2.3:1 
6 “ “ “ “ “ 180d 1 68 “ 2.8:1 
7 “ “ “ “ Toluenee 220d 10 (min) - “ - 
8 “ “ “ “ “ “ 1 (min) n/d “ 1.5:1 
9 “ “ “ 3 Toluene “ “ 65 “ 1:1 
10 “ “ “ 0.75 TFE “ “ 73 “ 1.8:1 
11 “ “ “ “ H2O “ “ 70 “ 2.4:1 
12 “ 1 2 “ Toluene 180d 1 71 “ 2.4:1 
 
a – endo assumed major product due to previous model system assignment; b – no product observed after 5 h at 60ºC; c – 
small amount of product seen after 5h at 60ºC. d – MW irradiation; e – Bmim ionic liquid 10 mol % additive; TFE- 
trifluoroethanol; n/d – not determined. 
Table 21 – Diels-Alder investigation. 
 
To begin the investigation, reaction of the 3 available N-aryl maleimide dienophiles was carried out in 
parallel (entries 1-3).  Reaction of 1,2-DHP 200 with the parent N-phenyl maleimide 210 required the 
same time as previously identified, giving a slightly improved yield of product 211 in 78%.  Monitoring 
the reaction by TLC showed no formation of di-isoproyl product 225 after 5 h at 60 ºC although small 
amounts of desired product 226 could be seen.  This could be attributed to the increased steric bulk 
of the diisopropyl maleimide 213.  In an effort to induce reaction, the temperature was increased to 
120 ºC for 16 h.  After this time complete consumption of 1,2-DHP 200 was observed and the 
reaction columned to give isolated yields of 61 and 59% respectively (entries 2 and 3).   
 
Despite the bulkyl substituents present on both 1,2-DHP 200 and N-aryl maleimides 213 and 224 no 
variation in endo/exo selectivity was observed in these reactions with all products isolated with a ratio 
close to 1:1.  Variation of further reaction conditions was investigated in an effort to increase the yield 
and influence the exo/endo selectivity. 
 
Firstly, use of microwave irradiation was investigated to allow for generation of elevated temperatures 
and reduced reaction times.  Irradiation at 140 ºC for 1.5 h (entry 5) significantly improved the ratio of 
Diels-Alder adducts giving a 2.3:1 ratio of un-assigned stereochemistry.  Increasing the temperature 
to 180 ºC increased the effect further, generating a 2.8:1 mixture (entry 6). In order to increase the 
potential temperature of the toluene reaction solvent, use of ionic liquid bmim as an additive was 
investigated (entries 7 and 8).198,199 An elevated temperature of 220 ºC was selected and after a 
reduced reaction time of 10 minutes the reaction solution was a dark brown-black viscous oil.  
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Analysis of the 1H NMR spectra of the crude material revealed no remaining starting material or 
product, potentially indicating the high temperature either degraded the reagents before being able to 
react or degraded the product.  The reaction was then repeated with heating sustained for only 1 
minute (entry 8).  Although some product was observable by analysis of the 1H NMR spectrum of the 
crude material, significant decomposition could also be seen (broad clusters of peaks throughout the 
NMR spectrum). 
 
An increase in reaction concentration was investigated; a 4-fold increase to 3M resulted in elimination 
of stereoselectivity to the cyclisation (entry 9).  Investigation into the effect of polar solvents on the 
adduct ratio was then carried out as it has been observed that the endo/exo selectivity can be 
affected by varying polar interactions.198 Despite this effect generally resulting in greater formation of 
the undesired endo adduct, an effect could shed light on assignment of the stereoisomer ratio 
observed.  The use of trifluoroethanol and H2O as solvents (entries 10 and 11) did diminish the 
observed ratio although not significantly enough to reliably ascribe the effect to increased formation 
of the endo isomer. 
 
The conditions identified in entry 6 were therefore seen as optimal and as a final test, alteration of the 
1:5 stoichiometry of 1,2-DHP:maleimide was reduced to 1:2 to see if this less material demanding 
ratio would still maintain the 1:2.8 ratio of Diels-Alder adducts (entry 12).  The altered stoichiometry 
did diminish the adduct ratio although only to a 1:2.4 ratio. 
 
2.2.2.5.4 Palladium Cross Coupling: 
Having optimised the Diels-Alder cycloaddition for the production of azabicylo[2.2.2]octane 226, 
investigation of the Hiyama cross coupling procedure was initiated.  To enable the investigation, 
synthesis of the vinyl iodide coupling partner 227 was required (Scheme 53). 
 
 
Scheme 53 – Synthesis of vinyl iodide 227. Reagents and conditions: (i) Cp2ZrCl2, Et3Al, CH2Cl2, 0 °C → RT, 48 
h. (ii) I2, THF, 0°C →RT, 48 h. 
 
A Negishi carbometallation200 procedure adapted by Agarwaal201 was utilitsed to generate vinyl iodide 
227 in a yield of 53%.  The reaction proceeds through regioselective addition of triethyl aluminium to 
propyne catalysed by zirconocene dichloride, generating an intermediate alkenyl allane.  Quenching 
with iodine then produces vinyl iodide 227.  A low yield was obtained due to loss of material during 
reduced pressure distillation. 
 
Hiyama cross coupling employing vinyl iodide 227 as a coupling partner was then investigated 
(Scheme 54). 
 
AlEt2 I
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Scheme 54 – Attempted Hiyama cross coupling. Reagents and conditions: Pd(dba)2, TBAF, THF, RT, 1 h. 
 
A protocol described by Trost202 and Denmark203 was applied.  Despite their successful alkenyl cross-
couplings, no formation of cross coupled product 228 was observed.  Instead, quantitative formation 
of de-silylated product 229 was observed within 1 h indicating facile proto-desilylation of the starting 
vinyl silane in the presence of fluoride. 
 
In order to overcome this adverse reactivity, an alternative cross-coupling procedure was sought.  To 
this end, synthesis of a vinyl stannane cross coupling partner for use in a Stille coupling was 
undertaken (Scheme 55). 
 
Scheme 55 – Synthesis of vinyl stannane 232. a – Yield based on conversion as observed in 1H NMR spectrum 
of crude material. Reagents and conditions: (i) (a) n-BuLi (1.1 equiv.), Et2O, -78°C, 30 min. (b) Bu3SnCl (1.1 
equiv.), THF, -78°C→RT, 1 h. (ii) (a) benzylchloroformate (1.1 equiv.), THF, -78 °C, 1 h. (b) N-selectride, -78 °C, 
1 h. (c) H2O2, NaOH, RT, 16 h. (iii) Toluene, 180 ºC, MW, 1 h. 
 
Synthesis was undertaken through the presviously described synthetic route.  Lithium halogen 
exchange followed by transmetallation with tributyltin chloride generated 3-stannyl pyridine 230 in 
97% yield.  Acylation with benzylchloroformate followed by reduction with N-selectride generated the 
1,6-DHP 231 in 98% crude yield (de-stannylation occurred during attempts to purify this material by 
silica gel chromatography).  The Diels-Alder reaction proceeded in a similar yield to when previously 
using 3-silyl-1,6-DHP 200, generating the desired vinyl stannane Diels-Alder product 232 in 58% 
yield as a 1:1.2 mixture of adducts. 
 
Vinyl stannane 232 was then utilised in a Stille coupling protocol apparently optimised for sterically 
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congested substrates described by Corey et al. (Scheme 56).204 
 
 
Scheme 56 – Stille coupling using vinyl stannane 232. Reagents and conditions: (i) PdPPh3 (10 mol%), CuCl (4 
equiv.), LiCl (5 equiv.), DMSO, THF, 60 ºC, 16 h. 
 
The reaction, which utilises lithium chloride as a coupling promoter, resulted in formation of cross-
coupled product 228 in an isolated yield of 34%.  This reaction was carried out on a small scale and 
repeat on a larger scale has not been possible in the time scale of this PhD research. 
 
2.2.2.5.5 Hydrogenation/Alkylation: 
Due to the small amount of cross-coupled diene 228 isolated (3 mg), investigation of the 
hydrogenation/alkylation was carried out on de-silylated material 229 (Scheme 57). 
 
 
Scheme 57 – Hydrogenation/alkylation of Diels-Alder product 229. Reagents and conditions: (i) iso-propanal, H2, 
MeOH, RT, 16 h. 
 
Use of the previously described conditions in the presence of isopropyl aldehyde resulted in 
hydrogenation of the alkene while also installing the desired i+1 2-methyl propyl substituent.  The 
desired product 230 was generated in quantitative yield with no requirement for purification. 
 
2.2.2.5.6 Imide Reduction: 
Due to the small amount of compound 230 generated from the hydrogenation/alkylation reaction 
described above, reduction of the succinyl imide system was carried out on model systems. This, 
previously synthesised N-aryl maleimides 210 and 224 were reduced to give simple N-aryl 
succinimides 231 and 232 for testing (Scheme 58). 
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Scheme 58 – Test succinimide reduction. Reagents and conditions: (i) acetic acid, 10% Pd-C, ammonium 
formate, Δ, 16 h. (ii) NaBH4, EtOH. 
 
Initial alkene reduction was carried out using a transfer hydrogenation protocol to reduce the electron 
deficient maleimide alkene to generate N-phenyl succinimide 231 and disubstituted analogue 232 in 
83% and 92% yields respectively.  Reduction of one imide bond was then investigated using sodium 
borohydride in ethanol.  Reduction of unsubstituted N-phenyl succinimide 231 was complete within 
10 minutes at 0 ºC resulting in an isolated yield of acyclic primary alcohol 223 of 98%.  Mirroring the 
reduced Diels-Alder reactivity of the disubstituted system, reduction of the disubstituted succinimide 
analogue 232 proceeded at a much slower rate with only trace reduction being observed after 1 h at 
0 ºC.  However, complete reduction could be achieved after 3 h at a raised temperature of 25 ºC, 
generating 234 in 95% yield. 
 
In order to test the reactivity of a more highly functionalised system, synthesis of all carbon 
bicyclic[2.2.2]octane succinimides 237 and 238 was undertaken (Scheme 59). 
 
 
Scheme 59 – Synthesis of bicyclic model succinimides 237 and 238. Reagents and conditions: (i) 1,3-
cyclohexadiene, toluene, Δ, 3 h. (ii) Pd (on charcoal), H2, methanol, RT, 2 h. 
 
The Diels-Alder reaction of both N-aryl maleimides 210 and 224 with cyclohexadiene generated the 
unsaturated bicyclic succinimides 235 and 236, in 93% and 97% yields respectively.  Hydrogenation 
was achieved using 10% palladium on charcoal catalysed hydrogenation conditions over 2 h; 
purification gave near quantitative amounts of saturated bicyclo[2.2.2]octanes 237 and 238. 
 
Having obtained bicyclic succinimides 237 and 238, investigation of imide reduction was undertaken 
(Table 22). 
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Entry Bicycle Reducing agent Solvent (conc.) Additive 
Temp 
(ºC) 
Time 
(h) 
Acyclic 
yield 
(conv.) 
Hemiamincal 
yield X 
(conv.) 
1 238 NaBH4 EtOH (0.1M) - 25 16 - - 
2 “ “ “ - 80 “ - - 
3 237 “ “ - 25 5 (min) - n/a (100)a 
4 “ “ MeCN:EtOH:Tolb - “ 3 - n/a (95)a 
5 “ “ EtOH (0.1M) 1M HCl “ 16 - n/a (100)a 
6 “ “ “ 2M 
NaOH 
60 “ - n/a (100)a 
7 “ LiBH4 “ - 60 5 (min) - n/a (100)a 
8 “ NaBH4 Benzyl alcohol “ 160c 0.5 - - 
9 “ “ EtOH (0.1M) “ 80 72 35 58 
10 “ “ EtOH (3M) “ “ 16 76 12 
11 238 “ “ “ “ 48d 72 6 
 
a – product not isolated. b – ratio of 45:45:10. c – Formation of white benzyl borane precipitate observed at elevated temp. d – 
solvent added after 24 h due to evaporation to dryness.  
Table 22 – Reduction of bicyclic succinimides 237 and 238. 
 
Initial reduction was attempted utilising the previously identified conditions on disubstituted bicyclic N-
aryl succinimide 238 (entry 1).  Despite the successful reduction of simpler succinimides using these 
conditions, no reaction was observed on this bicyclic Diels-Alder product.  In an effort to improve 
reactivity, the reaction was heated to 80 ºC (entry 2).  Despite the elevated temperature no reaction 
was again observed suggesting the bicyclo[2.2.2]octane ring system was restricting ring opening of 
intermediate hemiaminal XXI to acyclic aldehyde XXII (Scheme 60). 
 
 
Scheme 60 – Mechanism of imide reduction to acyclic system XXIV. 
 
Unlike the non-bicyclic succinimides 231 and 232, the equilibrium between hemiaminal XXII and 
acyclic aldehyde XXIII perhaps lies strongly in favour of the former due to the bicyclic constraint.  To 
investigate if this equilibrium was favourably perturbed in the absence of the bulky aryl side-chains of 
238, the investigation was moved onto studying the N-phenyl system 237 (entries 3-10). 
 
Reaction with sodium borohydride at 0 ºC resulted in almost immediate formation of hemiaminal 239.  
However, raising the temperature to 80 ºC did not result in formation of acyclic amide product 241.  
Following work carried out by Speckamp et al., an exploration of the effect of pH was carried out.  
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Speckamp found that pH had  a decisive influence on this type of ring opening equilibrium (entries 5 
and 6).205 The addition of 1M hydrochloric acid, described as hindering ring opening by favouring the 
protonated hemiaminal tautomer XXII, was indeed found to form the previously identified hemiaminal 
239 with quantitative conversion (entry 5).  However, the addition of base, which Speckamp found 
shifted the equilibrium in favour of the acyclic aldehyde XXIII, also resulted in formation of 
hemiaminal 239 (entry 6). 
 
Application of the more reactive hydride source, lithium borohydride was also gave hemiaminal 239 
with full conversion within 5 min at 0 ºC (entry 7).  To allow heating to a higher temperature, use of 
benzyl alcohol as a solvent was investigated (entry 8).  Despite facilitating an elevated temperature, 
formation of a larged amount of white precipitate (identified to be benzyl borane) was observed once 
temperatures over 120 ºC were reached.  Finally, the reaction was left to reflux for 3 days to observe 
if even traces of the product could be obtained over time (entry 9).  Over the 3 day time period, the 
reaction evaporated to dryness and analysis of the reaction mixture revealed formation of the desired 
acyclic product 241.  Isolation of the product was achieved in 35% yield while hemiaminal 239 was 
also retrieved in 58% yield. 
 
Formation of product while the reaction evaporated to dryness suggested that it was possible to 
overcome the unfavourable ring opening equilibrium at high concentrations.  To favour this, the 
reaction was carried out starting at a concentration of 3M followed by reflux for 16 h; again 
evapourating to dryness (entry 10).  From this increased concentration, acyclic product 241 was 
isolated in 76% yield while hemiaminal 239 was isolated in only 12% yield.  Reaction of disubstituted 
N-aryl succinimide 238 using these high concentration conditions was also carried out (entry 11).  
Again, reduced reactivity was observed with complete conversion requiring reflux to dryness over two 
successive 16 h periods.  However after this time, isolation of the desired acyclic product 246 was 
achieved in 72% yield along with a small amount of hemiaminal 240 (6% yield). 
 
Prior to achieving complete imide reduction to generate 242, synthesis of 4-nitro-N-aryl maleimide 
244 was undertaken to investigate the effect of such an electron withdrawing group on the imide 
reduction (Scheme 61). 
 
 
Scheme 61 – Synthesis and reactivity of 4-nitro-N-phenyl succinimide 245. Reagents and conditions: (i) (a) 
maleic anhydride, neat, 120 °C, 1 h. (b) Conc. H2SO4, Tol:DMSO 4:1, 135 °C, 16 h. (ii) 1,3-cyclohexadiene, 
toluene, Δ, 16 h. (iii) NaBH4, EtOH, 5 h. 
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Synthesis of 4-nitro-N-phenyl maleimide 244 was achieved in 91% yield utilising the previously 
described reaction conditions.  Diels-Alder cyclisation with 1,3-cyclohexadiene generated the 
unsaturated adduct 245 in quantitative yield after heating at reflux for 16 h.  Exposure of imide 245 to 
sodium borohydride at 0 ºC resulted in formation of the fully reduced terminal alcohol 246 in 76% 
yield together with 18% yield of 4-nitro aniline 243, indicating that the electron withdrawing properties 
of the nitro group promoted reduction of the amide bond of 246.  However, when the reaction was 
repeated at 60 ºC reduction of the 4-nitro group itself occurred giving aniline 242 in 30% yield. 
 
This reactivity suggests that incorporation of a nitro-group into the desired di-substituted N-aryl 
maleimide 224 could significantly improve the reactivity of the required system but would require care 
to carry through subsequent synthetic manipulations. 
 
2.2.2.5.7 Installation of i+5 Residue: 
Prior to the successful synthesis of primary alcohol 240, installation of the i+1 substituent was 
investigated using hemiaminal 241 (Table 23). 
 
 
Entry Conditions Alcohol Product Yield (%) 
1 i Benzyl X 92 
2 Ii “ X 87 
3 “ phenyl X 67a 
 
a – Reaction required 16h. 
Table 23 – Installation of substituents on hemiaminal 241. Reagents and conditions: (i) 2M HCl, BnOH, 5 ºC, 1 h. 
(ii) ROH, CuSO4, PPTS, CH2Cl2, RT, 5 h.  
 
Initial reactivity was tested utilising conditions described by Speckamp et al. in which acyl imminium 
intermediate 247 is quenched by the solvent alcohol (entry 1).205 Carrying out the reaction in benzyl 
alcohol generated benzyl hemiaminal 249 in 92% yield. 
 
With the prospect of the reaction needing to be carried out with solid and/or synthetically valuable 
alcohols, a reaction utilising 1 equivalent of alcohol was desired.  Simpkins et al. described such a 
procedure, which uses copper(I) sulphate as a dehydrating agent to generate acyl imminium salt 
247.206 This procedure was employed with both benzyl alcohol and phenol to generate the 
corresponding benzyl and phenyl hemiaminal species 249 and 248 in 87% and 67% isolated yields 
respectively (entries 2 and 3).  Due to its decreased electrophilicity relative to benzyl alcohol, the 
reaction of phenol required 16 h to go to completion. 
 
Following successful synthesis of primary alcohol 240 generation of its phenyl ether was investigated 
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using the Mitsonobu reaction (Table 24). 
 
 
Entry Solvent (conc.) Temp (ºC) Time (h) Yield (%) 
1 THF (0.1M) 0 16 - 
2 “ 60 “ - 
3 Toluene (0.3M) “ 1 53 
4 “ “ 0.5a 74 
 
a – reaction sonicated. 
Table 24 – Mitsonobu etherification of primary alcohol 240. 
 
Initial attempts were carried out using DIAD and triphenylphosphine in THF but no reaction occured 
up to 60 ºC (entries 1 and 2).  However, reaction was achieved when employing toluene at increased 
concentration; phenyl ether 250 was isolated in 53% yield (entry 3).  Sonication of the reaction, under 
otherwise identical conditions, generated the product 250 in 74% yield (entry 4). 
 
Having carried out the final 3 synthetic steps (hydrogenation/alkylation, imide reduction, Mitsonobu 
etherification) on a model system, application of the identified conditions to the desired 
azabicyclo[2.2.2]octane system was required. 
 
2.2.2.5.8 Circumventing Palladiumd Cross Coupling: 
The low yield and adverse reactivity observed when employing vinyl silane 226 and vinyl stannane 
232 in Hiyama and Stille coupling protocols instigated the search for a high yielding alternative to 
these Pd cross-coupling based approaches. 
 
One such simpler, although less convergent, strategy comes from installation of the i-1 isoleucine 
substituent onto the pyridine precursor to the 1,2-DHP Diels-Alder partner in the first reaction step 
(Scheme 62). 
 
 
Scheme 62 – Synthesis of 3-alkyl pyridine 252. Reagents and conditions: (i) 2-Bromobutane, LDA, -78 ºC → RT, 
2 h.  
 
Installation of the desired isoleucine side-chain can be achieved by lateral benzylic deprotonation of 
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3-picoline 251 and alkylation of the resulting benzyl lithium species with 2-bromobutane.  This 
allowed generation of the required 3-substituted pyridine 252 in 85% yield. 
 
2.2.2.6 Future Work 
Installation of the remaining substituents and generation of the complete mimetic 209 from 3-picoline 
derived pyridine 252 can be envisaged following a sequence of reactions similar to those described 
previously (Scheme 63). 
 
 
Scheme 63 – Proposed application of identified protocols for synthesis of complete α-helix mimetic 209. 
Reagents and conditions: (i) 2-Bromobutane, LDA, -78 ºC → RT, 2 h. (ii) (a) benzylchloroformate (1.1 equiv.), 
THF, -78 °C, 1h. (b) N-selectride, -78 °C, 1 h. (c) H2O2, NaOH, RT, 16 h. (iii) Toluene, 180 ºC, MW, 1 h. (iv) iso-
propanal, H2, MeOH, RT, 16 h. (v) NaBH4, EtOH (3M), Δ, 48 h. (vi) Phenol, DIAD, PPh3, Toluene (0.3M), 
sonicate, 60 ºC, 30 min.  
 
Using the described procedures, synthesis of the desired α-helix mimetic 209 should be achieved in 
6 steps from 3-picoline 251.  Mirroring the reactivity of the model system, hydrogenation of the 
bicyclic alkene 254 would be expected to occur from the desired face, resulting in the required 6R 
stereochemistry of the i-1 substituent.  Unlike investigation of the imide reduction on model succinyl 
imides, reduction of succinimide 255 requires regiochemical control for formation of the required 
acyclic system of 256.  Generation of such regiochemical control will require stringent investigation. 
 
Unfortunately, in the time frame of this PhD research complete synthesis of this mimetic has not been 
possible and will be handed on to a new student. 
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2.2.3 Cresset VS 
As an entry point to more conventional drug-like small molecule CBIs, a Cresset VS was employed.  
Unlike the Cresset VS undertaken to identify small molecule modulators acting at the LBP, no small 
molecule query exists for the LRH-1 AF-2.  The well-explored nature of cofactor binding to NR AF-2 
sites, however, presented an opportunity to utilise the coordinates from a section of an X-ray crystal 
structure of LRH-1 bound to corepressor protein Dax-1 as a novel query.  
 
2.2.3.1 Generation of VS Query 
6 of the 7 crystal structures of hLRH-1, published in 2005, were obtained through cocrystallisation 
with one of either coactivator NR-box TIF-2 or corepressor SHP peptides.  These peptides bind 
through the conserved LXXLL NR-boxes of cofactor proteins.  In 2008 however, Sablin et al. 
published the first X-ray crystal structure of a full cofactor protein bound to a NR.207  The structure of 
hLRH-1 bound to full corepressor protein Dax-1 revealed that the binding interface was mediated by 
a unique conserved PCFXLP sequence present on a loop portion of the cofactor (Figure 74). 
 
 
Figure 74 – Images of Sablin’s LRH-1/Dax-1 crystal structures (LRH-1, dark blue; Dax-1, light green; Dax-1 
PCFXLP interface, red). Left – Image of full LRH-1/Dax-1 trimeric structure. Right – Truncated Dax-1 PCFXLP 
interface at LRH-1 AF-2 (PDB:3F5C). 
 
The LRH-1/Dax-1 structure revealed a trimeric structure comprising LRH-1 bound to 2 Dax-1 units; 
both Dax-1 proteins were shown to be required for full repression of LRH-1 and both were observed 
to bind to LRH-1 via the previously unobserved PCFXLP interface.  The structure of this PCFXLP 
sequence was considered to present an exciting starting point for creation of a query for the Cresset 
VS. 
 
To this end, the PCFILP sequence of the Dax-1 interface was selected was use as a query.  To 
prepare the sequence for use as a VS query, removal of extraneous portions of the peptide was 
carried out.  Firstly, the i+1 proline residue was removed as it occupies the region over H12, which is 
very solvent exposed.  As a consequence, a small molecule occupying this region would incur 
entropic penalty through competition with native water.  Secondly, the i+3 phenylalanine was 
truncated to an alanine as this amino acid is solvent exposed, playing no role in the interface. 
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2.2.3.2 Cresset VS 
Having done this, Caroline Low generated field point structure 259 from the modified pentapeptide 
257 (Figure 75). 
 
 
Figure 75 – Generation of FieldPoint structure 259. 
 
In an analogues manner to the field point structure of 5l, field point structure 259 was utilised as the 
Cresset VS query identifying 200 hit compounds (electronic support information and Figure 76). 
 
 
Figure 76 – A selection of hits from Cresset VS output. 
 
Because the field point query 259 was big relative to that deployed previously, this resulted in 
identification of significantly larger and more branched small molecules than those identified in the 
previous Cresset VS.  Given the limitations identified in the Katzenellenbogen HTS approach to CBI, 
discovery of such hits represent a very promising highly branched area of chemical space. 
 
More so than for the first Cresset VS, financial resources were limited for procurement of hits so the 
selection critera were centered on the difference of hit compound structures.  12 compounds that 
contained varied heterocyclic components to their branched structures, and some polycyclic 
compounds, were selected from the top 30 VS hits (electronic supporting information). 
 
2.2.3.3 In Vivo Analysis 
The 12 purchased compounds were initially evaluated in the cell-based assay discussed above 
(Figure 77). 
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Figure 77 – Cell-based analysis of 12 Dax-1 Cresset sits. 
 
Gratifyingly, the majority of the compounds displayed very little agonism of LRH-1 relative to 5a 
described by Whitby et al.  Compounds AB_DC008 (264) and AB_DC012 (265) displayed consistent 
dose-dependant antagonism of LRH-1 (Figure 78). 
 
 
Figure 78 – Identified LRH-1 Antagonists. 
 
The two antagonists AB_DC008 (264) and AB_DC012 (265) displayed IC50s of 15.1 and 7.5 µM 
respectively.  Due to its lower IC50, AB_DC012 (265) was selected for lead development. 
 
2.2.3.4 Computational Investigation 
Following cell-based analysis and lead selection, I carried out a docking study on AB_DC012 (265) 
and utilised solvent mapping to analyse the LRH-1 AF-2. 
 
2.2.3.4.1 FTMAP Solvent Mapping Analysis: 
To first analyse the AF-2 of LRH-1, solvent mapping server, FTMAP,31 was utilised.  Appreciating the 
absence of protein flexibility in this software, all publically available 3D structures of LRH-1 were 
submitted in an effort to approximate the potential protein flexibility of this highly conserved region of 
the protein (electronic supporting information). 
 
As discussed above (section 1.2.3.1.2), the FTMAP software uses solvents to identify the most 
important areas of small molecule binding.  The software expresses these areas through output of 
the submitted 3D protein structure with the generated solvent clusters, ‘consensus sites’, 
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superimposed on top.  Quantitatively, it also generates tables with the number of H-bonding and 
nonbonding contacts made between all solvent probes and each amino acid throughout the mapping 
analysis. 
 
FTMAP analysis identified 3 consensus sites in the AF-2 region of LRH-1 (PDB code 1YUC) (Figure 
78). 
 
 
Figure 78 – FTMAP result of mapping LRH-1 (PDB code 1YUC) with no cofactor peptide. Largest consensus 
site, CS1 (pink) followed by second largest, CS2 (yellow) and CS3 (blue). 
 
The most highly ranked consensus site (CS1), a group of 20 probe clusters, is located in position of 
the cofactor i+1 leucine at the deepest section of the hydrophobic AF-2 region.  The second 
consensus site (CS2), occupies the position of the i+5 leucine with many of the solvent probes 
forming hydrogen bond interactions with the carbonyl backbone of the Q374 amino acid.  Finally, the 
third consensus site (CS3) occupies the cleft between R361 of the charge clamp and adjacent F354 
usually occupied by the i+4 leucine.  Despite the well-documented charge-clamp of the AF-2 R361 
and E534, CS3 forms very few hydrogen bond contacts with the hydrophilic arginine 361 amino acid. 
 
The numerical output of the non-bonding and H-bonding contacts between the protein and solvent 
probes was tabulated to allow for visual analysis (Figure 79). 
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Figure 79 – Number of non-bonding and H-bonding contacts by solvent probes per residues during FTMAP 
analysis. 
 
Analysis of the data suggests that the majority of the contacts formed during the solvent mapping 
were non-bonding, with these contacts often being 10-30 fold more numerous per amino acid than H-
bonding contacts.  This is unsurprising as the side chains of hydrophobic amino acids (such as V357, 
V371 and L378) form the majority of the AF-2 binding surface. 
 
The location and variation of H-bond contacts, however is less intuitive.  The well-described charge-
clamp residues, R361 and E534, generate a small percentage of the H-bond contacts with the 
fragment like solvent probes.  As visually identified from the location of CS1, the most H-bond 
contacted amino acid is Q374.  These contacts, along with the contacts made with V371 and M375, 
are H-bond donor interactions from acid probe hydrogen atoms to the main chain carbonyl oxygen.  
 
This analysis suggests that significant gains in binding efficiency will be made from entropy 
enhancing hydrophobic interactions over an extended area of the AF-2 surface; as suggested in the 
Katzenellenbogen analysis.  The concentration of H-bond contacts at less solvent exposed locations 
suggests that significant enthalpic gains can be achieved from use of these less obvious and intuitive 
heteroatom interactions. 
 
2.2.3.4.2 Docking Investigation: 
Following the FTMAP analysis, which aimed to provide an insight into beneficial interactions that can 
be made, docking of the Cresset VS antagonists was undertaken to guide design of analogues for 
synthesis. 
 
To begin the analysis, Glide docking followed by Prime MMGBSA scoring of AB_DC008 (264) and 
AB_DC012 (265) was carried out in an effort to understand their active binding mode (Figure 80). 
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Figure 80 – Top docking pose of (a) AB_DC008 (264) and (b) AB_DC012 (265) at LRH-1 AF-2. 
 
Of the 15 poses generated in Glide docking, the top 7-10 for each molecule displayed a near 
identical orientation suggesting a conserved binding mode.  The two molecules both occupy the 
majority of the areas occupied by cofoactor peptides and those areas highlighted in FTMAP analysis 
(above).  The hydrophobic cores of the molecules occupied the length of the groove with the 
branched region of the compounds occupying the i+5 leucine position and aromatic groups 
occupying the cleft between R361 and F366 occupied by the i+4 substituent. 
 
Functionality of both molecules also generated hydrogen bond interactions with the R361 charge-
clamp residue at the south of the AF-2 although non were generated with the highly solvent exposed 
E534.  Promisingly, no part of the molecules generated H-bond interactions highlighted by the 
FTMAP CS2 solvent probes suggesting positions for potential improvement in both antagonists if 
such contacts could be made. 
 
Both compounds displayed similar calculated binding efficiencies (ΔGbind) with AB_DC008 displaying 
-25.3 kCalmol-1 and AC_DC012 = -28.77 kCalmol-1.  The slightly elevated binding efficiency 
calculated for AB_DC012 concurs with the increased antagonism observed in vivo although relevant 
correlation from 2 data points is unreliable. 
 
To drive design of analogues, in silico modification of AB_DC012 was investigated. 
 
(a) Modification 1 - Based on its late installation in our envisaged chemical synthesis of this 
compound class (see 2.2.3.5), initial in silico modification was based on variation of the pyridyl ether 
moiety (Table 25). 
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Entry R X1 X2 ΔGbind (kCalmol-1) Compound # 
1 NO2 O N -28.77 266 
2 COOH “ “ -26.09 267 
3 COCH3 “ “ -27.97a 268 
4 NO2 O C -28.18b 269 
5 “ S N -31.65 270 
 
a – Top pose was not the same as AB_DC012; same pose was #5 and had ΔGbind = -27.11 kCalmol-1. b - Same pose was #12 
and had ΔGbind = -23.17 kCalmol-1. 
Table 25 – Docking of in silico modified pyridine analogues. 
 
Modification was initially made to the nitro substituent to observe if an alternative, less metabolically 
unstable, H-bond moiety could be identified (entries 2 and 3).  However, both carboxylic acid, 267, 
and methyl ketone, 268, moieties did not improve the binding displaying reduced ΔGbind of -26.09 and 
-27.97 kCalmol-1 respectively.  Interestingly the top 4 poses generated of methyl ketone analogue 
268 were not that of the AB_DC012 (266) pose (Figure 81). 
 
 
Figure 81 – (a) Top binding pose of 268. (b) 5th Binding pose of 268. 
 
The top 4 poses (Figure 81, a) prefer a binding position in which the amide bond is rotated 180º 
placing the pyridine group on the shelf adjacent to the hydrophobic grove (where the NR-box i-1 
leucine resides).  This preference could be caused by the increased bulk of the methyl ketone moiety 
sterically clashing with R361 or F366.  The preferred mode also suggests that modification of the 
molecule to allow occupation of this shelf while also occupying the R361/F366 cleft would 
significantly improve molecule binding. 
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Modification of the pyridine ring to a phenyl ring, 269, did not improve binding with the top pose, 
ΔGbind of -28.18 kCalmol-1, also preferring to occupy the AF-2 shelf region (entry 4).  Finally, 
modification of the aryl ether to a thioether, 270, actually improved binding displaying a ΔGbind of -
31.65 kCalmol-1 (entry 5).  This increased binding affinity was attributed to the increased bulk of 
sulphur, relative to oxygen, shifting the pyridine ring further into the R361/F366 cleft. 
 
(b) Modification 2 – Secondly, variation of the furan rings was investigated with the aim of generating 
H-bond contact with the Q374 backbone as identified through FTMAP analysis (Table 26). 
 
 
Entry X1 X2 ΔGbind (kCalmol-1) Compound # 
1 O O -28.77 271 
2 “ CH2 -31.04a 272 
3 CH2 O -27.90 273 
4 “ CH2 -26.31 274 
5 NH NH -26.11b 275 
 
a – Top pose was not the same as AB_DC012; same pose was #9 and had ΔGbind = -26.34 kCalmol-1. b - Same pose was #12 
and had ΔGbind = -21.80 kCalmol-1. 
Table 26 – Docking of in silico modified furan analogues. 
 
To first evaluate the requirement for the furan ring, alternation of the X1 and X2 oxygen for carbon 
was undertaken (entries 2-4).  Of these, only analogue 272, in which X2 is carbon resulted in an 
increase in the calculated binding efficiency (entry 2).  The increase bulk of CH2 in this analogue 
causes a shift in the core of 272, resulting in the pyridine again shifting out of the R361/F366 cleft.  
Finally, variation of the furan rings to pyrroles with alternation of X1 and X2 from oxygen to nitrogen 
was undertaken (entry 5).  It was hoped that the pyrrole NH bonds might act as H-bond donors, 
however, in the event these analogues did not generate the desired contacts: these compounds 
displayed a decreased ΔGbind of -26.11 kCalmol-1. 
 
(c) Modification 3 - Given the inability of the investigated heterocycles to generate H-bond contacts 
with the Q374 backbone, analogues 276 and 277 were created with acyclic alkyl alcohol side chains 
(Figure 82).  
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Figure 82 – Structure of compound 276 and its only observed binding mode (right). 
 
Initial analogue 257, designed based on deconstruction of the furan heterocycle, did not generate H-
bond contact with the Q374 backbone.  The propyl chain presented the hydroxyl group at a distance 
slightly further from the heterocyclic core, again resulting in the only observed pose being that of the 
pyridine occupying the shelf adjacent to the AF-2 cleft.  Despite this altered binding mode, the 
binding energy was calculated as being significantly improved with 257 displaying a ΔGbind of -32.09 
kCalmol-1. 
 
Docking of the shortened alkyl chain analogue 277 revealed some poses, which did generate H-
bonding with the Q372 backbone however the calculated binding affinity, ΔGbind = -27.23 kCalmol-1, 
suggested this contact would not improve the antagonism of AB_DC012 (265). 
 
Despite the inability to gain desired H-bond contacts with these analogues in silico, synthetic 
investigation of alternative aromatic and alkyl analogues was anticipated to reveal interesting SAR. 
 
(d) Modification 4 - In search of molecules capable of both occupying the R361/F366 cleft and the 
shelf region, analogues with extra branching from the N-1 nitrogen of the pyrrolidine ring of the core 
structure were investigated (Table 27). 
 
 
Entry Compound ΔGbind (kCalmol-1) 
1 278 -16.73 
2 279 -37.26 
3 280 -19.56 
Table 27 – Docking of N-1 alkyl analogues. 
 
These analogues, envisaged for synthesis via hydrogenation/alkylation, performed very poorly in 
docking experiments.  Despite the high-calculated binding efficiency of ethyl alcohol analogue 279, 
docking of these analogues identified no single conserved pose (Figure 83). 
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Figure 82 – Top 15 docking poses of (a) compound 278 and (b) compound 279. 
 
The lack of a conserved binding mode suggests the unsaturation in the core pyrrolidine ring is 
required for the observed cell-based antagonism and saturation of the ring would destroy this.  For 
this reason synthetic evaluation of these analogues was not prioritised for investigation. 
 
In order to evaluate the in silico modified structures, synthesis and cell-based analysis of hit analogue 
AB_DC012 was required. 
 
2.2.3.5 Synthesis and Evaluation of AB_DC012 
To validate the antagonism of AB_DC012 (265) observed in the cell-based assay, and to generate 
more material for use in further assays, synthesis of this compound was carried out (Scheme 64). 
 
 
Scheme 64 – Synthesis of AB_DC012 (265). Reagents and conditions: (i) 2M NaOH, furaldehyde, EtOH, 15 min. 
(ii) NH2NH2.H2O, MeOH, Δ, 16 h. (iii) Chloroacetyl chloride, K2CO3, EtOAc, 30 min. (iv) 3-Hydroxy-2-nitro 
pyridine, KI, K2CO3, Acetone, 24 h. 
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Synthesis commenced with condensation of cyclohexanone with furaldehyde in the presence of 
sodium hydroxide generating bis-α,β-unsaturated ketone 281 in 86% yield.  Cyclisation with 
hydrazine hydrate then allowed construction of the core heterocycle 282 as a mixture of 
stereoisomers at H-3a.  N-acylation was then carried out without purification to give the chloro acteyl 
derivative 283 in 72% yield over the two steps.  At this stage, separation of the two diastereoisomers, 
(3R*,3aR*) and (3R*,3aS*), was achieved by silica gel chromatography in yields of 14% and 70% 
respectively.  A portion of un-separated material was then subject to nucleophilic substitution of the 
α-chloro substituent by the 3-hydroxy-2-nitro pyridine to give product AB_DC012 (265) as a 4:1 
mixture of diastereomers in 40% yield. 
 
Having synthesised the two stereoisomers of AB_DC012, they were both submitted for evaluation in 
the cell-based dual reporter assay (Figure 84).  
 
Figure 84 – Activity of resynthesised AB_DC012 (265) (4:1 mixture of diastereomers). 
 
This data looked similar to that obtained from the commercial sample of this compound.  Guided by 
the docking investigation, synthesis of analogues was then undertaken. 
 
2.2.3.6 Analogue Synthesis and Evaluation 
(a) Modification 1 - Due to synthetic ease, generation of a small array of analogues varying the 
pyridine group was undertaken (Table 28). 
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Entry X R1 R2 Yield (%) Number Compound ID 
1 N 2-NO2 - 16 265 AB_DC012 
2 CH 2-NO2 - 48c 269 AB_DC015 
3 N - - 5 284 AB_DC016 
4 N (4-hydroxy) - - - b 285 AB_DC017 
5 N (2-hydroxy) - - 7 286 AB_DC018 
6 N 6-Me - 3 287 AB_DC019 
7 N (2-hydroxy) 3-NO2 4-Me 4 288 AB_DC020 
 
a compound is methylpyridine analogue. b no yield of compound. c compound isolated as a mixture of diastereomers. 
Table 28 – Synthesis of analogues of AB_DC012 (265) containing alternative phenol-based residues. Reagents 
and conditions: (i) 3-Hydroxy-2-nitro pyridine, KI, K2CO3, Acetone, 24 h. 
 
Synthetic selection was based on the availability of phenolic monomers and also some key 
analogues from the Maestro investigation. The yields of pyridine-based analogues were extremely 
poor.  Poor mass recovery following workup would suggest that this could be due to the formation of 
water-soluble pyridinium salts due to favoured N-alkylation (previous attempts had involved pre-
mixing of base and hydroxypyridine and portioned addition of the deprotinated salt; this method was 
not used due to the nature of the parallel synthesis).  Synthesis of AB_DC012 (265) itself was 
achieved in a reduced yield of 16% compared to the prior yield of 84% (entry 1).  Phenol analogue 
AB_DC015 (269) was identified in docking studies to have increased binding to the LRH-1 AF-2 and 
synthesis was achieved in a yield of 48%.  The remaining analogues, though sysnthesised in poor 
yield, were isolated in sufficient quantities to allow for initial in vivo analysis. 
 
Synthesis of analogues varying the nitro moiety was attempted but unfortunately the final substitution 
reactions with monomers containing the desired methyl ketone and carboxylic acid moieties yielded 
no product. 
 
Analysis in the dual-reporter assay revealed a number of these analogues displayed the same levels 
of antagonist behaviour as initial hit antagonist AB_DC012 (Figure 85). 
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Figure 85 – Activity of analogues in cell-based assasy. 
 
Two analogues, AB_DC015 (269) and AB_DC016 (284), both displayed antagonistic activity relative 
to AB_DC012 (265) although elucidation of their IC50 could not be achieved due to anomalous 
readings at 25 µM. 
 
These analogues were also evaluated in the newly developed AlphaScreen in vitro assay (Figure 
86). 
 
 
Figure 86 – In vitro analysis of synthesised analogues.  
 
In this assay the compounds were screened at a single concentration of 10 µM.  At this concentration 
only AB_DC15a,b and AB_DC16a effected a lower than 50% inhibition in peptide recruitment.  This 
data concurred with the cell-based data, which also identified these analogues as some of the most 
potent.   
 
Although this data does not confirm the mode of action of these molecules to be by direct competition 
with cofactor peptides, it does confirm the antagonism identified in the cell-based dual reporter assay 
previously utilised. 
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(b) Modifications 2 & 3 – Synthesis of a variety of analogues varying the furan rings of AB_DC012 
(265) was then undertaken (Table 29). 
 
 
Entry Condensation conditions R
1 R2 Yield Compound Number 
Final 
Yield 
(%)a 
Compound 
Number 
Compound 
Identifier 
1 i CH-2-pyrrole 2-pyrrol - 289 -
b 275 - 
2 i CH-3-furan 3-furan 85 290 36 297 AB_DC021 
3 i CH-2-thiophene 
2-
thiopehen 95 291 43 298 AB_DC022 
4 i phenyl phenyl 96 292 57 299 AB_DC023 
5 ii H 2-furan 72 293 63 300 AB_DC024 
6 iii CH-2-THF 2-THF 62 294 23 301 AB_DC025 
7 iii CH-nHex nHex 61 295 45 302 AB_DC026 
8 iii CH-iPr iPr 53 296 -b 303 - 
 
a – Yield over 2 steps from diene. b – Cyclisation failed. 
Table 29 – Synthesis of aryl and alkyl furyl analogues 275 and 297-302. Reagents and conditions: (i) 2M NaOH, 
Aldehyde, EtOH, 15 min. (ii) 1M NaOH, Aldehyde, EtOH (0.05M), 15 min. (iii) TMSCl, NaI, MeCN, RT, 16 h. (iv) 
(a) NH2NH2.H2O, MeOH, Δ, 16 h. (b) Chloroacetyl chloride, K2CO3, EtOAc, 30 min. (v) Hydroxy pyridine, KI, 
KHCO3, Acetone, 24 h. 
 
Initial condensation was carried out using a variety of aldehydes under 3 different reaction conditions.  
Condensation of aryl aldehydes was successful using base-catalysed condensation generating 
dienes 289-292 in >85% yields (entries 1-4).  Synthesis of mono α,β-unsatured furan analogue 293 
required excess of cyclohexanone to ensure minimal formation of the undesired disubstituted product 
(entry 4).  In the case of alkyl aldehydes, use of a milder Lewis acid catalysed procedure was 
required to eliminate deprotonation of the aldehyde Cα proton (entries 6-8).208 Use of the required 
alkyl aldehydes generated the desired dienes 294-296 in >46% yields. 
 
The generated α,β-unsaturated cyclohexanone analogues were then taken through the hydrazine 
cyclisation/acylation steps to complete the heterocyclic core and install the α-chloro amide moiety.  
α-Chloro ketone compounds were taken into the final substitution reaction with the required 3-
hydroxy-2-nitro-pyridine to generate the complete analogues AB_DC021-027 (297-302) in 23-63% 
yields. 
 
These analogues have been submitted for cell-based or in vitro analysis however analysis using 
these assays has not yet been carried out. 
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(c) Modification 4 - Branching of the lead CBI AB_DC012 (265) was found to be advantageous in 
docking studies due to occupation of a ‘shelf’ adjacent to the main hydrophobic groove at the AF-2.  
Investigation of the proposed hydrogenation/alkylation procedure was not considered for 
investigation due to the high disorder observed in the docking generated binding modes.  Analysis of 
the binding mode and geometry of AB_DC012 (265) revealed that substitution of the amide carbonyl 
with a similar, though substituted, sp2 moiety would enable occupation of both regions of the AF-2 
(Figure 87). 
 
 
Figure 87 – Proposed branched AB_DC012 analogue for occupation of the AF-2 shelf. 
 
Branching at this position was proposed by amidination allowing for installation of variable side 
chains.  Work by Charette et al.209 described a mild method for synthesis of amidines by electrophilic 
activation of amides.  Use of these conditions for the conversion of the amide in AB_DC012 (265) to 
a benzyl amidine 306 (cf. XXII) was attempted (Scheme 65). 
 
 
Scheme 65 – Attempted synthesis of branched amidine analogue 306. Reagents and conditions: (i) Pyridine (3 
equiv.), Tf2O (1.3 equiv.), CH2Cl2, -40 °C → RT, 2.5 h. (ii) BnNH.HCl (3 equiv.), -40 °C → RT, 20 h. 
 
Consumption of the amide starting material 265 was observed by TLC together with an upfield shift of 
the peak corresponding to the methylene α-to the amide in the 1H NMR spectrum of the crude 
material.  However, the spots observed by TLC were not significant products and analysis and 
isolation of compounds corresponding to the other spots did not identify the amidine product.  To 
validate the procedure, use of the model amide 307 described in the work of Charette et al. was 
carried out (Scheme 66).   
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Scheme 66 – Attempted model amidine synthesis. Reagents and conditions: (i) Pyridine (3 equiv.), Tf2O (1.3 
equiv.), CH2Cl2, -40 °C → RT, 2.5 h. (ii) BnNH.HCl (3 equiv.), -40 °C → RT, 20 h. 
 
Analogous to the reaction with AB_DC012 (265) the product was observed by TLC, and in the 1H 
NMR of the crude material, though isolation could not be achieved.  The crude mass recovery was 
150% (accounting for the presence of excess benzylamine) although fractions isolated from silica gel 
chromatography only accounted for 60% of this amount – the majority being recovered benzylamine. 
 
Synthesis of such analogues was not achieved during this PhD research despite the potential 
increase in binding affinity this modification would offer. 
 
2.2.3.7 Future Work 
Branched analogues of this nature could significantly improve the binding affinity of the AB_DC012 
antagonist.  Synthesis of branched amidine analogue 306 (or an analogous branched compound) 
would allow evaluation of the effect of such branching prior to synthesis of analogues combining the 
previously identified improvements. 
 
Eventual development of an assay to dissect the true mode of action of these analogues is required 
to confirm their true role as coactivator binding inhibitors. 
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Chapter 3 – Summary 
 
The primary objective of this work was to develop new modulators of LRH-1 with application as 
therapies for breast cancer. The absence of definitive natural ligand, the rigid nature of the LBD and 
the large LBP make discovery of small molecule modulators of LRH-1 challenging.  Given these 
challenges, this research combined multiple approaches investigating the creation of novel small 
molecules that, in the first instance, act at the large hydrophobic LBP, and secondly inhibited cofactor 
binding to the conserved AF-2 of LRH-1.   
 
Ligand Binding Pocket 
In the absence of a natural ligand, state-of-the-art ligand-based VS was utilised to access novel small 
molecules capable of binding at the LBP.  Synthesis of 10 of Whitby’s 1-amino-cis-bicyclo[3.3.0]oct-
2-ene enabled calibration of the cell-based dual reported assay utilised by our collaborators revealed 
an in vivo potency 10 fold weaker than the published in vitro EC50 values.  This decreased efficacy 
suggested concurrence with the increased complexity of in vivo NR modulation relative to the 
simplistic in vitro recruitment of cofactors.   
 
The cell-based nature of the utilised assay also resulted in the synthesised compounds displaying in 
vivo agonism that did not correlate to their described in vitro efficacy.  Consequently, compound 5l 
was selected as a query for ligand-based VS.  Submission of the query to Cresset and SHop VSs 
identified 2 promising agonist leads, which displayed significant reduced EC50 value to that of the 5l 
query (Scheme 68). 
 
 
Scheme 68 – Most promising hits identified by ligand-based VS. 
 
Synthesis of analogue arrays of these hit compounds revealed an analogue specific variability in the 
cell-based assay’s transfection efficiency; an apparent inherent limitation to such assay, which 
significantly skewed normalised data used in selection of the hit VS compound.  To circumvent this, 
an alternative AlphaScreenTM in vitro assay was utilised for screening although optimisation for 
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detection of antagonists resulted in limited insight into agonistic SAR.  Re-optimisation of this assay 
for detection of agonists is required for analysis and optimisation of the synthesised agonist arrays.   
 
Despite not observing antagonism in any of the synthesised compounds, collaboration with the group 
of Eric Ortlund is aimed at generating a small molecule co-crystal of these analogues with LRH-1 to 
facilitate rational extension of their structures into H-12.  In the mean time, further analysis and 
synthetic investigation is required to develop the potential of these new series of LRH-1 agonists and 
is currently being carried out by another Spivey group member, Melanie Mueller. 
 
AF-2 
α-Helix Mimetic - Due to the rigid nature of the LRH-1 H-12 created by its extended H-2, the ability of 
small molecules to disrupt cofactor binding through action at the LBP is unfounded.  By directly 
disrupting cofactor binding to the AF-2, small molecules would circumvent this uncertainty while also 
avoiding potential resistance observed in small molecule therapeutics acting at NR LBPs. 
 
The first approach to achieving this was the rational design of a small molecule mimetic of the α-
helical cofactor NR-box peptide.  Following alanine mutation experiments conducted by Xu et al., 
representation of 5 out of 6 consecutive amino acid residues was desired.  Geometric analysis of the 
X-ray coordinates of TIF-2 cofactor peptide bound to LRH-1 revealed the suitability of aza-
bicyclo[2.2.2]octane 146 as a novel, more comprehensive α-helix mimetic than those in literature 
(Figure 88). 
 
 
Figure 88 – Designed α-helix mimetic from TIF-2 crystal structure coordinates. 
 
The foundations for the synthesis of mimetic 146 were laid by investigation of model system 148, 
however low reactivity of acyclic dienophiles with 1,2-DHPs was insufficient to progress this synthetic 
route.  Subsequent re-design identified an alternative mimetic (203) with an inverted C-5 geometry 
allowing synthesis from highly reactive cyclic N-aryl maleimide dienophiles (Scheme 69). 
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Scheme 69 – Left – Disconnection of model mimetic 148. Right – Alternate mimetic 203 and disconnection to N-
aryl maleimide 224. 
 
The use of model systems has elucidated the synthetic sequence and conditions to affect all desired 
transformations.  Due to the low yield of attempted palladium cross coupling procedures to install the 
i-1 isoleucine substituent, future work requires these conditions to be applied to 3-alkyl pyridine 252 
(Figure 89). 
 
 
Figure 89 – 3-Alkyl pyridine 252 with pre-installed i-1 residue. 
 
Following complete synthesis, biological evaluation is required to determine the benefit of this more 
comprehensive α-mimetic. 
 
Cresset VS: As a parallel approach and to access more conventional drug-like CBIs, a cresset VS 
was carried out using the novel Dax-1 corepressor protein PCFILP interface.  12 highly branched VS 
hits were procured and 2 compounds [AB_DC008 (264) and AB_DC012 (265)] displayed single 
figure µM IC50 values in both in vivo and in vitro assays (Figure 90). 
 
 
Figure 90 – Antagonist molecules identified by Cresset VS. 
 
AB_DC012 (265) was selected and docking driven synthesis identified analogues, which displayed 
equal antagonistic potency.  Their single figure µM potency mirrors that of the CBI compounds 
described by Katzenellenbogen et al.131 During the docking investigation preferential occupation of 
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the AF-2 shelf by the hydroxyl pyridine moiety of AB_DC012 revealed the potential of branching off 
the amide carbonyl to increase potency and gain sub µM antagonism (Figure 91). 
 
 
Figure 91 – Amidine branching of antagonist AB_DC012. 
 
Although not achieved, synthesis of the proposed branched amidine analogues is required to 
establish if increased occupation of the AF-2 binding surface correlates to increased potency. 
 
These small molecules represent the first antagonists of LRH-1 although their precise mode of action 
required testing in more complex in vitro assays such as those described by Katzenellenbogen.132 
 
Overall 
The combination of ligand-based VS, docking driven synthesis and rational design in this research 
has resulted in identification of the first antagonists of LRH-1.  With on going synthetic and 
crystallographic investigations driving optimisation of all molecules discussed here, the goal of 
developing the first LRH-1 modulator as a small molecule therapy for breast cancer could be 
achieved.  
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Chapter 4 - Experimental 
 
General Directions 
Melting points were determined using a Reichardt hot stage apparatus and are uncorrected. Infra-red 
spectra were recorded using a Perkin-Elmer Paragon 1000 FT-IR infra-red spectrometer. All spectra 
were recorded as solid samples unless otherwise stated.  1H nuclear magnetic resonance (NMR) 
spectra were recorded at 400 MHz on a Bruker DRX spectrometer at ambient temperature. 13C 
nuclear magnetic resonance spectra were recorded at 100 MHz on a Bruker DRX spectrometer at 
ambient temperature.  All chemical shifts (δ) were referenced relative to the deuterated solvent used 
and are reported in parts per million (ppm).  The multiplicities of 1H signals are designated by the 
following abbreviations: s = singlet; d = doublet; dd = double doublet; t = triplet; q = quartet; br = 
broad; m = multiplet.  All coupling constants J are reported in Hertz. 13C Signals were assigned by 
running 1H/13C coupled HSQC/HMQC spectrum in the case of some compounds.  Mass spectra were 
recorded at low resolution (LRMS) and high resolution (HRMS) on either a VG platform II or VG 
autospec mass spectrometer using electron ionisation (EI).  Flash chromatography (FC) was carried 
out using Kieselgel 60 (230-400 mesh) using solvents specified.  Thin layer chromatography (TLC) 
was performed on pre-coated plates (0.25mm) silica UV254.  The plates were visualised by ultraviolet 
light followed by staining with or KMnO4, vanillin, ninhydrin, phosphomolybdic acid (PMA) or 
anisaldehyde.  
 
All reactions were performed under anhydrous conditions in an atmosphere of nitrogen unless stated 
otherwise.  All reagents were used as received from commercial suppliers unless stated otherwise. 
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Oct-1-en-6-yne (12).210  
n-Butyl lithium (8.12 mL, 16.25 mmol) was added dropwise to a stirring solution of 
propyne (Excess amount condensed in on cold finger) and DMPU (1.96 mL, 16.26 
mmol) in THF (40 mL) at -78 °C.  The solution was stirred for 1 h before adding a 
premixed, cold (-78 °C) solution of 5-bromopent-1-ene (1.75 mL, 14.77 mmol) and TBAI (0.54 g, 1.48 
mmol) in THF (15 mL).  The solution was allowed to warm to room temperature before heating at 
reflux for 16 h.  On completion the reaction was quenched with saturated ammonium chloride (50 mL) 
before extracting with diethyl ether (3 × 40 mL).  The combined extracts were washed with water (3 × 
30 mL), brine (3 × 30 mL), dried over magnesium sulfate and concentrated under reduced pressure 
to give a crude yellow-orange liquid.  Purification by FC (petroleum ether) gave enyne 12 as a 
colourless liquid (610 mg, 62%).  
Rf = 0.56 (Hexane); IR (neat): υmax = 3077 (C=CH2), 2920 (C≡C-CH3) cm-1; 1H NMR: δH (400 MHz, 
CDCl3); 5.81 (1H, ddt, J = 17.1, 10.2 and 6.7 Hz, CH2CH), 5.04 (1H, dq, J = 17.1 and 1.8 Hz, CH2a), 
4.96 (1H, ddt, J = 10.2, 1.8 and 1.1 Hz, CH2b), 2.12-2.18 (4H, m, CHCH2CH2CH2), 1.79 (3H, t, J = 
2.56 Hz, CH3), 1.58 (2H, quintet, J = 7.34 Hz, CH2CH2CH2); 13C NMR δC (100 MHz, CDCl3); 138.0 (d) 
(CH), 114.9 (t) (CH2), 78.9 (s) (CH2C≡C), 75.6 (s) (CCH3), 32.8 (t) (CH2C≡C), 28.2 (t) (CH2CH2CH2), 
18.1 (t) (CHCH2), 3.4 (q) (CH3); LRMS (EI) m/z 108 (M+, 100%), 93 (50), 84 (100), 57 (85); HRMS 
(EI): Found: m/z 108.0891 (M+). C8H12 Requires 108.0939; Δ = 0.4 ppm. 
 
Hept-6-en-1-ynylbenzene (13).210 
According to the method of Buck,210 n-butyl lithium (13.9 mL of 2.12 M in 
hexane, 29.5 mmol) was added to a stirring solution of phenyl acetylene (3.18 
mL, 28.9 mmol) in THF (80 mL) at -78 °C.  The solution was allowed to warm to 
room temperature before adding a premixed solution of 5-bromo-1-pentene (2.56 mL, 24.1 mmol) 
and TBAI (1.00g, 2.68 mmol) in THF (20 mL).  The mixture was heated at a gentle reflux for 16 h 
before cooling to room temperature and quenching with saturated ammonium chloride (90 mL).  The 
aqueous was extracted with diethyl ether (3 × 40 mL), the extracts combined and washed with H2O (3 
× 30 mL), brine (3 × 30 mL), dried with magnesium sulfate and concentrated under reduced pressure 
to give a crude yellow liquid.  Purification by FC (petroleum ether) gave 13 as a viscous colourless 
liquid (2.9g, 71%).  
1H NMR: δH (400 MHz, CDCl3); 7.43-7.40 (2H, m), 7.32-7.28 (4H, m), 5.86 (1H, ddt, J = 17.0, 10.3 
and 6.7 Hz), 5.12-5.07 (1H, m), 5.03 (1H, ddt, J = 10.2, 2.0 and 1.0 Hz), 2.45 (2H, t, J = 7.1 Hz), 2.25 
(2H, q, J = 7.3 Hz), 1.73 (2H, quintet, J = 7.3 Hz); LRMS (ESI) m/z = 170 (M+, 35%). 
 
Phenyl isonitrile.211     
Formanilide (2 g, 16.5 mmol) and DIPA (6.5 mL, 46 mmol) were dissolved in 
dichloromethane (15 mL) and cooled to 0 °C.  POCl3 (1.66 mL, 18.2 mmol) was added 
dropwise and stirring continued at 0 °C for a further 1.5 h.  After warming to room temperature 
sodium carbonate (3.3 g, 31.3 mmol) in H2O (15 mL) was added in a rate so that the temperature did 
not rise above 35 °C.  The mixture was stirred for 1.5 h before adding H2O (20 mL) and 
N
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dichloromethane (20 mL).  The aqueous was extracted with dichloromethane (3 × 20 mL), washed 
with H2O (3 × 20 mL), dried over magnesium sulfate and concentrated under reduced pressure to 
give a crude brown liquid.  Purification by distillation under reduced pressure (bp. 60 °C/ 25 mbar) 
gave phenyl isonitrile as a colourless liquid (0.9 g, 48%).  
1H NMR: δH (400 MHz, CDCl3); 7.39-7.43 (5H, m); LRMS (ESI) m/z = 103 (M+, 100%). 
 
General procedure A (synthesis of (±)-4-octenyl substituted bicyclo[3.3.0]oct-2-enes). 
According to the method of Whitby,212 n-butyl Lithium (1.6 M in hexanes; 1.63 mL, 2.6 mmol) was 
added dropwise to a stirring solution of Cp2ZrCl2 (380 mg, 1.3 mmol) in THF (6 mL) under argon at -
78 °C.  The solution was stirred at this temperature for 1 h before addition of a solution of the 
required enyne (1.3 mmol) in THF (5 mL).  The solution was allowed to warm to temperature over 1h 
followed by stirring for a further 2 h.  The solution was then cooled to -35 °C before addition of freshly 
Kugelrohr distilled phenyl isocyanide (135 mg, 1.3 mmol) followed immediately by 4-octyne (0.25 mL, 
1.61 mmol).  The reaction mixture was then allowed to warm to room temperature and stirred for 1.5 
h before refluxing for 2 h to afford a deep red solution.  The reaction was quenched with MeOH (2 
mL) before pouring onto H2O (20 mL), extracting with diethyl ether (4 × 30 mL), drying over MgSO4 
and concentrating under reduced pressure to give a crude oil. 
 
(±)-3-(E-Oct-4-en-4-yl)-1-phenylamino-2-phenyl-cis-bicyclo[3.3.0]oct-
2-ene (10) 5a.5  
Using the general procedure A, n-BuLi (2.3 M; 1.75 mL, 4 mmol), 
Cp2ZrCl2 (586 mg, 2 mmol), enyne 13 (340 mg, 2 mmol), phenyl isonitrile 
(208 mg, 2 mmol) and 4-octyne (370 µL, 2.5 mmol), after 7 h purifying by 
FC (neutralised with Et3N; 1% ethyl acetate:petroleum ether) gave 10 as 
a pale yellow solid (310 mg, 41%). 
1H NMR: δH (400 MHz, C6D6); 7.36-7.32 (2H, m), 7.30-7.27 (2H, m), 7.20-7.13 (3H, m), 6.89 (1H, t, J 
= 7.3 Hz), 6.77 (2H, d, J = 7.7 Hz), 5.58 (1H, t, J = 7.3 Hz), 3.80 (1H, br s), 3.13 (1H, dd, J = 17.2, 9.7 
Hz), 2.97-2.91 (1H, m), 2.40 (1H, dd, J = 17.2, 3.4 Hz), 2.19 (1H, ddd, J = 13.6, 9.0, 7.0 Hz), 2.07-
1.86 (5H, m), 1.64-1.46 (5H, m), 1.33 (2H, sextet, J = 7.3 Hz), 1.14 (1H, m, J = 12.4, 9.1, 7.0 Hz), 
0.91 (3H, t, J = 7.3 Hz), 0.86 (3H, t, J = 7.3 Hz); LRMS (EI) m/z = 293 ([M-PhNH]+, 80%). 
 
(±)-2-Methyl-3-(E-oct-4-en-4-yl)-1-phenylamino-cis-bicyclo[3.3.0]oct-
2-ene (17) 5b.5  
Using the general procedure A, n-BuLi (1.6 M; 1.62 mL, 2.6 mmol), 
Cp2ZrCl2 (380 mg, 1.3 mmol), enyne 12 (140 mg, 1.3 mmol), phenyl 
isonitrile (135 mg, 1.3 mmol) and 4-octyne (240 µL, 1.6 mmol), after 7 h 
purifying by FC (neutralised with Et3N; 1% ethyl acetate:petroleum ether) 
gave 17 as a pale yellow solid (380 mg, 91%).    
1H NMR: δH (400 MHz, CDCl3); 7.12-7.07 (2H, m), 6.65 (1H, tt, J = 7.3, 1.0 Hz), 6.59-6.56 (2H, m), 
5.26 (1H, t, J = 7.3 Hz), 3.91 (1H, br s), 2.92 (1H, ddq, J = 16.6, 9.8, 2.1 Hz), 2.74-2.68 (1H, m), 2.18-
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2.00 (5H, m), 1.94-1.89 (1H, m), 1.71-1.68 (1H, m, J = 5.1, 2.3 Hz), 1.56 (5H, m), 1.49-1.31 (6H, m), 
0.95 (3H, t, J = 7.3 Hz), 0.91 (3H, t, J = 7.3 Hz); LRMS (EI) m/z = 323 (M+, 30%). 
 
(±)-3-(E-Dodec-6-en-6-yl)-1-phenylamino-2-phenyl-cis-
bicyclo[3.3.0]oct-2-ene (18) 5i.5  
Using the general procedure A, n-BuLi (2.5 M; 1.6 mL, 4 mmol), 
Cp2ZrCl2 (586 mg, 2 mmol), enyne 13 (340 mg, 2 mmol), phenyl 
isonitrile (208 mg, 2 mmol) and 4-dodecyne (420 mg, 2.5 mmol), 
after 7 h purifying by FC (neutralised with Et3N; 1% ethyl 
acetate:petroleum ether) gave 18 as a pale yellow solid (130 mg, 42%).    
1H NMR: δH (400 MHz, CDCl3); 7.16-7.21 (6H, m), 7.03-7.05 (2H, m), 6.68-6.76 (3H, m), 5.29 (1H, t, J 
= 7.3 Hz), 3.01 (1H, m), 2.85-2.90 (1H, m), 2.36 (1H, dd, J = 17.1 and 3.1 Hz), 1.94-2.05 (5H, m), 
1.71-1.82 (2H, m), 1.54-1.66 (4H, m), 1.05-1.29 (11H, m), 0.87 (6H, t, J = 7.3 Hz); LRMS (ESI) m/z = 
441 (M+, 80%). 
 
General procedure B (Pauson-Khand mediated synthesis of (±)-bicyclo[3.3.0]octen-1-en-3-
ones). 
According to the method of Whitby,212 the desired enyne (400 mg, 3.69 mmol) was added dropwise 
to a stirring solution of cobalt carbonyl (1.26g, 3.69 mmol) in THF (25 mL) under argon at room 
temperature.  The solution was strirred for 2 h for before addition of DMSO (1.57 mL, 22.14 mmol) in 
one portion and heating the solution at 50 °C for a further 16 h.  The mixture was then concentrated 
under reduced pressure and purified by FC (petroleum ether).   
 
(±)-2-Phenyl-bicyclo[3.3.0]oct-1-en-3-one (20).213  
Using the general procedure B, enyne 13 (1.77g, 10.4 mmol), cobalt carbonyl 
(3.55g, 10.4 mmol), and DMSO (4.42 mL, 62 mmol) after 18 h purifying by FC (6:1 
petroleum ether:ethyl acetate) gave 20 as a clear colourless oil (1.16 g, 60%). 
1H NMR: δH (400 MHz, CDCl3); 7.61 (2H, d, J = 7.2 Hz), 7.40-7.43 (2H, t, J = 7.2 Hz), 7.32 (1H, t, J = 
7.4 Hz), 2.87-2.96 (2H, m), 2.84 (1H, dd, J = 17.7, 6.6 Hz), 2.68 (1H, m), 2.28 (1H, m), 2.27 (1H, dd, 
J = 17.7, 3.1 Hz), 2.12 (2H, m), 1.18 (1H, m); LRMS (ESI) m/z = 198 (M+, 80%). 
 
(±)-2-Methyl-bicyclo[3.3.0]oct-1-en-3-one (30).  
Using the general procedure B, enyne 12 (400 mg, 3.7 mmol), cobalt carbonyl (1.26 
g, 3.69 mmol), and DMSO (1.57 mL, 22.1 mmol) after 18 h purifying by FC (6:1 
petroleum ether:ethyl acetate) gave 30 as a clear colourless oil (240 mg, 48%).  
Rf = 0.3 (5:1 petroleum ether:ethyl actetate; IR (neat): υmax = 2958 (w), 2867 (w), 1702 (s) (C=O), 
1663 (s) (C=O) cm-1; 1H NMR: δH (400 MHz, CDCl3); 2.74 (1H, m, CH2CHCH2), 2.63 (1H, dd, J = 
17.8, 6.2 Hz, COCH2a), 2.46-2.50 (2H, m, CH2C=C), 2.16 (1H, m, COCH2b), 1.98-2.06 (3H, m, 
CH2CH2bCH2), 1.69 (3H, dt, J = 2.3, 1.2 Hz, CH3), 1.05 (1H, qd, J = 11.7, 8.2 Hz, CH2CH2aCH2);  13C 
NMR δC (125 MHz, CDCl3); 211.04 (s) (CO), 183.99 (s) (CH2C=C), 131.89 (s) (CH3C=C), 44.35 (t) 
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(COCH2), 41.63 (t) (CH2C=C), 31.36 (d) (CH), 25.61 (t) (CHCH2), 24.97 (t) (CHCH2CH2), 8.59 (q) 
(CH3); LRMS (EI) m/z 136 (M+, 100%); HRMS (EI):  m/z 136.0884 (M+). C9H12O Requires 136.0888; 
Δ = 0.03 ppm. 
 
General procedure C (Grinard reagent addition to 2-substituted-bicyclo[3.3.0]oct-1-en-3-ones).212 
According to the method of Whitby,212 CeCl3.7H2O (5 mmol) was heated under vacuum (0.2 mm Hg) 
at 140 °C for 2 h before cooling to room temperature under argon.  A solution of the desired 2-
substituted-bicyclo[3.3.0]oct-1-en-3one (5 mmol) in THF (35 mL) was then added and the solution 
stirred for 1 h.  The mixture was cooled to 0 °C before dropwise addition of the required Grinard 
reagent (solution in diethyl ether; 25 mmol) and stirring at 0 °C for 30-60 min.  Sat. NH4Cl (20 mL) 
was then added dropwise and the solution stirred for 5 min before pouring onto sat NH4Cl (100 mL), 
extracting with diethyl ether (3 × 50 mL), washing with H2O (50 mL) and brine (50 mL), drying over 
MgSO4 and concentrating under reduced pressure to afford the crude tertiary alcohols. 
 
Tertiary alcohols were carried through to the next step of the synthesis crude due to their instability 
on silica gel. 
 
General procedure D (conversion of 2-substituted-bicyclo[3.3.0]oct-1-en-3ones to 1-arylamino-
2-substituted-cis-bicyclo[3.3.0]oct-2-enes). 
According to the method of Whitby,212 the required aryl amine (5 mmol) and CSA (0.05 mmol) were 
added to a stirring solution of crude tertiary alcohol (0.5 mmol) in THF (5 mL) at room temperature.  
The reaction was heated to a mild reflux and stirred for a further 16 h.  The reaction was then allowed 
to cool to room temperature before pouring onto H2O (25 mL) and extracting with diethyl ether (3 × 20 
mL).  The ethereal extracts were then washed with sat. NaHCO3 (3 × 20 mL), water (3 × 20 mL) and 
brine (3 × 20 mL), dried over Na2SO4 and concentrated in vacuo to afford the crude product. 
 
(±)-3-Methyl-1-phenylamino-2-phenyl-cis-bicyclo[3.3.0]oct-2-ene (24) 5l.  
Using the general procedure D, aniline (1.62 mL, 17.7 mmol), CSA (40 mg, 0.18 
mmol) and tertiary alcohol (380 mg, 1.77 mmol) after 16 h purifying by FC 
(neutralised with Et3N; 2% ethyl acetate in petroleum ether) gave 24 as a pale 
yellow solid (350 mg, 68%). 
1H NMR: δH (400 MHz, CDCl3); 7.31-7.35 (2H, m), 7.17-7.26 (5H, m), 6.88 (1H, td, J = 7.5, 0.7 Hz), 
6.71 (2H, dd, J = 7.5, 0.7 Hz), 3.75 (1H, br s), 2.85-2.95 (2H, m), 1.97 (3H, d, J = 14.9 Hz), 1.64 (3H, 
s), 1.46-1.59 (3H, m), 1.18 (1H, m); LRMS (EI) m/z = 289 (M+, 80%).   
 
(±)-3-Dodecyl-1-phenylamino-2-phenyl-cis-bicyclo[3.3.0]oct-2-
ene (25) 5o.  
Using the general procedure D, aniline (1.2 mL, 12.6 mmol), CSA 
(30 mg, 0.12 mmol) and tertiary alcohol (460 mg, 1.26 mmol) after 
16 h purifying by FC (neutralised with Et3N; 2% ethyl acetate in 
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petroleum ether) gave 25 as a pale yellow solid (125 mg, 23%). 
1H NMR: δH (400 MHz, CDCl3); 7.26-7.31 (3H, m), 7.18-7.22 (2H, m), 7.01-7.04 (2H, m), 6.72-6.76 
(1H, m), 6.66 (2H, d, J = 7.8 Hz), 4.02 (1H, br s), 3.06 (1H, dd, J = 17.3 and 9.5 Hz), 2.88 (1H, t, J = 
8.7 Hz), 2.16 (1 H, dd, J 17.4 and 3.1 Hz), 1.95-2.12 (4H, m), 1.75 (1H, m), 1.59-1.68 (2H, m), 1.41-
1.48 (3H, m), 1.21-1.38 (18H, m), 0.95 (3H, t, J = 6.9 Hz); LRMS (EI) m/z = 443 (M+, 90%).   
 
(±)-3-Hexyl-2-phenyl-1-(4-trifluoromethoxyphenyl)amino-cis-
bicyclo[3.3.0]oct-2-ene (26) 5t.  
Using the general procedure D, 4-trifluoromethoxy aniline (1.65 
mL, 12.3 mmol), CSA (30 mg, 0.12 mmol) and tertiary alcohol 
(350 mg, 1.2 mmol) after 16 h purifying by FC (neutralised with 
Et3N; 2% ethyl acetate in petroleum ether) gave 26 as a pale 
yellow solid (103 mg, 20%). 
1H NMR: δH (400 MHz, CDCl3); 7.25-7.30 (3H, m), 7.03 (2H, dd, J = 9.0 and 0.9 Hz), 6.96 (2H, dd, J = 
7.4 and 2.0 Hz), 6.57 (2H, d, J = 7.4 Hz), 4.06 (1H, br s), 3.00 (1H, dd, J = 17.4 and 9.0 Hz), 2.79-
2.83 (1H, m), 2.15 (1H, dd, J = 17.4 and 3.1 Hz), 1.95-2.07 (4H, m), 1.73 (1H, td, J = 7.0 and 3.1 Hz), 
1.57-1.64 (2H, m), 1.42 (3H, q, J = 7.0 Hz), 1.20-1.31 (5H, m), 0.88 (4H, d, J = 14.1 Hz); LRMS (EI) 
m/z = 443 (M+, 90%).   
 
(±)-1-(4-tert-Butylphenyl)amino-3-hexyl-2-phenyl-cis-
bicyclo[3.3.0]oct-2-ene (27) 5u. 
Using the general procedure D, 4-tertbutyl aniline (2 mL, 12.3 
mmol), CSA (30 mg, 0.12 mmol) and tertiary alcohol (350 mg, 
1.2 mmol) after 16 h purifying by FC (neutralised with Et3N; 2% 
ethyl acetate in petroleum ether) gave 27 as a pale yellow solid 
(130 mg, 25%). 
1H NMR: δH (400 MHz, CDCl3); 7.24-7.30 (3H, m), 7.20 (2H, d, J = 8.5 Hz), 7.04 (2H, dd, J = 7.8 and 
1.6 Hz), 6.60 (2H, d, J = 8.5 Hz), 3.89 (1H, br s), 3.01 (1H, dd, J = 17.2 and 9.5 Hz), 2.85 (1H, t, J = 
8.7), 2.05-2.15 (3H, m), 2.00 (1H, m), 1.89-1.95 (1H, m), 1.71 (1H, m), 1.55-1.64 (2H, m), 1.36-1.48 
(4H, m), 1.33 (9H, s), 1.22-1.31 (5H, m), 0.90 (3H, t, J = 7.0 Hz); LRMS (EI) m/z = 415 (M+, 10%), 
267 ([M - NHC6H4C(CH3)3]+, 100%). 
 
(±)-3-Hexyl-1-(4-iodophenyl)amino-2-phenyl-cis-
bicyclo[3.3.0]oct-2-ene (28) 5v. 
Using the general procedure D, 4-iodo aniline (2.7 g, 12.3 mmol), 
CSA (30 mg, 0.12 mmol) and tertiary alcohol (350 mg, 1.23 mmol) 
after 16 h purifying by FC (neutralised with Et3N; 2% ethyl acetate 
in petroleum ether) gave 28 as a pale yellow solid (175 mg, 30%). 
1H NMR: δH (400 MHz, CDCl3); 7.41 (2H, d, J = 8.9 Hz), 7.25-7.29 (3H, m), 6.97 (2H, d, J = 6.3 Hz), 
6.43-6.45 (2H, m), 4.05 (1H, br s), 2.94 (1H, m), 2.80 (1H, t, J = 8.7 Hz), 2.12 (1H, dd, J = 17.4 and 
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2.8 Hz), 1.94-2.06 (4H, m), 1.72 (1H, m), 1.55-1.62 (2H, m), 1.37-1.42 (3H, m), 1.19-1.29 (6H, m), 
0.88 (3H, t, J = 7.0 Hz); LRMS (ESI) m/z = 485 (M+, 80%). 
 
(±)-3-Hexyl-1-(1-naphthyl)amino-2-phenyl-cis-bicyclo[3.3.0]oct-
2-ene (29) 5w.  
Using the general procedure D, 1-napthylamine (2.92 g, 20.4 
mmol), CSA (47 mg, 0.20 mmol) and tertiary alcohol (580 mg, 2.04 
mmol) after 16 h purifying by FC (neutralised with Et3N; 2% ethyl 
acetate in petroleum ether) gave 29 as a pale yellow solid (200 mg, 
25%).  
1H NMR: δH (400 MHz, C6D6); 7.83 (1H, dd, J = 8.0, 0.7 Hz), 7.63-7.57 (2H, m), 7.40 (2H, ddd, J = 
8.0, 6.1 and 1.4 Hz), 7.32 (1H, ddd, J = 8.4, 6.9 and 1.4 Hz), 7.21-7.19 (2H, m), 7.09-7.06 (4H, m), 
4.68 (1H, br s), 3.15-3.03 (2H, m), 2.28-2.10 (4H, m), 1.92 (1H, d, J = 36.2 Hz), 1.69 (2H, d, J = 29.6 
Hz), 1.61-1.50 (3H, m), 1.34 (9H, d, J = 100.0 Hz); LRMS (ESI) m/z = 409 (M+, 45%).   
 
(±)-3-Methyl-1-(phenyl)amino-2-methyl-cis-bicyclo[3.3.0]oct-2-ene (32) 5x.  
Using the general procedure D, aniline (1.62 mL, 17.7 mmol), CSA (40 mg, 0.18 
mmol) and tertiary alcohol (270 mg, 1.77 mmol) after 16 h purifying by FC 
(neutralised with Et3N; 2% ethyl acetate in petroleum ether) gave 32 as a pale 
yellow liquid (320 mg, 79%).   
Rf = 0.6 (2% Ethyl Acetate in petroleum ether); IR (neat): υmax = 3426 (w), 2943 (m), 2859 (m), 1600 
(s), 1499 (s), 747 (s), 691 (s) cm-1; 1H NMR: δH (400 MHz, CDCl3); 7.12-7.08 (2H, m, Ar-H), 6.64 (1H, 
tt, J = 7.8, 6.8 Hz, Ar-H), 6.52-6.49 (2H, m, Ar-H), 3.86 (1H, br s, NH), 2.84 (1H, m, C=CCH2a), 2.69 
(1H, m, C=CCH2b), 1.97-1.86 (3H, m, CHCH2), 1.69 (3H, s, NHCCCH3), 1.58-1.41 (4H, m, 
NHCCH2CH2), 1.48 (3H, s, C=CCH3); 13C NMR: δC (125 MHz, CDCl3); 147.55 (s) (C-Ar), 133.64 (s) 
(C=C), 133.52 (s) (C=C), 128.94 (d) (C-Ar), 116.53 (d) (C-Ar), 113.73 (d) (C-Ar), 80.66 (s) (NHC), 
45.28 (t) (C=CCH2), 42.23 (t) (NHCCH2), 41.61 (d) (CH), 35.34 (t) (CHCH2CH2), 24.23 (t) (CHCH2), 
14.46 (q) (CH2CCH3), 10.16 (q) (CCCH3); LRMS (EI) m/z 227 (M+, 50%), 198 (40), 135 (100), 107 
(40); HRMS (EI) m/z 227.1671 (M+). C16H21N Requires 227.1674; Δ = 0.01 ppm. 
 
General Procedure E (synthesis of 3-sulfenylindoles).159 
According to the method of Yadav,159 the required indole (1 mmol) and anhydrous FeCl3 (1.2 mmol) 
were dissolved in acetonitrile (5 mL) before adding the required thiophenol (1 mmol) in one shot and 
heating at 80 ºC for 20 h under argon.  After the required time, the suspension was quenched with 
H2O (15 mL) and extracted with CH2Cl2 (3 x 15 mL).  The combined extracts were dried over Na2SO4 
and concentrated under reduced pressure. 
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3-(Phenylsulfanyl)-1H-indole (41) AB_WC088.159  
Using the general procedure E, indole (117 mg, 1 mmol), FeCl3 (33 mg, 0.2 
mmol) and thiophenol (103 µL, 1 mmol) after 24 h purifying by FC (9:1 
hexane:ethyl acetate) gave 41 as a yellow solid (80 mg, 37%). 
1H NMR: δH (400 MHz, CDCl3); 8.30 (1H, br s), 6.85–7.72 (10H, m). LRMS (EI) 
m/z = 225 (M+, 95%), 185 (10), 109 (60), 84 (25).   
 
3-(4-Chlorophenylthio)-1H-indole (43) AB_WC103.159  
Using the general procedure E, indole (117 mg, 1 mmol), FeCl3 (33 mg, 0.2 
mmol) and 4-chlorothiophenol (98 mg, 1 mmol) after 24 h purifying by FC 
(9:1 hexane:ethyl acetate) gave 43 as a yellow solid (92 mg, 36%). 
1H NMR: δH (400 MHz, CDCl3); 8.45-8.48 (1H, br s), 7.60 (1H, dd, J = 7.9 
and 1.0 Hz), 7.53 (1H, d, J = 2.6 Hz), 7.48 (1H, dt, J = 7.9 and 0.9 Hz), 7.31 (1H, m), 7.21 (1H, ddd, J 
= 7.9, 7.1 and 0.9 Hz), 7.15 (2H, d, J = 8.8 Hz), 7.05 (2H, d, J = 8.8 Hz). LRMS (ESI) m/z = 260 (M+, 
100%).   
 
3-(4-Methoxyphenylthio)-1H-indole (44) AB_WC104.214  
Using the general procedure E, indole (117 mg, 1 mmol), FeCl3 (33 mg, 
0.2 mmol) and 4-methoxythiophenol (103 µL, 1 mmol) after 24 h purifying 
by FC (9:1 hexane:ethyl acetate) gave 44 as a yellow solid (92 mg, 
36%). 
1H NMR: δH (400 MHz, CDCl3); 8.41 (1H, br s), 7.65 (1H, dd, J = 7.9 and 1.1 Hz), 7.50 (1H, d, J = 2.6 
Hz), 7.44-7.46 (1H, m), 7.25-7.29 (1H, m), 7.15-7.20 (3H, m), 6.77 (2H, d, J 8.9 Hz), 3.76 (3H, s). 
LRMS (ESI) m/z = 255 (M+, 100%). 
 
3-(3,4-dichlorophenylthio)-1H-indole (45) AB_WC105.  
Using the general procedure E, indole (117 mg, 1 mmol), FeCl3 (33 mg, 0.2 
mmol) and 3,4-dichlorothiophenol (103 mg, 1 mmol) after 24 h purifying by 
FC (9:1 hexane:ethyl acetate) gave 45 as a yellow solid (58 mg, 20%), mp 
130-132 ºC (recryst. ethanol).  
Rf = 0.2 (10:1 hexane:ethyl acetate); IR (neat): υmax = 3403 (m) (Ar-NH), 
2923 (m) (Ar-H), 1640 (s) (Ar), 1505 (s) (Ar), 1473 (m) (Ar), 1452 (m) (Ar), 1008, 811 (m) (Ar-H), 745 
(m) (Ar-H) cm–1; 1H NMR: δH (400 MHz, CDCl3); 8.52 (1H, br s, NH), 7.60 (1H, d, J = 8.1, NHCCH), 
7.53 (1H, d, J = 2.7 Hz, SCCCH), 7.49 (1H, d, J = 8.1 Hz, Ar-H), 7.33 (1H, dd, J = 8.2, 7.1 Hz, 
NCCHCH), 7.21-7.25 (2H, m, 2 x Ar-H), 7.18 (1H, d, J = 2.2 Hz, Ar-H), 6.93 (1H, dd, J = 8.2 Hz, Ar-
H). ; 13C NMR: δC (125 MHz, CDCl3); 139.87 (s) (NHC), 136.53 (s) (NHCC), 132.80 (s) (SC), 131.04 
(d) (Ar-C), 130.34 (d) (Ar-C), 128.64 (d) (Ar-C), 128.61 (d) (Ar-C), 127.14 (d) (Ar-C), 125.08 (d) (Ar-
C), 123.40 (s) (Ar-C), 121.28 (d) (Ar-C), 119.37 (d) (Ar-C), 111.81 (d) (Ar-C), 101.55 (s) (SC); LRMS 
(ESI) m/z 293 (M+, 100%); HRMS (ESI) m/z 292.9912 (M+). C14H9Cl2NS Requires 292.9833; Δ = 2.7 
ppm. 
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3-(4-Methylphenylthio)-1H-indole (46) AB_WC106.159  
Using the general procedure E, indole (117 mg, 1 mmol), FeCl3 (33 mg, 0.2 
mmol) and 4-methylthiophenol (110 µL, 1 mmol) after 24 h purifying by FC 
(9:1 hexane:ethyl acetate) gave 46 as a yellow solid (72 mg, 31%),  
1H NMR: δH (400 MHz, CDCl3); 8.43 (1H, br s), 7.65 (1H, dt, J = 7.9 and 0.9 
Hz), 7.51 (1H, d, J = 2.6 Hz), 7.47 (1H, m), 7.29 (1H, m), 7.19 (1H, dd, J 8.0 and 7.0 Hz), 7.05-7.07 
(2H, m), 6.99-7.02 (2H, m), 2.28 (3H, s). LRMS (ESI) m/z = 239 (M+, 100%). 
 
2-Methyl-3-(phenylthio)-1H-indole (40) AB_WC066.159  
Using the general procedure E, 2-methylindole (130 mg, 1 mmol), FeCl3 (33 
mg, 0.2 mmol) and thiophenol (103 µL, 1 mmol) after 24 h purifying by FC (9:1 
hexane:ethyl acetate) gave 40 as a yellow solid (65 mg, 40%). 
1H NMR: δH (400 MHz, CDCl3); 8.12 (1H, br s), 7.50 (1H, d, J = 8.1 Hz), 7.20–
7.33 (1H, m), 6.89–7.19 (7H, m), 2.51 (3H, s). LRMS (ESI) m/z = 239 (M+, 100%). 
 
2-Methyl-3-(4-chlorophenylthio)-1H-indole (47) AB_WC107.159  
Using the general procedure E, 2-methylindole (130 mg, 1 mmol), FeCl3 
(33 mg, 0.2 mmol) and 4-chlorothiophenol (100 mg, 1 mmol) after 24 h 
purifying by FC (9:1 hexane:ethyl acetate) gave 47 as a yellow solid (85 
mg, 30%).  
1H NMR: δH (400 MHz, CDCl3); 8.29 (1H, br s), 7.53-7.55 (1H, m), 7.38 (1H, dt, J = 8.0 and 0.9 Hz), 
7.24 (1H, ddd, J = 8.0, 7.0 and 1.2 Hz), 7.19 (1H, d, J = 1.2 Hz), 7.14 (2H, d, J = 8.8 Hz), 6.99 (2H, d, 
J = 8.8 Hz), 2.54 (3H, s). LRMS (ESI) m/z = 278 (M+, 100%). 
 
2-Methyl-3-(3,4-dichlorophenylthio)-1H-indole (48) AB_WC108.  
Using the general procedure E, 2-methylindole (130 mg, 1 mmol), FeCl3 
(33 mg, 0.2 mmol) and 3,4-dichlorothiophenol (130 mg, 1 mmol) after 24 h 
purifying by FC (9:1 hexane:ethyl acetate) gave 48 as a yellow solid (73 
mg, 24%), mp 135-137 ºC.  
Rf = 0.16 (10:1 hexane:ethyl acetate); IR (neat): υmax = 3405 (m), 2924 (m), 
1640 (s), 1479 (m), 1462 (m), 824 (m), 752 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 8.35 (1H, br s, 
NH), 7.53 (1H, dd, J = 7.8 and 1.1 Hz, NHCCH), 7.39 (1H, d, J = 8.0 Hz, SCCCH), 7.16-7.27 (3H, m, 
3 x Ar-H), 7.11 (1H, d, J = 2.2 Hz, Ar-H), 6.87 (1H, dd, J = 8.4 and 2.2 Hz, Ar-H), 2.54 (3H, s, CH3); 
13C NMR: δC (125 MHz, CDCl3); 141.49 (s) (NHC), 140.03 (s) (NHCC), 135.48 (s) (SC), 132.80 (d) 
(Ar-C), 130.34 (d) (Ar-C), 129.83(d) (Ar-C), 128.32 (s) (Ar-C), 126.74 (d) (Ar-C), 124.75 (d) (Ar-C), 
122.53 (s) (Ar-C), 121.04 (d) (Ar-C), 118.72 (d) (Ar-C), 110.85 (d) (Ar-C), 98.16 (s) (Ar-C), 12.19 (q) 
(CH3).; LRMS (ESI) m/z 307 (M+, 100%); HRMS (ESI) m/z 306.9956 (M+). C14H9Cl2NS Requires 
306.9989; Δ = - 7.3 ppm. 
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2-Methyl-3-(3,4-dichlorophenylthio)-1H-indole (49) AB_WC109.215  
Using the general procedure E, 2-methylindole (130 mg, 1 mmol), FeCl3 
(33 mg, 0.2 mmol) and 4-methoxythiophenol (110 mg, 1 mmol) after 24 
h purifying by FC (9:1 hexane:ethyl acetate) gave 49 as a yellow solid 
(127 mg, 47%).  
1H NMR: δH (400 MHz, CDCl3); 8.23 (1H, br s), 7.60 (1H, m), 7.35 (1H, dt, J = 7.8 and 0.9 Hz), 7.21 
(1H, ddd, J = 8.0, 7.0 and 1.2 Hz), 7.16 (1H, dd, J = 7.7 and 1.2 Hz), 7.08 (2H, d, J = 8.9 Hz), 6.76 
(2H, d, J = 9.0 Hz), 3.76 (3H, s), 2.56 (3H, s). LRMS (ESI) m/z = 307 (M+, 100%). 
 
2-Methyl-3-(4-methylphenylthio)-1H-indole (50) AB_WC110.159  
Using the general procedure E, 2-methylindole (130 mg, 1 mmol), FeCl3 (33 
mg, 0.2 mmol) and 4-metyhlthiophenol (103 µL, 1 mmol) after 24 h purifying 
by FC (9:1 hexane:ethyl acetate) gave 49 as a yellow solid (30 mg, 12%).  
1H NMR: δH (400 MHz, CDCl3); 8.26 (1H, br s), 7.58 (1H, dd, J = 7.8 and 0.6 
Hz), 7.37 (1H, m), 7.22 (1H, ddd, J = 8.1, 7.0 and 1.2 Hz), 7.15 (1H, td, J = 7.4 and 1.0 Hz), 6.99 (4H, 
s), 2.55 (3H, s), 2.27 (3H, s). LRMS (ESI) m/z = 253 (M+, 100%). 
 
2-Phenyl-3-(phenylthio)-1H-indole (51) AB_WC111.216  
Using the general procedure E, 2-phenylindole (193 mg, 1 mmol), FeCl3 (33 
mg, 0.2 mmol) and thiophenol (103 µL, 1 mmol) after 24 h purifying by FC (9:1 
hexane:ethyl acetate) gave 51 as a yellow oil (69 mg, 23%).  
1H NMR: δH (400 MHz, CDCl3); 8.60 (1H, br s), 7.79 (2H, m), 7.67 (1H, dd, J = 
7.9 and 1.1 Hz), 7.40-7.51 (4H, m), 7.31 (1H, m), 7.18-7.23 (3H, m), 7.12-7.15 (2H, m), 7.09 (1H, m). 
LRMS (ESI) m/z = 301 (M+, 100%). 
 
5-Bromo-3-(phenylthio)-1H-indole (52) AB_WC112.159  
Using the general procedure E, 5-bromoindole (210 mg, 1 mmol), FeCl3 
(33 mg, 0.2 mmol) and thiophenol (103 µL, 1 mmol) after 24 h purifying by 
FC (9:1 hexane:ethyl acetate) gave 52 as a yellow solid (25 mg, 9%).  
1H NMR: δH (400 MHz, CDCl3); 8.50 (1H, br s), 7.79 (1H, d, J = 1.8 Hz), 
7.52 (1H, d, J = 2.7 Hz), 7.36 (2H, qd, J = 8.7 and 1.8), 7.19-7.23 (2H, m), 7.09-7.13 (3H, m). LRMS 
(ESI) m/z = 303 (M+, 100%). 
 
6-methyl-1H-benzimidazole-2-thiol (58).217 
According to the method of Mavrova,218 diaminotoluene (8.2 mmol) was added to 
a solution of aqueous sodium hydroxide (1.5mL;  6M) and carbondisulfide (8.8 
mmol) in ethanol (10 mL).  The solution was heated at 85 ºC for 3 h before slowly adding charcoal 
(3g) and refluxing for a further 10 minutes.  The suspension was then filtered through celiteTM and the 
filtrate heated to 70 ºC before quenching with warm water (10 mL) followed by 50% glacial acetic 
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acid (5 mL).  The solution was allowed to cool to room temperature and the precipitate collected by 
filtration and dried under high vacuum to give 58 (0.9g, 68%) as a pale brown solid. 
1H NMR: δH (400 MHz, CDCl3); 12.42 (1H, br s), 7.03 (1H, dd, J = 7.9 and 0.6 Hz), 6.93-6.96 (2H, m), 
2.34 (3H, s). LRMS (ESI) m/z = 164 (M+, 100%). 
 
General Procedure F (S-benzylation of 6-methyl-1H-benzimidazole-2-thiol 58). 
According to the method of Klimesova,219 sodium methoxide (0.55 mmol) was dissolved in methanol 
and stirred until dissolved.  A solution of benzimidazole-2-thiol 58 (0.5 mmol) in DMF was then added 
and stirring continued for 10 min before slow addition of the required benzylbromide (0.5 mmol) and 
stirring for a further 7 h.  The solution was then poured onto ice water (20 mL) and left over night 
before filtering the precipitate and washing with cold water (2 x 10 mL). 
 
6-methyl-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 
(53) AB_WC057.  
Using general procedure F, sodium methoxide (30 mg, 0.55 mmol), 
benzimidazole-2-thiol 58 (75 mg, 0.5 mmol) and 2-methylbenzylbromide (70 µL, 0.53 mmol) after 20 
h drying in a dessicator (CaCl3) gave 53 (95 mg, 75%) as a pale yellow solid, mp 135-139 ºC.  
Rf = 0.65 (2:1 petroleum ether:ethyl acetate); IR (neat): υmax = 3432, 3064–2054 (C-H), 1505 (s), 
1477 (m), 1452 (m), 1011 (m), 820 (m), 747 (m) cm-1; 1H NMR: δH (400 MHz, CDCl3); 7.45 (1H, br s, 
NH), 7.19-7.35 (5H, m, Ar-H), 7.13 (1H, m, Ar-H), 7.06 (1H, m, Ar-H), 4.57 (2H, s, CH2), 2.48 (3H, s, 
Ar-CH3), 2.44 (3H, s, Ar-CH3); 13C NMR: δC (125 MHz, CDCl3); 137.05 (d) (5-C), 134.45 (d) (5-C), 
130.65 (d) (Ar-C), 130.06 (d) (Ar-C), 128.10 (d) (Ar-C), 126.33 (d) (Ar-C), 123.91 (d) (4-C), 35.75 (t) 
(CH2), 21.67 (q) (CH3), 19.26 (q) (CH3); LRMS (EI) m/z 268 (M+, 65%), 164 (20), 105 (100); HRMS 
(EI) m/z 268.1034 (M+). C16H16N2S Requires 268.1032; Δ = - 0.8 ppm. 
 
6-methyl-2-{[(2-iodophenyl)methyl]sulfanyl}-1H-benzimidazole 
(61).  
Using general procedure F, sodium methoxide (100 mg, 1.73 mmol), 
benzimidazole-2-thiol 58 (200 mg, 1.3 mmol) and 2-iodobenzylbromide (435 mg, 1.46 mmol) after 20 
h purifying by FC (8:1 to 4:1 petroleum ether:ethyl acetate gradient) gave 61 (350 mg, 58%) as a 
white solid, mp 121-123 ºC.  
Rf = 0.80 (2:1 petroleum ether:ethyl acetate); IR (neat): υmax = 3435 , 3054–2083 (C-H), 1505 (s), 
1333 (m), 1269 (m), 1156 (m), 827 (m), 734 (m) cm-1; 1H NMR: δH (400 MHz, d6-DMSO); 7.90 (1H, 
dd, J = 7.7 and 1.2 Hz, Ar-H), 7.57 (1H, dd, J = 7.7 and 1.6 Hz, Ar-H), 7.31-7.36 (2H, m, Ar-H and 6-
H), 7.25 (1H, s, 8-H), 7.03 (1H, td, J = 7.6 and 1.6 Hz, Ar-H), 6.95 (1H, dd, J = 8.2 and 1.6, Ar-H), 
4.61 (2H, s, CH2), 2.39 (3H, s, CH3); 13C NMR: δC (125 MHz, d6-DMSO); 157.41 (s) (NCNH), 148.86 
(s) (6-C), 140.04 (s) (Ar-C), 139.90 (d) (Ar-C), 131.87 (3a-C), 130.87 (d) (Ar-C), 130.17 (d) (Ar-C), 
129.12 (d) (Ar-C), 128.05 (s) (7a-C), 123.91 (d) (7-C), 101.58 (s) (Ar-CI), 41.56 (t) (CH2), 21.68 (q) 
(CH3); LRMS (EI) m/z 380 (M+, 45%), 253 (M+- I, 100), 220 (50), 217 (40); HRMS (EI) m/z 379.9844 
(M+). C15H13IN2S Requires 379.9833; Δ = - 3.0 ppm. 
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Methyl 5-[2-(chloromethyl)phenyl]pent-4-ynoate (63). 
According to the method of Zhang,220 2-iodobenzyl chloride (200 mg, 
0.8 mmol), Pd(PPh3)2Cl2 (55mg, 0.08 mmol) and CuI (7.5 mg, 0.04 
mmol) were dissolved in Et3N (4 mL) and stirred for 2 mins before 
addition of methyl pentynoate (135 mg, 1.3 mmol).  The reaction was stirred for 3 h before diluting 
with ether, filtering through Celite® and concentrating under reduced pressure to give a crude yellow 
oil.  Purification was achieved by silica gel chromatography (10:1 petroleum ether:ethyl acetate) to 
give 63 (195 mg, 99%) as a colourless liquid. 
Rf = 0.58 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax = 2950 (w), 2344 (w) (C≡C), 1737 (s) 
(C=O), 1505 (s), 1487 (m), 1437 (m) cm-1; 1H NMR: δH (400 MHz, CDCl3); 7.43-7.46 (2H, m, Ar-H), 
7.26-7.34 (2H, m, Ar-H), 4.76 (2H, s, Ar-CH2), 3.77 (3H, s, CH3), 2.81-2.85 (2H, m, COCH2), 2.69-
2.73 (2H, m, C≡CCH2); 13C NMR: δC (125 MHz, CDCl3); 172.36 (s) (CO), 138.91 (s) (Ar-CCH2Cl), 
132.39 (d) (Ar-C), 129.20 (d) (Ar-C), 128.35 (d) (Ar-C), 123.23 (s) (Ar-CC≡C), 93.69 (s) (Ar-C≡C), 
78.41 (s) (Ar-C≡C), 51.96 (q) (OCH3), 44.77 (t) (Ar-CH2), 33.38 (t) (COCH2), 15.61 (t) (C≡CCH2); 
LRMS (EI) m/z 236 (M+, 15%), 162 (100), 141 (90); HRMS (EI) m/z 236.0604 (M+). C13H13ClO2 
Requires 236.0602; Δ = - 0.9 ppm. 
 
Methyl -5-(2-[(6-methyl-1H-benzimidazol-2-yl)sulfanyl]methyl 
phenyl)pent-4-ynoate (62) AB_WC113. 
Using the general procedure F, sodium methoxide (55 mg, 1 mmol), 
benzimidazole thio 58 (100 mg, 0.67 mmol) and benzyl chloride 63 
(175 mg, 0.73 mmol) after 4 h purifying by silica gel chromatography 
(3:1 petroleum ether:ethyl acetate) gave 62 (175 mg, 75%) as a pale yellow oil. 
Rf = 0.56 (3:1 petroleum ether:ethyl acetate); IR (neat): υmax = 3415 (w) (NH), 2918 (m), 1737 (s) 
(C=O), 1505 (s), 1485 (m), 1437 (m) cm-1; 1H NMR: δH (400 MHz, CDCl3); 7.43 (1H, m, 4-H), 7.38-
7.41 (2H, m, 2 x Ar-H), 7.32 (1H, m, 7-H), 7.19-7.21 (2H, m, Ar-H), 7.06 (1H, dd, J = 8.2 and 1.1 Hz, 
5-H), 4.61 (2H, s, Ar-CH2), 3.74 (3H, s, OCH3), 2.75-2.78 (2H, m, COCH2), 2.64-2.68 (2H, m, 
C≡CCH2), 2.47 (3H, s, Ar-CH3); 13C NMR: δC (125 MHz, CDCl3); 132.27 (d) (Ar-C), 129.48 (d) (Ar-C), 
128.35 (d) (Ar-C), 127.57 (d) (Ar-C), 123.82 (2d) (Ar-C), 123.25 (d) (Ar-C), 52.14 (q) (OCH3), 36.45 (t) 
(Ar-CH2), 33.36 (q) (Ar-CH3), 21.67 (t) (COCH2), 15.59 (t) (C≡CCH2); LRMS (ESI) m/z 364 (M+, 
100%); HRMS (ESI) m/z 364.1238 (M+). C21H20N2OS Requires 364.1245; Δ = - 1.9 ppm. 
 
Methyl (4E)-5-(2-[(5-methyl-1H-benzimidazol-2-yl)sulfanyl]methyl 
phenyl)pent-4-enoate (65) AB_WC114. 
According to the method of Trost,160 triethyl silane (67 µL, 0.36 mmol) 
was added to a solution of 62 (50 mg, 0.3 mmol) in CH2Cl2 (0.5 mL) 
before cooling to 0 ºC. [Cp*Ru(MeCN)3]PF6 (3 mg, 0.003 mmol) was 
then added and the reaction removed from the cooling bath and stirred 
for 2h.  The reaction was diluted with diethyl ether (5 mL) and filtered through Florasil® eluting with 
further diethyl ether (2 x 10 mL).  The reaction was concentrated under reduced pressure before 
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taking up in THF (0.7 mL) and adding CuI (26 mg, 0.3 mmol).  TBAF (1M in THF; 0.42 mL, 0.42 
mmol) was then added dropwise an the orange suspension stirred at 35 ºC for 16 h.  The suspension 
was filtered through Celite® and the eluent concentrated under reduced pressure to give a crude 
orange oil.  Purification was achieved by FC (4:1 to 2:1 petroleum ether:ethyl acetate gradient) to 
give 65 (3.5 mg, 25%) as a pale yellow oil.  
Rf = 0.52 (3:1 petroleum ether:ethyl acetate); IR (neat): υmax = 1737 (s) (C=O), 1634 (w) (C=C), 1436 
(s) cm-1; 1H NMR: δH (400 MHz, CDCl3); 7.59-7.65 (1H, m, 4-H), 7.51-7.58 (1H, m, 7-H), 7.45 (1 H, 
dd, J = 7.7 and 1.2 Hz, Ar-H), 7.33 (1H, dd, J = 7.7 and 1.2, Ar-H), 7.24-7.29 (1H, m, Ar-H), 7.19 (1H, 
td, J = 7.7 and 1.4 Hz, Ar-H), 7.07-7.09 (1H, m, 5-H), 6.80 (1H, d, J = 15.6 Hz, ArCH=CH), 6.15 (1H, 
dt, J = 15.6 and 6.6 Hz, Ar-CH=CH), 4.56 (2H, s, Ar-CH2), 3.72 (3H, s, OCH3), 2.52-2.57 (4H, m, 
COCH2CH2), 2.49 (3H, s, CH3); LRMS (ESI) m/z 366 (M+, 100%); HRMS (ESI) m/z 364.1405 (M+). 
C21H22N2OS Requires 366.1402; Δ = - 0.9 ppm. 
 
Methyl (4Z)-5-(2-[(5-methyl-1H-benzimidazol-2-yl)sulfanyl]methyl 
phenyl)pent-4-enoate (66) AB_WC115. 
Adams catalyst (20 mol%) was added to a solution of 62 (25 mg, 0.069 
mmol) in ethyl acetate (0.3 mL) and the suspension submitted to an 
atmosphere of hydrogen (1 atm.).  The mixture was stirred at room 
temperature for 72 h before diluting with ethyl acetate (10 mL), filtering through Celite®, and the 
solvent removed under reduced pressure to give a pale orange oil.  Purification was achieved by FC 
(4:1 to 2:1 petroleum ether:ethyl acetate gradient) to give 66 (5 mg, 20%) as a pale yellow oil.  
Rf = 0.52 (3:1 petroleum ether:ethyl acetate); IR (neat): υmax = 1736 (s) (C=O), 1651 (w) (C=C) cm-1; 
1H NMR: δH (400 MHz, CDCl3); 7.30-7.35 (2H, m, Ar-H), 7.14-7.28 (4H, m, Ar-H), 7.06 (1H, dd, J = 
8.2 and 1.1 Hz, Ar-H), 6.65 (1H, d, J = 11.1 Hz, Ar-CH=CH), 5.76 (1H, dt, J = 11.1 and 6.4 Hz, Ar-
CH=CH), 4.48 (2H, s, Ar-CH2), 3.70 (3H, s, COCH3), 2.43-2.51 (7H, m, Ar-CH3 and COCH2CH2); 13C 
NMR: δC (125 MHz, CDCl3); 134.67 (d) (Ar-C), 131.98 (d) (Ar-C), 131.92 (d) (Ar-C=C), 129.89 (d) (Ar-
C), 129.74 (d) (Ar-C=C), 128.48 (d) (Ar-C), 128.08 (d) (Ar-C), 127.65 (d) (Ar-C), 127.48 (d) (Ar-C), 
51.81 (t) (Ar-CH2), 35.89 (q) (OCH3), 33.90 (q) (Ar-CH3), 24.03 (t) (Ar-CH=CHCH2), 21.64 (t) 
(COCH2); LRMS (ESI) m/z 366 (M+, 100%); HRMS (ESI) m/z 364.1412 (M+). C21H22N2OS Requires 
366.1402; Δ = - 2.5 ppm. 
 
 (E)-4-Phenylbut-3-en-1-ol (78).221 
To a round bottomed flask containing trans-3-styryl acetic acid (2 g, 12.4 mmol), 
and THF (10 mL), was added Lithium aluminium hydride (15 mL, 15 mmol, 1 M solution in THF) 
dropwise. The reaction was stirred at 0 °C for 20 min, and at RT for 40 min. It was then quenched 
with H2O (0.7 mL), followed by 10% NaOH solution (2 mL). The reaction mixture was then filtered 
through Celite®, and the solvent removed under reduced pressure. The resulting red oil was purified 
by FC (10:1 petroleum ether:ethyl acetate) to give 78 as a clear colourless oil (1.6 g, 87% yield).  
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1H NMR: δH (400 MHz, CDCl3); 7.32 (5H, m, CHAr), 6.52 (1H, d, J = 15.6 Hz, C=CH), 6.23 (1H, dt, J = 
15.6, 7.2 Hz, C=CH), 3.78 (2H, t, J = 6 Hz, OCH2CH2,), 2.5 (2H, dt, J = 7.2, 6 Hz, CH2CH2,), OH 
absent; LRMS (EI) m/z 149 (MH+, 20%), 130 (85), 117 (100), 91 (50). 
 
General Procedure G (Oxonuim-Prins Reactions): 
To a 50 mL round-bottomed-flask containing homoallylic alcohol (0.57 mmol) and aldehyde (0.57 
mmol) in CH2Cl2 (4 mL) at -78 °C was added solid tin(IV) bromide (0.28 g, 0.6 mmol) and TMS-Br (79 
mL, 0.6 mmol). The reaction was stirred at -78 °C until the homoallylic alcohol 78 was seen to be 
consumed by TLC before being quenched with saturated NaHCO3 solution (4 mL). The reaction was 
allowed to warm to RT before adding further NaHCO3 (4 mL). The organic layer was then separated, 
the aqueous layer extracted further with CH2Cl2 (3 × 10 mL) and the combined organic extracts 
washed with brine (3 × 10 mL), and dried over MgSO4. Following this it was filtered and the solvent 
was removed under reduced pressure. The reaction mixture was then purified by silica gel 
chromatography (petroleum ether:ethyl acetate or diethyl ether:pentane) to yield the substituted THF. 
 
(±)-3-[Bromo(phenyl)methyl]-2-methyltetrahydrofuran (81). 
Using the general procedure G, (E)-4-phenylbut-3-en-1-ol (80 mg, 0.54 
mmol) and acetaldehyde (70 mg, 0.54 mmol) after 1.5 h, purifying by 
silica gel chromatography (1:1 diethyl ether:pentane), yielded the THF 81 
as a thick clear colourless oil (60 mg, 55% yield) comprising an 
inseparable mixture of two diastereoisomers (81a:81b, 60:40 by 1H NMR  
integration).  
Rf = 0.18 (20:1 petroleum ether:ethyl acetate); IR (CH2Cl2): υmax = 2973, 2931, 2875, 1497, 1456, 
1415, 1378, 1151 cm-1; LRMS (CI) m/z 272/274 (MNH4+, 100%), 236 (60), 192 (70), 175 (20), 132 
(90); HRMS (CI) m/z 272.0650 (MNH4+). C12H19NO7Br Requires 272.0650; Δ = 0.0 ppm.  
 
(2S*,3S*,1’R*)-THF 81a: 1H NMR: δH (CDCl3, 400MHz): 7.29-7.47 (5H, m, CHAr), 4.95 (1H, d, CHPh, 
J = 11.5 Hz), 4.07 (1H, td, J = 8.8 and 2.7 Hz, OCH2), 3.96 (1H, dq, J = 7, 6.4 Hz, OCHMe), 3.89 (1H, 
ddd, J = 9.3, 8.6 and 7.2 Hz, OCH2), 3.34 (1H, ddd, J = 12,  9.2, 7.2 Hz, OCH(Me)CH), 2.50 (1H, dtd, 
OCH2CH2), 2.09 (1H, ddt, OCH2CH2), 0.88 (3H, d, J = 6.5 Hz, CH3); 13C NMR: δC (CDCl3, 100MHz): 
141.2 (s), 128.9 (2 × d), 128.7 (d), 128.4 (2 × d), 74.9 (d), 65.8 (d), 55.4 (d), 49.8 (d), 32.4 (t), 15.7 (t).  
(2S*,3S*,1’S*)-THF 81b: 1H NMR δH (CDCl3, 400MHz) – distinguishable/diagnostic peaks only: 7.31-
7.46 (5H, m, CH), 4.74 (1H, d, J = 12 Hz, CHBrPh), 3.81 (1H, m, OCH2), 3.24 (1H, m, OCH(Me)CH), 
1.40-1.62 (2H, m, OCH2CH2), 1.30 (3H, d, J = 6.4 Hz, CH3).  
 
(±)-3-[Bromo(phenyl)methyl]-2-
isopropyltetrahydrofuran (82). 
Using the general procedure G, (E)-4-phenylbut-3-en-1-ol 
(100 mg, 0.68 mmol) and isobuteraldehyde (70 mg, 0.68 
mmol) after 3 h, purifying by silica gel chromatography 
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(20:1 petroleum ether:ethyl acetate) yielded the THF 82 as a white solid (175 mg, 92% yield) 
comprising an inseparable mixture of three diastereoisomers (3c:3d:3a, 80:12:8 by 1H NMR 
integration). m.p. 70-71 °C. 
IR (CH2Cl2): υmax 2957, 2928, 2871, 1499, 1467, 1454, 1388, 1370, 1205, 1178, 1046 cm-1; LRMS 
(CI) m/z: 300/302 (MNH4+, 100%), 220 (80), 203 (50); HRMS (CI) m/z (M-H7Br)NH4+ 220.1707. 
C14H22NO Requires 220.1701; Δ = 2.5 ppm. 
(2S*,3S*,1’R*)-THF 82a: 1H NMR: δH (CDCl3, 400MHz): 7.30- 7.48 (5H, m, CHAr), 5.24 (1H, d, J = 
9.2 Hz, CHPh), 4.12 (1H, m, OCH2), 3.87 (1H, m, OCH2), 3.62 (1H, dd, J = 5.2, 7.0 Hz, OCH(iPr)), 
3.22 (1H, m, OCH(iPr)CH), 2.38 (1H, m, OCH2CH2), 2.27 (1H, m, OCH2CH2), 1.64 (1H, m, CH(Me)2), 
1.01 (3H, d, J = 6.8 Hz, CHCH3), 0.74 (3H, d, J = 6.8 Hz, CHCH3); 13C NMR: δC (CDCl3, 100MHz): 
141.9 (s), 128.9 (2 × d), 128.5 (d), 127.4 (2 × d), 84.9 (d), 66.9 (d), 55.0 (d), 48.6 (t), 32.8 (t), 28.7 (d), 
21.1 (q), 18.8 (q).  
(2S*,3S*,1’S*)-THF 82b: 1H NMR: δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 7.30-
7.50 (5H, m, CHAr), 4.90 (1H, d, J = 8.8 Hz, CHPh), 3.74-3.94 (2H, m, OCH2), 3.35 (1H, dd, J = 5.2, 
5.2 Hz, OCH(iPr)), 2.77 (1H, dddd, J = 8.4, 5.2, 4.8, 4 Hz, OCH(iPr)CH), 2.22-2.43 (2H, m, 
OCH2CH2), 1.17 (1H, m, CH(Me)2), 1.10 (3H, d, J = 6.8 Hz, CHCH3), 0.81 (3H, d, J = 6.8 Hz, 
CHCH3).  
(2S*,3R*,1’R*)-THF 82c: 1H NMR: δH (CDCl3, 400MHz) distinguishable/diagnostic peaks only: 7.30-
7.50 (5H, m, CHAr), 4.88 (1H, d, J = 6.8 Hz, CH(OH)(Ph)), 3.93 (1H, dd, J = 6, 3.6 Hz, OCH(iPr)), 
3.75-3.85 (2H, m, OCH2CH2), 2.97 (1H, dddd, J = 13, 6.8, 3.6, 1.2 Hz, CHC(H)(OH)(Ph)), 1.92 (1H, 
m, CH(Me)2), 1.86 (1H, m, OCH2CH2), 1.48 (1H, m, OCH2CH2), 1.08 (3H, d, J = 6.8 Hz, CHCH3), 
1.01 (3H, d, J = 6.4 Hz, CHCH3).  
 
(±)-3-[Bromo(phenyl)methyl]-2-phenyltetrahydrofuran 
(83) 
Using the general procedure G, (E)-4-phenylbut-3-en-1-ol 
(100 mg, 0.67 mmol) and benzaldehyde (70 mg, 0.67 mmol) 
after 1.5 h, purifying by silica gel chromatography (1:1 diethyl  
ether:pentane) yielded the 83 as a clear colourless solid (125 mg, 60% yield) comprising an 
inseparable mixture of three diastereoisomers (83a:83c:83d, 11:77:12 by 1H NMR integration). IR 
υmax (CH2Cl2): 3062, 3033, 2927, 2869, 1605, 1587, 1495, 1454, 1212, 1161 cm-1; LRMS (CI) m/z 
334/336 (MNH4+, 100%), 256 (15), 237 (50), 167 (20), 96 (100); HRMS (CI) m/z MNH4+ 334.0811. 
C17H21NOBr Requires 334.0807; Δ = 1.3 ppm. 
 
(2R*,3R*,1’R*)-THF 83c: 1H NMR: δH (CDCl3, 400MHz): 7.23-7.34 (8H, m, CHAr), 7.07 (2H, m, 
CHAr), 5.03 (1H, d, J = 8 Hz, CH(Br)Ph), 4.57 (1H, d, J = 6.4 Hz, OCHPh), 4.22 (1H, m, OCH2CH2), 
4.09 (1H, m, OCH2CH2), 2.90 (1H, dddd, J = 8, 6.4, 6, 1.6 Hz, OCH(Ph)CH), 2.35-2.45 (2H, m, 
OCH2CH2); 13C NMR: δC (CDCl3, 100MHz): 128.6 (s), 128.5 (s), 128.4 (d), 128.3 (2 × d), 127.9 (d), 
127.8 (2 × d), 127.8 (d), 127.7 (2 × d), 127.5 (d), 126.0 (d), 67.9 (s), 57.5 (s), 55.9 (d), 31.6 (d).  
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(2R*,3R*,1’S*)-THF 83d: 1H NMR δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 4.90 
(1H, d, J = 5.8 Hz, OCHPh), 4.45 (1H, d, J = 11.6 Hz, CHBrPh), 4.01- 4.12 (2H, m, OCH2), 3.23 (1H, 
m, OCH(Ph)CH), 2.0 (1H, m, OCH2CH2), 1.58 (1H, m, OCH2CH2).  
(2R*,3S*,1’R*)-THF 83a: 1H NMR δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 6.75 
(2H, m, CHAr), 5.33 (1H, d, J = 3.2 Hz, OCHPh), 5.02 (1H, d, J = 10.8 Hz, CHBrPh), 4.40 (1H, m, 
OCH2), 4.15 (1H, m, OCH2), 3.68 (1H, m, OCH(Ph)CH), 2.61 (1H, m, OCH2CH2), 2.38 (1H, m, 
OCH2CH2).  
 
(±)-3-[Bromo(phenyl)methyl]-2-(2-bromophenyl) 
tetrahydrofuran (84).  
Using the general procedure G, (E)-4-phenylbut-3-en-1-ol (60 
mg, 0.4 mmol) and 2- bromobenzaldehyde (0.04 mL, 0.4 
mmol) after 2 h, yielded a pale yellow oil comprising 84 as a 
mixture of two diastereoisomers (84a:84c, 72:28 by 1H NMR integration). The isomers were 
separated by silica gel chromatography (1:1 diethyl ether:pentane) to give:  
(2R*,3S*,1’R*)-THF 84a as a yellow oil (40mg, 27% yield): IR υmax (CH2Cl2): 3064, 2931, 2881, 1573 
1497, 1463, 1453, 1436, 1247, 1206, 1165, 1118, 1060 cm-1; 1H NMR: δH (CDCl3, 400MHz): 7.65 
(1H, dd, J = 7.8, 1,7 Hz, OCHCCHAr), 7.32 (1H, dt, J = 7.5, 1.1 Hz, CHAr), 7.22 (1H, dd, J = 8.0, 1.2 
Hz, C(Br)CHAr), 7.12-7.16 (3H, m, CHAr), 7.03-7.07 (3H, m, CHAr), 5.17 (1H, d, J = 7.15 Hz, 
OCH(Ph-Br)), 4.74 (1H, d, J = 8.4 Hz, CH(Br)(Ph)), 4.36 (1H, td, J = 8.2, 4.4 Hz, OCH2), 3.92 (1H, m, 
OCH2), 3.60-3.67 (1H, m, OCH(Ph-Br)CH), 2.49-2.65 (2H, m, OCH2CH2); 13C NMR: δC (CDCl3, 
100MHz): 141.2 (s), 137.5 (s), 132.3 (d), 129.4 (d), 129.0 (2 × d), 128.3 (d), 127.8 (2 × d), 127.4 (d), 
127.1 (d), 123.1 (s), 81.7 (d), 66.9 (d), 57.5 (d), 48.0 (t), 33.3 (t); LRMS (CI) m/z 412/414/416/418 
(MNH4+, 100%), 334 (50), 317 (60); HRMS (CI) m/z MNH4+ 411.9907. C17H20NOBr2 Requires 
411.9912; Δ = -1.1 ppm).  
(2R*,3R*,1’R*)-THF 84c as a pale yellow oil (70 mg, 44% yield): IR (CH2Cl2) υmax 3064, 2931, 2881, 
1573, 1497, 1463, 1453, 1436, 1247, 1206, 1165, 1118, 1060 cm-1; 1H NMR: δH (CDCl3, 400MHz): 
7.41 (1H, dd, J = 8, 1.2 Hz, CHArC(Br)), 7.31 (3H, m, CHAr), 7.27 (1H, m, CHAr), 7.20 (3H, m, 
CHAr), 7.08 (1H, dd, J = 7.2, 2 Hz, C(Br)C(H)CHAr), 5.20 (1H, d, J = 7.6 Hz, OCH(Ph)), 5.03 (1H, d, 
J = 6.8 Hz, OCH(Ph-Br)), 4.27 (1H, ddd, J = 7.8, 7.6, 6 Hz, OCH2), 4.15 (1H, ddd, J = 8, 7.8, 7.6 Hz, 
OCH2), 3.01 (1H, m, OCH(Ph)CH), 2.45 (2H, m, OCH2CH2); 13C NMR: δC (CDCl3, 100MHz): 140.5 
(s), 140.3 (s), 132.9 (d), 129.1 (d), 128.7 (2 × d), 128.3 (2 × d), 128.0 (d), 127.7 (d), 127.5 (d), 122.8 
(s), 83.0 (d), 68.1 (d), 57.4 (d), 54.8 (t), 31.8 (t); LRMS (CI) m/z 412/414/416/418 (MNH4+, 100%), 
334 (50), 317 (60); HRMS (CI) m/z MNH4+ 411.9911. C17H20NOBr2 Requires 411.9912; Δ = -0.1 ppm. 
 
(±)-(2R*,3S*,1’R*)-3-[Bromo(phenyl)methyl]-2-(2-
nitrophenyl)tetrahydrofuran 85a.  
Using the general procedure G, (E)-4-phenylbut-3-en-1-ol (90 mg, 0.6 mmol) 
and 2- nitrobenzaldehyde (90 mg, 0.6 mmol) after 2.5 h, purifying by silica gel 
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chromatography (20:1 petroleum ether:ethyl acetate) yielded the 85a as an off-white solid (270 mg, 
83% yield), m.p. 81-82 °C. 
IR (CHCl3): υmax 1612, 1579 (NO2), 1521, 1454, 1339, 1243 (C-O), 1193, 1060 cm-1; 1H NMR: δH 
(CDCl3, 400MHz): 7.93 (1H, d, J = 7.6 Hz, o-(NO2)C6H4(H)), 7.69 (1H, d, J = 7.6 Hz, o-
(NO2)C6H4(H)), 7.58 (1H, dd, J = 7.6, 7.2 Hz, o-(NO2)C6H4(H)), 7.27 (1H, d, J = 7.2, 6.8 Hz, o- 
(NO2)C6H4(H)), 6.88-7.03 (5H, m, Ph(H)), 5.47 (1H, d, J = 6.4Hz, CH(Br)(Ph)), 4.78 (1H, d, J = 6.4 
Hz, OCH(Ph-NO2)), 4.33 (1H, m, OCH2), 3.89 (1H, m OCH2), 3.85 (1H, m, OCH2CH2CH), 2.60 (2H, 
m, OCH2CH2); 13C NMR δC (CDCl3, 100MHz): 146.9 (s), 140.8 (s), 134.7 (s), 133.3 (d), 129.4 (d), 
128.3 (d), 128.2 (2 × d), 127.6 (2 × d), 127.1 (d), 124.9 (d), 79.1 (d), 66.6 (d), 58.2 (d), 48.3 (t), 34.1 
(t); LRMS (CI) m/z 379/381 (MNH4+, 30%) 299 (30), 282 (20), 270 (25), 248 (100); HRMS (CI) m/z 
MNH4+ 379.0652. C17H20N2O3Br Requires 379.0657; Δ = -1.4 ppm. 
 
(±)-3-[Bromo(phenyl)methyl]-2-(2-methoxyphenyl) 
tetrahydrofuran (86).  
Using the general procedure G, (E)-4-phenylbut-3-en-1-
ol (100 mg, 0.67 mmol) and 2- methoxybenzaldehyde (90 
mg, 0.67 mmol) after 4 h, yielded a thick pale yellow oil 
comprising 86 as a mixture of two diastereomers (86c:86d, 87:13 by 1H NMR integration). The major 
isomer was purified by silica gel chromatography (20:1 petroleum ether:ethyl acetate) to give:  
(2R*,3R*,1’R*)-THF 86c as a white solid (135 mg, 58% yield), m.p. 64-65 °C; IR (CH2Cl2): υmax 2938, 
2877, 1602 (C=CAr), 1589, 1489, 1453, 1243 (C-O), 1050, 1027, 751 cm-1; 1H NMR: δH (CDCl3, 
400MHz): 7.34 (2H, m, CHAr), 7.16-7.28 (5H, m, CHAr), 6.87 (1H, t, J = 7.2 Hz, CHAr), 6.72 (1H, d, J 
= 8.4 Hz, CHAr), 5.15 (1H, d, J = 8.4 Hz, OCH(C6H4-OMe)), 4.91 (1H, d, J = 5.2 Hz, CHPhBr), 4.23 
(1H, m, OCH2), 4.13 (1H, m, OCH2), 3.65 (3H, s, OCH3), 3.02 (1H, m, OCH(o-(OMe)C6H4-)CH), 2.41 
(1H, m, OCH2CH2), 2.33 (1H, m, OCH2CH2); 13C NMR: δC (CDCl3, 100MHz): 156.3 (s), 141.0 (d), 
129.9 (d), 128.5 (d), 128.2 (d), 128.1(d), 127.1 (d), 120.5 (d), 110.2 (s), 79.3 (d), 67.7 (d), 58.5 (d), 
54.9 (d), 54.0 (t), 31.5 (t); LRMS (CI) m/z 364/366 (MNH4+, 55%) 299 (12), 286 (30), 267 (100), 197 
(30); HRMS (CI) m/z MNH4+ 364.0910. C18H23NO2Br Requires 364.0912; Δ = -0.6 ppm. 
(2R*,3S*,1’S*)-THF 86d: 1H NMR: δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 5.20 
(1H, d, J = 6.8 Hz, CH(Ph)(Br)), 4.72 (1H, d, J = 10.4 Hz, OCH(o-(OMe)C6H4)), 4.30 (1H, m, -CH2), 
3.90 (1H, m, CH2), 3.58 (1H, m, OCH(o-(OMe)C6H4-)CH), 3.37 (3H, s, OCH3), 2.50 (2H, m, 
OCH2CH2),.  
 
(±)-3-[Bromo(phenyl)methyl]-2-(4-
bromophenyl)tetrahydrofuran (87).  
Using the general procedure G, (E)-4-
phenylbut-3-en-1-ol (100 mg, 0.67 
mmol) and 4-Bromobenzaldehyde (140 
mg, 0.67 mmol) after 2 h, purifying by silica gel chromatography (20:1 petroleum ether:ethyl acetate) 
yielded the THF 87 as a yellow oil (145 mg, 55% yield) comprising an inseparable mixture of three 
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diastereoisomers (87a:87c:87d, 12:68:20 by 1H NMR integration). IR (CH2Cl2) υmax 2947, 2874, 1734, 
1591, 1486, 1455, 1275, 1243, 1066, 1007 cm-1; LRMS (CI) m/z 412/414/416/418 (MNH4+, 70%) 
334 (30), 317 (100); HRMS (CI) m/z MNH4+ 411.9896. C17H20NOBr2 Requires 411.9912; Δ = -3.8 
ppm. 
(2R*,3R*,1’R*)-THF 87c: 1H NMR: δH (CDCl3, 400MHz): 7.51 (2H, d, J = 8.4 Hz, CHAr), 7.30-7.41 
(5H, m, CHAr), 6.88 (2H, d, J = 8.4 Hz, CHAr), 4.97 (1H, d, J = 8.4 Hz, , CHPh), 4.48 (1H, d, J =  6.4 
Hz, CH(Br)(Ph)), 4.19 (1H, m, OCH2), 4.07 (1H, m, OCH2), 2.83 (1H, m, OCH(C6H4Br)CH), 2.37 
(2H, m, OCH2CH2); 13C NMR: δC (CDCl3, 100MHz): 140.6 (s), 131.3 (s), 128.9 (2 × d), 128.6 (2 × d), 
128.5 (d), 127.8 (2 × d), 127.4 (d), 127.1 (d), 125.9 (s), 83.3 (d), 67.6 (d), 57.0 (d), 56.2 (t), 31.8 (t).  
(2R*,3R*,1’S*)-THF 87d: 1H NMR: δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 6.62 
(1H, d, J = 8.3, , CHAr), 5.22 (1H, d, J = 3.6 Hz, CHPh), 5.01 (1H, d, J =  11.2 Hz, CH(Br)(Ph)), 4.05 
(1H, m, OCH2), 3.95 (1H, m, OCH2), 3.32 (1H, m, OCH(C6H4Br)CH), 2.00 (1H, m, OCH2CH2), 1.55 
(1H, m, OCH2CH2).  
(2R*,3S*,1’R*)-THF 87c: 1H NMR: δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 4.86 
(1H, d, J = 8 Hz, CHPh), 4.42 (1H, d, J =  11.6 Hz, CH(Br)(Ph)), 3.63 (1H, m, OCH(C6H4Br)CH).  
 
(±)-3-[Bromo(phenyl)methyl]-2-(naphthalen-2-yl) 
tetrahydrofuran (88).162 
Using the general procedure G, (E)-4-phenylbut-3-en-1-ol (100 
mg, 0.67 mmol) and 2-naphthaldehyde (100 mg, 0.67 mmol) 
after 4 h, purifying by silica gel chromatography (20:1 
petroleum ether:ethyl acetate) yielded 88 as a thick clear colourless oil (120 mg, 48%) comprising an 
inseparable mixture of two diastereoisomers (88c:88d, 90:10 by 1H NMR integration). LRMS (CI) 
m/z 304 [(M-HBr)NH4+, 90%] 287 (100), 190 (20), 174 (20);  
(2R*,3R*,1’R*)-THF 88c: 1H NMR: δH (CDCl3, 400MHz): 7.81 (1H, m, CHAr), 7.53 (1H, d, J = 8.4Hz, 
CHAr), 7.70 (1H, m, CHAr), 7.45-7.47 (2H, m, CHAr), 7.18-7.31 (5H, m, CHAr), 6.96-7.01 (2H, m, 
CHAr), 5.06 (1H, d, J = 8 Hz), 4.72 (1H, d, J = 6 Hz), 4.29 (1H, ddd, OCH2, J = 7.2, 6, 1.2 Hz), 4.13 
(1H, m, OCH2), 2.93 (1H, dddd, J = 8, 6.4, 6, 1.6 Hz, OCH(Nap)CH), 2.45 (2H, m, OCH2CH2).  
(2R*,3R*,1’S*)-THF 88d: 1H NMR: δH (CDCl3, 400MHz) - distinguishable/diagnostic peaks only: 5.45 
(1H), d, J = 5 Hz, CHPh), 5.10 (1H, m, OCH(Nap)), 4.49 (1H, t, J = 8.4 Hz, OCH2), 4.40 (1H, d, J = 
11.6 Hz, OCH(Ph)Br), 4.13 (1H, m, OCH2), 3.73 (1H, m, OCH(Nap)CH), 2.66 (1H, m, OCH2CH2), 
2.45 (1H, m, OCH2CH2).  
 
General Procedure H (Debromination Reactions).  
The required THF substrate (0.17 mmol) and NiCl2·6H2O (0.34 mmol) were fully dissolved in MeOH 
(2.5 mL). NaBH4 (1.02 mmol) was then added in a single portion and the reaction stirred at RT for 15 
min before diluting with MeOH (5 mL) and filtering through Celite®. The filtrate was concentrated 
under reduced pressure and the resulting oil was dissolved in EtOAc (10 mL), washed with H2O (5 
mL), dried over MgSO4 and concentrated in vacuo to yield the crude de-brominated THF product.  
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Mono-debromination of 82a, b and c to give (±)-
3-[phenylmethyl]-2-isopropyltetrahydrofurans 
93a and b. 
Using the general procedure H, a mixture of 3-
[bromo(phenyl)methyl]-2-isopropyltetrahydrofurans 
82 (48mg, 0.17 mmol, 8:80:12, 82a:82b:82c), 
NiCl2·6H2O (51 mg, 0.22 mmol) and NaBH4 (25 mg, 0.65 mmol) after 15 min, purifying by silica gel 
chromatography (19:1 hexane:ethyl acetate), yielded a colourless oil (12.2 mg, 47% yield) comprising 
an seperable mixture of two diastereomers (93a and 94b). IR (CH2Cl2) υmax 3061, 3027, 2933, 1602, 
1494, 1452, 1081, 1053 cm-1; LRMS (ESI) m/z 205 (M+H+, 100%); HRMS (CI) m/z MH+ 205.1517. 
C14H20O Requires 204.1514; ∆ = 0.4 ppm.  
(2R*,3S*,1’R*)-THF 93a: 1H NMR δH (CDCl3, 400MHz): 7.30-7.34 (2H, m, Ar-H), 7.19-7.25 (3H, m, 
Ar-H), 3.99 (1H, q, J = 8.2 Hz, OCH), 3.84 (1H, ddd, J = 9.6, 8.3 and 3.9 Hz, OCH), 3.39 (1H, dd, J = 
9.7 and 3.8 Hz, Ar-CH2), 2.91 (1 H, dd, J 13.4 and 3.8, Ar-CH2), 2.40-2.47 (1H, m, ArCH2CH), 2.32 
(1H, m, OCH2CH2), 1.80-1.95 (2H, m), 1.72 (1H, dddd, J = 12.8, 7.6, 3.8 and 1.6, OCH2CH2), 1.11 
(3H, d, J = 6.4 Hz, CH3), 1.02 (3H, d, J = 6.6 Hz, CH3). 
 
13C NMR δC (CDCl3, 100MHz): 141.0 (s), 140.6 (d), 128.8 (d), 128.3 (d), 128.1 (2 × d), 127.1 (d), 
126.5 (2 × d), 125.9 (d), 83.4 (d), 67.5 (s), 45.1 (s), 36.0 (d), 30.7 (d);  
(2R*,3R*,1’R*)-THF 93b: 1H NMR δH (CDCl3, 400MHz): 7.30-7.34 (2H, m, Ar-H), 7.19-7.25 (3H, m, 
Ar-H), 3.78-3.87 (2H, m), 3.41 (1H, t, J = 5.9), 2.82 (1H, dd, J = 13.6 and 5.6 Hz), 2.57 (1H, dd, J = 
13.6 and 9.6 Hz), 2.23-2.29 (1H, m), 1.92 (1H, ddt, J = 12.3, 8.0 and 6.8 Hz), 1.62-1.72 (2H, m), 0.94 
(6H, dd, J = 6.8 and 1.2, 2 x CH3). 
 
Mono-debromination of 83 to give (±)-3-
[phenylmethyl]-2-phenyltetrahydrofurans 94a and 
b. 
Using the general procedure H, a mixture of 3-
[bromo(phenyl)methyl]-2-phenyltetrahydrofurans 83 
(34mg, 0.11 mmol, 77:12:11, 83a:83b:83c), 
NiCl2·6H2O (51 mg, 0.22 mmol) and NaBH4 (25 mg, 0.65 mmol) after 15 min, purifying by silica gel 
chromatography (19:1 hexane:ethyl acetate), yielded a colourless oil (14.7 mg, 57% yield) comprising 
an inseparable mixture of two diastereomers (94a:94b, 84:16 by 1H NMR integration).  
(2R*,3S*,1’R*)-THF 94a: IR (CH2Cl2) υmax 3061, 3027, 2933, 1602, 1494, 1452, 1081, 1053 cm-1; 1H 
NMR δH (CDCl3, 400MHz): 7.06-7.41 (10H, m, CHAr), 5.13 (1H, d, J = 6.7 Hz, OCHPh), 4.27 (1H, td, 
J = 8.3, 5.1 Hz, OCH2), 3.96 (1H, td, J = 8.3, 7.5 Hz, OCH2), 2.76 (1H, m, OCHCH), 2.41 (1H, dd, 
13.9, 4.4 Hz, CHPh), 1.96-2.02 (1H, m, OCH2CH2), 1.76-1.86 (1H, m, OCH2CH2). 13C NMR δC 
(CDCl3, 100MHz): 141.0 (s), 140.6 (d), 128.8 (d), 128.3 (d), 128.1 (2 × d), 127.1 (d), 126.5 (2 × d), 
125.9 (d), 83.4 (d), 67.5 (s), 45.1 (s), 36.0 (d), 30.7 (d); LRMS (CI) m/z 256 (MNH4+, 100%), 238 
(MH+, 10); HRMS (CI) m/z MH+ 239.1446. C17H18O Requires 238.1409; ∆ = 0.4 ppm.  
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(2R*,3R*,1’R*)-THF 94b: IR (CH2Cl2) υmax 3062, 2935, 1602, 1495, 1462, 1080, 1055 cm-1; 1H NMR 
δH (CDCl3, 400MHz): 7.16-7.37 (10H, m, CHAr), 4.56 (1H, d, J = 7.3 Hz), 4.05-4.15 (2H, m, OCH2), 
2.92 (1H, dd, J = 13.5, 5.3 Hz, CH2Ph), 2.63 (1H, dd, CH2Ph, J = 13.5, 9.7 Hz), 2.45-2.36 (1H, m, 
OCHCH), 2.05-2.13 (1H, m, OCH2CH2), 1.78-1.86 (1H, m, OCH2CH2); 13C NMR δC (CDCl3, 
100MHz): 140.4 (d), 128.9 (2 x d), 128.4 (2 × d), 128.4 (d), 127.5 (2 × d), 126.2 (d), 89.0 (d), 68.0 (s), 
49.9 (s), 38.3 (d), 32.3 (d); LRMS (CI) m/z 256 (MNH4+, 100%), 238 (MH+, 10); HRMS (CI) m/z MH+ 
239.1448. C17H18O requires 238.1409; ∆ = 0.5 ppm. 
 
Di-debromination of 84a to give (±)-(2R*,3R*)-3-
[phenylmethyl]-2-(2- phenyl)tetrahydrofuran 94a.  
Using the general procedure H, (2R*,3S*,1’R*)-3-
[bromo(phenyl)methyl]-2-(2-bromophenyl)tetrahydrofuran 84a 
(50mg, 0.13 mmol), NiCl2·6H2O (60 mg, 0.25 mmol) and 
NaBH4 (30 mg, 0.76 mmol) after 15 min, purifying by silica gel 
chromatography (19:1 hexane:ethyl acetate), yielded the THF 94a as a colourless oil (3.1 mg, 10%). 
Spectroscopic data as above. 
 
Didebromination of 84c to give (±)-(2R*,3S*)-3-
[phenylmethyl]-2-(2-phenyl)tetrahydrofuran 94b 
Using the general procedure H, (2R*,3R*,1’R*)-3-
[bromo(phenyl)methyl]-2-(2-bromophenyl)tetrahydrofuran 94b 
(50mg, 0.13 mmol), NiCl2·6H2O (60 mg, 0.25 mmol) and 
NaBH4 (30 mg, 0.76 mmol) after 15 min, purifying by silica gel 
chromatography (19:1 hexane:ethyl acetate) yielded the THF 94b as a colourless oil (4.4 mg, 13%). 
Spectroscopic data as above. 
 
(±)-3-Phenyl-1-(phenyl)amino-2-methyl-cis-bicyclo[3.3.0]oct-2-ene (96) 
5y. 
Using the general procedure D, aniline (780 µL, 8.6 mmol), CSA (20 mg, 0.09 
mmol) and tertiary alcohol (184 mg, 0.86 mmol) after 17 h purifying by FC 
(neutralised with Et3N; 2% ethyl acetate in petroleum ether) gave 96 as a 
pale yellow solid (103 mg, 60%), m.p. 127 ºC.  
Rf = 0.5 (2% ethyl acetate in petroleum ether); IR (neat): υmax = 3403 (m) (Ar-NH), 2943 (m) (Ar-H), 
cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.34-7.41 (4H, m, Ar-H), 7.09-7.13 (2H, m, Ar-H), 6.61-6.69 
(3H, m, Ar-H), 3.99 (1H, br s, NH), 3.23 (1H, ddq, J = 16.7, 9.8 and 2.2 Hz, C=C(Ph)CH2), 2.85 (1H, 
m, CH), 2.44 (1H, ddq, J = 16.7, 4.0 and 2.2, C=C(Ph)CH2), 1.95-2.11 (2H, m, NHCCH2), 1.73-1.78 
(3H, m, CH3), 1.53-1.68 (4H, m, CH2CH2); 13C NMR: δC (125 MHz, CDCl3); 129.07 (d) (Ar-C), 128.17 
(d) (Ar-C), 127.71 (d) (Ar-C), 126.66 (d) (Ar-C), 116.89 (d) (Ar-C), 113.78 (d) (Ar-C), 81.48 (s) (C-
NH), 43.68 (t) (CH2), 42.18 (t) (CH2), 42.04 (d) (CH2), 35.43 (t) (CH2), 24.32 (t) (CH2), 11.98 (q) (CH3). 
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LRMS (EI) m/z 289 (M+, 40%), 197 [(M-NHC6H4)+, 100]; HRMS (EI) m/z 289.1830. C21H23N Required 
289.1828; Δ = -0.9 ppm. 
 
(E)-3-Penten-1-ol (99).174 
A solution of pentenoic acid 98 (5g, 50 mmol) in diethyl ether (60 mL) was added dropwise to a slurry 
of LiAlH4 (2.85g, 75 mmol) in diethyl ether (60 mL) at 0 ºC over 30 mins followed by a further 1 h at 
room temperature.  The slurry was then cooled to 0 ºC before slow, cautious addition of H2O (20 mL).  
The solution was then added slowly onto 50% H2SO4 (75 mL).  The organic was then separated and 
the aqueous extracted with diethyl ether (4 x 70 mL). The organic extracts were then combined and 
washed with H2O (2 x 40 mL), brine (50 mL), dried over MgSO4 and concentrated under reduced 
pressure to give 99 (2.46g, 61%) as a colourless liquid.  
1H NMR: δH (400 MHz, CDCl3): 8.78 (1H, br s, OH), 5.65-5.55 (1H, m, CHCHCH3), 5.43 (1H, dddd, J 
= 15.5, 8.4, 2.9, 1.4 Hz, CHCHCH3), 3.65 (2H, t, J = 6.2 Hz, CH2CH2OH), 2.35-2.20 (2H, m, 
CH2CH2OH), 1.71 (3H, dd, J = 6.3, 1.2 Hz, CHCHCH3).  LRMS (ESI) m/z 87 (MH+, 100%). 
 
(2R*, 3S*,4S*)-4-Bromo-3-methyl-2-phenyltetrahydro-2H-pyran (100).174  
Using the general oxonia Prins procedure G, pentenol 99 (2g, 23.3 mmol), benzaldehyde 
(1.97 mL, 19.3 mmol), SnBr4 (8.5g, 19.3 mmol) and TMS bromide (2.55 mL, 19.3 mmol) 
after 2 h generated 100 (4.8g, 97%) as a pale yellow oil. 
1H NMR: δH (400 MHz, CDCl3): 7.36 (5H, m, Ar-H) 4.09 (1H, ddd, J = 11.9, 4.8, 2.1 Hz, CH2O) 4.03 
(1H, ddd, J = 11.9, 10.8, 4.8 Hz, CHBr), 3.95 (1H, d, J = 9.8 Hz, CHPh), 3.62 (1H, ddd, J = 12.1, 11.9 
, 2.4 Hz, CH2O), 2.43 (1H, dddd, J = 13.1, 12.1, 11.9, 4.8 Hz,  CH2CH2O), 2.38 (1H, dddd,  J = 13.1 , 
4.8, 2.4, 2.1 Hz, CH2CH2O), 2.10 (1H, ddq,  J = 10.8, 9.8, 6.5 Hz,  CHMe), 0.90 (3H, d, J = 6.5 Hz, 
CH3). LRMS (ESI) m/z 255 (MH+, 100%). 
 
(±)-(2R*, 3S*, 4R*)-4-Iodo-3-methyl-2-phenyltetrahydro-2H-pyran (101)174, (±)-(2R*)-3-methyl-2-
phenyl-5,6- dihydro-2H-pyran (102)174 and (±)-(2R*, 3S*)-3-methyl-2-phenyl-3,6-dihydro-2H-
pyran (104)222. 
 
 
 
 
 
NaI (2.8g, 20 mmol) was added to a solution of bromo-THP 100 (255 mg, 1 mmol) in acetone (10 
mL).  The vessel was sealed and the reaction heated at 85 ºC for 42 h before allowing to cool and 
concentrating under reduced pressure.  The solid was dissolved in diethyl ether (60 mL) and washed 
with 2M sodium thiosulfate (20 mL) and brine (2 x 20 mL).  The organic layer was then dried over 
MgSO4 and concentrated under reduced pressure to give a colourless oil.  Purification by FC (2% 
ethyl acetate in petroleum ether) gave iodo-THP 101 (18 mg, 6%), dihydropyran 102 (125 mg, 72%) 
and dihydropyran 104 (43 mg, 22%) as pale yellow oils. 
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Iodo-THP 101: 1H NMR: δH (400 MHz, CDCl3); 7.38 – 7.34 (5H, m, Ar-H), 4.19 – 4.12 (1H, m, CHI), 
3.97 (1H, d, J = 9.7 Hz, CHPh), 3.90 (1H, ddd, J = 11.3, 4.8, 1.5 Hz, OCH2), 3.58 (1H, td, J = 12.5, 
2.1 Hz, OCH2), 2.69 (1H, ddd, J = 25.4, 12.5, 4.8 Hz, CH2CH2O), 2.53-2.46 (1H, m, CH2CH2O), 2.43-
2.30 (1H, m, CHCH3), 0.89 (3H, d, J = 6.6 Hz, CH3). LRMS (CI) m/z 302 (M+, 100%). 
5,6-Dihydropyran 102: 1H NMR: δH (400 MHz, CDCl3); 7.53 – 7.31 (5H, m, Ar-H), 5.88 – 5.73 (1H, m, 
CHCHMe), 4.96 (1H, br m, CHPh), 3.92 (1H, ddd, J = 15.4, 7.5, 4.1,CH2O), 3.71 (1H, ddd, J = 5.4, 
7.5, 3.6 Hz, CH2O), 2.36 (1H, m, CH2CH2O), 2.20 – 2.08 (1H, m, CH2CH2O), 1.47 (3H, s, CH3). 
LRMS (CI) m/z 174 (M+, 100%). 
3,6-Dihydropyran 102: 1H NMR: δH (400 MHz, CDCl3); 7.29-7.40 (5H, m, Ar-H), 5.76-5.86 (2H, m, 
CH=CH), 4.35 (2H, dt, J = 3.4 and 2.1 Hz, OCH2), 4.02 (1H, d, J = 9.2 Hz, Ar-CH), 2.48-2.57 (1H, m, 
CHCH3), 0.86 (3H, d, J = 7.1 Hz, CH3). LRMS (CI) m/z 174 (M+, 100%). 
 
General Procedure I (Aniline Substitution Reaction). 
Triethylamine (46 µL) was added to a solution of iodo-THP 102 (50 mg, 0.17 mmol) and the required 
aniline (0.33 mmol) before sealing the reaction vessel and heating at 80 ºC for 24 h.  The suspension 
was concentrated under reduced pressure before purifying by FC. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-para-tolyltetrahydro-2H-pyran-4-amine 
(103).174   
Using the general procedure I, triethylamine (46 µL), iodo-THP 102 (50 mg, 0.17 
mmol) and p-toluidine (35 mg, 0.33 mmol) purifying by FC (9:1 petroleum ether:ethyl 
acetate) gave 103 (35 mg, 75%) as a colourless oil.  
1H NMR: δH (400 MHz, CDCl3); 7.41-7.31 (5H, m, Ar-H), 7.02 (2H, d, J = 8.2 Hz, Ar-H), 6.59 (2H, d, J 
= 8.2, Ar-H), 4.17 (1H, m, CH2O), 4.04 (1H, d, J = 9.8 Hz, CHPh), 3.71 (1H, m, CH2O), 3.34-3.23 (2H, 
m, CH2CH2O), 2.20 (1H, m, CHNH), 2.26 (3H, s, Ar-CH3), 1.68 (1H, m, CHMe), 0.82 (3H, d, J = 6.5 
Hz, CH3); LRMS (CI) m/z 282 (MH+, 100%). 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-phenyltetrahydro-2H-pyran-4-amine (95) 
THP_002.  
Using the general procedure I, triethylamine (50 µL, 0.33 mmol), iodo-THP 102 (50 
mg, 0.17 mmol) and aniline (31 mg, 0.33 mmol) purifying by FC (9:1 petroleum 
ether:ethyl acetate) gave 95 (7 mg, 48%) as a colourless oil.  
1H NMR: δH (400 MHz, C6D6); 7.48 (2H, m, Ar-H), 7.30-7.37 (4H, m, Ar-H), 6.87-6.91 
(1H, m, Ar-H), 6.57-6.59 (2H, m, Ar-H), 4.00 (1H, ddd, J = 11.7, 4.7 and 1.7 Hz, CHNH), 3.85 (1H, d, 
J = 9.7 Hz, Ar-CH), 3.38 (1H, ddd, J = 12.5, 11.7 and 2.0 Hz, OCH2), 3.03 (1H, qd, J = 10.3 and 4.0 
Hz, OCH2CH2), 2.88 (1H, br d, J = 9.4 Hz, NH), 1.90 (1H, ddt, J = 13.1, 4.1 and 2.0 Hz, OCH2), 1.26-
1.41 (2H, m), 0.76 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 147.91 (s) (Ar-CNH), 
141.76 (s) (Ar-C), 129.43 (2 x d) (Ar-C), 128.18 (2 x d) (Ar-C), 127.70 (2 x d) (Ar-C), 117.28 (d) (Ar-
C), 113.31 (2 x d) (Ar-C), 86.16 (d) (Ar-CH), 66.92 (t) (OCH2), 55.74 (d) (NHCH), 44.41 (t) 
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(OCH2CH2), 33.84 (d) (CHCH3), 13.93 (q) (CH3); LRMS (EI) m/z 267 (M+, 100%). HRMS (EI) m/z 
267.1623. C18H21NO Required 267.1621; Δ = -0.8 ppm 
 
(±)-(2R*, 3S*,4S*)-4-Bromo-3-methyl-2-(4-methoxyphenyl)tetrahydro-2H-
pyran (product of table 7, entry 2). 
Using the general oxonia Prins procedure G, pentenol 99 (60 mg, 0.7 mmol), 
4-methoxybenzaldehyde (60 mL, 0.48 mmol), SnBr4 (212 mg, 0.48 mmol) 
and TMS bromide (64 µL, 0.48 mmol) after 2h generated 100 (84 mg, 89%) 
as a pale yellow oil. 
Rf = 0.2 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax = 2961 (m), 2932 (w), 2837 (w), 1613 
(w), 1514 (m), 1242 (s), 1174 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.27 (2H, d, J = 8.7 Hz, Ar-H), 
6.91 (2H, d, J = 8.8 Hz, Ar-H), 3.98-4.09 (2H, m, CHBr and OCH2), 3.91 (1H, d, J = 9.8, Ar-CH), 3.83 
(3H, s, OCH3), 3.59 (1H, td, J = 12.0 and 2.5, OCH2), 2.32-2.48 (2H, m), 2.03-2.13 (1H, m, 
(Br)CHCH2), 0.90 (3H, d, J = 6.6, CH3); 13C NMR: δC (125 MHz, CDCl3); 159.51 (s) (Ar-COCH3), 
132.59 (d) (Ar-C), 128.49 (s) (Ar-C), 113.87 (d) (Ar-C), 86.09 (q) (OCH3), 68.33 (d) (CHAr), 56.77 (t) 
(OCH2), 55.32 (d) (CHBr), 46.59 (OCH2CH2),  38.93 (d) (CHCH3), 16.75 (q) (CH3). LRMS (ESI) m/z 
284 (M+, 100%). 
 
(±)-(2R*, 3S*,4S*)-4-Bromo-3-methyl-2-(4-methylphenyl)tetrahydro-2H-pyran 
(Prins product of table 7, entry 3). 
Using the general oxonia Prins procedure G, pentenol 99 (60 mg, 0.7 mmol), 4-
methylbenzaldehyde (60 µL, 0.48 mmol), SnBr4 (212 mg, 0.48 mmol) and TMS 
bromide (64 µL, 0.48 mmol) after 2 h generated 100 (105 mg, 82%) as a pale 
yellow oil. 
Rf = 0.35 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax = 2963 (m), 2926 (w), 2848 (w), 1516 
(w) 1087 (s) (COC), 811 (s) (COC) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.18-7.26 (4H, m, Ar-H), 
4.00-4.10 (2H, m), 3.92 (1H, d, J = 9.8 Hz, Ar-CH), 3.60 (1 H, td, J = 12.0 and 2.5 Hz, OCH2), 2.47-
2.50 (1H, m, OCH2CH2), 2.38 (3H, s, Ar-CH3), 2.34 (1H, m, OCH2CH2), 2.06-2.16 (1H, m, CHCH3), 
0.91 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (125 MHz, CDCl3); 137.99 (s) (Ar-C), 137.33 (s) (Ar-C), 
129.17 (d) (Ar-C), 127.25 (d) (Ar-C), 86.42 (Ar-CH), 68.36 (Ar-CH3), 56.82 (OCH2), 46.48 (CHBr), 
38.95 (OCH2CH2), 21.24 (CHCH3), 16.73 (CH3). LRMS (ESI) m/z 268 (M+, 100%). 
 
(±)-(2R*, 3S*,4S*)-4-Bromo-3-methyl-2-(4-chlorophenyl)tetrahydro-2H-pyran 
(Prins product of table 7, entry 4). 
Using the general oxonia Prins procedure G, pentenol 99 (60 mg, 0.7 mmol), 4-
chlorobenzaldehyde (48 mg, 0.48 mmol), SnBr4 (212 mg, 0.48 mmol) and TMS 
bromide (64 µL, 0.48 mmol) after 2 h gave 100 (124 mg, 90%) as a pale yellow 
oil. 
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Rf = 0.53 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 2961 (m), 2920 (w), 2851 (w), 1598 (w), 
1460 (s), 1087 (s) (COC), 822 (s) (COC) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.35 (2H, d, J = 8.6 
Hz, Ar-H), 7.29 (2H, d, J = 8.4 Hz, Ar-H), 4.08 (1H, ddd, J = 11.9, 4.7 and 2.0 Hz, CHBr), 4.01 (1H, 
dt, J = 11.4 and 5.6 Hz, OCH2), 3.93 (1H, d, J = 9.8 Hz, Ar-CH), 3.60 (1H, td, J = 11.4 and 2.7 Hz, 
OCH2), 2.34-2.48 (2H, m, OCH2CH2), 1.98-2.08 (1H, m, CHCH3), 0.89 (3H, d, J = 6.6, CH3); 13C 
NMR: δC (125 MHz, CDCl3); 138.77 (s) (Ar-C), 133.98 (s) (Ar-C), 128.7 (s) (Ar-C), 128.67 (s) (Ar-C), 
85.76 (d) (Ar-CH), 68.36 (t), 56.12 (d), 46.55 (d), 38.75 (t), 16.57 (q). LRMS (ESI) m/z 288 (M+, 
100%). 
 
(±)-(2R*, 3S*,4S*)-4-Bromo-3-methyl-2-(3,4-dichlorophenyl)tetrahydro-2H-
pyran (Prins product of table 7, entry 5). 
Using the general oxonia Prins procedure G, pentenol 99 (60 mg, 0.7 mmol), 3,4-
dichlorobenzaldehyde (64 mg, 0.48 mmol), SnBr4 (212 mg, 0.48 mmol) and TMS 
bromide (64 µL, 0.48 mmol) after 2 h gave 100 (145 mg, 94%) as a pale yellow 
oil. 
Rf = 0.59 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax = 2965 (m), 2926 (w), 2849 (w), 1516 
(w) 1086 (s) (COC), 570 (s), cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.44-7.47 (2H, m, Ar-H), 7.18 (1H, 
dd, J = 8.2 and 2.1 Hz, Ar-H), 4.08 (1H, ddd, J = 11.8, 4.6 and 2.0 Hz, CHBr), 3.98 (1H, td, J = 11.0 
and 5.3 Hz, OCH2), 3.91 (1H, d, J = 9.8 Hz, Ar-CH), 3.55-3.62 (1H, m, OCH2), 2.34-2.47 (2H, m, 
OCH2CH2), 1.94-2.04 (1H, m, CHCH3), 0.91 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (125 MHz, CDCl3); 
140.47 (s) (Ar-C(Cl)), 132.64 (s) (Ar-C(Cl)), 132.23 (s) (Ar-C), 130.41 (d) (Ar-C), 129.35 (d) (Ar-C), 
126.72 (d) (Ar-C), 85.15 (d) (Ar-CH), 68.36 (t), 55.61 (d), 46.47 (d), 38.61 (t), 16.52 (q). LRMS (ESI) 
m/z 322 (M+, 100%). 
 
(±)- (2R*,3S*,4S*)-4-Bromo-3-propyl-2-(phenyl)tetrahydro-2H-pyran (Prins 
product of table 7, entry 6). 
Using the general oxonia Prins procedure G, heptenol (77 mg, 0.67 mmol), 
benzaldehyde (48 µL, 0.48 mmol), SnBr4 (210 mg, 0.48 mmol) and TMS bromide 
(63 µL, 0.48 mmol) after 5 h gave 100 (110 mg, 58%) as a colourless oil. 
Rf = 0.63 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 2957 (m), 2932 (w), 2869 (w), 1454 (w) 
1081 (s) (COC), 757 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.32-7.41 (5H, m, Ar-H), 4.22 (1H, td, J 
= 11.2 and 5.3 Hz, CHBr), 4.13 (1H, d, J = 10.0 Hz, Ar-CH), 4.06 (1H, ddd, J = 11.8, 4.6 and 2.0 Hz, 
OCH2), 3.55-3.61 (1H, m, OCH2), 2.36-2.50 (2H, m, OCH2CH2), 2.03-2.10 (1H, m, CHCH2), 1.46-1.55 
(1H, m, CHCH2), 0.99-1.25 (3 H, m, CH2CH2CH3), 0.74 (3H, t, J = 7.2 Hz, CH3); 13C NMR: δC (125 
MHz, CDCl3); 140.19 (s) (Ar-C), 128.53 (2 x d) (Ar-C), 128.34 (d) (Ar-C), 127.30 (2 x d) (Ar-C), 84.71 
(d) (Ar-CH), 68.28 (t), 54.44 (d), 50.72 (d), 39.04 (t), 31.98 (t), 18.23 (t), 14.42 (q). LRMS (ESI) m/z 
283 (M+, 100%). 
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(±)-(2R*, 3S*,4S*)-4-Bromo-3-pentyl-2-(phenyl)tetrahydro-2H-pyran (Prins 
product of table 7, entry 7). 
Using the general oxonia Prins procedure G, nonenol (105 mg, 0.67 mmol), 
benzaldehyde (48 µL, 0.48 mmol), SnBr4 (210 mg, 0.48 mmol) and TMS 
bromide (63 µL, 0.48 mmol) after 5h gave 100 (110 mg, 58%) as a colourless 
oil. 
Rf = 0.65 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 2955 (m), 2929 (w), 2858 (w), 1454 (w) 
1093 (s) (COC), 811 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.32-7.41 (5H, m, Ar-H), 4.24 (1H, td, J 
= 11.2 and 5.2 Hz, CHBr), 4.14 (1H, d, J = 10.0 Hz, Ar-CH), 4.06 (1H, ddd, J = 11.8, 4.6 and 2.0 Hz, 
OCH2), 3.55-3.61 (1H, m, OCH2), 2.36-2.50 (2H, m, OCH2CH2), 2.03-2.10 (1H, m, CH(pent)), 1.48-
1.56 (1H, m, CHCH2), 0.88-1.24 (7H, m, CH2CH2CH2CH2), 0.82 (3H, t, J = 7.2 Hz, CH3); 13C NMR: δC 
(125 MHz, CDCl3); 140.18 (s) (Ar-CCH), 128.51 (2 x d) (Ar-C), 128.35 (d) (Ar-C), 127.32 (2 x d) (Ar-
C), 84.65 (d) (Ar-CHO), 68.28 (t) (OCH2), 54.39 (d) (CHBr), 50.77 (d) (CH), 39.06 (t) (OCH2CH2), 
32.03 (t), 29.56 (t), 24.40 (t), 22.28 (t), 13.96 (q) (CH3). LRMS (ESI) m/z 310 (M+, 100%). 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-(4-methoxyphenyl)-N-phenyltetrahydro-2H-
pyran-4-amine (104) THP_014. 
Using the general aniline substitution procedure I, triethylamine (32 µL), iodo-
THP (36 mg) and aniline (22 µL) after 5 h purifying by FC (9:1 petroleum 
ether:ethyl acetate) gave 104 (7.5 mg, 48%) as a colourless oil.  
Rf = 0.4 (10:1 petroleum ether:ethyl acetate);   (neat): vmax 2954 (m), 2929 
(w), 2853 (w), 1453 (w), 1278 (m), 1093 (s) (COC), 818 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.42 
(2H, d, J = 8.7 Hz, Ar-H), 7.32 (2H, m, Ar-H), 6.99 (2H, d, J = 8.7 Hz, Ar-H), 6.90 (1H, t, J = 7.3 Hz, 
Ar-H), 6.59-6.61 (2H, m, Ar-H), 4.02 (1H, ddd, J = 11.6, 4.6 and 1.5 Hz, OCH2), 3.87 (1H, d, J = 9.7 
Hz, Ar-CH), 3.46 (3H, s, OCH3), 3.41 (1H, dd, J = 12.1 and 1.5 Hz, OCH2), 3.06 (1H, m, NHCH), 2.93 
(1H, br s, NH), 1.93 (1H, m, CHCH3), 1.29-1.48 (2H, m, OCH2CH2), 0.81 (3H, d, J = 6.6 Hz, CH3); 13C 
NMR: δC (125 MHz, CDCl3); 159.59 (s) (Ar-COCH3), 129.44 (2 x d) (Ar-C), 128.75 (2 x d) (Ar-C), 
117.28 (d) (Ar-C), 113.68 (2 x d) (Ar-C), 113.33 (d) (Ar-C), 85.78 (d) (Ar-CHO), 66.93 (t) (OCH2), 
55.91 (d) (CHNH), 54.58 (q) (Ar-OCH3), 44.58 (t) (OCH2CH2), 33.95 (d) (CHCH3), 14.04 (q) (CH3). 
HRMS (ESI) m/z 298.1804 (MH+). C19H23NO2 Required 297.1807; Δ = -1.0 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(3-fluorophenyl)tetrahydro-2H-pyran-4-
amine (110) THP_003. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 mmol), 
iodo-THP 102 (50 mg, 0.17 mmol) and 3-fluoro aniline (32 µL, 0.33 mmol) after 5 h 
purifying by FC (9:1 petroleum ether:ethyl acetate) gave 110 (0.9 mg, 4%) as a 
colourless oil.  
Rf = 0.64 (10:1 petroleum ether:ethyl acetate); IR (neat): vmax 2952 (m), 2928 (w), 2854 (w), 1483 (w), 
1292 (m), 1101 (s) (COC), 976 (s) cm–1; 1H NMR: δH (400 MHz, C6D6); 7.46-7.48 (2H, m, Ar-H), 7.35 
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(3H, dd, J = 8.1 and 6.7 Hz, Ar-H), 7.05 (1H, td, J = 8.2 and 6.8 Hz, Ar-H), 6.54-6.59 (1H, m, Ar-H), 
6.35 (1H, dt, J = 11.8 and 2.3 Hz, Ar-H), 6.21 (1H, dd, J = 8.2 and 2.2 Hz, Ar-H), 3.96 (1H, ddd, J = 
11.7, 4.7 and 1.7 Hz, OCH2), 3.80 (1H, d, J = 9.7 Hz, Ar-CH), 3.31 (1H, ddd, J = 12.5, 11.7 and 1.7, 
OCH2), 2.83-2.93 (2H, m, OCH2CH2), 1.77 (1H, m, CHCH3), 0.68 (3H, d, J = 6.6 Hz, CH3); HRMS 
(ESI) m/z 285.1531 (MH+). C18H20FNO Required 285.1531; Δ = 0.2 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(4-fluorophenyl)tetrahydro-2H-pyran-4-
amine (111) THP_004. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 mmol), 
iodo-THP 102 (50 mg, 0.17 mmol) and 4-fluoro aniline (32 µL, 0.33 mmol) after 5 h 
purifying by FC (20:1 petroleum ether:ethyl acetate) gave 111 (6.7 mg, 17%) as a 
colourless oil.  
Rf = 0.24 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.49 (2H, dd, J = 8.2 
and 1.2 Hz, Ar-H), 7.36 (2H, dd, J = 8.1 and 6.8 Hz, Ar-H), 7.27 (1H, m), 6.99 (2H, t, J = 8.7 Hz, Ar-
H), 6.29 (2H, dd, J = 9.0 and 4.4 Hz, Ar-H), 4.00 (1H, ddd, J = 11.7, 4.7 and 1.7 Hz, OCH2), 3.85 (1H, 
d, J = 9.7 Hz, Ar-CH), 3.37 (1H, m, OCH2), 2.85 (1H, m, NHCH), 2.67 (1H, br s, NH), 1.81 (1H, ddt, J 
= 13.1, 4.1 and 2.0 Hz, OCH2CH2), 1.19-1.39 (2H, m), 0.75 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC 
(400 MHz, C6D6); 157.08 (s) (Ar-C), 144.18 (s) (Ar-C), 141.69 (2 x d), 128.21 (s) (Ar-C), 115.91 (2 x 
d) (Ar-C), 115.68 (2 x d) (Ar-C), 114.09 (2 x d) (Ar-C), 114.03 (d) (Ar-C), 86.14 (d) (ArCHO), 66.89 (t), 
56.47 (d), 44.41 (t), 33.70 (d), 13.92 (q); HRMS (ESI) m/z 285.1613 (MH+). C18H20FNO Required 
285.1607; Δ = 2.1 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(3,4-difluorophenyl)tetrahydro-2H-
pyran-4-amine (112) THP_005. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 mmol), 
iodo-THP 102 (50 mg, 0.17 mmol) and 3,4-difluoro aniline (32 µL, 0.33 mmol) after 
5 h purifying by FC (20:1 petroleum ether:ethyl acetate) gave 112 (3.3 mg, 9%) as a 
colourless oil.  
Rf = 0.27 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.48 (2H, dd, J = 8.2 
and 1.2 Hz, Ar-H), 7.36 (2H, dd, J = 8.1 and 6.8 Hz, Ar-H), 7.28 (1H, m, Ar-H), 6.87 (1H, dt, J = 10.2 
and 9.0 Hz, Ar-H), 6.23 (1H, ddd, J = 12.9, 6.6 and 2.9 Hz, Ar-H), 5.89 (1H, dtd, J = 8.9, 3.1 and 1.5 
Hz, Ar-H), 3.96 (1H, ddd, J = 11.7, 4.7 and 1.7 Hz, OCH2), 3.80 (1H, d, J = 9.7 Hz, Ar-CH), 3.30 (1H, 
m, OCH2), 2.64-2.75 (2H, m), 1.70 (1H, ddt, J = 13.1, 3.9 and 1.9 Hz, OCH2CH2), 1.26 (1H, m, 
CHCH3), 0.67 (3H, d, J = 6.6 Hz, CH3); HRMS (ESI) m/z 304.1513 (MH+). C18H20F2NO Required 
304.1513; Δ = 0 ppm. 
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(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(4-fluorophenyl)tetrahydro-2H-pyran-4-
amine (113) THP_006. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 mmol), 
iodo-THP 102 (50 mg, 0.17 mmol) and 4-iodo aniline (73 mg, 0.33 mmol) after 5 h 
purifying by FC (20:1 petroleum ether:ethyl acetate) gave 113 (3.7 mg, 8%) as a 
pale yellow oil.  
Rf = 0.25 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.55 (2H, d, J = 8.8 Hz, 
Ar-H), 7.47 (2H, dd, J = 8.2 and 1.2 Hz, Ar-H), 7.35 (2H, d, J = 7.0 Hz, Ar-H), 7.30 (1H, m, Ar-H), 6.11 
(2H, d, J = 8.9 Hz, Ar-H), 3.97 (1H, ddd, J = 11.7, 4.7 and 1.8 Hz, OCH2), 3.81 (1H, d, J = 9.7 Hz, Ar-
CH), 3.32 (1H, ddd, J = 12.5, 11.7 and 1.8 Hz, OCH2), 2.75-2.87 (2H, m), 1.74 (1H, ddt, J = 13.2, 4.0 
and 2.0 Hz, OCH2CH2), 1.18-1.32 (2H, m), 0.67 (3H, d, J = 6.6 Hz, CH3); HRMS (ESI) m/z 394.0651 
(MH+). C18H20INO Required 394.0668; Δ = -4.3 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(2,3-dimethylphenyl)tetrahydro-2H-
pyran-4-amine (114) THP_007. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 mmol), 
iodo-THP 102 (50 mg, 0.17 mmol) and 2,3-dimethyl aniline (40 mg, 0.33 mmol) after 
5 h purifying by FC (20:1 petroleum ether:ethyl acetate) gave 114 (3.7 mg, 8%) as a 
pale orange oil.  
Rf = 0.24 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.46 (2 
H, dd, J = 8.2 and 1.2 Hz, Ar-H), 7.31 (2H, ddd, J = 8.0, 6.5 and 1.3 Hz, Ar-H), 7.23 (2H, m, Ar-H), 
6.79 (1H, d, J = 7.4 Hz, Ar-H), 6.65 (1H, d, J = 8.1 Hz, Ar-H), 3.98 (1H, ddd, J = 11.7, 4.7 and 1.7 Hz, 
OCH2), 3.86 (1H, d, J = 9.7, Ar-CH), 3.40 (1H, m, OCH2), 3.04-3.15 (2H, m, OCH2CH2 and CHNH), 
2.26 (3H, s, Ar-CH3), 2.00 (1H, ddt, J = 13.2, 4.0 and 2.0 Hz, OCH2CH2), 1.86 (3H, s, Ar-CH3), 1.38 
(1H, tdd, J = 12.9, 11.0 and 4.7 Hz, CHCH3), 0.79 (3H, d, J = 6.6 Hz, CHCH3); 13C NMR: δC (100 
MHz, C6D6); 145.54 (s) (Ar-C), 141.78 (s) (Ar-C), 136.53 (s) (Ar-C), 128.16 (d) (Ar-C), 127.95 (s) (Ar-
C), 127.74 (d) (Ar-C), 126.40 (2 x d) (Ar-C), 120.03 (s) (Ar-C), 119.42 (2 x d) (Ar-C), 109.11 (d) (Ar-
C), 86.19 (d) (Ar-CH), 66.95 (t) (OCH2), 56.12 (d) (CHNH), 44.65 (OCH2CH2), 34.33 (q) (Ar-CH3), 
20.79 (q) (Ar-CH3), 14.01 (t) (CHCH3), 12.38 (q) (CH3); HRMS (ESI) m/z 296.2013 (MH+). C20H26NO 
Required 296.2014; Δ = -0.3 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(4-tertbutylphenyl)tetrahydro-2H-
pyran-4-amine (115) THP_008. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 
mmol), iodo-THP 102 (50 mg, 0.17 mmol) and 4-tertbutyl aniline (49 mg, 0.33 
mmol) after 5 h purifying by FC (20:1 petroleum ether:ethyl acetate) gave 115 
(18.9 mg, 50%) as a pale orange oil.  
Rf = 0.29 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.50 
(2H, dd, J = 8.3 and 1.2 Hz, Ar-H), 7.34-7.42 (4H, m, Ar-H), 7.26 (1H, m, Ar-H), 6.61 (2H, d, J = 8.7 
Hz, Ar-H), 4.02 (1H, ddd, J = 11.6, 4.7 and 1.7 Hz, OCH2), 3.88 (1H, d, J = 9.7 Hz, Ar-CH), 3.42 (1H, 
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ddd, J = 12.5, 11.6 and 2.0 Hz, OCH2), 3.09 (1H, qd, J = 10.0 and 3.5 Hz, CHNH), 2.86 (1H, br d, J = 
8.7 Hz, NH), 1.97 (1H, ddt, J = 13.1, 4.0 and 2.0 Hz, OCH2CH2), 1.46 (9H, s, C(CH3)3), 1.30-1.42 
(2H, m), 0.82 (3H, d, J = 6.6 Hz, CH3); HRMS (ESI) m/z 324.2328 (MH+). C22H30NO Required 
324.2327; Δ = 0.3 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(4-propan-2-onephenyl)tetrahydro-
2H-pyran-4-amine (116) THP_009. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 
mmol), iodo-THP 102 (50 mg, 0.17 mmol) and 4-propan2-one aniline (45 mg, 
0.33 mmol) after 5 h purifying by FC (20:1 petroleum ether:ethyl acetate) gave 
116 (11.6 mg, 28%) as a pale yellow oil.  
Rf = 0.12 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.48 (2H, dd, J = 8.2 
and 1.2 Hz, Ar-H), 7.35 (2H, dd, J = 8.1 and 6.8 Hz, Ar-H), 7.25-7.27 (3H, m, Ar-H), 6.51 (2H, d, J = 
8.6 Hz, Ar-H), 3.99 (1H, ddd, J = 11.7, 4.7 and 1.7 Hz, OCH2), 3.85 (1H, d, J = 9.7, Ar-CH), 3.54 (2H, 
s, Ar-CH2), 3.44 (3H, s, COCH3), 3.34-3.41 (1H, m, OCH2), 2.99 (1H, m, CHNH), 2.85-2.89 (1H, br d, 
NH), 1.87 (1H, ddt, J = 13.2, 4.1 and 2.0 Hz, OCH2CH2), 1.24-1.39 (2H, m), 0.75 (3H, d, J = 6.6 Hz, 
CH3); 13C NMR: δC (100 MHz, C6D6); 146.90 (s) (Ar-C), 141.77 (s) (Ar-C), 130.28 (2 x d) (Ar-C), 
122.77 (s) (Ar-C), 113.33 (2 x d) (Ar-C), 86.11 (d) (Ar-CHO), 66.89 (t) (OCH2), 55.80 (t) (ArCH2CO), 
51.13 (d) (NHCH), 44.38 (d) (CHCH3), 40.43 (t) (OCH2CH2), 33.79 (q) (COCH3), 13.91 (q) (CH3); 
HRMS (ESI) m/z 340.1926 (MH+). C21H26NO2 Required 340.1913; Δ = 3.8 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(4-N,N-dimethylphenyl)tetrahydro-2H-
pyran-4-amine (117) THP_010. 
Using the general aniline substitution procedure I, triethylamine (50 µL, 0.33 
mmol), iodo-THP 102 (50 mg, 0.17 mmol) and DMAP (45 mg, 0.33 mmol) after 5 
h purifying by FC (20:1 petroleum ether:ethyl acetate) gave 117 (17 mg, 73%) as 
a pale yellow oil.  
Rf = 0.10 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.51 
(2H, dd, J = 8.2 and 1.2 Hz, Ar-H), 7.36 (2H, ddd, J = 8.0, 6.6 and 1.3 Hz, Ar-H), 7.26 (1H, m, Ar-H), 
6.91 (2H, m, Ar-H), 6.68 (2H, m, Ar-H), 4.05 (1H, ddd, J = 11.6, 4.7 and 1.7 Hz, OCH2), 3.90 (1H, d, J 
= 9.7 Hz, Ar-CH), 3.43 (1H, ddd, J = 12.5, 11.6 and 2.0, OCH2), 3.05 (1H, td, J = 10.7 and 4.1 Hz, 
CHNH), 2.76 (6H, s, N(CH3)2), 2.63 (1H, br s, NH), 2.03 (1H, m), 1.32-1.52 (2 H, m), 0.90 (3H, d, J = 
6.6 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 141.97 (s) (Ar-C), 140.28 (s) (Ar-C), 127.74 (2 x d) (Ar-
C), 127.71 (2 x d) (Ar-C), 115.92 (2 x d) (Ar-C), 115.43 (2 x d) (Ar-C), 86.30 (d) (Ar-CHO), 67.11 (t) 
(OCH2), 57.37 (d) (CHCH3), 44.70 (NHCH), 41.90 (2 x q) (NCH3), 34.25 (OCH2CH2), 14.09 (q) (CH3); 
HRMS (ESI) m/z 310.2037 (M+). C20H26N2O Required 310.2045; Δ = -2.6 ppm. 
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(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(3,4-dichlorophenyl)tetrahydro-2H-
pyran-4-amine (118) THP_011. 
Using a modified general aniline substitution procedure I, triethylamine (100 µL, 
0.66 mmol), iodo-THP 102 (100 mg, 0.17 mmol) and 3,4-dichloro aniline (110 mg, 
0.66 mmol) after 2 h at 160 ºC (microwave irradiation) purifying by FC (20:1 
petroleum ether:ethyl acetate) gave 118 (5 mg, 12%) as a pale yellow oil.  
Rf = 0.26 (10:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, C6D6); 7.47 (2H, dd, J = 8.2 
and 1.2 Hz, Ar-C), 7.36 (2H, m, Ar-C), 7.26 (1H, m, Ar-C), 7.16 (1H, d, J = 8.7 Hz, Ar-C), 6.58 (1H, d, 
J = 2.8 Hz, Ar-C), 6.02 (1H, dd, J = 8.7 and 2.8, Ar-C), 3.94 (1H, ddd, J = 11.7, 4.7 and 1.7 Hz, 
OCH2), 3.76 (1H, d, J = 9.7, Ar-CH), 3.23-3.29 (1H, m, Ar-CH2), 2.71-2.76 (2H, m, CHNH and NH), 
1.67 (1H, m), 1.15-1.30 (2H, m), 0.63 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 147.26 
(s), 141.43 (s), 130.75 (s), 128.24 (2 x d), 128.06 (2 x d), 127.94 (d), 127.70 (d), 119.48 (d), 114.09 
(d), 112.61 (d), 85.80 (d) (Ar-CH), 66.62 (t) (OCH2, 55.63 (d), 44.24 (t), 33.37 (d), 13.75 (q); HRMS 
(ESI) m/z 336.0913 (MH+). C18H19Cl2NO Required 336.0922; Δ = -2.7 ppm. 
 
(±)-(2R*, 3R*,4S*)-4-Azido-3-methyl-2-phenyltetrahydro-2H-pyran (120). 
Sodium azide (22mg, 0.33 mmol) was added to a solution of iodo-THP 102 (50 mg, 
0.17 mmol) in DMF (0.4 mL) and heated at 50 ºC for 4 h.  Sat. aqueous sodium 
chloride (1 mL) was then added and the mixture extracted with ethyl acetate (3 x 10 
mL) and the combined extracts dried over Na2SO4.  The organic was then 
concentrated under reduced pressure to give a crude yellow solid before purifying by FC (10:1 
petroleum ether:ethyl acetate) yielding a pale yellow oil (20 mg, 40%) comprising an inseperable 
mixture of product 120 and starting iodo-THP 102 (3:1 as determined by 1H NMR integration).  
(2R*, 3R*,4S*)-4-Azido-THP 120: Rf = 0.58 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 2953 
(m), 2931 (w), 2848 (w), 1474 (w) 1102 (s) (COC), 811 (s) cm–1; 1H NMR: δH (400 MHz, C6D6); 7.31-
7.39 (5H, m, Ar-H), 4.22 (1H, ddd, J = 11.9, 4.8 and 1.8 Hz, OCH2), 3.95 (1H, m, Ar-CH), 3.66 (1H, 
td, J = 12.1 and 2.2 Hz, OCH2), 3.22 (1H, td, J = 11.1 and 4.5 Hz, N3CH), 1.92-2.04 (2H, m, 
OCH2CH2), 1.75 (1H, m, CHCH3), 0.82 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 
139.92 (s), 128.51 (2 x d), 127.41 (2 x d), 127.25 (d), 80.75 (d), 64.41 (t), 62.13 (d) (CHN3), 42.59 (t), 
31.84 (d), 14.85 (q); LRMS (CI) m/z 235 [(M+NH4)+, 100%], 192 (20), 96 (15); HRMS (CI) m/z 
235.1563 (MNH4+). C12H19N4O Required 235.1559; Δ = 1.8 ppm. 
 
(±)-(2R*, 3R*,4S*)-4-Amino-3-methyl-2-phenyltetrahydro-2H-pyran (121). 
PPh3 (71 mg, 0.27 mmol) and H2O (17 µL) were added to a solution of azido-THP 
120 (20mg, 0.9 mmol) was added to a solution of iodo-THP 102 (50 mg, 0.17 mmol) 
in THF (0.15 mL) and the reaction stirred at RT for 2 h. The mixture was then 
concentrated under reduced pressure before purifying by FC (10 to 20% methanol in 
CH2Cl2) to give 121 (8mg, 45%; over two steps) as an oil.  
Rf = 0.25 (10% methanol in CH2Cl2); IR (neat): υmax 2924 (m), 2858 (w), 1587 (m) (NH2), 1454 (m) 
1092 (s) (COC), 991 (m), 699 (s) cm–1; 1H NMR: δH (400 MHz, C6D6); 7.30-7.39 (5H, m, Ar-H), 4.15 
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(1H, ddd, J = 11.6, 4.7 and 1.6 Hz, OCH2), 3.91 (1H, d, J = 9.9 Hz, Ar-CH), 3.67 (1H, td, J = 12.1 and 
2.1 Hz, OCH2), 2.70 (1H, td, J = 10.6 and 3.9 Hz, CHNH2), 2.21 (2H, br s, NH2), 1.93 (1H, ddt, J = 
13.0, 4.1 and 1.9 Hz, OCH2CH2), 1.73 (1H, m, OCH2CH2), 1.56 (1H, tq, J = 9.8 and 6.6 Hz, CHCH3), 
0.79 (3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 140.73 (s), 128.40 (2 x d), 127.97 (d), 
127.51 (2 x d), 85.60 (d), 67.29 (t), 54.56 (d), 45.46 (t), 35.69 (d), 13.71 (q); LRMS (ESI) m/z 192 
(MH+, 100%); HRMS (ESI) m/z 192.1386 (MH+). C12H18NO Required 192.1388; Δ = -1.0 ppm. 
 
General Procedure J (Reductive amination for installation of N-alkyl-THP substituents). 
Aldehyde (1 mmol) was added to a solution of 4-amino THP 121 (1 mmol) in dichloroethane (3 mL) 
and the solution stirred for 5 mins before addition of NaCNBH3 (1.4 mmol) and stirring for a further 16 
h.  The reaction mixture was then quenched by addition of 3M NaOH (1 mL) and extracted with 
diethyl ether (3 x 10 mL).  The combined extracts were dried over MgSO4 before concentrating under 
reduced pressure. 
 
(±)-(2R*,3R*,4S*)-3-Methyl-2-phenyl-N-(cyclohexylmethyl)tetrahydro-2H-pyran-
4-amine (94) THP_023. 
Using general procedure J, cyclohexaldehyde (7 µL, 0.057), 4-amino THP 121 (10 
mg, 0.05 mmol) and NaCNBH3 (5 mg, 0.073 mmol) after 16 h purifying by FC (10% 
methanol in CH2Cl2) gave 94 (2.7 mg, 17%) as a pale yellow oil. 
Rf = 0.53 (10% methanol in CH2Cl2); 1H NMR: δH (400 MHz, C6D6); 7.31-7.37 (5H, m, 
Ar-H), 4.18 (1H, ddd, J = 11.9, 4.7 and 1.7 Hz, OCH2), 3.94 (1H, d, J = 9.9, Ar-CH), 
3.64 (1H, td, J = 11.9 and 1.7, OCH2), 2.66 (1H, dd, J = 11.6 and 7.1 Hz, CH2NH), 2.52 (1H, dd, J = 
11.2 and 6.5 Hz, CH2NH), 2.07 (1H, m, CHNH), 1.78 (6H, m, CH2), 1.56 (1H, br s, NH), 1.17-1.34 (5 
H, m, CH2), 0.97 (2H, m, CHs), 0.80 (3H, d, J = 6.6 Hz, CH3); HRMS (ESI) m/z 287.2251 (MH+). 
C19H30NO Required 287.2249; Δ = -0.7 ppm. 
 
(±)-(2R*,3R*,4S*)-3-Methyl-2-phenyl-N-(propyl)tetrahydro-2H-pyran-4-amine (97) 
THP_024. 
Using general procedure J, propanal (5 µL, 0.057), 4-amino THP 121 (10 mg, 0.05 
mmol) and NaCNBH3 (5 mg, 0.073 mmol) after 16 h purifying by FC (10% methanol 
in CH2Cl2) gave 97 (5.3 mg, 37%) as a pale yellow oil. 
Rf = 0.50 (10% methanol in CH2Cl2); 1H NMR: δH (400 MHz, C6D6); 7.30-7.39 (5H, m, 
Ar-H), 4.21 (1H, ddd, J = 11.4, 4.3 and 2.1 Hz, OCH2), 3.90 (1H, d, J = 9.7 Hz, Ar-CH), 3.58 (1H, m, 
OCH2), 2.33-2.50 (3H, m), 1.71-1.80 (2H, m, CH2CH3), 1.59 (1H, br s, NH), 1.45 (1H, m, CHCH3), 
0.90 (3H, t, J = 7.3 Hz, CH2CH3), 0.76 (3H, d, J = 6.5 Hz, CHCH3); HRMS (ESI) m/z 233.1782 (MH+). 
C15H23NO Required 233.1780; Δ = 0.8 ppm. 
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(±)-(2R*,3R*,4S*)-3-Methyl-2-phenyl-N-(3-methylbutyl)tetrahydro-2H-pyran-4-
amine (98) THP_025. 
Using general procedure J, valeraldehyde (6 µL, 0.057), 4-amino THP 121 (10 mg, 
0.05 mmol) and NaCNBH3 (5 mg, 0.073 mmol) after 16 h purifying by FC (10% 
methanol in CH2Cl2) gave 98 (3.9 mg, 26%) as a pale yellow oil. 
Rf = 0.51 (10% methanol in CH2Cl2); 1H NMR: δH (400 MHz, C6D6); 7.30-7.39 (5H, 
m, Ar-H), 4.21 (1H, ddd, J = 11.4, 4.3 and 2.1 Hz, OCH2), 3.91 (1H, d, J = 9.6 Hz, 
Ar-CH), 3.59 (1H, td, J = 11.3 and 3.2 Hz, OCH2), 2.57 (2H, ddd, J 12.8, 9.1 and 7.2, OCH2CH2), 
2.43-2.50 (1H, m, CHNH), 2.34 (2H, ddd, J = 13.0, 8.3 and 5.0 Hz, NHCH2), 1.72-1.80 (3H, m), 1.61-
1.66 (2H, m), 0.92 (6H, dd, J = 6.6 and 5.7 Hz, CH(CH3)2), 0.75 (2H, d, J = 6.5 Hz, CH3); HRMS (ESI) 
m/z 276.2325 (MH+). C17H27NO Required 276.2327; Δ = -0.7 ppm. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-(methylphenyl)tetrahydro-2H-pyran-4-
amine (99) THP_026. 
Using general procedure J, benzaldehyde (6 µL, 0.057), 4-amino THP 121 (10 mg, 
0.05 mmol) and NaCNBH3 (5 mg, 0.073 mmol) after 16 h purifying by FC (10% 
methanol in CH2Cl2) gave 99 (4.8 mg, 25%) as a pale yellow oil. 
Rf = 0.60 (10% methanol in CH2Cl2); 1H NMR: δH (400 MHz, C6D6); 7.28-7.38 (10H, 
m, Ar-H), 4.17 (1H, ddd, J = 11.6, 4.7 and 1.7 Hz, OCH2), 4.00 (1H, d, J = 13.0, Ar-
CH2), 3.91 (1H, d, J = 9.9 Hz, Ar-CHO), 3.78 (1H, d, J = 13.0 Hz, Ar-CH2), 3.63 (1H, m, OCH2), 2.52 
(1H, m, CHNH), 2.11 (1H, ddt, J = 12.9, 4.1 and 2.0 Hz, OCH2CH2), 1.63-1.75 (2H, m), 0.78 (3H, d, J 
= 6.6 Hz, CH3); HRMS (ESI) m/z 282.1861 (MH+). C19H24NO Required 282.1858; Δ = 1.1 ppm. 
 
General procedure K (One pot synthesis of 4-thiophenyl THPs). 
According the method of Yadav,175 TFA (10 mmol) was added to a solution of homoallylic alcohol 99 
(1mmol), benzaldehyde (1.3 mmol) and the required thiophenol (2mmol) in CH2Cl2 (5 mL) at 0 ºC.  
After complete addition the reaction was warmed to room temperature and stirring continued for 2 h.  
The reaction was quenched with sat. aqueous NaHCO3 (5 mL) and the organic extracted with CH2Cl2 
(3 x 15 mL).  The combined extracts were dried over Na2SO4 and concentrated under reduced 
pressure. 
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-S-phenyltetrahydro-2H-pyran-4-thiol (125) 
THP_012. 
Using general procedure K, TFA (0.76 mL, 10 mmol), homoallylic alcohol 99 (86mg, 
1mmol), benzaldehyde (132 µL, 1.3 mmol) and thiophenol (200 µL, 2mmol) after 2 h 
purifying by FC (20:1 petroluem ether:ethyl acetate) gave a colourless oil (55 mg, 
20%) comprising of an unseperable mix of diastereomers ((2R*, 3R*,4S*)-125:(2R*, 
3R*,4R*)-125, 10:1 by 1H NMR intergration).  
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Rf = 0.42 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 3030(w), 2953 (m), 2961 (m), 2842 (w), 
1780 (w), 1476(m), 1090 (s) (COC), 811 (s) cm–1; HRMS (ESI) m/z 285.1298 (MH+). C18H21SO 
Required 285.1313; Δ = -5.3 ppm. 
(2R*, 3R*,4S*)-125: 1H NMR: δH (400 MHz, C6D6); 7.49-7.51 (2H, m, Ar-H), 7.29-7.39 (8H, m, Ar-H), 
4.10 (1H, m, OCH2), 3.96 (1H, d, J = 9.7 Hz, ArCH), 3.59 (1H, m, OCH2), 3.01 (1H, td, J = 11.1 and 
5.0 Hz, CHS), 1.90-2.03 (2H, m, OCH2CH2), 1.82 (1H, ddq, J = 10.9, 9.7 and 6.6 Hz, CHCH3), 0.97 
(3H, d, J = 6.6 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 140.84 (s), 133.79 (s), 133.49 (2 x d), 128.94 
(2 x d), 128.45 (d), 128.10 (d) , 127.58 (2 x d), 127.46 (2 x d), 86.96 (d), 68.29 (d), 52.10 (d), 42.12 
(t), 34.68 (d), 15.80 (q). 
(2R*, 3R*,4S*)-125: 1H NMR: δH (400 MHz, C6D6) – distinguishable/diagnostic peaks only: 4.99 (td, J 
= 10.8 and 4.8 Hz, CHS), 4.22 (ddd, J = 12.0, 5.0 and 1.8 Hz, OCH2), 4.02 (d, J = 10.1 Hz, Ar-CH), 
3.71 (td, J = 12.3 and 2.2 Hz, OCH2), 0.74 (d, J = 6.6 Hz, CH3).  
 
(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-S-(4-chlorophenyl)tetrahydro-2H-pyran-
4-thiol (126) THP_013. 
Using general procedure K, TFA (0.89 mL, 11.6 mmol), homoallylic alcohol 99 (100 
mg, 1.16 mmol), benzaldehyde (153 µL, 1.5 mmol) and 4-chloro thiophenol (264 
µL, 2.32 mmol) after 2 h purifying by FC (20:1 petroluem ether:ethyl acetate) gave 
a colourless oil (110 mg, 32%) comprising of an unseperable mix of diastereomers 
((2R*, 3R*,4S*)-126:(2R*, 3R*,4R*)-126, 10:3.8 by 1H NMR intergration).  
Rf = 0.36 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 3028 (w), 2954 (m), 2954 (m), 2843 
(w), 1780 (w), 1482 (m), 1090 (s) (COC), 811 (s) cm–1; HRMS (ESI) m/z 318.0847 (MH+). 
C18H20ClSO Required 318.0845; Δ = -5.3 ppm. 
(2R*, 3R*,4S*)-126: 1H NMR: δH (400 MHz, C6D6) –distinguishable/diagnostic peaks only: 7.29-7.43 
(10H, m, Ar-H), 4.09 (1H, ddd, J = 11.6, 4.4 and 2.1 Hz, OCH2), 3.94 (1H, d, J = 9.7 Hz, Ar-CH), 
3.55-3.61 (1H, m, OCH2), 2.96 (1H, td, J = 11.0 and 5.1 Hz, CHS), 1.79 (1H, ddq, J = 10.8, 9.7 and 
6.6 Hz, CHCH3), 0.92 (3H, d, J = 16.7 Hz, CH3). 
(2R*, 3R*,4S*)-125: 1H NMR: δH (400 MHz, C6D6) – distinguishable/diagnostic peaks only: 4.98 (1H, 
td, J = 10.8 and 4.9 Hz, CHS), 4.21 (1H, ddd, J = 12.0, 5.0 and 1.8 Hz, OCH2), 4.01 (1H, d, J = 10.1 
Hz, Ar-CH), 3.70 (1H, td, J = 12.3 and 2.2 Hz, OCH2), 0.73 (3H, d, J = 6.6 Hz, CH3).  
 
General procedure L (α-alkylation of penten-3-oic acid). 
According to the method of Corey,223 n-butyl lithium (6 mmol) was added dropwise to a solution of 
diisopropylamine (6 mmol) in THF (8 mL) at -78 ºC.  The reaction was allowed to warm to 0 ºC before 
adding penten-3-oic acid (3 mmol) and stirring for a further 1 h.  The required alkylating agent (9 
mmol) was then added and the reaction stirred at RT for 1 h. A H2O:THF mix (1:1, 5 mL) was then 
added followed by 1M HCl (5 mL) before extracting the organic with diethyl ether (3 x 15 mL).  The 
combined extracts were washed with 1M HCl (5 mL), sat. aqueous sodium thiosulfate (10 mL), H2O 
(10 mL), brine (10 mL), dried over magnesium sulfate and concentrated under reduced pressure. 
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(±)-2-Methyl-cis-3-pentenoic acid (127).224 
Using the general procedure K, n-butyl lithium (2.4 M; 2.5 mL, 6 mmol), 
diisopropylamine (0.85 mL, 6 mmol), penten-3-oic acid (300 mg, 3 mmol) and 
methyl iodide (0.56 mL, 9 mmol) after 3 h gave 127 (390 mg, 100%) as a colourless liquid. 
1H NMR: δH (400 MHz, CDCl3): 5.51-5.68 (2H, m, CH=CH), 3.12 (1H, m, CH), 1.71-1.74 (3H, m, 
CH=CHCH3), 1.28 (3H, d, J = 7.0 Hz, CH3); LRMS (ESI) m/z 115 (MH+, 100 %). 
 
 (±)-2-Benzyl-cis-3-pentenoic acid (128). 
Using the general procedure K, n-butyl lithium (1.6 M; 6.5 mL, 10.5 mmol), 
diisopropylamine (1.41 mL, 10 mmol), penten-3-oic acid (0.5 mL, 5 mmol) and 
benzyl bromide (1.78 mL, 15 mmol) after 3 h gave 128.  This material was taken 
through crude to the next reaction. 
 
General procedure L (reduction of α-alkyl-β ,γ-unsaturated acids). 
Acid (3.4 mmol) in diethyl ether (5 mL) was added dropwise to a slurry of LiAlH4 (5.1 mmol) in diethyl 
ether (5 mL) at 0 ºC.  The reaction was stirred at this temperature for 30 min before warming to RT 
for 1 h.  H2O (3 mL) was then cautiously added and the resulting slurry poured onto 50% H2SO4 (5 
mL).  The organic was separated and the aqueous extracted with diethyl ether (3 x 10 mL).  The 
combined organic extracts were then washed with H2O (10 mL), brine (2 x 10 mL), dried over sodium 
sulphate and concentrated under reduced pressure. 
 
(±)-2-Methyl-cis-3-penten-1-ol (129).  
Using the general procedure L, acid 127 (400 mg, 3.4 mmol) and LiAlH4 (193 mg, 
5.1 mmol) after 1.5 h purifying by FC (5:1 petroleum ether:ethyl acetate) gave 129 (120 mg,  
69%) as a colourless oil. 
Rf = 0.27 (5:1 petroleum ether:ethyl acetate); IR (neat): υmax 3335 (OH) (br, m), 2952 (w), 2924 (w), 
2972 (w), 1713 (w), 1451 (w), 1378 (w), 1031 (s), 964 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 5.59 
(1H, dqd, J = 15.3, 6.6 and 1.0 Hz, CH=CHCH3), 5.31 (1H, ddq, J = 15.3, 7.9 and 1.6 Hz, CH=CH), 
3.50 (1H, m, OHCH2), 3.38 (1H, m, OHCH2), 2.27-2.37 (1H, m, CHCH3), 1.72 (3H, ddd, J = 6.4, 1.6 
and 0.7 Hz, CH=CHCH3), 1.49 (1H, br s, OH), 1.00 (3H, d, J = 6.8 Hz, CHCH3); 13C NMR: δC (100 
MHz, CDCl3); 133.56 (d) (CH=CH), 126.75 (d) (CH=CH), 67.35 (t) (OHCH2), 39.78 (d) (CH), 18.09 (q) 
(CHCH3), 16.59 (q) (CH3); LRMS (CI) m/z 100 (M+, 100%); HRMS (CI) m/z 100.0890 (M+). C6H12O 
Required 100.0888; Δ = 2.0 ppm. 
 
(±)-2-Benzyl-cis-3-penten-1-ol (130).  
Using the general procedure L, acid 128 (2.4 g, 12.6 mmol) and LiAlH4 (720 mg, 
18.9 mmol) after 1.5 h purifying by FC (5:1 petroleum ether:ethyl acetate) gave 
130 (1.8 g, 84%) as a colourless oil. 
Rf = 0.35 (5:1 petroleum ether:ethyl acetate); IR (neat): υmax 3336 (OH) (br, m), 2953 (w), 2924 (w), 
2972 (w), 1713 (w), 1451 (w), 1378 (w), 1029 (s), 965 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.28-
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7.33 (2H, m, Ar-H), 7.18-7.24 (3H, m, Ar-H), 5.55 (1H, dqd, J = 15.3, 6.4 and 0.8 Hz, CH=CH), 5.34 
(1H, ddq, J 15.3, 8.3 and 1.6, CH=CH), 3.60 (1H, ddd, J = 10.5, 7.8 and 4.9 Hz, OHCH2), 3.45 (1H, 
ddd, J = 10.5, 7.8 and 4.9 Hz, OHCH2), 2.69 (2H, qd, J = 13.0 and 7.2 Hz, Ar-CH2), 2.53 (1H, qt, J = 
7.6 and 3.8 Hz, CH), 1.70-1.72 (3H, m, CH3), 1.48 (1H, dd, J = 7.7 and 4.4 Hz, OH); 13C NMR: δC 
(100 MHz, CDCl3); 139.97 (s) (Ar-C), 131.73 (d) (CH=CH), 129.20 (2 x d) (Ar-C), 128.34 (d) (Ar-C), 
128.23 (2 x d) (Ar-C), 125.96 (CH=CH), 65.18 (t) (OHCH2), 47.10 (d) (CH), 37.90 (t) (Ar-CH2), 18.16 
(q) (CH3); LRMS (EI) m/z 176 (M+, 10%), 158 (20), 145 (15), 91 (100), 84 (30); HRMS (CI) m/z 
176.1200 (M+). C12H16O Required 176.1201; Δ = -0.7 ppm. 
 
(4S)-3-[(3E)-pentenoyl]-4-(propan-2-yl)-2-oxazolidinone (132).  
To a solution of penten-3-oic acid (500 mg, 3.9 mmol) in THF (13 mL) at -78 ºC 
was added Et3N (0.54 mL, 3.9 mmol) followed by pivaloyl chloride (0.46 mL, 
3.7 mmol).  The mixture was stirred at -78 ºC for 1 h.  In a separate flask, n-
BuLi (1.6 M; 2.5 mL, 4.1 mmol) was added to oxazolidinone 131 (300 mg, 3.9 mmol) in THF (23 mL) 
at -78 ºC.  This was stirred at -78 ºC for 1h before addition by syringe to the anhydride. The complete 
slurry was then allowed to warm to room temperature and stirred for a further 3 h.  The reaction was 
then quenched with sat. aqueous ammonium chloride (30 mL) and the aqueous extracted with ethyl 
acetate (3 x 50 mL).  The combined extracts were then washed with NaHCO3 (30 mL), H2O (2 x 30 
mL), brine (30 mL), dried over MgSO4 and concentrated under reduced pressure to give a crude 
white solid.  Purification was achieved by FC (5:1 petroleum ether:ethyl acetate) to give 132 (650 mg, 
88%) as a white solid (m.p. 136 ºC). 
Rf = 0.39 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 5.57-5.70 (2H, m, 
CH=CH), 4.44 (1H, ddd, J = 8.3, 3.8 and 3.2 Hz, CHCH(CH3)2), 4.29 (1H, t, J = 8.7 Hz, OCH2), 4.23 
(1H, dd, J = 9.1 and 3.1 Hz, OCH2), 3.59-3.73 (2H, m, C(O)CH2), 2.39 (1H, dtd, J = 14.0, 7.0 and 3.9 
Hz, CH(CH3)2), 1.72-1.73 (3H, m, CH=CHCH3), 0.91 (6H, dd, J = 17.7 and 7.0 Hz, CH(CH3)2); 13C 
NMR: δC (100 MHz, CDCl3); 171.83 (s) (C=O), 130.06 (d) (CH=CH), 122.31 (d) (CH=CH), 63.39 (t) 
(OCH2), 58.43 (t) (COCH2), 39.20 (d) (NCH), 28.32 (q) (CH=CHCH3), 27.01 (d) (CH(CH3)2), 18.08 (q) 
(CH3)2), 17.97 (q) (CH3)2); LRMS (ESI) m/z 212 (MH+, 100%); HRMS (ESI) m/z 212.1196 (MH+). 
C11H17NO3 Required 212.1208; Δ = 4.8 ppm. 
 
General procedure M (Aldol condensation of 132). 
According to the method of Charette,225 diisopropylamine (0.32 mmol) was added to a solution of β,γ-
unsaturated acyl oxizolidinone 132 (0.36 mmol) in CH2Cl2 (0.75 mL).   The solution was cooled to -78 
ºC before dropwise addition of Bu2BOTf (1 M in CH2Cl2; 0.36 mmol) and the solution stirred for 2 h.  A 
solution of aldehyde (0.28 mmol) in CH2Cl2 (0.14 mL) was then added dropwise and the solution 
stirred for a further 1 h at -78 ºC before warming to 0 ºC and stirring for another 1 h.  The reaction 
was quenched by addition of phosphate buffer (pH 7, 0.8 mL), methanol (1.2 mL) and peroxide (30% 
weight in H2O; 0.4 mL) and stirred for 1 h.  The solvent was then removed under reduced pressure 
and the aqueous extracted with CH2Cl2 (3 x 10 mL).  The combined extracts were washed with 
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NaHCO3 (10 mL), H2O (10 mL), brine (10 mL), dried over MgSO4 and concentrated under reduced 
pressure to yield the crude product. 
 
(2′S,3′S,4S)-3-[3′-Hydroxy-1′-oxo-3′-phenyl-2′-(1-methylethen-E-
yl)propyl]-4-(propan-2-yl)-2-oxazolidinone (133).226 
Using general procedure M, diisopropylamine (47 µL, 0.28 mmol), β,γ-
unsaturated acyl oxizolidinone 132 (70 mg, 0.25 mmol), Bu2BOTf (1M in 
CH2Cl2; 0.25 mL, 0.25 mmol) and benzaldehyde (29 µL, 0.28 mmol) after 2 h purifying by FC (5:1 
petroleum ether:ethyl acetate) gave 133 (90 mg, 94%) as a colourless oil. 
1H NMR: δH (400 MHz, CDCl3): 7.28-7.41 (5H, m), 5.80-5.89 (1H, m), 5.67 (1H, ddq, J = 15.4, 8.8 and 
1.6 Hz), 4.98 (1H, dd, J = 6.5 and 2.0 Hz), 4.90 (1H, dd, J = 8.8 and 6.5 Hz), 4.21 (1H, ddd, J = 8.3, 
4.0 and 2.7 Hz), 4.09 (1H, dd, J = 9.0 and 2.7 Hz), 3.92 (1H, dd, J = 8.9 and 8.4 Hz), 2.95 (1H, d, J = 
2.0 Hz), 2.30 (1H, quintet, J = 7.0 and 4.0 Hz), 1.76 (3H, dd, J = 6.4 and 1.6 Hz), 0.89 (3H, d, J = 7.0 
Hz), 0.83 (3H, d, J = 6.9 Hz); LRMS (ESI) m/z 317 (MH+, 100 %). 
 
(2′S,3′S,4S)-3-[3′-Hydroxy-1′-oxo-3-2′-(1-methylethen-E-
yl)nonyl]-4-(propan-2-yl)-2-oxazolidinone (134).  
Using general procedure M, diisopropylamine (94 µL, 0.55 mmol), 
β,γ-unsaturated acyl oxizolidinone 132 (140 mg, 0.5 mmol), 
Bu2BOTf (1 M in CH2Cl2; 0.5 mL, 0.5 mmol) and heptanal (80 µL, 0.56 mmol) after 2 h purifying by 
FC (5:1 petroleum ether:ethyl acetate) gave 133 (86 mg, 53%) as a colourless oil. 
Rf = 0.27 (5:1 petroleum ether:ethyl acetate); IR (neat): υmax 2958 (w), 2928 (w), 2857 (w), 2873 (w), 
1776 (s) (C=O), 1693 (s) (C=O), 1384 (m), 1198 (s), 971 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 
5.81-5.90 (1H, m, CH=CH), 5.59 (1H, ddq, J = 15.4, 9.1 and 1.7 Hz, CH=CH), 4.48-4.54 (2H, m, 
OCH2), 4.21 (1H, dd, J = 9.2 and 3.2 Hz, OHCH), 3.94 (1H, m, NCH), 3.14 (1 H, m, C(=O)CH), 2.34 
(1H, quintet, J = 7.0 and 3.9 Hz, CH(CH3)2), 1.74 (3H, dd, J = 6.5 and 1.7 Hz, CH=CHCH3), 1.23-1.52 
(10H, m, CH2CH2CH2CH2CH2), 0.92 (6H, d, J = 7.1 Hz, CH(CH3)2), 0.85 (3H, d, J = 6.9 Hz, CH3); 13C 
NMR: δC (100 MHz, CDCl3); 175.34 (s) (C=O), 153.46 (s) (C=O), 132.75 (d) (CH=CH), 123.64 (d) 
(CH=CH), 71.54 (t) (OCH2), 63.06 (d) (OHCH), 58.15 (d) (NCH), 50.86 (d) (C(O)CH), 34.08 (q), 31.81 
(t), 29.25 (d), 28.12 (t), 25.65 (t), 22.64 (t), 18.30 (t), 17.90 (q), 14.47 (q), 14.11 (q); LRMS (ESI) m/z 
326 (MH+, 100%); HRMS (ESI) m/z 326.2332 (MH+). C18H32NO4 Required 326.2331; Δ = 0.3 ppm. 
 
(2′S,3′S,4S)-3-[3′-Hydroxy-1′-oxo-2′-(1-methylethen-E-yl)pentyl]-4-(propan-
2-yl)-2-oxazolidinone (135).226 
Using general procedure M, diisopropylamine (94 µL, 0.55 mmol), β,γ-
unsaturated acyl oxizolidinone 132 (140 mg, 0.5 mmol), Bu2BOTf (1M in 
CH2Cl2; 0.5 mL, 0.5 mmol) and propanal (41 µL, 0.58 mmol) after 2 h purifying 
by FC (5:1 petroleum ether:ethyl acetate) gave 135 (87 mg, 65%) as a colourless oil. 
1H NMR: δH (400 MHz, CDCl3): 5.82-5.91 (1H, m), 5.60 (1H, ddq, J = 15.4, 9.1 and 1.7 Hz), 4.56 (1H, 
dd, J = 9.1 and 3.3 Hz), 4.48-4.52 (1H, m), 4.29 (1H, t, J = 8.8 Hz), 4.22 (1H, dd, J = 9.2 and 3.3 Hz), 
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3.87 (1H, dddd, J = 8.0, 5.2, 3.0 and 2.5 Hz), 3.16 (1H, dd, J = 2.3 and 0.9 Hz), 2.35 (1H, td, J = 7.0 
and 3.9 Hz), 1.74 (3H, dd, J = 6.5 and 1.7 Hz), 1.44-1.57 (2H, m), 0.97 (3H, t, J = 7.4 Hz), 0.92 (3H, 
d, J = 7.0 Hz), 0.85 (3H, d, J = 6.9 Hz); LRMS (ESI) m/z 270 (MH+, 100 %). 
 
(±)-5-Methyl-4-bromo-3-methyl-2-(phenyl)tetrahydro-2H-
pyran (136). 
Using the general oxonia Prins procedure G, homoallylic 
alcohol 129 (60 mg, 0.57 mmol), benzaldehyde (48 µL, 0.48 
mmol), SnBr4 (210 mg, 0.48 mmol) and TMS bromide (63 µL, 
0.48 mmol) after 5 h gave a colourless oil (110mg, 85%) comprising an inseparable mix of two 
diastereomers (136a:136b, 1:0.12 by 1H NMR integration).  
Rf = 0.38 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2956 (m), 2931 (w), 2869 (w), 1438 (m) 
1102 (s) (COC), 759 (s) cm–1; LRMS (ESI) m/z 269 (MH+, 100%), HRMS (ESI) m/z 269.0456. 
C13H18BrO Required 269.0463; Δ = -2.6 ppm. 
(±)-(2R*,3S*,4S*,5R*)-136a: 1H NMR: δH (400 MHz, CDCl3); 7.31-7.39 (5H, m, Ar-H), 4.06 (1H, dd, J 
= 11.8 and 4.8 Hz, OCH2), 3.94 (1H, d, J = 9.9 Hz, Ar-CH), 3.67 (1H, t, J = 10.7 Hz, CHBr), 3.27 (1H, 
t, J = 11.8 Hz, OCH2), 2.33 (1H, m, CH(CH3)), 2.18 (1H, m, CH(CH3)), 1.11 (3H, d, J = 6.6 Hz, CH3), 
0.91 (3H, d, J = 6.5 Hz, CH3); 13C NMR: δC (100 MHz, CDCl3); 140.18 (s) (Ar-C), 128.51 (2 x d) (Ar-
C), 128.32 (2 x d) (Ar-C), 127.36 (d) (Ar-C), 86.65 (d) (Ar-CHO), 73.63 (t) (OCH2), 66.64 (d) (CHBr), 
46.36 (d) (CHCH3), 41.30 (d) (CHCH3), 16.97 (q) (CH3), 16.60 (q) (CH3). 
(±)-(2R*,3S*,4S*,5S*)-136b – distinguishable/diagnostic peaks only: 1H NMR: δH (400 MHz, CDCl3); 
4.30 (1H, dd, J = 11.4 and 4.5 Hz, CHBr), 3.99-4.02 (1H, m, OCH2), 3.76-3.80 (1H, m, OCH2), 1.47-
1.49 (3 H, m, CH3), 0.88 (3H, d, J = 6.6 Hz, CH3). 
 
(±)-5-Methylphenyl-4-bromo-3-methyl-2-
(phenyl)tetrahydro-2H-pyran (137). 
Using the general oxonia Prins procedure G, 
homoallylic alcohol 130 (200 mg, 1.14 
mmol), benzaldehyde (96 µL, 0.95 mmol), 
SnBr4 (420 mg, 0.96 mmol) and TMS bromide (125 µL, 0.96 mmol) after 5 h gave a white solid (255 
mg, 74% - m.p 138 ºC) comprising an inseparable mix of two diastereomers (137a:137b, 1:0.1 by 1H 
NMR integration).  
Rf = 0.38 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2954 (m), 2938 (w), 2874 (w), 1359 (m) 
1098 (s) (COC), 957 (s), 843 (m) cm–1; LRMS (ESI) m/z 264 [(M-HBr)+, 100%], HRMS (ESI) m/z 
264.1516. C19H20O Required 264.1516; Δ = -0.3 ppm. 
(±)-(2R*,3S*,4S*,5R*)-137a: 1H NMR: δH (400 MHz, CDCl3); 7.24-7.36 (10H, m, Ar-H), 3.99 (1H, dd, 
J = 12.0 and 4.2 Hz, OCH2), 3.89 (1H, d, J = 10.0 Hz, Ar-CH), 3.81 (1H, t, J = 10.6 Hz, CHBr), 3.27-
3.37 (2H, m, OCH2CH), 2.52 (2H, m, Ar-CH2), 2.24 (1H, m, CHCH3), 0.94 (3H, d, J = 6.5 Hz, CH3); 
13C NMR: δC (100 MHz, CDCl3); 140.18 (s) (Ar-C), 138.56 (s) (Ar-C), 129.16 (2 x d) (Ar-C), 128.50 (4 
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x d) (Ar-C), 128.32 (d) (Ar-C), 127.32 (2 x d) (Ar-C), 126.46 (d) (Ar-C), 86.67 (d) (Ar-CH), 71.82 (t) 
(OCH2), 64.76 (CHBr), 47.29 (CHCH3), 46.76 (CHCH2), 37.63 (Ar-CH2), 17.13 (CH3). 
(±)-(2R*,3S*,4S*,5S*)-136b – distinguishable/diagnostic peaks only: 1H NMR: δH (400 MHz, CDCl3); 
4.46 (1H, dd, J = 11.5 and 4.5 Hz, OCH2), 3.56 (1H, dt, J = 11.9 and 1.9 Hz, OCH2), 3.44 (1H, dt, J = 
13.2 and 2.2 Hz, CHBr), 0.93 (3H, d, J = 6.4 Hz). 
 
(2R,3S,4S,5R,6S)-6-Phenyl-5-{Carbonyl[(propan-2-yl)-2-
oxazolidinone]}-4-bromo-3-methyl-2-(phenyl)tetrahydro-2H-pyran 
(138). 
Using the general oxonia Prins procedure G, homoallylic alcohol 133 
(120 mg, 0.38 mmol), benzaldehyde (32 µL, 0.32 mmol), SnBr4 (140 mg, 
0.32 mmol) and TMS bromide (42 µL, 0.32 mmol) after 5 h gave 138 (48 
mg, 36%) a colourless oil. 
Rf = 0.32 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2968 (w), 1759 (m) (C=O), 1707 (s) 
(C=O), 1388 (m), 1332 (m), 757 (m), 697 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.32-7.50 (10H, m, 
Ar-H), 4.75 (1H, d, J = 10.0 Hz, OCHC(=O)), 4.4 (2H, m, OCH2), 4.22 (1H, d, J = 10.3 Hz, OCHAr), 
4.14 (1H, m, ArCH), 3.68 (1H, m, CHBr), 3.25 (1H, m, CHN), 2.21-2.31 (2H, m, CH(CH3)2 and 
CHCH3), 0.98 (6H, d, J = 6.5 Hz, CH(CH3)2), 0.90 (3H, m, CH3); 13C NMR: δC (100 MHz, CDCl3); 
138.45 (s), 128.61 (2 x d), 128.43 (2 x d), 127.89 (2 x d), 127.44 (2 x d), 83.97 (t), 77.86 (d), 47.60 
(d), 31.63 (d), 28.41 (d), 20.30 (d), 14.18 (d), 12.78 (q); LRMS (ESI) m/z 486 (MH+, 100%), HRMS 
(ESI) m/z 486.1263. C25H28BrNO4 Required 486.1280; Δ = -3.5 ppm. 
 
(2R,3S,4S,5R,6S)-6-Hexyl-5-{Carbonyl[(propan-2-yl)-2-
oxazolidinone]}-4-bromo-3-methyl-2-(phenyl)tetrahydro-2H-pyran 
(139). 
Using the general oxonia Prins procedure G, homoallylic alcohol 134 (90 
mg, 0.23 mmol), benzaldehyde (20 µL, 0.19 mmol), SnBr4 (84 mg, 0.19 
mmol) and TMS bromide (25 µL, 0.19 mmol) after 5 h gave 139 (85 mg, 
91%) a colourless oil. 
Rf = 0.27 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2965 (w), 
2930 (w), 2854 (w), 1759 (m) (C=O), 1707 (s) (C=O), 1327 (m), 757 (m), 697 (s) cm–1; 1H NMR: δH 
(400 MHz, CDCl3); 7.31-7.40 (5H, m, Ar-H), 4.91 (1H, dd, J = 10.9 and 9.5 Hz, CHC(=O)), 4.54 (1H, 
dt, J = 6.6 and 3.9 Hz, OCH2), 4.28-4.36 (3H, m, OCH2CHN and CHBr), 4.07 (1H, d, J = 10.0 Hz, Ar-
CH), 3.64 (1H, dt, J = 9.2 and 2.7 Hz, OCH), 2.50 (1H, dtd, J = 13.9, 6.9 and 3.4 Hz, CH(CH3)2), 2.15 
(1H, m, CHCH3), 1.65 (1H, m, OCHCH2), 1.45 (1H, m, OCHCH2), 1.16-1.33 (8H, CH2CH2CH2CH2), 
0.99 (6H, dd, J = 7.0 and 4.9 Hz, CH(CH3)2), 0.92 (3H, d, J = 6.5 Hz, CH3); 13C NMR: δC (100 MHz, 
CDCl3); 172.49 (s) (C=O), 153.39 (s) (C=O), 140.09 (s) (Ar-C), 128.38 (2 x d) (Ar-C), 128.22 (d) (Ar-
C), 127.49 (2 x d) (Ar-C), 85.84 (d) (OCHAr), 80.51 (t) (OCH2), 62.92 (d) (CHN), 59.28 (d) (OCH), 
58.96 (CHBr), 54.34 (d), 44.93 (d), 33.73 (d), 31.70 (t), 29.13 (t), 28.18 (t), 25.45 (t), 22.59 (t), 18.16 
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(q), 16.04 (q), 14.83 (q), 14.08 (q); LRMS (ESI) m/z 494 (MH+, 100%), HRMS (ESI) m/z 494.1889. 
C25H36BrNO4 Required 494.1906; Δ = -3.4 ppm. 
 
(2R,3S,4S,5R,6S)-6-Ethyl-5-{Carbonyl[(propan-2-yl)-2-
oxazolidinone]}-4-bromo-3-methyl-2-(phenyl)tetrahydro-2H-pyran 
(140). 
Using the general oxonia Prins procedure G, homoallylic alcohol 135 (90 
mg, 0.27 mmol), benzaldehyde (23 µL, 0.25 mmol), SnBr4 (98 mg, 0.25 
mmol) and TMS bromide (30 µL, 0.25 mmol) after 5 h gave 139 (54 mg, 
56%) a colourless oil. 
Rf = 0.24 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2969 (w), 2875 (w), 1759 (m) (C=O), 
1705 (s) (C=O), 1389 (m), 1372 (m), 1335 (w), 758 (m), 700 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 
7.31-7.41 (5H, m, Ar-H), 4.07-4.66 (3H, m, OCH2CHN), 4.00 (1H, d, J = 10.0 Hz, Ar-CHO), 3.70-3.77 
(2H, m, OCH and CHBr), 2.40 (1 H, m, CH2), 2.24 (1H, ddd, J = 14.3, 7.5 and 2.5 Hz, OCH), 2.02 
(1H, m, CHCH3), 1.90 (1H, m, CH2), 1.08 (3H, d, J = 6.7 Hz, CHCH3), 1.02 (3H, t, J = 7.4 Hz, 
CH2CH3), 0.96 (3H, d, J = 6.5 Hz, CH(CH3)2), 0.91 (3H, d, J = 6.5 Hz, CH(CH3)2); 13C NMR: δC (100 
MHz, CDCl3); 128.53 (2 x d) (Ar-C), 128.41 (d) (Ar-C), 127.35 (2 x d) (Ar-C), 83.07 (d) (Ar-CHO), 
75.82 (t) (OCH2), 41.82 (d) (OCH), 33.01 (d), 28.52 (d), 26.92 (d), 20.58 (t), 20.42 (t), 12.77 (q), 11.49 
(q), 9.18 (q); LRMS (ESI) m/z 438 (MH+, 100%), HRMS (ESI) m/z 438.1278. C21H28BrNO4 Required 
438.1280; Δ = -1.6 ppm. 
 
(±)-(2R*,3S*,4S*,5R*)-5-Methyl-3-methyl-2-phenyl-N-(phenyl)tetrahydro-2H-
pyran-4-amine (141) THP_026. 
Using the general aniline substitution procedure I, triethylamine (35 µL, 0.98 
mmol), iodo-THP (60 mg, 0.19 mmol) and aniline (53 mg, 0.38 mmol) after 5 h 
purifying by FC (10:1 petroleum ether:ethyl acetate) gave 141 (5.4 mg, 10%) as 
an orange oil.  
Rf = 0.54 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 3376 (w) (NH), 2956 (w), 2923 (w), 
1600 (s) (C=O), 1505 (m), 1455 (m), 1377 (w), 1081 (m) (COC), 751 (m), 696 (s) cm–1; 1H NMR: δH 
(400 MHz, CDCl3); 7.31-7.38 (5H, m, Ar-H), 7.13-7.20 (2H, m, NHAr-H), 6.63-6.73 (3H, m, NHAr-H), 
4.09 (1H, dd, J = 11.7 and 4.6 Hz, OCH2), 4.04 (1H, d, J = 10.0 Hz, Ar-CHO), 3.37 (1H, t, J = 11.4 
Hz, OCH2), 2.95 (1H, t, J = 10.2 Hz, CHNH), 1.85 (1H, m, OCH2CH), 1.68 (1H, ddd, J = 13.3, 8.3 and 
5.1 Hz, OCHCH), 1.57 (1H, br s, NH), 0.95 (3H, d, J = 6.7 Hz, CH3), 0.74 (3H, d, J = 6.7 Hz, CH3); 
HRMS (ESI) m/z 282.1584 (MH+). C19H24NO Required 282.1858; Δ = -1.4 ppm. 
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(±)-5-Methylphenyl-3-methyl-2-phenyl-N-
(phenyl)tetrahydro-2H-pyran-4-amine 
(142) THP_027. 
Using the general aniline substitution 
procedure I, triethylamine (180 µL, 1.28 
mmol), iodo-THP (250 mg, 0.64 mmol) and 
aniline (117 mg, 3.2 mmol) after 5 h purifying 
by FC (10:1 petroleum ether:ethyl acetate) gave and orange oil (9.9 mg, 5%) comprising an 
inseparable mixture of two diastereomers (142a:142b, 3:2.3 determined by 1H NMR integration).  
Rf = 0.58 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 3387 (w) (NH), 3027 (w), 2918 (w), 
1600 (s) (C=O), 1507 (s), 1496 (s), 1453 (m), 1377 (w), 750 (s), 697 (s) cm–1; HRMS (ESI) m/z 
358.2156 (MH+). C25H28NO Required 358.2171; Δ = -4.2 ppm. 
(±)-(2R*,3S*,4S*,5R*)-142a: 1H NMR: δH (400 MHz, CDCl3); 7.26-7.34 (5H, m, Ar-H), 7.13-7.22 (3H, 
m, Ar-H), 6.63-6.74 (2H, m, Ar-H), 4.04 (2H, m, Ar-CH and OCH2), 3.41 (1H, t, J = 11.4 Hz, OCH2), 
3.18 (1 H, dd, J 13.9 and 3.3, CHNH), 3.01 (1H, dd, J = 13.8 and 5.0 Hz, Ar-CH2), 2.53 (1H, dd, J = 
13.8 and 8.2 Hz, Ar-CH2), 2.08 (1H, m, Ar-CH2CH), 1.73 (1H, m, CHCH3), 0.67 (3H, d, J = 6.6 Hz, 
CH3).  
 
(2R,3S,4S,5R-6S)-6-Phenyl-5-5-{Carbonyl[(propan-2-yl)-2-
oxazolidinone]}-3-methyl-2-phenyl-N-(phenyl)tetrahydro-2H-pyran-
4-amine (143) THP_028. 
Using the general aniline substitution procedure I, triethylamine (4 µL, 
0.08 mmol), iodo-THP (20 mg, 0.04 mmol) and aniline (18 mg, 0.2 
mmol) after 5 h purifying by FC (10:1 petroleum ether:ethyl acetate) 
gave 143 (3.1 mg, 17%) as an orange oil.  
Rf = 0.28 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 3490 (w) (NH), 2965 (w), 2926 (w), 
2861 (w), 1754 (s) (OC(=O)N), 1699 (s) (C=O), 1465 (w), 1385 (m), 1193 (m), 1071 (m), 763 (m), 
700 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.28-7.43 (15H, m, Ar-H), 4.80 (1H, d, J = 9.8 Hz, 
OCH(Ar)CHC(=O)), 4.51 (1H, t, J = 9.8 Hz, OCHCH(C=O)), 4.26 (1H, d, J = 10.1 Hz, OCH), 4.08 
(2H, ddd, J = 8.4, 5.3 and 2.6 Hz, OCH2), 3.94 (1H, q, J = 10.0 Hz, CHNH), 3.79 (1H, dd, J = 9.3 and 
8.4 Hz, CHN), 2.39 (1H, td, J = 7.0 and 4.0 Hz, CH(CH3)2), 2.26 (1H, d, J = 9.8 Hz, NH), 1.95 (1H, tq, 
J = 10.0 and 6.6 Hz, CHCH3), 0.91 (9H, m, CH3); HRMS (ESI) m/z 498.2521 (MH+). C31H34N2O4 
Required 498.2519; Δ = -0.7 ppm. 
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(2R,3S,4S,5R-6S)-6-Hexyl-5-{Carbonyl[(propan-2-yl)-2-
oxazolidinone]}-3-methyl-2-phenyl-N-(phenyl)tetrahydro-2H-pyran-4-
amine (144) THP_029. 
Using the general aniline substitution procedure I, triethylamine (4 µL, 
0.08 mmol), iodo-THP (20 mg, 0.04 mmol) and aniline (18 mg, 0.2 mmol) 
after 5 h purifying by FC (10:1 petroleum ether:ethyl acetate) gave 144 
(5.3 mg, 12%) as an orange oil.  
Rf = 0.28 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 3490 (w) 
(NH), 2970 (w), 2926 (w), 1774 (s) (OC(=O)N), 1689 (s) (C=O), 1385 (m), 1205 (m), 1205 (m), 1111 
(m) (COC), 759 (m), 701 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.31-7.40 (10H, m, Ar-H), 4.44 (1H, 
m, OCH2), 4.09 (2H, m), 3.98 (1H, d, J = 10.0 Hz, Ar-CHO), 3.85 (1H, m, CHNH), 3.74 (1H, ddd, J = 
9.8, 7.8 and 2.2 Hz, OCH2), 2.89 (1H, br s, NH), 2.66 (1 H, m, CHCH3), 2.22 (1H, dddd, J = 16.4, 7.9, 
5.6 and 2.4 Hz, OCHCH2), 1.98-2.05 (1H, m, CH(CH3)2), 1.79 (1H, m, OCHCH2), 1.59 (1H, m, 
OCHCH2), 1.41-1.48 (2H, m, CH2), 1.24-1.32 (7H, m, CH2CH2CH2CH2), 1.09 (3H, d, J = 6.6, CHCH3), 
0.89 (9H, m, CH3).; HRMS (ESI) m/z 507.3149 (MH+). C31H42N2O4 Required 507.3145; Δ = -1.3 ppm. 
 
(2R,3S,4S,5R-6S)-6-Ethyl-5-{Carbonyl[(propan-2-yl)-2-
oxazolidinone]}-3-methyl-2-phenyl-N-(phenyl)tetrahydro-2H-pyran-
4-amine (145) THP_030. 
Using the general aniline substitution procedure I, triethylamine (28 µL, 
0.2 mmol), iodo-THP (50 mg, 0.1 mmol) and aniline (18 µL, 0.5 mmol) 
after 5h purifying by FC (10:1 petroleum ether:ethyl acetate) gave 145 
(19 mg, 43%) as an orange oil.  
Rf = 0.24 (10:1 petroleum ether:ethyl acetate); IR (neat): υmax 3429 (w) (NH), 2965 (w), 2933 (w), 
2882 (w), 1753 (s) (OC(=O)N), 1694 (s) (C=O), 1388 (m), 1205 (m), 1192 (m), 1100 (m) (COC), 759 
(m), 700 (s) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.32-7.42 (10H, m, Ar-H), 4.424 (1H, m, OCH2), 
4.08-4.13 (2H, m, OCH2 and CHNH), 3.99 (1H, d, J = 10.0 Hz, Ar-CH), 3.85 (1H, m, OCHCHC=O), 
3.71 (1H, ddd, J = 9.7, 7.3 and 2.5 Hz, OCH2), 2.68 (1H, dd, J = 12.2 and 9.7 Hz, OCHCH2), 2.46 
(1H, dt, J = 10.9 and 6.6 Hz, CH(CH3)2), 2.27 (1H, ddd, J = 14.2, 7.5 and 2.5 Hz, OCHCH2), 2.03 (1H, 
m, CHCH3), 1.87 (1H, dt, J = 14.3 and 7.2 Hz, OCHCH2), 1.62 (1H, br s, NH), 1.09 (3H, d, J = 6.6 Hz, 
CHCH3), 1.02 (3H, t, J = 7.4 H, CH2CH3), 0.91 (6H, dd, J = 6.6 and 2.9 Hz, CH(CH3)2); HRMS (ESI) 
m/z 376.2127 (MH+). C21H30N2O4 Required 376.2124; Δ = 0.8 ppm. 
 
General procedure N (NaBH4 based synthesis of dihydropyridines). 
A solution of chloroformate (61.6 mmol) in diethyl ether (10 mL) was added dropwise to a stirring 
solution of the required pyridine (61.6 mmol) and NaBH4 (2.33 g, 61.6 mmol) in methanol (20 mL) at -
78 °C ensuring the solution temperature did not rise above - 65 °C.  After addition, the mixture was 
stirred at this temperature for 2 h before warming to room temperature and pouring onto ice water 
(100 mL).  The mixture was extracted with diethyl ether (3 × 70 mL), washed with H20 (3 × 70 mL), 
dried over MgSO4 and concentrated under reduced pressure to give a pale yellow oil. 
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N-Benzylalkoxy-4-methyl-1,2-dihydropyridine (152).227 
Using the general procedure N, benzylchloroformate (8.8 mL, 61.6 mmol), 4-
picoline (6.0 mL, 61.6 mmol) and NaBH4 (2.33 g, 61.6 mmol) after 2 h purifying 
by by FC (10:1 pet. ether:diethyl ether) gave 152 (8.2 g, 58 %) as a colourless 
oil.  
1H NMR: δH (400 MHz, CDCl3); 7.42-7.32 (5H, m), 6.76 (1H, dd, J = 36.2, 7.8 
Hz), 5.21 (1H, m), 5.22, (3H, s), 5.05 (1H, dd, J = 31.2, 7.8 Hz), 4.35-4.39 (2H, m), 1.73 (2H, m); 
LRMS (ESI) m/z = 229 (M+, 45%). 
 
1-Benzyl-3-methyl-1,2,5,6-tetrahydropyridine (155). 228 
A mixture of 3-picoline (5 mL, 51.5 mmol) and benzyl bromide (6.7 mL, 56 mmol) was left 
standing at room temperature for 1 week.  The solidified product was washed with ether 
(2 × 100 mL) and the supernatant removed under positive pressure.  The resulting pure 1-
benzyl-3-methylpyridinium bromide 154 (13.6 g, 51.5 mmol) was dissolved in ethanol (100 mL) and 
added slowly by canula to a suspension of NaBH4 (7.8 g, 206 mmol) in ethanol (150 mL) at 0 °C.  
The mixture was then stirred for 3 h before warming to room temperature and continuing stirring for a 
further 16 h.  Precipitated solid was removed by filtration and rinsed with ethanol.  The ethanol was 
concentrated under reduced pressure and dissolved in H2O (100 mL), extracted with diethyl ether (3 
× 80 mL), washed with brine (3 × 50 mL), dried over Na2SO4 and concentrated under reduced 
pressure to give 155 (9.21g, 93%) as a yellow liquid.   
1H NMR: δH (400 MHz, CDCl3); 7.41-7.28 (5H, m), 5.48 (1H, m), 3.62 (2H, s), 2.88 (2H, m), 2.53 (2H, 
t, J = 5.8 Hz), 2.15 (2H, m), 1.66-1.64 (3H, m); LRMS (EI) m/z = 187 (M+, 5%), 172 (10), 140 (50), 91 
(100). 
 
General procedure O (synthesis of 1-carboalkoxy-3-methyl-1,2,5,6-tetrahydropyridines).  
According to the method of Fowler,228 a solution of tetrahydropyridine 155 (4.6 g, 24.6 mmol) and the 
required alkyl chloroformate (49 mmol) in toluene (25 mL) was heated at 85 °C for 16 h until 
complete.  Concentration under reduced pressure gave the crude oil.  
 
1-Carbomethoxy-3-methyl-1,2,5,6-tetrahydropyridine (156).228 
Using the general procedure O, tetrahydropyridine 155 (4.6 g, 24.6 mmol) and 
methyl chloroformate (3.8 mL, 49 mmol) after 16h purifying by distillation under 
reduced pressure (~0.2 mbar, 63-66 °C) gave carbamate 156 (3 g, 78 %) as a 
colourless oil. 
1H NMR: δH (400 MHz, CDCl3); 5.48 (1H, s), 3.75-3.72 (2H, m), 3.70-3.64 (3H, m), 3.44 (2H, s), 2.05 
(2H, s), 1.63 (3H, s); LRMS (ESI) m/z = 156 (MH+, 100%). 
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1-Carbobenyloxy-3-methyl-1,2,5,6-tetrahydropyridine (157).228 
Using the general procedure O, tetrahydropyridine 155 (4.6 g, 24.6 mmol) 
and benzyl chloroformate (7.0 mL, 49 mmol) after 16h purifying by distillation 
under reduced pressure (~0.2 mbar, 155-158 °C) gave benzyl carbamate 
157 (5 g, 82 %) as a colourless oil.  
1H NMR: δH (400 MHz, CDCl3); 7.39-7.33 (5H, m), 5.54 (1H, s), 5.18 (2H, s), 3.85 (2H, s), 3.54 (2H, t, 
J = 5.7 Hz), 2.12 (2H, s), 1.69 (3H, s); LRMS (EI) m/z = 217 (M+, 10%) 187 (5), 172 (10), 140 (50), 91 
(100). 
 
General Procedure P (synthesis of 1-carboalkoxy-3,4-dibromo-3-methylpiperidines).  
According to the method of Fowler,228 a solution of bromine (1 mL, 19.3 mmol) in CH2Cl2 (7 mL) was 
added dropwise to a stirring solution of tetrahydropyridine (19.3 mmol) in CH2Cl2 (20 mL) at -78 °C 
over 30 min.  The reaction mixture was then stirred at this temperature for 1 h before allowing 
warming to room temperature and quenching with sat. sodium thiosulphate solution (10 mL).  The 
organic layer was extracted with CH2Cl2 (3 × 20 mL), washed with brine (3 × 20 mL), dried over 
MgSO4 and concentrated under reduced pressure to give a the resulting dibromopiperidine as a 
yellow semi-solid. 
 
1-Carbomethoxy-3,4-dibromo-3-methylpiperidine (158).228 
Using the general procedure P, bromine (1 mL, 19.34 mmol) and tetrahydropyridine 
156 (3 g, 19.34 mmol) after 1 h purifying by FC (10:1 petroleum ether:ethyl acetate) 
to give 158 (3.9 g, 80 %) as a clear colourless liquid.  
1H NMR: δH (400 MHz, CDCl3); 4.61 (1H, t, J = 4.2 Hz), 3.90-4.09 (3H, m), 3.72 (3H, 
s), 3.44-3.64 (2H, m), 2.69 (1H, m), 1.92 (3H, s); LRMS (ESI) m/z = 314 (MH+, 100%). 
 
 1-Carbobenzyloxy-3,4-dibromo-3-methylpiperidine (159).228 
Using the general procedure P, bromine (0.55 mL, 10.8 mmol) and 
tetrahydropyridine 157 (2.53 g, 10.8 mmol) after 1 h purifying by FC (10:1 
petroleum ether:ethyl acetate) to gave 159 (3.45 g, 82 %) as a clear 
colourless oil.  
1H NMR: δH (400 MHz, CDCl3); 7.29-7.42 (5H, m), 5.15-5.19 (2H, m), 4.63 
(1H, t, J = 4.1 Hz), 3.89-4.16 (2H, m), 3.64 (1H, m), 3.50 (1H, m), 2.73 (1H, m), 1.96 (3H, m); LRMS 
(ESI) m/z = 391 (M+, 100%). 
 
5-Methyl-N-carbobenzyloxy-1,2-dihydropyridine (160).228  
Dibromopiperidine 158 (0.25 g, 0.642 mmol) was combined with DBU (1 mL, 
11 mmol) and heated to 100 °C with stirring for 90 min.  The reaction was 
allowed to cool to room temperature before purification by FC (ethyl acetate) 
to give 1,2-dihyropiridine 160 (100 mg, 68 %) as a colourless oil.  
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1H NMR: δH (400 MHz, CDCl3); 7.49 (5H, m, 5H), 6.54 (2H, s), 6.42 (1H, s), 5.74 (1H, m), 5.58 (1H, 
m), 4.28 (2H, m), 1.71 (3H, s). LRMS (ESI) m/z = 230 (MH+, 100%). 
 
General procedure Q (thermal Diels-Alder reactions). 
According to the method of Krow,178 dihydropyridines (1 equivalent) were placed in glass tubes with 
the desired dienophile (5 equivalent) before being frozen, put under vacuum, allowing to thaw, 
flushing with argon (repeated 3 times) and sealed.  The tubes were heated at 120 °C for 48 h.  After 
cooling the contents were removed and held under vacuum (0.2 mbar) to remove excess dieonphile.  
The crude mixtures were purified by FC (2:1 pet. ether:ethyl acetate). 
 
(±)-2-Benzyl 6-methyl 5,8-dimethyl-2-azabicyclo[2.2.2]oct-7-ene-2,6-dicarboxylate (161). 
Using the general procedure Q, DHP 152 (100 mg, 0.45 mmol) and methyl crotonate (0.2 mL, 2.2 
mmol) after 48h purifying by FC (5:1 petroleum ether:ethyl acetate) gave a colourless oil (4mg, 5%) 
comprising a mixture of two Diels-Alder adducts (161a:161b, 1:2 ratio determine by 1H NMR). 
Rf 0.27 (5:1 petroleum ether:ethyl acetate). LRMS (EI) m/z = 329 (M+, 30%), 314 (10), 194 (50), 91 
(100). 
 
 
5,6-Exo-bicycle[2.2.2]octene 161a: 1H NMR: δH (400 MHz, CDCl3); 7.33-7.41 (5H, m, Ar-H), 5.97 (1H, 
m, C=CH), 5.16 (2H, m, Ar-CH2), 4.89 (1H, m, NCH), 3.68 (3H, s, OCH3), 3.56 (1H, m, NCH2), 2.92 
(1H, m, NCH2), 2.48 (1H, m, C(=O)CH), 2.31 (1H, m, C(CH3)CH), 2.08 (1H, m, CHCH3), 1.87 (3H, d, 
J = 1.4 Hz, C=C(CH3)), 1.21 (3H, d, J = 7.0 Hz, CHCH3).  
5,6-Endo-bicycle[2.2.2]octene 161b: Distinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, 
CDCl3); 6.11 (1H, dt, J = 6.3 and 1.7, C=CH), 5.03 (1H, m, NCH), 3.41 (1H, dd, J = 10.3 and 2.1 Hz, 
NCH2), 3.06 (1H, dd, J 10.3 and 2.6 Hz, NCH2), 1.88 (3H, s, C=C(CH3)), 0.95 (3H, d, J = 6.9 Hz, 
CH3).  
 
N-(E-Crotonyl)oxazolidin-2-one (163).229 
According to the method of Evans,186 n-BuLi (2.61 M in ether; 10.53 mL, 27.5 
mmol) was added dropwise to a stirring solution of 2-oxazolidinone (2.2 g, 25 
mmol) in THF at -78 °C.  The solution was stirred at -78 °C for 1 h before dropwise addintion of 
crotonyl chloride (2.87 mL, 30 mmol).  The mixture was stirred at -78 °C for 2 h before warming to 
room temperature and quenching with sat. ammonium chloride (5 mL).  The organics were extracted 
with diethyl ether (3 × 30 mL), washed with sat. NaHCO3 (3 × 30 mL), brine (2 × 40 mL), dried over 
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MgSO4 and concentrated under reduced pressure to give a yellow oil.  Purification was achieved by 
FC (2:1 petroleum ether:ethyl acetate) to give 163 (2.83 g, 73%) as a white solid.  
1H NMR: δH (400 MHz, CDCl3); 7.15-7.30 (2H, m), 4.44 (2H, t, J = 8.0 Hz), 4.08 (2H, t, J = 8.0 Hz), 
1.98 (3H, dd, J = 6.4, 1.1 Hz); LRMS (ESI) m/z = 164 (MH+, 45%). 
 
(E)-1-(2-Butenoyl)-3,5-dimethylpyrazole (164).230 
A solution of 3,5-dimethylpyrazole (1.92 g, 20 mmol), pyridine (1.7 mL, 21 
mmol) and DMAP (0.24 g, 2 mmol) in CH2Cl2 (30 mL) was added dropwise by 
canula to a solution of crotonyl chloride (2.00 mL, 21 mmol) in CH2Cl2 at 0 °C.  
The reaction was stirred at this temperature for 15 min before pouring onto H2O (50 mL).  Organics 
were extracted with CH2Cl2, combined, washed with brine (3 × 40 mL), dried over MgSO4 and 
concentrated under reduced pressure to give a pale yellow liquid.  Purification was achieved by FC 
(20:1 petroleum ether:ethyl acetate) to give 164 (2.79 g, 85%) as a colourless oil.  
1H NMR: δH (400 MHz, CDCl3); 7.18-7.25 (2H, m), 5.99 (1H, d, J = 0.6 Hz), 2.59 (3H, d, J = 0.9 Hz), 
2.27 (3H, s), 2.02 (3H, dd, J = 6.6, 1.4 Hz).  LRMS (EI) m/z = 164 (M+, 60%), 149 (90), 136 (15), 95 
(30), 69 (100). 
 
1-(3,5-Dimethyl-pyrazol-1-yl)-propynone (171).231 
According to the method of Brown,231 propiolic acid (0.96 mL, 15.6 mmol) was 
added to a stirring solution of 3,5-dimethyl pyrazole (1.5 g, 15.6 mmol) and DCC 
(3.86 g, 18.7 mmol) in dry CH2Cl2 (50 mL) at -78 °C.  The reaction was stirred for 
4 h before warming to room temperature and passing through celite to remove DCU.  The crude 
solution was then evaporated under reduced pressure to give a red solid.  Purification was achieved 
by FC (5:1 petroleum ether:ethyl acetate) to give 171 (1.54, 76%) as a pale orange solid.  
1H NMR: δH (400 MHz, CDCl3); 6.06 (1H, s), 3.49 (1H, s), 2.56 (3H, s), 2.32 (3H, s); LRMS (ESI) m/z 
= 149 (MH+, 100%). 
 
General Procedure R (Cu2+ catalysed Diels-Alder reactions). 
According to the method of Evans,183 Cu(X)2 (0.024 mmol) and PhBOX 167 (8 mg, 0.024 mmol) were 
combined in a glove box and stirred vigorously in CH2Cl2 (0.5 mL) for 3 h.  The catalyst solution was 
cooled to -78 °C before adding the required dienophile (0.24 mmol) followed immediately by the 
required diene (2.4 mmol).  The flasks were allowed to warm to room temperature and stirring 
continued for 40-48 h. The reaction was then diluted with 2:1 petroleum ether:ethyl acetate (5 mL) 
before passing through a small plug of silica, eluting with 1:1 petroleum ether:ethyl acetate (20 mL).  
The eluent was concentrated under reduced pressure to give a yellow oil 
 
Procedure for Diels-Alder reaction using propynyl pyrazol 171 dienophile. 
Cu(OTf)2 (21.7 mg, 0.06 mmol), PhBOX 167 (22 mg, 0.066 mmol) and 4Å molecular sieves (100 
mg) were combined in a glove box and stirred vigorously in CH2Cl2 (1.5 mL) for 3 h.  The catalyst 
solution was cooled to -78°C before adding propynyl pyrazole (44.4 mg, 0.3 mmol) followed 
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immediately by the desired diene (1.2 mmol).  The reaction was then placed in a bath at -20 °C and 
stirred continuously for 48 h.  
 
Synthesis of [Cu((S,S)-phenyl-box)](SbF6)2 (173). 232 
According to the method of Evans,232 CuCl2 (24 mg, 0.17 mmol) 
and PhBox 39 (56 mg, 0.167 mmol) were weighed into a flask in 
an inert atmosphere glove box.  AgSbF6 (110 mg, 3.22 mmol) was 
weighed into a separate foil wrapped flask within the glove box 
and both flasks sealed.  Once removed from the glove box, the flask containing CuCl2 and PhBox 
were dissolved in CH2Cl2 and then stirred vigorously for 1 h to give a bright green suspension.  
AgSbF6 was dissolved in CH2Cl2 (1 mL) and vigorously stirred for 1 h before addition of the CuCl2, 
PhBox solution by canula with a CH2Cl2 rinse (0.5 mL).  This mixture was then stirred vigorously 
(~1000 rpm) for 3 h in the dark.  The resultant blue solution was filtered through cotton wool in an 
oven-dried pipette to remove silver salts.  The solution was concentrated under reduced pressure to 
give 173 as a pale blue crystalline solid (53 mg, 98%).  
 
N-(E-Acryloyl)oxazolidin-2-one (174).229 
DCC (4.74g, 22.9 mmol) was added to a stirring solution of 2-oxazolidinone (1 g, 
11.5 mmol), DMAP (0.14 g, 1.15 mmol) and acrylic acid (1.57 mL, 22.1 mmol) in 
CH2Cl2 at 0 °C.  After 10 mins the solution was allowed to warm to RT and stir for a 
further 24 h. The crude reaction slurry was filtered through Celite® and the precipitate washed with 
CH2Cl2 (50 mL).  The filtrate was washed with sat. NaHCO3 (3 × 30 mL), dried over MgSO4 and 
concentrated under reduced pressure to give a yellow solid.  Purification was achieved by FC (3:1 
petroleum ether:ethyl acetate) to give 173 (900 mg, 56%) as a white solid.  
1H NMR: δH (400 MHz, CDCl3); 7.52 (1H, dd, J = 17.0 and 10.5 Hz), 6.59 (1H, dd, J = 17.0 and 1.8 
Hz), 5.93 (1H, dd, J = 10.5 and 1.8 Hz), 4.47 (2H, dd, J = 8.5 and 7.6 Hz), 4.11 (2H, t, J = 8.0 Hz); 
LRMS (EI) m/z = 141 (M+, 40%), 113 (40), 84 (25), 55 (100). 
 
3-[(1S,2S,4S)-Bicyclo[2.2.2]oct-5-ene-2-ylcarbonyl]-2-oxazolidinone (product 
of table 11, entry 15).233 
Using the general procedure R, Cu(SbF6)2 (30 mg, 0.042 mmol), 1,3-
cyclohexadiene (200 µL, 2.12 mmol) and acryloyl diene 174 (30 mg, 0.21 mmol) 
after 4 h purifying by FC (2:1 pet. ether:ethyl acetate) gave the bicycl[2.2.2]oct-5-
ene product (46 mg, 98%) as a pure white solid.   
1H NMR: δH (400 MHz, CDCl3); 6.36 (1H, td, J = 7.4, 1.1 Hz), 6.17 (1H, ddd, J = 8.0, 6.6 and 1.3 Hz), 
4.40 (2H, ddd, J = 8.8, 7.4 and 2.7 Hz), 3.97-4.01 (2H, m), 3.77 (1H, ddd, J = 9.9, 5.7 and 1.9 Hz), 
2.53 (1H, m), 2.64 (1H, m), 1.87 (1H, ddd, J = 12.5, 9.9 and 2.7 Hz), 1.73 (1H, m), 1.52-1.66 (2H, m), 
1.26-1.31 (2H, m).  LRMS (EI) m/z = 221 (M+, 25%), 193 (20), 142 (50), 106 (30), 80 (100). 
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General Procedure S (Et2AlCl catalysed Diels-Alder reactions). 
Et2AlCl (0.14 mmol) was added to a stirring solution of the required dienophile (0.07 mmol) in CH2Cl2 
(1.5 mL) at -78 °C.  The solution was stirred at this temperature for 30 min before addition of the 
desired diene (1.65 mmol).  The reaction was allowed to warm to room temperature and stirring 
continued for 48 h.  The reaction was then poured onto 1M HCl (50 mL), extracted with CH2Cl2 (3 × 
30 mL), dried over MgSO4 and filtered through silica (eluting with CH2Cl2 and ethyl acetate).  The 
eluent was concentrated under reduced pressure to give a crude yellow oil. 
 
3-[(1S,2S,4S)-3-Methyl-bicyclo[2.2.2]oct-5-ene-2-ylcarbonyl]-2-oxazolidinone 
(product of table 11, entry 17).233 
Using the general procedure S, Et2AlCl (1 M in hexanes; 0.28 mL, 0.28 mmol) , 
crotonyl oxazolidinone 163 (30 mg, 0.19 mmol) and 1,3-cyclohexadiene (0.46 mL, 
4.8 mmol) after 5 h purifying by FC (5:1 petroleum ether:ethyl acetate) gave the 
desired Diels-Alder adduct (21 mg, 49%). 
1H NMR: δH (400 MHz, CDCl3); 6.53 (1H, td, J = 7.5 and 1.2 Hz), 6.00 (1H, td, J = 7.3 and 1.1 Hz), 
4.41 (2H, t, J = 8.1 Hz), 3.96-4.08 (2H, m), 3.29 (1H, dd, J = 6.4 and 1.4 Hz), 2.75 (1H, m), 2.35 (1H, 
m), 2.21 (1H, m), 1.74-1.81 (2H, m), 1.58 (1H, s), 1.11 (1H, m), 1.04 (3H, d, J = 7.0 Hz; LRMS (ESI) 
m/z = 236 (MH+, 100%). 
 
General Procedure T (N-acylation of camphor sultams).  
According to the procedure of Oppolzer,234 a solution of (2R,1S)-bornane-10,2-sultam (300 mg, 1.4 
mmol) in toluene (2.5 mL) was added dropwise to a stirring suspension of NaH (60% in mineral oil; 
84 mg, 2.1 mmol) in toluene.  The suspension was stirred at RT for 30 mins before adding a solution 
of acyl chloride (1.67 mmol) in toluene (1 mL).  The suspension was stirred for a further 90 mins 
before quenching with ice cold H2O (5 mL) and extracting with ethyl acetate (3 x 5 mL).  The 
combined extracts were then washed with brine (10 mL), dried over MgSO4 and concentrated under 
reduced pressure to give a white solid. 
 
(1S,2R)-N-[(E)-Crotonyl]bornane-10,2-sultam (178).234 
Using the general procedure T, (2R,1S)-bornane-10,2-sultam (300 mg, 1.4 
mmol), NaH (60% in mineral oil; 84 mg, 2.1 mmol) and crotonyl chloride (175 
mg, 1.67 mmol) after 2 h purifying by recrystallization (ethyl acetate) gave 178 
(300 mg, 77%) as a white crystalline solid. 
1H NMR: δH (400 MHz, CDCl3); 7.13 (1H, dq, J = 15.0 and 7.0 Hz), 6.62 (1H, dq, J = 15.0 and 1.7 
Hz), 3.96 (1H, dd, J = 7.6 and 5.1 Hz), 3.50 (2H, q, J = 13.8 Hz), 2.09-2.17 (2H, m), 1.91-1.97 (7H, 
m), 1.43 (2H, dt, J = 17.8 and 8.7 Hz), 1.20 (3H, s), 1.00 (3H, s); LRMS (ESI) m/z = 283 (M+, 15%), 
219 (20), 204 (40), 134 (20), 69 (100). 
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(1S,2R)-N-[(E)-Acryloyl]bornane-10,2-sultam (179).234 
Using a modified general procedure T, (2R,1S)-bornane-10,2-sultam (300 mg, 1.4 
mmol), NaH (60% in mineral oil; 84 mg, 2.1 mmol), CuCl (10 mg, 0.07 mmol) and 
acryloyl chloride (160 µL mg, 1.67 mmol) after 2 h purifying by FC (4:1 petroleum 
ether:ethyl acetate) gave 179 (173 mg, 46%) as a white crystalline solid. 
1H NMR: δH (400 MHz, CDCl3); 6.87 (1H, dd, J = 16.6 and 10.3 Hz), 6.50 (1H, dd, J = 16.6 and 1.3 
Hz), 5.86 (1H, dd, J = 10.3 Hz and 1.3 Hz), 3.94 (1H, dd, J = 7.2 and 5.4 Hz), 3.53 (1H, d, J = 13.6 
Hz), 3.45 (1H, d, J = 13.8 Hz), 2.14 (2H, m), 1.9 (3H, m), 1.39 (2H, s), 1.17 (3H, m), 0.98 (3H, m); 
LRMS (ESI) m/z = 270 (MH+, 100%). 
 
N-Phenylcarboxy-1,2-dihydropyridine (175).187  
Using the general procedure N, phenylchloroformate (3.8 mL, 30 mmol), pyridine 
(2.4 mL, 30 mmol) and NaBH4 (1.13 g, 30 mmol) after 2 h purifying by by 
recrystallization (diethyl ether) gave 175 (4.4 g, 73 %) as a white solid.  
1H NMR: δH (400 MHz, CDCl3); 7.41 (2H, t, J = 7.9 Hz), 7.26 (1H, m), 7.16 (2H, dd, J = 7.6 and 1.0 
Hz), 6.87 (1H, m), 5.93 (1H, m), 5.64 (1H, m), 5.29 (1H, m), 4.56 (2H, m); LRMS (ESI) m/z = 202 
(MH+, 100%). 
General procedure U (boronic acid catalysed Diels-Alder reaction). 
According to the method of Hall,189 to a solution of dienophile (1.39 mmol) in CH2Cl2 (2 mL) was 
added ortho-bromophenylboronic acid (20 mol%) followed by the diene (2.78 mmol). This solution 
was stirred at 25 ºC for 72 h before filtering through Celite® eluting with CH2Cl2. The filtrate was then 
extracted with aqueous NaOH solution (1 M, 2 x 20 mL), aqueous HCl solution (1 M, 2 x 20 mL), 
brine (2 x 20 mL) and the organic phase dried with Na2SO4.  The organic was concentrated under 
reduced pressure to give a crude colourless oil. 
 
(±)-3,4-Dimethyl cyclohex-3-ene carboxylic acid (product of table 14, Entry 
4).235 
Using the general procedure U, acrylic acid (100 mg, 1.39 mmol), ortho-
bromophenylboronic acid (56 g, 0.28 mmol) and 2,3-butadiene (230 mg, 2.77 mmol) after 72 h 
purifying by FC (5:1 petroleum ether:ethyl acetate) gave the Diels-Alder product (35 mg, 15%) as a 
white solid. 
1H NMR: δH (400 MHz, CDCl3); 2.50 (1H, m), 2.11 (2H, m), 1.86–1.93 (3H, m), 1.62 (1H, m), 1.55 
(6H, s); LRMS (ESI) m/z = 155 (MH+, 100%). 
 
(±)-Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid (product of table 14, Entry 5).236 
Using the general procedure U, acrylic acid (125 mg, 1.73 mmol), ortho-
bromophenylboronic acid (56 mg, 0.28 mmol) and cyclopentadiene (130 mg, 1.58 
mmol) after 72 h purifying by FC (3:1 pentane:diethyl ether) gave the Diels-Alder 
product (93 mg, 25%) as a white solid. 
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1H NMR: δH (400 MHz, CDCl3); 1.41 (2H, m), 1.92 (2H, m), 2.25 (1H, m), 3.01 (1H, m), 3.24 (1H, s), 
6.00 (1H, m), 6.23 (1H, m); LRMS (ESI) m/z = 139 (MH+, 100%). 
 
(±)-Bicyclo[2.2.2]oct,5-ene-2-carboxylic acid (product of table 14, Entry 8).237 
Using the general procedure U, acrylic acid (100 mg, 1.39 mmol), ortho-
bromophenylboronic acid (56 mg, 0.28 mmol) and 1,3-cyclohexadiene (264 µL, 2.77 
mmol) after 120 h at 80 ºC. 
1H NMR: δH (400 MHz, CDCl3); Diagnostic peaks from 1H NMR of crude material only - 6.32 (1H, t, J 
= 7.7 Hz), 6.17 (1H, t, J = 7.7 Hz), 2.92 (1H, m), 2.77-2.58 (2H, m), 1.18-2.04 (6H, m). 
 
(±)-Bicyclo[2.2.2]oct,5-ene-2-carboxylic acid (product of table 14, 
Entry 9).  
Using the general procedure U, acrylic acid (75 µL, 1.09 mmol), 
ortho-bromophenylboronic acid (44 mg, 0.218 mmol) and DHP 152 
(500 mg, 2.18 mmol) after 72 h. 
1H NMR: δH (400 MHz, CDCl3); Diagnostic peaks from 1H NMR of crude material only - 7.25-7.43 
(5H, m), 5.98-6.08 (1H, m, CH), 5.22-5.24 (2H, m, Ar-CH2), 3.30 (1H, ddd, J = 10.4, 3.7 and 2.3 Hz, 
NCH2), 3.12 (1H, m, NCH2), 3.04 (1H, m, CHC(=O)), 2.64 (1H, m), 1.87 (3H, m). 
 
S-tert-butyl (E)-2-butenethioate (185).238 
2-Methyl-2-propanethiol (9.0 g, 0.1 mol) was added to a stirring solution of 
crotonyl chloride (10.4 g, 0.1 mol) and anhydrous zinc chloride (0.1 g, 0.7 mmol). A fast and 
exothermic reaction started at once and was allowed to proceed freely. When heat evolution ceased 
the dark liquid was diluted with toluene (40 mL) and triethylamine (10.1 g, 0.1 mol) was added. The 
reaction mixture was heated under reflux for 30 mins and then poured onto H2O. The organic layer 
was washed with HCl (0.1 M; 3 × 10 mL), water (3 × 10 mL), dried over MgSO4 and concentrated 
under reduced pressure to give dark brown oil. Purification by distillation of the crude afforded, 185 
(8.7 g, 45%) as a pale yellow oil.  
1H NMR: δH (400 MHz, CDCl3); 6.83 (1H, dq, J = 15.4 and 6.9 Hz), 6.04 (1H, dq, J = 15.4 and 1.7 
Hz), 1.85 (3H, dd, J = 6.9 and 1.7 Hz), 1.50 (9H, s); LRMS (CI) m/z = 176 [(M+NH4)+, 100%)], 159 
(MH+, 60). 
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(±)-2-Benzyl 6-acetyl-5,8-dimethyl-2-azabicyclo[2.2.2]oct-7-ene-2-carboxylate (Product of table 
15, Entry 1). 
 
Using the general procedure Q, DHP 152 (145 mg, 0.63 mmol) and penten-2-one (460 µL, 4.6 mmol) 
after 48h purifying by FC (5:1 petroleum ether:ethyl acetate) gave a colourless oil (90 mg, 42%) 
comprising a mixture of two Diels-Alder adducts (exo:endo, 1:2 ratio determine by 1H NMR). 
Rf 0.27 (5:1 petroleum ether:ethyl acetate). LRMS (EI) m/z = 313 (M+, 10%), 229 (70), 184 (65), 91 
(100). HRMS (EI) m/z = 313.1682. C19H23NO3 Required 313.1678; Δ = 1.3 ppm. 
Exo-bicylco[2.2.2]octene: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 
7.30-7.39 (5H, m), 6.09 (1H, dt, J = 6.3 and 1.8 Hz, C=CH), 5.08 (2H, m, Ar-CH2), 4.83 (1H, dd, J = 
6.3 and 1.9 Hz, NCH), 3.33 (1H, td, J = 9.4 and 2.2 Hz, NCH), 3.02 (1H, td, J = 10.4 and 2.6 Hz), 
2.47 (1H, m, C(=O)CH), 2.40 (1H, m, CH), 2.07 (3H, s, C=C(CH3)), 1.94 (1H, dd, J = 6.8 and 1.7 Hz, 
CHCH3), 1.89 (3H, m, CH3), 1.29 (3H, d, J = 6.3 Hz, CH3). 
Endo-bicylco[2.2.2]octene: 1H NMR: δH (400 MHz, CDCl3); 7.30-7.39 (5H, m, Ar-H), 6.15 (1H, dt, J = 
6.3 and 1.8 Hz, C=CH), 5.08 (2H, m, Ar-CH2), 5.02 (1H, dd, J = 6.2 and 2.1 Hz, NCH), 3.33 (1H, td, J 
= 9.4 and 2.2 Hz, NCH2), 3.02 (1H, td, J = 10.4 and 2.6 Hz, NCH2), 2.52 (1H, m, C(=O)CH), 2.36 (1H, 
m, C=C(CH3)CH), 2.32 (3H, s, C=OCH3), 2.15 (1H, dd, J = 4.4 and 2.0 Hz, CHCH3), 1.89 (3H, t, J 1.9 
Hz, C=C(CH3)), 0.88 (3H, d, J = 7.0 Hz, CHCH3).13C NMR: δC (100 MHz, CDCl3); 207.55 (s) (C=O), 
143.38 (s), 136.87 (s), 128.56 (d), 128.41 (2 x d), 127.63 (2 x d), 126.99 (d, 123.82 (s), 67.05 (t), 
66.78 (t), 61.69 (d), 48.77 (d), 46.89 (d), 42.64 (d), 29.96 (q), 21.62 (d), 21.45 (q), 14.22 (q). 
 
(±)-2-Benzyl 6-tert-butyl-5,8-dimethyl-2-azabicyclo[2.2.2]oct-7-ene-2-carboxylate-6-thioate 
(Product of table 15, Entry 2). 
 
Using the general procedure Q, DHP 152 (145 mg, 0.63 mmol) and tert-butyl thioester 185 (500 mg, 
3.16 mmol) after 48 h purifying by FC (5:1 petroleum ether:ethyl acetate) gave a colourless oil (80 
mg, 36%) comprising a mixture of two Diels-Alder adducts (exo:endo, 1:3 ratio determine by 1H 
NMR). 
Rf 0.32 (5:1 petroleum ether:ethyl acetate). LRMS (CI) m/z = 405 [M+NH4)+, 60%], 388 (MH+, 100), 
237 (30), 229 (20). HRMS (CI) m/z = 388.1948. C22H30NO3S Required 388.1946; Δ = 0.5 ppm. 
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Exo-bicylco[2.2.2]octene: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 
6.12 (1H, m, C=CH), 3.42 (1H, dd, J = 10.2 and 2.1 Hz, NCH2), 3.06 (1H, dd, J = 10.2 and 2.6 Hz, 
NCH2), 2.37 (1H, m, C=C(CH3)CH), 2.16 (1H, dd, J = 4.6 and 2.0 Hz, C(=O)CH). 
Endo-bicylco[2.2.2]octene: 1H NMR: δH (400 MHz, CDCl3); 7.30-7.43 (5H, m, Ar-H), 5.95 (1H, dt, J = 
6.0 and 1.7 Hz, C=CH), 5.08-5.18 (2H, m, Ar-CH2), 4.96 (1H, dd, J = 6.0 and 2.6 Hz, NCH2), 3.53 
(1H, dd, J = 11.0 and 2.2 Hz, NCH2), 2.91 (1H, ddd, J = 10.9, 2.6 and 1.5 Hz, C=C(CH3)CH), 2.63 
(1H, dd, J = 5.9 and 2.6 Hz, C(=O)CH), 1.88 (3H, t, J = 1.6 Hz, C=C(CH3)), 1.46 (9H, s, C(CH3)3), 
1.20 (3H, m, CHCH3). 13C NMR: δC (100 MHz, CDCl3); 207.6 (s) (C=O), 143.5 (s), 127.1 (d), 128.8 (2 
x d), 127.6 (2 x d), 127.1 (d), 123.8 (s), 67.3 (t), 65.7 (t), 61.4 (d), 48.8 (d), 46.9 (d), 30.0 (q), 21.7 (d), 
21.5 (q), 14.3 (4 x q). 
 
(±)-6-Acetyl-5,8-dimethyl-2-azabicyclo[2.2.2]oct-7-ene (187). 
Palldium on charcoal (15 mg) was added to a solution of benzyl carbamate (100 mg, 
0.35 mmol) in ethanol (2 mL) and the suspension submitted to a hydrogen 
atmosphere (1 atm).  The reaction was stirred at room temperature for 16 h before 
filtering through Celite®.  The filtrate was concentrated under reduced pressure to give 187 (52 mg, 
60%) as a colourless oil. 
Rf = 0.15 (10% methanol in CH2Cl2); IR (neat): υmax 3420 (w) (NH), 2966 (w), 2935 (w), 2883 (w), 
1690 (s) (C=O), 1387 (m), 1200 (m), 759 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 3.23 (1H, m, 
NCH2), 2.90 (1H, m, NCH2), 2.69 (1H, s, NH), 2.51 (2H, m), 2.32 (1H, m, CHCH3), 2.20 (3H, s, 
C(=O)CH3), 1.93 (2H, m, NHCHCH2), 1.29 (1H, m, NHCH2CH), 1.23 (1H, m, CHCH3), 1.04 (6H, m, 
CHCH3); 13C NMR: δc (100 MHz, CDCl3); 207.93 (s) (C=O), 61.10 (d), 51.56 (t), 47.56 (d), 43.00 (d), 
37.33 (d), 32.42 (d), 31.59 (d), 29.71 (q), 23.48 (d), 19.29 (q), 19.00 (q); LRMS (ESI) m/z 389 (MH+, 
100); HRMS (ESI) m/z 182.1538 (MH+). C11H20NO Required 182.1545; Δ = 2.5 ppm. 
 
General procedure V (one pot benzyl carbamate hydrogenation reductive amination). 
Palladium on charcoal (20 mol%) was added to a solution of the required benzyl carbamate (1 
equivalent) and aldehyde (3 equivalent) in ethanol (0.3 M) and submitted to a hydrogen atmosphere 
(1 atm).  The reaction was stirred at room temperature for 16 h before filtering through Celite®.  The 
eluent was concentrate under reduced pressure to give a colourless oil. 
 
(±)-(1R,4S,5S,6S)-6-Acetyl-2,5,8-trimethyl-2-azabicyclo[2.2.2]oct-7-ene (188). 
Using the general procedure V, Palladium on charcoal (35 mg), benzyl carbamate 
(100 mg, 0.32 mmol) and formaldehyde (37% wt. in H2O; 72 µL, 0.96 mmol) after 16h 
gave 188 (63 mg, 98%) as a colourless oil. 
Rf = 0.45 (10% methanol in CH2Cl2); IR (neat): υmax 2966 (w), 2935 (w), 2883 (w), 1691 (s) (C=O), 
1387 (m), 1200 (m), 759 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 2.83 (1H, ddd, J = 10.4, 3.8 and 
1.5 Hz, NCH2), 2.75 (1H, m, NCH), 2.47-2.57 (2H, m, NCH2 and CH), 2.42 (3H, s, NCH3), 2.15 (3H, 
s, C(=O)CH3), 1.91-1.96 (2H, m, C(=O)CH and CH), 1.12-1.15 (2H, m, CHCH3), 1.00 (3H, d, J = 6.5, 
CH3), 0.96 (3H, d, J = 6.8 Hz, CH3); 13C NMR: δc (100 MHz, CDCl3); 208.85 (s) (C=O), 55.70 (d), 
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53.15 (t), 50.67 (q), 46.34 (t), 42.35 (t), 38.95 (q), 31.12 (d), 29.29 (d), 23.41 (q), 18.73 (q); LRMS 
(ESI) m/z 196 (MH+, 100); HRMS (ESI) m/z 196.1694 (MH+). C12H22NO Required 196.1701; Δ = -3.6 
ppm. 
 
(±)-(1R,2S,3S,4S)-2-Acetyl-3-methyl-bicyclo[2.2.2]oct-5-ene (192).239 
Using the general procedure S, 1,3-cyclohexadiene (5 mL, 52.5 mmol), penten-2-one 
(0.5 mL, 5.4 mmol) and Et2AlCl (1 M in hexane; 7 mL, 7 mmol) after 1 h purifying by FC 
(20:1 petroleum ether:ethyl acetate) gave 192 (260 mg, 98%) as a colourless oil. 
1H NMR: δH (400 MHz, CDCl3); 6.41 (1H, ddd, J = 8.1, 6.8 and 1.2 Hz), 6.11 (1H, ddd, J = 7.9, 6.6 
and 1.1 Hz), 2.81 (1H, m), 2.30 (1H, m), 2.13 (3H, s), 2.07 (1H, dd, J = 6.2 and 1.8 Hz), 1.90 (1H, m), 
1.79 (1H, dddd, J = 12.7, 10.0, 4.4 and 2.5 Hz), 1.55 (1H, dddd, J = 12.3, 9.9, 4.4 and 2.5 Hz), 1.33 
(1H, m), 1.06-1.15 (4H, m); LRMS (ESI) m/z = 165 (MH+, 100%). 
 
(±)-2-Acetyl-3-methyl-bicyclo[2.2.2]octane (193).239 
Palladium on charcoal (15 mg) was added to a solution of bicyclooctene 192 (100 mg, 
0.61 mmol) in ethyl acetate (0.8 mL) and submitted to a hydrogen atmosphere (1 atm).  
The suspension was stirred for 16 h before filtering through Celite® to give 193 (60 mg, 
98%) as a colourless oil. 
Rf 0.42 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2945 (w), 2931 (w), 2887 (w), 1691 (s) 
(C=O), 1387 (m), 1200 (m), 759 (m) cm–1; 1H NMR: δH (400 MHz, C6D6); 2.47 (1H, m, C(=O)CH), 
1.83-1.86 (4H, m, C(=O)CH3 and CH), 1.66 (1H, m, CH), 1.58 (2H, m, CH2), 1.46-1.51 (1H, m), 1.38-
1.44 (3H, m), 1.21-1.32 (3H, m), 0.90 (3H, d, J = 7.0 Hz, CH3); 13C NMR: δC (100 MHz, C6D6); 207.64 
(s) (C=O), 59.36 (d) (C(=O)C), 30.43 (q) (C(=O)CH3), 30.28 (d) (CH), 28.38 (d) (CH), 28.26 (d) (CH), 
26.69 (t), 26.49 (t), 21.02 (t), 20.16 (q), 20.09 (q); LRMS (CI) m/z = 184 [(M+NH4)+, 70%], 167 (MH+, 
5), 123 (30), 106 (100); HRMS (CI) m/z 184.1701 (M+NH4). C11H22NO Required 184.1701; Δ = -0.2 
ppm. 
 
General procedure W (formation of silylenolethers). 
Methyl ketone (0.3 mmol) was dissolved in CH2Cl2 under argon before addition of triethylamine (0.21 
mL, 1.5 mmol) and tert-butyldimethylsilyl triflate (0.28 mL, 1.2 mmol) and stirring for 2.5 h.  The 
reaction was diluted with CH2Cl2 (6 mL) before quenching with sat. aqueous NaHCO3 (10 mL).  The 
organic layer was rapidly separated and dried over Na2SO4 before concentrating under reduced 
pressure to give a biphasic oil. 
 
(±)-Tert-butyldimethyl[(1-{3-methylbicyclo[2.2.2]octan-2-yl}ethenyl)oxy] 
silane (196).  
Using the general procedure W, methyl ketone 193 (50 mg, 0.3 mmol), 
triethylamine (0.21 mL, 1.5 mmol) and tert-butyldimethylsilyl triflate (0.28 mL, 1.2 
mmol) after 2.5 h purifying by passing through a plug of silica (elute with petroleum ether) to give 196 
(81 mg, 96%) as a colourless oil. 
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Rf 0.87 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2953 (w), 1722 (w), 1342 (m), 1156 (w), 
1097 (m), 1035 (m), 1014 (s), 817 (m) cm–1; 1H NMR: δH (400 MHz, C6D6); 4.34-4.35 (2H, m, 
C=CH2), 1.96-2.04 (2H, m), 1.87 (2H, m), 1.51-1.70 (5H, m), 1.38 (3H, m), 1.08 (3H, m), 1.06 (9H, s, 
C(CH3)3), 0.25 (6H, d, J = 3.4 Hz, Si(CH3)2); 13C NMR: δC (100 MHz, C6D6); 161.71 (t) (C=CH), 88.98 
(d), 52.70 (d), 33.84 (d), 31.24 (d), 29.21 (d), 27.32 (t), 27.08 (t), 25.78 (t), 21.25 (t), 20.29 (q), 19.41 
(3 x q), -4.50 (s), -4.82 (2 x q); LRMS (CI) m/z = 298 [(M+NH4)+, 10%], 281 (MH+, 100), 240 (10), 199 
(10), 132 (20); HRMS (CI) m/z 281.2294 (MH+). C17H33OSi Required 281.2301; Δ = -2.4 ppm. 
 
(±)-3-Methylbicyclo[2.2.2]octane-2-carboxylic acid (194).240 
According to the method of Yang,241 to a mixture of enol ether 196 (84 mg, 0.3 mmol) 
and RuCl3 (1 mg, 0.05 mmol) in dichloroethane (2 mL) and H2O (1.3 mL) NaIO4 (256 
mg, 1.2 mmol) was added portionwise and the reaction stirred for 16 h.  The reaction 
was then quenched with sat. aqueous NaHCO3 (2 mL), the organic separated and the aqueous 
extracted with CH2Cl2 (2 x 5 mL) before acidifying the aqueous (pH 1) and extracting with further 
CH2Cl2 (3 x 5 mL).  The extracts were combined, dried over Na2SO4 and concentrated under reduced 
pressure to give a brown oil.  Purification was achieved by FC (10:1 to 1:1 petroleum ether:ethyl 
acetate gradient to give 194 (35 mg, 70 %) as a colourless oil. 
1H NMR: δH (400 MHz, C6D6); 1.94-2.19 (2H, m), 1.48-1.73 (5H, m), 1.34-1.47 (3H, m), 1.13-1.34 
(2H, m), 1.05 (2H, m, CH3), 0.78-0.97 (2H, m); LRMS (ESI) m/z = 169 (MH+, 100%). 
 
(±)-Tert-butyldimethyl[(5-{2,4-dimethylazabicyclo[2.2.2]octan-5-
yl}ethenyl)oxy]silane (197).  
Using the general procedure W, methyl ketone 188 (24 mg, 0.12 mmol), 
triethylamine (0.11 mL, 0.25 mmol) and tert-butyldimethylsilyl triflate (34 µL, 
1.2 mmol) after 3 h purifying by FC (elute with petroleum ether) to give 196 (81 mg, 96%) as a 
colourless oil. 
Rf 0.87 (20:1 petroleum ether:ethyl acetate); IR (neat): υmax 2975 (w), 1722 (w), 1342 (m), 1167 (w), 
1112 (m), 1076 (m), 1034 (s), 783 (m) cm–1; 1H NMR: δH (400 MHz, C6D6); 4.28-4.31 (2H, m, 
C=CH2), 2.83 (1H, m, NCH2), 2.38-2.46 (2H, m, NCH2 and NCH) 2.02 (1H, m), 1.87 (1H, m), 1.61-
1.74 (4H, m), 1.38 (4H, m), 1.08 (3H, m), 1.06 (9H, s, C(CH3)3), 0.25 (6H, d, J = 3.4 Hz, Si(CH3)2); 
13C NMR: δC (100 MHz, C6D6); 162.8 (t) (C=CH), 88.98 (d), 52.70 (d), 33.84 (d), 31.24 (d), 29.21 (d), 
27.32 (t), 27.08 (t), 25.78 (t), 21.25 (t), 20.29 (q), 19.41 (3 x q), -4.50 (s), -4.82 (2 x q); LRMS (CI) m/z 
= 327 [(M+NH4)+, 100%], 310 (MH+, 100), 246 (10), 196 (40), 178 (40); HRMS (ESI) m/z 310.2552 
(MH+). C18H36ONSi Required 310.2556; Δ = -4.5 ppm. 
 
General procedure X (hydrolysis of tert-butyl thioester). 
2M Aqueous KOH (6.3 mmol) was added to a solution of thioester (0.63 mmol) in ethanol (5 mL) and 
the reaction heated at the required temperature until complete.  The solution was then diluted with 
H2O (5 mL) and the organic separated.  The aqueous was then extracted with CH2Cl2 (3 x 10 mL) 
before acidifying with HCl to pH 1 and extracting with ethyl acetate (3 x 10 mL).  The ethyl acetate 
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extracts were combined, dried over MgSO4 and concentrated under reduced pressure to give a pale 
yellow oil. 
 
(±)-2-Benzyl 5,8-dimethyl-2-azabicyclo[2.2.2]oct-7-ene-2-carboxylate-6-carboxylic acid 
(Product of table 16, Entry 13). 
 
Using the general procedure X, 2M Aqueous KOH (5.5 mL, 11 mmol) and thioester (350 mg, 1.1 
mmol) after 3 h at 45 ºC gave a colourless oil (210 mg, 78%) comprising a mixture of two 
diasteromers (exo:endo, 1:3 ratio determine by 1H NMR). 
LRMS (CI) m/z = 333 [M+NH4)+, 25%], 316 (MH+, 100), 298 (5), 237 (15), 229 (10). HRMS (ESI) m/z 
= 316.1535. C18H22NO4 Required 316.1549; Δ = -4.4 ppm. 
Exo-(5R,6S)-199: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 7.34-7.39 
(5H, m, Ar-H), 6.11 (1H, dd, J = 22.6 and 5.9 Hz, C=CH), 3.40 (1H, t, J = 10.6 Hz, NCH2), 3.06 (1H, 
m, NCH), 2.40 (1H, m, C(=O)CH), 1.89 (3H, s, C=C(CH3)), 0.98 (3H, t, J = 5.6 Hz, CHCH3). 
Endo-(5S,6R)-199: 1H NMR: δH (400 MHz, CDCl3); 9.04 (1H, s, COOH), 7.34-7.39 (5H, m, Ar-H), 
5.99 (1H, ddt, J = 22.1, 5.9 and 1.7 Hz, C=CH), 5.15 (2H, m, Ar-CH2), 4.98 (1H, dd, J = 5.9 and 2.7, 
NCH), 3.56 (1H, dd, J = 7.8 and 2.5 Hz, NCH2), 2.92 (1H, m, NCH2), 2.51 (1 H, dd, J = 5.7 and 2.7, 
CH(COOH)), , 2.31 (1H, dt, J = 17.0 and 2.1 Hz, CHCH3), 2.08 (1H, m, C=C(CH3)CH), 1.89 (3H, s, 
C=C(CH3)), 1.22 (3H, t, J = 6.6 Hz, CHCH3); 13C NMR: δC (100 MHz, CDCl3); 128.50 (d), 127.97 (2 x 
d), 127.89 (d) (C=CH), 127.82 (2 x d), 122.85 (d), 66.95 (d), 52.86 (t), 48.07 (t), 42.47 (d), 40.54 (t), 
31.94 (d), 31.72 (q), 19.49 (q). 
 
(±)-Benzyl 7-[(2,5-dimethylphenyl)carbamoyl]-5,8-dimethyl-2-azabicyclo[2.2.2]oct-5-ene-2-
carboxylate (198). 
 
Carboxylic acid 199 (22 mg, 0.09 mmol) was dissolved in CH2Cl2 (0.5 mL) and the solution cooled to 
0 ºC before addition of oxalyl chloride (10.5 µL, 0.12 mmol) followed by DMF (1 drop).  The reaction 
was stirred for 10 min before warming to room temperature and stiring for a further 1 h.  The orange 
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solution was then concentrated under reduced pressure to remove excess oxalyl chloride.  The oil 
was then redissolved in CH2Cl2 (0.5 mL) before adding 2,5-dimethylaniline (12 µL, 0.1 mmol) 
followed by AgCN (12 mg, 0.9 mmol).  The crude suspension was filtered through Celite® and 
concentrated under reduced pressure to give a pale yellow oil.  Purification was achieved by FC (5:1 
petroleum ether:ethyl acetate) to give a colourless oil (20 mg, 63%) comprising a mixture of two 
diastereomers (1:2, exo-198:endo-198 as determined by 1H NMR integration). 
Rf = 0.24 (5:1 petroleum ether:ethyl acetate); IR (neat): vmax 3475 (w), 2975 (w), 1722 (w), 1667 (s) 
(C(=O)NH), 1342 (m), 1167 (w), 1112 (m), 1076 (m), 1034 (s), 783 (m) cm–1; LRMS (CI) m/z = 436 
[M+NH4)+, 25%], 419 (MH+, 90), 388 (40), 371 (90), 316 (100), 200 (20). HRMS (ESI) m/z = 
419.2336. C26H31N2O3 Required 419.2335; Δ = 0.2 ppm. 
Exo-(5R,6S)-198: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 4.85-4.87 
(1H, m, C=CH), 2.53 (1H, dd, J = 6.0 and 2.5 Hz, CHC(=O)), 2.42 (1H, m, C=C(CH3)CH), 1.29 (3H, 
d, J = 6.9 Hz, CHCH3). 
Endo-(5S,6R)-198: 1H NMR: δH (400 MHz, CDCl3); 7.65 (1H, s, Ar-H), 7.35-7.40 (5H, m, Ar-H), 7.06 
(1H, t, J = 8.7 Hz, Ar-H), 6.89 (1H, t, J = 7.1 Hz, Ar-H), 6.05 (1H, ddt, J = 5.6, 3.7 and 1.8 Hz, C=CH), 
5.17 (2H, d, J = 0.4 Hz, Ar-CH2), 4.96 (1H, dd, J = 5.9 and 2.6 Hz, NCH), 3.61 (1H, td, J = 10.6 and 
1.8 Hz, NCH2), 2.95-3.01 (1H, m, NCH2), 2.57 (1H, dd, J = 5.6 and 2.7 Hz, CHC(=O)), 2.37 (1H, t, J = 
2.1 Hz, NCH2CH), 2.28-2.35 (4H, m, Ar-CH3 and CHCH3), 2.13 (3H, s, Ar-CH3), 1.95 (3H, dd, J = 4.9 
and 1.7 Hz, C=C(CH3)), 1.23 (3H, d, J = 7.0 Hz, CHCH3); 13C NMR: δC (100 MHz, CDCl3); 135.43 (d), 
130.22 (d), 128.59 (2 x d), 128.14 (d), 128.03 (s), 127.78 (2 x d), 123.55 (d), 121.68 (d), 66.99 (d), 
55.59 (t), 49.68 (d), 49.53 (d), 42.72 (d), 42.63 (d), 40.51 (q), 31.34 (q), 19.62 (q), 18.89 (q). 
 
(±)-(1R,4S,5S,6R)-6-[(2,5-dimethylphenyl)carbamoyl]-2,5,8-tiimethyl-
2-azabicyclo[2.2.2]octane (148). 
Using the general procedure V, Palladium on charcoal (40 mg), benzyl 
carbamate 198 (52 mg, 0.12 mmol) and formaldehyde (37% wt. in H2O; 
40 µL, 3.73 mmol) after 16h gave 188 (31 mg, 82%) as a white solid. 
Rf = 0.45 (10% methanol in CH2Cl2); IR (neat): υmax 2968 (w), 2938 (w), 2864 (w), 1667 (s) (C=O), 
1375 (m), 1203 (m), 832 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.72 (1H, s, Ar-H), 7.08 (1H, d, J = 
7.7 Hz, Ar-H), 7.04 (1H, s, NH), 6.90 (1H, d, J = 7.5 Hz, Ar-H), 2.71-2.84 (2H, m, NCH2), 2.57 (1H, m, 
CHCH3), 2.47 (3H, s, NCH3), 2.43 (1H, d, J = 8.4 Hz, NCH), 2.34 (3H, s, Ar-CH3), 2.23 (3H, s, Ar-
CH3), 1.98-2.07 (2H, m, CHCH3 and CHC=O), 1.40 (1H, m, NCHCH2), 1.24 (1H, s, NCH2CH), 1.10 
(6H, dd, J = 6.7 and 2.6 Hz, CH3); 13C NMR: δc (100 MHz, CDCl3); 171.61 (s) (C=O), 136.61 (s) (Ar-
C), 135.57 (s) (Ar-C), 130.23 (d) (Ar-C), 125.75 (d) (Ar-C), 125.34 (s) (Ar-C), 123.40 (d) (Ar-C), 57.59 
(d) (NCH), 53.15 (t) (NCH2), 50.53 (q) (NCH3), 42.60 (q) (Ar-CH3), 39.13 (d) (CHC(=O), 30.54 (q) (Ar-
CH3), 29.58 (d) (CHCH3), 24.99 (d) (CHCH3), 21.14 (t) (NCHCH2), 18.84 (q) (CH3), 17.38 (q) (CH3); 
LRMS (ESI) m/z 301 (MH+, 100); HRMS (ESI) m/z 301.2267 (MH+). C19H29N2O Required 301.2280; Δ 
= -4.3 ppm. 
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(±)-(1R,4S,5R,6S)-6-[(2,5-dimethylphenyl)carbamoyl]-2,5,8-tiimethyl-2-
azabicyclo[2.2.2]octane (148). 
Using the general procedure V, Palladium on charcoal (40 mg), benzyl carbamate 
198 (51 mg, 0.12 mmol) and formaldehyde (37% wt. in H2O; 40 µL, 3.73 mmol) after 
16h gave 188 (22 mg, 58%) as a white solid. 
Rf = 0.45 (10% methanol in CH2Cl2); IR (neat): υmax 2968 (w), 2938 (w), 2864 (w), 
1667 (s) (C=O), 1375 (m), 1203 (m), 832 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 
7.71 (1H, s, NH), 7.19 (1H, s, Ar-H), 7.09 (1H, d, J = 7.6 Hz, Ar-H), 6.91 (1H, d, J = 
7.7 Hz, Ar-H), 2.79-2.85 (3H, m, NCH2 and NCH), 2.59 (1H, m, CHCH3), 2.49-2.52 (4H, m, NCH3 and 
NCH), 2.34 (3H, s, Ar-CH3), 2.24 (3H, s, Ar-CH3), 1.93-2.07 (3H, m, NCHCH2 and CH and NCH2), 
1.43 (1H, dd, J = 12.6 and 7.0 Hz, CHC(=O)), 1.27 (1H, s, NCHCH2), 1.12 (6H, d, J = 6.6 Hz, 
CHCH3); 13C NMR: δc (100 MHz, CDCl3); 174.6 (s) (C=O), 137.5 (s) (Ar-C), 135.5 (s) (Ar-C), 130.2 (d) 
(Ar-C), 125.8 (d) (Ar-C), 125.4 (s) (Ar-C), 124.1 (d) (Ar-C), 58.6 (d) (NCH), 53.2 (t) (NCH2), 50.6 (q) 
(NCH3), 43.2 (q) (Ar-CH3), 39.1 (d) (CHC(=O), 31.1 (q) (Ar-CH3), 29.7 (d) (CHCH3), 25.0 (d) (CHCH3), 
21.1 (t) (NCHCH2), 18.8 (q) (CH3), 17.4 (q) (CH3); LRMS (ESI) m/z 301 (MH+, 100); HRMS (ESI) m/z 
301.2267 (MH+). C19H29N2O Required 301.2282; Δ = -6.4 ppm. 
 
3-Benzyldimethylsilyl pyridine (201). 
n-BuLi (1.52 M in hexanes; 2.9 mL, 4.4 mmol) was added dropwise to a stirring 
solution of 3-bromopyridine (390 µL, 4 mmol) in diethyl ether (10 mL) at -78 ºC 
and stirred for 1 h.  Benzyldimethylsilyl chloride (800 µL, 4.4 mmol) was then 
added dropwise and the reaction allowed to warm to room temperature and 
stirred for 4 h.  The reaction was then quenched with phosphate buffer (pH 7, 1M) and the organic 
layer separated.  The aqueous was extracted with CH2Cl2 (3 x 20 mL), the extracts combined, dried 
over MgSO4 and concentrated under reduced pressure to give an orange oil.  Purification was 
achieved by FC (5:1 petroleum ether:ethyl acetate) to give 201 (960 mg, 97 %) as a pale yellow 
liquid. 
Rf = 0.22 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.64 (1H, dd, J = 1.8 
and 1.0 Hz, Ar-H), 8.61 (1H, dd, J = 4.9 and 1.9 Hz, Ar-H), 7.68 (1H, dt, J = 7.5 and 1.9 Hz, Ar-H), 
7.25 (1H, ddd, J = 7.5, 4.9 and 1.1 Hz, Ar-H), 7.21 (2H, m, Ar-H), 7.10 (1H, m, Ar-H), 6.94 (2H, m, Ar-
H), 2.35 (2H, s, Ar-CH2), 0.32 (6H, s, Si(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 154.14 (d) (Ar-C), 
150.16 (d) (Ar-C), 141.49 (d) (Ar-C), 138.82 (s) (Ar-C), 133.18 (s) (Ar-C), 128.29 (4 x d) (Ar-C), 
124.41 (d) (Ar-C), 123.13 (d) (Ar-C), 25.90 (t) (Ar-CH2), -3.58 (q) (Si(CH3)2); LRMS (CI) m/z 455 
[(2M+H)+, 70], 228 (MH+, 100), 153 (20), 136 (5); HRMS (ESI) m/z 228.1214 (MH+). C14H18NSi 
Required 228.1209; Δ = 2.2 ppm. 
 
General procedure Y (N-Selectride® based synthesis of DHPs).  
The required pyridine (0.88 mmol) was dissolved in THF (6 mL) and cooled to -78 ºC before dropwise 
addition of benzyl chloroformate (0.97 mmol) and stirring continued for 1 h.  N-Selectride® (1M in 
hexanes; 1.85 mmol) was then added dropwise ensuring the temperature does not rise above -65 ºC 
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and stirring continued until complete.  A mix of H2O2 (37% weight in H2O) and 1 M NaOH (4:6, 1 mL) 
was added and the reaction stirred over night. The suspension was then poured onto ice water (20 
mL) before extracting with ethyl acetate (3 x 20 mL).  The combined extracts were then washed with 
brine (20 mL), dried over MgSO4 and concentrated under reduced pressure to give a yellow oil. 
 
Synthesis of 3-Dimethylsilyl-N-Carbobenzyloxy-1,6-dihydropyridine (200) and 3-Dimethylsilyl-
N-Carbobenzyloxy-1,4-dihydropyridine (202). 
 
Using the general procedure Y, 3-dimethylsilyl pyridine 201 (200mg, 0.88 mmol), benzyl 
chloroformate (140 µL, 0.97 mmol) and N-Selectride® (1M in hexanes; 1.85 mL, 1.85 mmol) after 6h 
purifying by silica gel chromatography gave 1,6-DHP 200 (130mg, 59%) and 1,4-DHP 202 (14 mg, 
10%) as colourless oils.  
1,6-DHP 200: Rf = 0.38 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.40 
(5H, m, Ar-H), 7.23 (2H, m, Ar-H), 7.11 (1H, m, Ar-H), 7.04 (2H, m, Ar-H), 6.81 (1H, m, NCH), 5.82 
(1H, m, C(Si)CH), 5.45 (1H, m, NCH2CH), 5.26 (2H, s, Ar-CH2), 4.39 (2H, br s, NCH2), 2.20 (2H, s, 
SiCH2), 0.12 (6H, s, Si(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 139.67 (s), 136.01 (s), 132.00 (d), 
131.18 (d), 128.62 (d), 128.17 (d), 127.01 (d), 124.11 (d), 123.85 (d), 118.59 (s), 118.00 (d), 110.94 
(d), 67.80 (t) (Ar-CH2), 43.74 (t) (SiCH2, 25.54 (t) (NCH2, -4.05 (2 x q) (Si(CH3)2); LRMS (CI) m/z 364 
(MH+, 100); HRMS (ESI) m/z 364.1731 (MH+). C22H26NO2Si Required 364.1733; Δ = -0.5 ppm. 
1,6-DHP 202: Rf = 0.43 (20:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.32-
7.39 (5H, m, Ar-H), 7.21 (2H, m, Ar-H), 7.09 (2H, m, Ar-H), 7.02 (1H, m, Ar-H), 6.88 (2H, br m, NCH), 
4.95 (1, br m, NCHCH), 4.71 (2H, s, Ar-CH2), 2.75 (1H, br s, CH2), 2.25 (2H, s, SiCH2), 0.16 (6H, s, 
Si(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 128.62 (d), 128.41 (d), 128.37 (d), 128.30 (s), 128.22 (d), 
127.14 (d), 126.47 (d), 124.25 (d), 64.94 (t), 26.74 (t), 23.86 (t), -2.32 (2 x q) (Si(CH3)2); LRMS (CI) 
m/z 364 (MH+, 100); HRMS (ESI) m/z 364.1731 (MH+). C22H26NO2Si Required 364.1736; Δ = -1.9 
ppm. 
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(±)-2-Benzyl 7-dimethylsilyl-6-tert-butyl-5-methyl-2-azabicyclo[2.2.2]oct-7-ene-2-carboxylate-6-
thioate (product of table 19, Entry3). 
 
Using a modified general procedure Q, DHP 200 (220 mg, 0.7 mmol) and tert-butyl thioester (0.71 
mL, 4.9 mmol) after 4 h at 180 ºC (microwave irradiation) purifying by FC (10:1 petroleum ether:ethyl 
acetate) gave a colourless oil (74 mg, 22 %) comprising an inseparable mixture of two Diels-Alder 
adducts (exo:endo, 1:2 ratio determine by GCMS). 
Rf 0.43 (5:1 petroleum ether:ethyl acetate). LRMS (ESI) m/z = 522 (MH+, 100%). HRMS (ESI) m/z 
522.2500. C30H40NO3SSi Required 522.2498; Δ = 0.4 ppm. 
1H NMR: Diastereomer peaks coalesce - δH (400 MHz, CDCl3); 7.30-7.44 (5H, m, Ar-H), 6.93-7.27 
(5H, m, Ar-H), 6.34-6.57 (1H, m, C=CH), 4.91-5.21 (3H, m, Ar-CH2 and NCH), 3.39-3.59 (1H, m, 
NCH2), 2.87-3.06 (1H, m, NCH2), 2.51-2.69 (1H, m, C=CHCH), 2.17-2.33 (2H, m, C(=O)CH and 
CHCH3), 1.39-1.43 (2H, m, Ar-CH2), 0.82-0.96 (3H, m, CHCH3), 0.07-0.20 (9H, m, C(CH3)3).  
 
(±)-2-Benzyl 7-dimethylsilyl-6-acetyl-5-methyl-2-azabicyclo[2.2.2]oct-7-ene-2-carboxylate 
(product of table 19, Entry 4). 
 
Using a modified general procedure Q, DHP 200 (350 mg, 1.1 mmol) and MVK (0.46 mL, 5.5 mmol) 
after 4 h at 180 ºC (microwave irradiation) purifying by FC (10:1 petroleum ether:ethyl acetate) gave 
a colourless oil (275 mg, 75 %) comprising an inseparable mixture of two Diels-Alder adducts 
(exo:endo, 1:2 ratio determine by GCMS). 
Rf 0.35 (5:1 petroleum ether:ethyl acetate). LRMS (CI) m/z = 451 [(M+NH4)+, 10%], 434 (MH+, 100), 
342 (15), 228 (25). HRMS (ESI) m/z 434.2155 (MH+). C26H32NO3Si Required 434.2151; Δ = 0.9 ppm. 
1H NMR: Diasteromer peaks coalesce - δH (400 MHz, CDCl3); 7.29-7.41 (5H, m, Ar-H), 7.16-7.23 
(2H, m, Ar-H), 7.06-7.12 (1H, m, Ar-H), 6.93-7.00 (2H, m, Ar-H), 6.69 (1H, m, C=CH), 5.12-5.17 (2H, 
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m, Ar-CH2), 5.05 (1H, m, NCH), 3.32 (1H, m, NCH2), 2.90-2.98 (1H, m, NCH2), 2.71-2.81 (1H, m, 
NCH2CH), 2.15-2.28 (5H, m, CH3 and CH2), 1.24-1.31 (1H, m), 0.09-0.22 (6H, m, Si(CH3)2).  
 
(±)-Benzyl 10-methyl-3,5-dioxo-4-phenyl-4,8-diazatricyclo[5.2.2.02,6]undec-10-ene-8-
carboxylate (212). 
 
Using the general procedure Q, DHP 152 (200 mg, 0.87 mmol) and N-phenyl maleimide (750 mg, 4.4 
mmol) after 20 min at 60 ºC purifying by FC (4:1 petroleum ether:ethyl acetate) gave a colourless oil 
(290 mg, 83 %) comprising an inseparable mixture of two Diels-Alder adducts (exo-212:endo-212, 
1:1.1 ratio determined by 1H NMR integration). 
Rf = 0.35 (2:1 petroleum ether:ethyl acetate); IR (neat): vmax 3115 (w), 3078 (w), 2997 (w),1790 (w) 
(C=O), 1600 (m) (C=O), 1406 (m), 1253 (w), 1012 (m), 976 (m), 783 (m) cm–1; LRMS (ESI) m/z = 
403 (MH+, 100%); HRMS (ESI) m/z = 403.1584. C24H23N2O4 Required 403.1580; Δ = 1.4 ppm. 
Exo-212: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3; 6.10-6.11 (1H, m, 
C=CH), 3.28 (1H, m, C=C(CH3)CH). 
Endo-212: 1H NMR: δH (400 MHz, CDCl3); 7.37-7.49 (8H, m, Ar-H), 7.13-7.16 (2H, m, Ar-H), 6.17 
(1H, m, C=CH), 5.35 (1H, m, NCH), 5.19 (2H, m, Ar-CH2), 3.42-3.53 (2H, m, NCHCH and NCH2), 
3.32 (1H, m, C=C(CH3)CH), 3.15-3.21 (2H, m, NCH2CHCH), 1.90 (3H, d, J = 1.5 Hz, CH3); 13C NMR: 
δC (100 MHz, CDCl3); 210.19 (s) (C=O), 145.56 (s), 130.22 (d), 128.59 (s x d), 128.54 (s), 128.14 (d), 
128.03 (s), 127.78 (2 x d), 123.55 (s), 114.00 (s), 66.99 (d), 55.59 (t), 49.68 (d), 49.53 (d), 42.72 (d), 
42.63 (d), 40.51 (q), 31.34 (q), 19.62 (q), 18.89 (q). 
 
(±)-Benzyl 11-dimethylbenzylsilyl-3,5-dioxo-4-phenyl-4,8-diazatricyclo[5.2.2.02,6]undec-10-ene-
8-carboxylate (212). 
 
Using the general procedure Q, DHP 200 (250 mg, 0.8 mmol) and N-phenyl maleimide (700 mg, 3.99 
mmol) after 3 h at 80 ºC purifying by FC (4:1 petroleum ether:ethyl acetate) gave a colourless oil (280 
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mg, 79 %) comprising an inseparable mixture of two Diels-Alder adducts (exo-211:endo-211, 1:1.08 
ratio determined by 1H NMR integration). 
Rf = 0.42 (2:1 petroleum ether:ethyl acetate); IR (neat): vmax 3023 (w), 2957 (w),1710 (s) (C=O), 1598 
(w), 1412 (m), 1382 (m), 1184 (m), 826 (m), 698 (s) cm–1; LRMS (ESI) m/z = 537 (MH+, 100%); 
HRMS (ESI) m/z = 537.2201. C32H33N2O4Si Required 537.2210; Δ = -1.7 ppm. 
Exo-212: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 6.82 (2H, d, J = 
7.2 Hz, Ar-H), 6.57 (1H, d, J = 5.9 Hz, C=CH), 5.53 (1H, dd, J = 4.1 and 1.1 Hz, NCH). 
Endo-212: 1H NMR: δH (400 MHz, CDCl3); 7.32-7.48 (8H, m, Ar-H), 7.03-7.20 (5H, m, Ar-H), 6.86 
(2H, d, J = 7.2 Hz, Ar-H), 6.64 (1H, d, J = 5.9 Hz, C=CH), 5.34 (1H, dd, J = 4.1 and 1.1 Hz, NCH), 
5.18 (2H, m, Ar-CH2O), 3.43-3.55 (3H, m), 3.04-3.17 (2H, m), 2.16 (1H, d, J = 5.7 Hz, Ar-CH2Si), 2.05 
(1H, d, J = 2.7 Hz, Ar-CH2Si), -0.02-0.13 (6H, m, Si(CH3)2). 
 
General procedure Z (synthesis of N-aryl maleimides). 
According to the method of Miller,242 maleic anhydride (5 mmol) and the required aniline (5 mmol) 
were heated at 120 ºC for 1 h before dissolving in toluene (1.5 mL) and DMSO (370 µL) before 
adding conc. H2SO4 (30 µL) and heating to 135 ºC for 16 h.  The solution was the concentrated under 
reduced pressure and passed through a plug of silica (eluting with ethyl acetate) to yield the pure N-
aryl maleimide. 
 
N-[2,6-Bis(propan-2-yl)phenyl] maleimide (213).243  
Using the general procedure Z, maleic anhydride (500 mg, 5 mmol) and 2,6-
diisopropyl aniline (0.94 mL, 5 mmol) after 17 h gave 213 (1.12g, 88%) as a pale 
white solid. 
1H NMR: δH (400 MHz, CDCl3); 7.46 (1H, t, J = 7.8 Hz), 7.28 (2H, d, J = 7.8 Hz), 
6.88 (2H, s), 2.65 (2H, sep, J = 6.9 Hz), 1.19 (12H, d, J = 6.9 Hz); LRMS (ESI) m/z = 258 (MH+, 
100%). 
 
General Procedure AA (ortho functionalisation of N-boc aniline). 
According to the method of Muchowski,244 t-BuLi (5.69 mmol) was added dropwise to a solution of N-
boc aniline (2.59 mmol) in THF (2.6 mL) at -78 ºC.  The reaction was stirred at -78 ºC for 10 min 
before warming to -20 ºC and stirring for a further 2 h.  The required electrophile (3.1 mmol) was then 
added and the reaction stirred until complete.  The reaction is then quenched with H2O, extracted 
with ethyl acetate (3 x 40 mL) and the combined extracts washed with sat. aqueous sodium 
thiosulfate (10 mL), NaHCO3 (30 mL), H2O (30 mL) and brine (30 mL) before drying over MgSO4 and 
concentrating under reduced pressure to give a yellow oil. 
 
Tert-butyl N-[2-(2-methylpropyl)phenyl]carbamate (217). 
Using general procedure AA, t-BuLi (1.56 M in hexanes; 3.65 mL, 5.69 
mmol), N-boc aniline (500 mg, 2.59 mmol) and 2-methyl bromo propane 
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(338 µL, 3.1 mmol) after 4 h purifying by FC (10:1 petroleum ether:ethyl acetate) gave 217 (125 mg, 
25%) as a colourless oil. 
Rf = 0.87 (5:1 petroleum ether:ethyl acetate); IR (neat) vmax 3434 (w), 2925 (w), 2360 (w), 1704 (s) 
(C=O), 1625 (m), 1525 (m), 1238 (s), 1158 (m), 1055 (w), 1021 (m), 762 (s) cm-1; 1H NMR: δH (400 
MHz, CDCl3); 7.78 (1H, br d, J = 7.5 Hz, Ar-H), 7.22 (1H, td, J = 7.6 and 1.5 Hz, Ar-H), 7.13 (1H, dd, 
J = 7.6 and 1.5 Hz, Ar-H), 7.05 (1H, td, J = 7.5 and 1.5 Hz, Ar-H), 6.29 (1H, s, NH), 2.46 (2H, d, J = 
7.3 Hz, Ar-CH2), 1.88 (1H, dquintet, J = 13.6 and 6.8 Hz, CH2CH), 1.55 (9H, s, C(CH3)3), 0.97 (6H, d, 
J = 6.6 Hz, CH(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 153.36 (s) (Ar-C), 135.89 (d) (Ar-C), 130.51 
(d) (Ar-C), 126.75 (d) (Ar-C), 123.82 (d) (Ar-C), 122.18 (s) (Ar-C), 80.38 (s) (C(=O)OC), 40.73 (t) (Ar-
CH2), 29.02 (d) (Ar-CH2CH), 28.39 (2 x q), 22.61 (3 x q); LRMS (ESI) m/z 250 (MH+, 100); HRMS 
(ESI) m/z 250.1731 (MH+). C15H23NO2 Required 250.1729; Δ = 0.7 ppm. 
 
Tert-butyl N-[2-(3-methylbut-2-en-1-yl)-6-(2-methylpropyl)phenyl] 
carbamate (218). 
Using general procedure AA, t-BuLi (1.56 M in hexanes; 230 µL, 0.35 
mmol), N-boc aniline 217 (40 mg, 0.16 mmol) and 3,3-dimethyl 
allylbromide (22 µL, 0.19 mmol) after 16 h at room temperature purifying 
by FC (15:1 petroleum ether:ethyl acetate) gave 218 (34 mg, 78%) as a 
colourless oil. 
Rf = 0.38 (15:1 petroleum ether:ethyl acetate); IR (neat) vmax 3435 (w), 2931 (w), 2362 (w), 1705 (s) 
(C=O), 1675 (m) (C=C), 1528 (m), 1089 (m), 1055 (w), 1026 (m), 773 (s) cm-1; 1H NMR: δH (400 MHz, 
CDCl3); 7.00-7.24 (3H, m, Ar-H), 5.35 (1H, br t, J = 6.8 Hz, C=CH), 4.42 (1H, m, Ar-CH2CH=C), 3.79 
(1H, dd, J = 14.7 and 7.5 Hz, Ar-CH2CH=C), 2.52 (1H, m, Ar-CH2), 2.35 (1H, m, Ar-CH2), 2.06 (1H, 
m, CH(CH3)2), 1.69 (3H, br s, CH3), 1.54 (3H, br s, CH3), 1.43 (3H, br s, ), 1.35 (6H, br s, CH3), 0.90-
0.96 (6H, m, CH(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 155.18 (s), 129.80 (d), 129.23 (d), 126.76 
(d), 126.01 (d), 120.18 (s), 47.43 (t), 40.34 (t), 28.39 (d), 28.32 (q), 25.72 (q), 22.95 (q), 22.57 (q), 
17.61 (q); LRMS (ESI) m/z 318 (MH+, 100); HRMS (ESI) m/z 318.2359 (MH+). C20H31NO2 Required 
318.2355; Δ = 1.2 ppm. 
 
Tert-butyl N-[2-(2-methylpropoxy)phenyl]carbamate (220). 
Using general procedure AA, t-BuLi (1.56 M in hexanes; 3.65 mL, 5.69 mmol), N-
boc aniline (500 mg, 2.59 mmol) and 2-methyl bromo propane (338 µL, 3.1 mmol) 
after 4 h purifying by FC (10:1 petroleum ether:ethyl acetate) gave 217 (125 mg, 
25%) as a colourless oil. 
Rf = 0.87 (5:1 petroleum ether:ethyl acetate); IR (neat) vmax 3437 (w), 2926 (w), 
2359 (w), 1702 (s) (C=O), 1615 (m), 1537 (m), 1238 (s), 1215 (m), 958 (w), 872 (m), 722 (s) cm-1; 1H 
NMR: δH (400 MHz, CDCl3); 8.09 (1H, br s, Ar-H), 7.09 (1H, br s, Ar-H), 6.96 (2H, dt, J = 6.6 and 3.0 
Hz, Ar-H), 6.85 (1H, m, Ar-H), 3.80 (2H, d, J = 6.6 Hz, Ar-OCH2), 2.18 (1H, dquintet, J = 13.4 and 6.7 
Hz, CH2CH), 1.56 (9H, s, C(CH3)3), 1.08 (6H, d, J = 6.7 Hz, CH(CH3)2); 13C NMR: δc (100 MHz, 
CDCl3); 152.86 (s) (C=O), 147.02 (s), 128.29 (s), 122.31 (d), 120.95 (d), 118.17 (d), 111.06 (d), 80.30 
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(s), 75.01 (t), 28.41 (3 x q), 28.23 (d), 19.36 (2 x q); LRMS (ESI) m/z 266 (MH+, 100); HRMS (ESI) 
m/z 266.1762 (MH+). C15H24NO3 Required 266.1756; Δ = 2.3 ppm. 
 
Tert-butyl N-[2-(methylpropoxy)-6-(2-methylpropyl)phenyl] 
carbamate (221). 
Using general procedure AA, t-BuLi (1.56 M in hexanes; 230 µL, 0.35 
mmol), N-boc aniline (42 mg, 0.16 mmol) and 2-methyl bromo propane 
(21 µL, 0.19 mmol) after 16 h at room temperature purifying by FC (15:1 
petroleum ether:ethyl acetate) gave 221 (1 mg, 1%) as a colourless oil. 
Rf = 0.35 (15:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.13 (1H, t, J = 8.0 Hz, 
Ar-H), 6.80 (1H, dd, J = 7.8 and 1.1 Hz, Ar-H), 6.75 (1H, dd, J = 8.2 and 1.2 Hz, Ar-H), 5.86 (1H, br s, 
NH), 3.74 (2H, d, J = 6.5 Hz, OCH2), 2.55 (2H, d, J = 7.2 Hz, Ar-CH2), 2.12 (1H, dquintet, J = 13.3 
and 6.7 Hz, OCH2CH), 1.94 (1H, dquintet, J 13.5 and 6.8 Hz, CH2CH), 1.06 (6H, d, J = 6.5 Hz, 
OCH2CH(CH3)2), 0.92 (6H, d, J = 6.5 Hz, Ar-CH2CH(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 126.6 (d) 
(Ar-C), 121.9 (d) (Ar-C), 109.3 (d) (Ar-C), 74.1 (s) (C(=O)OC), 40.8 (t) (Ar-CH2), 29.1 (d) (Ar-CH2CH), 
28.1 (d) (Ar-OCH2CH), 22.6 (q), 18.8 (q); LRMS (ESI) m/z 322 (MH+, 100); HRMS (ESI) m/z 
321.2310 (MH+). C19H31NO3 Required 321.2304; Δ = 2.3 ppm. 
 
Tert-butyl N-[2-(2-methylprop-2-en-1-yl)-6-(2-methylpropoxy)phenyl] 
carbamate (222). 
Using general procedure AA, t-BuLi (1.56 M in hexanes; 345 µL, 0.44 
mmol), N-boc aniline (50 mg, 0.19 mmol) and 1-bromo-2-methyl propene 
(45 µL, 0.42 mmol) after 2 h purifying by FC (20:1 petroleum ether:ethyl 
acetate) gave 222 (50 mg, 74%) as a colourless oil. 
Rf = 0.77 (5:1 petroleum ether:ethyl acetate); IR (neat) vmax 2965 (w), 2931 (w), 1731 (s) (C=O), 1703 
(s), 1587 (w), 1469 (s), 1450 (s), 1365 (s), 1236 (s), 1160 (s), 1049 (m), 1022 (m), 889 (m), 765 (s) 
cm-1; 1H NMR: δH (400 MHz, CDCl3); 7.15 (1H, t, J = 8.0 Hz, Ar-H), 6.83 (1H, dd, J = 8.0 and 1.2 Hz, 
Ar-H), 6.78 (1H, dd, J = 8.0 and 1.2 Hz, Ar-H), 5.95 (1H, br s, NH), 4.84 (1H, m, C=CH2), 4.70 (1H, 
m, C=CH2), 3.76 (2H, d, J = 6.5 Hz, OCH2), 3.39 (2H, s, Ar-CH2), 2.13 (1H, dquintet, J = 13.3 and 6.7 
Hz, CH2CH), 1.70 (3H, d, J = 0.3 Hz, C(=C)CH3), 1.06 (6H, d, J = 6.7 Hz, CH(CH3)2); 13C NMR: δc 
(100 MHz, CDCl3); 154.42 (s), 144.55 (s), 138.11 (s), 127.04 (d), 125.05 (s), 121.81 (t), 111.92 (d), 
110.09 (d), 79.61 (s), 74.78 (t), 40.34 (t), 28.43 (d), 28.35 (q), 22.39 (q), 19.29 (q); LRMS (ESI) m/z 
320 (MH+, 100); HRMS (ESI) m/z 320.2221 (MH+). C19H30NO3 Required 320.2226; Δ = -1.6 ppm. 
 
2-(2-methylpropoxy)-6-(2-methylpropyl)anline (223). 
Pd-C (220 mg) was added to a solution of substituted N-boc aniline 222 
(2.1 g, 6.6 mmol) in methanol (13 mL) and the reaction submitted to a 
hydrogen atmosphere (1 atm).  After stirring for 16 h the suspension was filtered through Celite® and 
concentrated under reduced pressure to give a colourless oil before dissolving in CH2Cl2 (15 mL) and 
TFA (7.5 mL).  The reaction was stirred for 10 min before concentrating under reduced pressure, 
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taking up in ethyl acetate (50 mL) and washing with sat. aqueous NaHCO3 (3 x 20 mL), brine (3 x 10 
mL), drying over MgSO4 and concentrating under reduced pressure to give 223 (1.5 g, 98%) as a 
colourless oil. 
Rf = 0.32 (5:1 petroleum ether:ethyl acetate); IR (neat) vmax 2954 (w), 2925 (w), 2813 (w), 1614 (w), 
1598 (w), 1467 (s), 1366 (w), 1217 (s), 1171 (m), 733 (s) cm-1; 1H NMR: δH (400 MHz, CDCl3); 6.67-
6.71 (3H, m, Ar-H), 3.83 (2H, br s), 3.78 (2H, d, J = 6.5 Hz, OCH2), 2.43 (2H, d, J = 7.0 Hz, Ar-CH2), 
2.16 (1H, dquintet, J = 13.3 and 6.5 Hz, OCH2CH), 1.99 (1H, dquintet, J = 13.6 and 7.0 Hz, Ar-
CH2CH), 1.08 (6H, d, J = 6.5 Hz, OCH2CH(CH3)2), 0.99 (6H, d, J = 7.0 Hz, Ar-CH2CH(CH3)2); 13C 
NMR: δc (100 MHz, CDCl3); 146.76 (s) (Ar-CO), 134.16 (s) (Ar-CNH2), 126.31 (s) (Ar-CCH2), 122.79 
(d) (Ar-C), 117.38 (d) (Ar-C), 108.94 (d) (Ar-C), 74.68 (t) (Ar-OCH2), 40.90 (t) (Ar-CH2), 28.46 (d), 
27.86 (d), 22.85 (2 x q), 19.45 (2 x q); LRMS (ESI) m/z 222 (MH+, 100); HRMS (ESI) m/z 222.1782 
(MH+). C14H23NO Required 222.1780; Δ = 0.2 ppm. 
 
N-[2-(2methylpropoxy)-6-(2-methylpropyl)phenyl] maleimide (224).  
Using general procedure Z, maleic anhydride (630 mg, 6.4 mmol) and 
aniline 223 (1.5 g, 6.4 mmol) after 17 h gave 224 (1.83 g, 93%) as a pale 
white solid, m.p. 145 ºC. 
Rf = 0.48 (5:1 petroleum ether:ethyl acetate); IR (neat) vmax 2957 (w), 
2871 (w), 1714 (s) (C=O), 1586 (w), 1466 (m), 1376 (m), 1271 (w), 1151 (m), 1054 (w), 692 (m) cm-1; 
1H NMR: δH (400 MHz, CDCl3); 7.32 (1H, t, J = 8.0 Hz, Ar-H), 6.89-6.91 (3H, m, CH=CH and Ar-H), 
6.82 (1H, dd, J = 8.0 and 1.2 Hz, Ar-H), 3.71 (2H, d, J = 6.5 Hz, OCH2), 2.36 (2H, d, J = 7.0 Hz, Ar-
CH2), 1.97 (1H, dqunitet, J = 13.2 and 6.5 Hz, OCH2CH), 1.80 (1H, dquintet, J = 13.6 and 7.0 Hz, Ar-
CH2CH), 0.92 (6H, d, J = 6.5 Hz, OCH2CH(CH3)2), 0.88 (6H, d, J = 7.0 Hz, Ar-CH2CH(CH3)2); 13C 
NMR: δc (100 MHz, CDCl3); 170.38 (s) (Ar-CO), 142.62 (s) (Ar-CN), 134.52 (2 x d) (CH=CH), 130.03 
(Ar-CH2), 122.24 (d), 109.82 (d), 74.48 (t) (Ar-OCH2), 40.95 (t) (Ar-CH2), 29.18 (d) (Ar-OCH2CH), 
28.20 (d) (Ar-CH2CH), 22.66 (2 x q), 19.11 (2 x q); LRMS (ESI) m/z 302 (MH+, 100); HRMS (ESI) m/z 
302.1760 (MH+). C18H24NO3 Required 302.1756; Δ = 1.3 ppm. 
 
(±)-Benzyl 11-dimethylbenzylsilyl-3,5-dioxo-4-[2,6-Bis(propan-2-yl)phenyl]-4,8-diazatricyclo 
[5.2.2.02,6]undec-10-ene-8-carboxylate (225). 
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Using the general procedure Q, DHP 200 (100 mg, 0.32 mmol) and N-aryl maleimide 213 (410 mg, 
1.6 mmol) after 16 h at 120 ºC (microwave irradiation) purifying by FC (5:1 petroleum ether:ethyl 
acetate) gave a colourless oil (120 mg, 61 %) comprising an inseparable mixture of two Diels-Alder 
adducts (exo-225:endo-225, 1:1 ratio determined by 1H NMR integration). 
Rf = 0.32 (5:1 petroleum ether:ethyl acetate); IR (neat): vmax 2957 (w), 2915 (w), 1710 (s) (C=O), 
1598 (w) cm–1; LRMS (ESI) m/z = 621 (MH+, 75%), 587 (15), 404 (10), 228 (50), 189 (100); HRMS 
(ESI) m/z = 621.3134. C38H45N2O4Si Required 621.3149; Δ = -2.4 ppm. 
Exo-225: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 6.89-6.93 (2H, m, 
Ar-H), 6.68 (1H, m, C=CH), 5.62 (1H, dd, J = 4.4 and 1.2 Hz, NCH2). 
Endo-225: 1H NMR: δH (400 MHz, CDCl3); 7.34-7.45 (5H, m, Ar-H), 7.14-7.26 (5H, m, Ar-H), 7.07 
(1H, dd, J = 6.2 and 4.0 Hz, Ar-H), 6.89-6.93 (2H, m, Ar-H), 6.63 (1H, m, C=CH), 5.44 (1H, dd, J = 
4.4 and 1.2 Hz, NCH2), 5.16-5.26 (2H, m, Ar-CH2), 3.68 (1H, dd, J = 8.7 and 4.4 Hz, NCH2), 3.45-
3.53 (2H, m, NCHCH), 3.24 (1H, td, J = 8.5 and 2.7 Hz, NCH2CH), 2.99-3.09 (1H, m, NCH2CHCH), 
2.41-2.58 (2H, m, CH(CH3)2), 2.21 (1H, br s, SiCH2), 2.08 (1H, d, J = 2.7 Hz, SiCH2), 1.23 (3H, m, 
CH3), 1.14 (6H, d, J = 6.8 Hz, CH3), 1.08 (3H, d, J = 6.8 Hz, CH3), 0.03-0.16 (6H, m, Si(CH3)2). 13C 
NMR: δC (400 MHz, CDCl3); 154.48 (s) (C=O), 146.76 (s), 146.36 (s), 145.31 (s), 141.55 (s), 141.26 
(d), 139.02 (d), 130.37 (d), 128.67 (d), 128.48 (d), 128.24 (d), 127.34 (d), 124.18 (d), 67.37 (d), 46.27 
(t), 45.98 (t), 45.67 (d), 41.35 (d), 41.28 (d), 33.82 (d), 33.62 (d), 29.39 (d), 28.56 (d), 24.37 (q), 23.83 
(q), -5.64 (q). 
 
(±)-Benzyl 11-dimethylbenzylsilyl-3,5-dioxo-4-[2-(2methylpropoxy)-6-(2-methylpropyl)phenyl]-
4,8-diazatricyclo [5.2.2.02,6]undec-10-ene-8-carboxylate (226). 
 
Using the general procedure Q, DHP 200 (100 mg, 0.32 mmol) and N-aryl maleimide 214 (500 mg, 
1.6 mmol) after 1 h at 180 ºC (microwave irradiation) purifying by FC (5:1 petroleum ether:ethyl 
acetate) gave a colourless oil (145 mg, 68 %) comprising an inseparable mixture of two Diels-Alder 
adducts (exo-226:endo-226, 1:2.8 ratio determined by 1H NMR integration). 
Rf = 0.37 (5:1 petroleum ether:ethyl acetate); IR (neat): vmax 1710 (s) (C=O) cm–1; LRMS (ESI) m/z = 
665 (MH+, 100%), 621 (5), 426 (15), 326 (10); HRMS (ESI) m/z = 665.3414. C40H49N2O5Si Required 
665.3411; Δ = 0.5 ppm. 
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Exo-225: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 6.70 (1H, m, 
C=CH), 5.59 (1H, dd, J = 4.4 and 1.2 Hz, NCH2), 3.59 (1H, dd, J = 8.7 and 4.4 Hz, NCH2). 
Endo-225: 1H NMR: δH (400 MHz, CDCl3); 7.33-7.44 (5H, m, Ar-H), 7.05-7.21 (4H, m, Ar-H), 6.89 
(3H, m, Ar-H), 6.76-6.79 (1H, m, Ar-H), 6.65 (1H, m, C=CH), 5.41 (1H, dd, J = 4.4 and 1.2 Hz, NCH2), 
5.15-5.25 (2H, m, Ar-CH2), 3.69 (2H, d, J = 6.1 Hz, Ar-OCH2), 3.54 (1H, dd, J = 8.7 and 4.4 Hz, 
NCH2), 3.44-3.52 (2H, m, NCHCH), 3.14 (1H, ddd, J = 11.9, 9.0 and 2.8 Hz, NCH2CH), 3.06 (1H, dd, 
J = 10.4 and 2.4 Hz, NCH2CHCH), 2.18-2.28 (4H, m, Ar-CH2 and SiCH2), 1.92-2.03 (2H, m), 0.95 
(9H, m), 0.89 (3H, d, J = 6.6 Hz, CHCH3), 0.07 (6H, dd, J = 39.1 and 20.6 Hz, Si(CH3)2). 
 
 (Z)-1-iodo-2-methyl-1-butene (227).201 
According to the method of Aggarwal,201 Cp2ZrCl2 (4.7 g, 16 mmol) was dissolved in 
CH2Cl2 (40 mL) and cooled to 0 ºC. Et3Al (1 M in hexanes; 32 mL, 32 mmol) was slowly added before 
condensing propyne (excess) into the yellow solution and stirring for 30 min before allowing to warm 
to room temperature and stir for a further 48 h.  The suspension was then cooled to 0 ºC before 
dropwise addition of a solution of iodine (6.09 g, 24 mmol) in THF (37 mL) and stirring at room 
temperature for a further 48 h.  The reaction was then cautiously quenched with H2O (16 mL) and the 
resulting solid filtered and washed with diethyl ether (20 mL).  The organic was then separated and 
the aqueous extracted with diethyl ether (2 x 30 mL) and the combined ethereal extracts dried over 
MgSO4 and the solvents distilled at reduced pressure (280 mbar, 24 ºC).  The remaining oil was then 
distilled under reduced pressure (50 mbar, 42-44 ºC) giving 227 (4.3 g, 53%) as a colourless liquid. 
1H NMR: δH (400 MHz, CDCl3); 5.80 (1H, q, J = 1.4 Hz), 2.24 (2H, q, J = 7.6 Hz), 1.90 (3H, d, J = 1.4 
Hz), 1.03 (3H, t, J = 7.6 Hz); LRMS (ESI) m/z = 196 (MH+, 70%), 96 [(M-I)+, 100]. 
 
(±)-Benzyl 3,5-dioxo-4-[2-(2methylpropoxy)-6-(2-methylpropyl)phenyl]-4,8-diazatricyclo 
[5.2.2.02,6]undec-10-ene-8-carboxylate (229). 
 
According to the method of Denmark,203 TBAF (1 M in THF; 223 µL, 0.22 mmol) was added to a 
solution of 226 (40 mg, 0.075 mmol) and the solution stirred for 10 mins.  Vinyl iodide 227 (12 mg, 
0.068 mmol) followed by Pd(dba)2 (4 mg, 0.007 mmol) were added and the deep red suspension 
stirred for a further 1 h.  The reaction was quenched with H2O (100 µL), diluted with ethyl acetate (3 
mL) and filtered through a plug of silica gel (eluting with ethyl acetate) and the solution concentrated 
under reduced pressure to give an orange oil.  Purification was achieved by FC (2:1 petroleum 
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ether:ethyl acetate) gave a colourless oil (25 mg, 98 %) comprising an inseparable mixture of two 
Diels-Alder adducts (exo-229:endo-229 ratio unable to be determined by 1H NMR integration). 
Rf = 0.45 (2:1 petroleum ether:ethyl acetate); IR (neat): vmax 2956 (w), 2927 (w), 2870 (w), 1711 (s) 
(C=O), 1465 (m), 1376 (m), 1301 (w), 1190 (m), 1109 (m), 736 (w) cm–1; 1H NMR: δH (400 MHz, 
CDCl3); 7.40-7.43 (6H, m, Ar-H), 7.27-7.32 (2H, m, Ar-H), 6.78-6.86 (2H, m, Ar-H), 6.45-6.62 (2H, m, 
C=CH), 5.35-5.49 (1H, m, NCH), 5.16-5.26 (2H, m, Ar-CH2), 3.70 (2H, dd, J = 6.6 and 2.1 Hz, OCH2), 
3.46-3.57 (3H, m, NCH2), 3.15-3.20 (2H, m), 2.20-2.22 (2H, m, Ar-CH2), 2.00 (1H, m, OCH2CH), 1.68 
(1H, m, Ar-CH2CH), 0.97 (6H, dd, J = 13.7 and 6.7 Hz, OCH2CH(CH3)2), 0.86 (6H, t, J = 6.0 Hz, Ar-
CH2CH(CH3)2). 13C NMR: δC (100 MHz, CDCl3); 153.62 (s), 141.35 (s), 130.07 (d), 128.58 (d), 128.33 
(d), 128.30 (d), 128.07 (d), 122.33 (d), 122.15 (d), 109.84 (d), 74.96 (t), 74.35 (d), 41.45 (t), 40.47 (d), 
29.02 (t), 28.67 (d), 28.26 (d), 27.92 (d), 22.75 (d), 22.52 (d), 19.41 (q), 19.19 (q); LRMS (EI) m/z = 
516 (M+, 45 %), 215 (60), 170 (55), 91 (100); HRMS (EI) m/z = 516.2625. C31H36N2O5 Required 
516.2625; Δ = 0.2 ppm. 
 
3-(Tributylstannyl)pyridine (230).245  
n-BuLi (1.88 M in hexanes; 3.7 mL, 6.96 mmol) was added dropwise to a stirring 
solution of 3-bromopyridine (620 µL, 6.33 mmol) in diethyl ether (16 mL) at -78 ºC 
and stirred for 1 h.  Tributyltin chloride (1.9 mL, 6.96 mmol) was then added dropwise and the 
reaction allowed to warm to room temperature and stirred for 1 h.  The reaction was then quenched 
with phosphate buffer (pH 7, 1M) and the organic layer separated.  The aqueous was extracted with 
CH2Cl2 (3 x 20 mL), the extracts combined, dried over MgSO4 and concentrated under reduced 
pressure to give an orange oil.  Purification was achieved by FC (7:1 petroleum ether:ethyl acetate) 
to give 201 (2.1 mg, 97 %) as a pale yellow liquid. 
1H NMR: δH (400 MHz, CDCl3); 8.62 (1H, t, J = 1.3 Hz), 8.53 (1H, dd, J = 4.9 and 1.9 Hz), 7.76 (1H, 
dt, J = 7.3 and 1.7 Hz), 7.25 (1H, ddd, J = 7.3, 4.9 and 1.1 Hz), 1.52-1.58 (6H, m), 1.35 (6H, dd, J = 
14.9 and 7.3 Hz), 1.10-1.14 (6H, m), 0.91 (9H, t, J = 7.3 Hz); LRMS (ESI) m/z 370 (MH+, 100). 
 
(±)-Benzyl 11-tributylstannyl-3,5-dioxo-4-[2,6-Bis(propan-2-yl)phenyl]-4,8-diazatricyclo 
[5.2.2.02,6]undec-10-ene-8-carboxylate (232). 
 
Using the general procedure Q, DHP 231 (100 mg, 0.19 mmol) and N-aryl maleimide 213 (250 mg, 
0.8 mmol) after 1 h at 180 ºC (microwave irradiation) purifying by FC (5:1 petroleum ether:ethyl 
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acetate) gave a colourless oil (78 mg, 58 %) comprising an inseparable mixture of two Diels-Alder 
adducts (exo-232:endo-232, 1:1 ratio determined by 1H NMR integration). 
Rf = 0.32 (5:1 petroleum ether:ethyl acetate); IR (neat): vmax 2957 (w), 2915 (w), 1709 (s) (C=O), 
1608 (w), 1543, (m), 1412 (m), 1122 (m), 826 (m), 676 (s) cm–1; LRMS (ESI) m/z = 621 (MH+, 75%), 
587 (15), 404 (10), 228 (50), 189 (100); HRMS (ESI) m/z = 621.3134. C38H45N2O4Si Required 
621.3149; Δ = -2.4 ppm. 
Exo-225: Diastinguishable/diagnostic peaks only - 1H NMR: δH (400 MHz, CDCl3); 5.50 (1H, d, J = 
4.4 Hz, NCH). 
Endo-225: 1H NMR: δH (400 MHz, CDCl3); 7.34-7.47 (5H, m, Ar-H), 7.25-7.32 (2H, m, Ar-H), 6.76-
6.89 (3H, m, Ar-H), 6.55-6.66 (1H, m, C=CH), 5.34-5.50 (1H, m, NCH), 5.13-5.26 (2H, m, Ar-CH2), 
3.67-3.72 (2H, m, OCH2), 3.43-3.48 (3H, m), 3.10 (2H, m), 2.18-2.26 (2H, m, Ar-CH2), 1.86-2.05 (2H, 
m, 2 x CH(CH3)2), 1.25-1.49 (18H, mL), 0.86-0.97 (21H, m, 7 x CH3). 13C NMR: δC (400 MHz, CDCl3); 
177.88 (s) (Ar-C), 175.33 (s) (Ar-C), 153.55 (s), 141.32 (d), 128.59 (d), 128.53 (d), 128.33 (d), 127.82 
(d), 122.41 (s), 119.86 (s), 109.85 (s), 74.25 (d) (NCH), 67.32 (t) (OCH2), 50.57 (t) (NCH2), 47.71 (t) 
(Ar-CH2, 46.06 (d), 45.06 (d), 40.65 (t) (Ar-CH2), 29.18 (t), 27.62 (t), 22.26 (t), 13.67 (t), 9.26 (q). 
 
(±)-Benzyl 11-[(1Z)-2-methylbut-1-en-1-yl]-4-[2-(2-
methylpropoxy)-6-(2-methylpropyl)phenyl]-3,5-dioxo-4,8-
diazatricyclo[5.2.2.02,6]undec-10-ene-8-carboxylate (228).  
According to the method of Corey,204 LiCl (6 mg, 0.14 mmol) was 
flame dried under high vacuum before addition of Pd(PPh3)4 (2 mg, 
0.001 mmol) and CuCl (11 mg, 0.11 mmol).  The reaction was 
degassed under high vacuum and the flask purged with argon before addition of degassed DMSO 
(120 µL) and THF (120 µL). Vinyl iodide 227 (5 mg, 0.022 mmol) and vinyl stannane 232 (9 mg, 
0.011 mmol) were then added and the reaction stirred at 60 ºC for 48 h. The reaction was then 
cooled to room temperature, diluted with diethyl ether (3 mL) and quenched with 3% aqueous 
NH4OH (500 µL) and the mixture stirred for 30 min.  The organic was then separated and the 
aqueous extracted with ethyl acetate (3 x 5 mL).  The combined extracts were dried over Na2SO4 and 
concentrated under reduced pressure to give a yellow oil.  Purification was achieved by FC (5:1 
petroleum ether:ethyl acetate) to give 228 (3 mg, 34%) as a colourless oil.  
Rf = 0.37 (5:1 petroleum ether:ethyl acetate); IR (neat): vmax 2957 (w), 2932 (w), 2873 (w), 1713 (s) 
(C=O), 1469 (m), 1362 (m), 1284 (w), 1165 (m), 953 (m), 770 (w) cm–1; 1H NMR: δH (400 MHz, 
CDCl3); 7.37-7.40 (5H, m, Ar-H), 7.27 (1H, m, Ar-H), 6.76-6.88 (2H, m, Ar-H), 6.08-6.14 (1H, m, 
CHCH=C), 5.64 (1H, t, J = 18.8 Hz, CH=CCH=C), 5.42 (1H, m, NCH), 5.14-5.19 (2H, m, Ar-CH2), 
3.69 (2H, d, J = 6.2 Hz, OCH2), 3.48-3.53 (3H, m), 3.14-3.22 (2H, m), 2.15-2.22 (2, m, Ar-CH2CH), 
1.95-2.05 (2H, m, CH(CH3)2), 1.78 (2H, dd, J = 10.5 and 5.6 Hz, CH2CH3), 1.29 (3H, d, J = 2.1 Hz, 
CH=C(CH3)), 0.92-0.97 (9H, m, CH3), 0.83 (6H, dd, J = 11.3 and 6.6 Hz, CH3). 13C NMR: δC (100 
MHz, CDCl3); 178.34 (s) (C=O), 153.73 (s) (C=C), 132.89 (s) (Ar-C), 132.52 (2 x d) (C=CH), 129.74 
(2 x d) (Ar-C), 122.33 (d), 109.78 (d), 77.25 (t), 61.92 (d), 45.00 (d), 44.95 (d), 41.18 (t), 40.51 (t), 
31.91 (d), 31.51 (d), 28.67 (d), 27.94 (d), 23.85 (t), 22.78 (q), 22.52 (q), 19.45 (2 x q), 19.19 (2 x q); 
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LRMS (ESI) m/z = 585 (MH+, 75 %); HRMS (ESI) m/z = 585.3255. C36H44N2O5 Required 585.3250; Δ 
= 3.4 ppm. 
 
(±)-4-[2-(2-methylpropoxy)-6-(2-methylpropyl)phenyl]-8-(2-
methylpropyl)-4,8-diazatricyclo[5.2.2.02,6]undecane-3,5-dione 
(230).  
Using the general procedure V, Palladium on charcoal (16 mg), 
benzyl carbamate 229 (16 mg, 0.027 mmol) and isobutyraldehyde 
(8 µL, 0.082 mmol) after 16h gave 230 (11 mg, 98%) as a 
colourless oil. 
Rf = 0.78 (2:1 petroleum ether:ethyl acetate); IR (neat): υmax 2954 (m), 2870 (w), 1712 (s) (C=O), 
1464 (m), 1369 (m), 1183 (m), 1052 (w), 772 (w) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.31 (1H, t, J 
= 8.0 H, Ar-H), 6.89 (1H, dd, J = 7.8 and 1.1 Hz, Ar-H), 6.82 (1H, dd, J = 8.3 and 1.1 Hz, Ar-H), 3.72 
(2H, d, J = 6.2 Hz, OCH2), 3.42 (1H, ddd, J = 10.1, 4.1 and 1.8 Hz, NCHCH), 3.17 (1H, br m, NCH), 
3.12 (1H, ddd, J = 10.0, 3.9 and 1.2 Hz, NCHCHCH), 2.95 (1H, dd, J = 10.2 and 2.6 Hz, NCH2), 2.79 
(1H, d, J = 10.0 Hz, NCH2), 2.32-2.42 (5H, m, Ar-CH2 and NCH2CH(CH3)2 and NCH2CH), 2.03 (2H, 
m, NCHCH2 and OCH2CH), 1.84 (1H, dd, J = 13.6 and 6.9 Hz, NCH2CH(CH3)2), 1.70-1.80 (4H, m, 
Ar-CH2CH(CH3)2 and NCHCH2CH2), 0.97 (6H, d, J = 6.7 Hz, CH3), 0.94 (6H, dd, J = 6.6 and 4.0 Hz, 
CH3), 0.90 (6H, dd, J = 6.6 and 1.2 Hz, CH3); 13C NMR: δc (100 MHz, CDCl3); 153.72 (s), 141.39 (s), 
129.85 (d), 122.29 (d), 109.87 (d), 74.37 (d), 65.23 (t), 55.89 (t), 51.39 (t), 43.68 (d), 43.52 (d), 40.92 
(t), 29.04 (d), 28.29 (d), 28.11 (d), 26.75 (d), 22.56 (t), 21.65 (t), 20.87 (2 x q), 20.65 (2 x q), 19.20 (2 
x q); LRMS (EI) m/z 440 (M+, 10), 411 (30), 397 (100), 355 (15); HRMS (EI) m/z 440.3042 (M+). 
C27H40N2O3 Required 440.3039; Δ = -1.9 ppm. 
 
General procedure AB (maleimide reduction). 
According to the method of Pande,246 a suspension of the required maleimide (0.58 mmol), Pd-C (14 
mg) and acetic acid (0.87 mL) was heated to 110 ºC before addition of ammonium formate (1.4 
mmol).  After 15 min the reaction was cooled to room temperature, diluted with CH2Cl2 (20 mL) and 
filtered through Celite®.  The eluent was washed with H2O (2 x 10 mL), 1 M NaOH (2 x 10 mL), H2O 
(10 mL), dried over Na2SO4 and concentrated under reduced pressure to give the pure succinyl 
product. 
 
N-Phenyl succinimide (231).247  
Using the general procedure AB, N-phenyl maleimide 210 (100 mg, 0.58 mmol), Pd-
C (14 mg), acetic acid (0.87 mL) and ammonium formate (87 mg, 1.4 mmol) after 30 
min gave 231 (93 mg, 83%) as a white solid. 
1H NMR: δH (400 MHz, CDCl3); 7.49-7.53 (2H, m), 7.41-7.45 (1H, m), 7.30-7.33 (2H, 
m), 2.93-2.93 (4H, s); LRMS (ESI) m/z 176 (MH+, 100), 98 (50), 77 (10). 
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N-[2-(2-Methylpropoxy)-6-(2-methylpropyl)phenyl] succinimide 
(232).  
Using the general procedure AB, N-aryl maleimide 224 (170 mg, 0.58 
mmol), Pd-C (14 mg), acetic acid (0.87 mL) and ammonium formate (87 
mg, 1.4 mmol) after 30 min gave 232 (165 mg, 92%) as a white solid, 
m.p. 110-112 ºC. 
IR (neat): υmax 2954 (w), 2915 (w), 2870 (w), 1690 (s) (C=O), 1464 (m), 1369 (m), 1183 (m), 1052 
(w), 772 (w) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.31 (1H, t, J = 8.0 Hz, Ar-H), 6.89 (1H, dd, J = 8 
and 1.1 Hz, Ar-H), 6.83 (1H, dd, J = 8.0 and 1.1 Hz, Ar-H), 3.72 (2H, d, J = 6.3 Hz, OCH2), 2.92 (4H, 
d, J = 1.5 Hz, CH2CH2), 2.31 (2H, d, J = 7.3 Hz, Ar-CH2), 2.01 (1H, dquintet, J = 13.2 and 6.3 Hz, 
OCH2CH), 1.79 (1H, dquintet, J = 13.5 and 6.8 Hz, Ar-CH2CH), 0.96 (6H, d, J = 6.8 Hz), 0.89 (6H, d, 
J = 6.3 Hz); 13C NMR: δc (100 MHz, CDCl3); 180.1 (s) (C=O), 153.7 (s) (Ar-COCH3), 141.0 (s), 129.3 
(s), 121.8 (d), 115.3 (d), 110.0 (d), 74.4 (t), 55.7 (t), 35.4 (2 x t), 29.1 (d), 28.3 (d), 20.9 (2 x q), 20.7 
(2 x q); LRMS (ESI) m/z 304 (MH+, 30), 205 (100), 98 (50); HRMS (ESI) m/z 304.1835 (MH+). 
C18H25NO3 Required 304.1834; Δ = 0.2 ppm. 
 
General procedure AC (imide reduction). 
NaBH4 (1.1 mmol) was added to a solution of the required imide (0.11 mmol) in ethanol (0.1 M; 1.1 
mL) and the reaction stirred at the required temperature until complete.  The reaction was then 
quenched with H2O (1 mL), extracted with chloroform (3 x 10 mL) and the combined organic dried 
over MgSO4 and concentrated under reduced pressure. 
 
4-Hydroxy-N-phenylbutyramide (233).248  
Using the general procedure AC, NaBH4 (43 mg, 1.1 mmol), imide 231 (20 mg, 0.11 
mmol) after 10 min at 0 ºC gave 233 (21 mg, 98%) as a colourless oil. 
1H NMR: δH (400 MHz, CDCl3); 7.52-7.54 (2H, m), 7.35 (2H, t, J = 7.9 Hz), 7.12-
7.16 (1H, m), 3.79-3.83 (2H, m), 2.58 (2H, t, J = 6.8 Hz), 2.27 (1H, br s), 1.99-2.05 
(2H, m); LRMS (ESI) m/z 180 (MH+, 100). 
 
4-Hydroxy-N-[2-(2-Methylpropoxy)-6-(2-methylpropyl)phenyl] 
butyramide (234).  
Using the general procedure AC, NaBH4 (20 mg, 0.52 mmol), imide 232 
(16 mg, 0.052 mmol) after 3 h at room temperature gave 234 (14 mg, 
95%) as a colourless oil. 
IR (neat): υmax 3430 (w), 3155 (w), 2927 (w), 2852 (w), 1667 (s) (C=O), 1599 (m) cm–1; 1H NMR: δH 
(400 MHz, CDCl3); 7.18 (1H, t, J = 8.0 Hz, Ar-H), 6.86 (1H, br s, NH), 6.83 (1H, d, J = 7.9 Hz, Ar-H), 
6.77 (1H, d, J = 8.2 Hz, Ar-H), 3.81 (2H, t, J = 5.8 Hz, C(=O)CH2), 3.75 (2H, d, J = 6.5 Hz, OCH2), 
2.61 (2H, t, J = 6.8 Hz, C(=O)CH2CH2), 2.49 (2H, d, J = 7.2 Hz, Ar-CH2), 2.06 (2H, m, CH2CH2CH2), 
1.86 (2H, m, CH), 1.66 (1H, br s, OH), 1.04 (6H, d, J = 6.7 Hz, CH(CH3)2), 0.91 (6H, d, J = 6.6 Hz, 
CH(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 172.57 (s), 140.51 (s), 127.67 (s), 122.28 (d), 109.99 (d), 
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109.55 (d), 74.69 (t), 62.49 (t), 41.21 (t), 34.15 (d), 29.26 (t), 28.39 (t), 28.27 (d), 22.69 (2 x q), 19.33 
(2 x q); LRMS (EI) m/z 307 (M+, 50), 248 (25), 221 (80), 165 (100), 122 (85); HRMS (EI) m/z 
307.2151 (M+). C18H29NO3 Required 307.2147; Δ = 4.2 ppm. 
 
(±)-4-Phenyl-4-azatricyclo[5.2.2.02,6]undec-8-ene-3,5-dione (235).249 
1,3 Cyclohexadiene (0.82 mL, 5.66 mmol) and N-phenyl maleimide 210 (300 
mg, 1.73 mmol) were dissolved in toluene (1.73 mL) and heated at 80 ºC for 
1h.  The suspension was concentrated under reduced pressure to give 235 
(430 mg, 98%) as a white solid. 
1H NMR: δH (400 MHz, CDCl3); 7.44-7.49 (2H, m), 7.37-7.41 (1H, m), 7.20 (2H, dd, J = 8.4 and 1.3 
Hz), 6.32 (2H, dd, J = 4.6 and 3.1 Hz), 3.28 (2H, ddd, J = 4.4, 3.0 and 1.4 Hz), 3.04 (2H, t, J = 1.6 
Hz), 1.68-1.70 (2H, m), 1.45-1.49 (2H, m); LRMS (ESI) m/z 254 (MH+, 100). 
 
(±)-4-[2-(2-Methylpropoxy)-6-(2-methylpropyl)phenyl]-4-azatricyclo 
[5.2.2.02,6]undec-8-ene-3,5-dione (236).  
1,3 Cyclohexadiene (0.32 mL, 3.32 mmol) and N-aryl maleimide 224 (200 
mg, 0.66 mmol) were dissolved in toluene (0.66 mL) and heated at 80 ºC for 
16 h.  The suspension was concentrated under reduced pressure to give 236 
(250 mg, 98%) as a pale yellow solid, m.p. 183-186 ºC. 
IR (neat): υmax max 1667 (s) (C=O) cm–1; 1H NMR: δH (400 MHz, CDCl3); 
7.25-7.28 (1H, m, Ar-H), 6.77 (2H, d, J = 7.7 Hz Ar-H), 6.36 (2H, dd, J = 4.3 and 3.4 Hz, CH=CH), 
3.69 (2H, d, J = 6.2 Hz, OCH2), 3.29 (2H, br s, C(=O)CH), 3.04 (2H, br s, C(=O)CHCH), 2.24 (2H, d, 
J = 7.6 Hz, Ar-CH2), 1.95-2.06 (2H, m, CH(CH3)2), 1.71 (2H, m, CH2CH2), 1.46 (2H, m, CH2CH2), 0.95 
(6H, d, J = 6.7 Hz, CH(CH3)2), 0.86 (3H, d, J = 6.6 Hz, CH(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 
176.49 (s) (C=O), 154.06 (s), 141.22 (s), 130.08 (d), 122.22 (d) (CH=CH), 120.14 (s), 110.04 (d), 
74.50 (t), 40.87 (t), 28.98 (d), 28.72 (1 x d), 28.24 (2 x d), 22.72 (2 x t), 19.14 (q); LRMS (EI) m/z 381 
(M+, 100%), 325 (90), 283 (50), 202 (30), 146 (50); HRMS (EI) m/z 381.2305 (M+). C24H31NO3 
Required 381.2304; Δ = 0.3 ppm. 
 
(±)-4-Phenyl-4-azatricyclo[5.2.2.02,6]undecane-3,5-dione (237).   
Pd-C (40 mg) was added to a solution of 235 (400 mg, 1.58 mmol) in methanol 
(15 mL) before submitting to a hydrogen atmosphere (1 atm.) and stirring for 
16 h.  The suspension was filtered through Celite® before concentrating under 
reduced pressure to give 237 (403 mg, 98%) as a colourless oil. 
Rf = 0.26 (5:1 petroleum ether:ethyl acetate); IR (neat): υmax 2937 (w), 2846 (w), 1715 (s) (C=O), 
1599 (m), 1375 (m), 1109 (w), 983 (m), 776 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.50-7.54 (2H, 
m, Ar-H), 7.43 (1H, m, Ar-H), 7.31-7.33 (2H, m, Ar-H), 3.02 (2H, d, J = 0.7 Hz, C(=O)CH), 2.31 (2H, 
d, J = 1.3 Hz, C(=O)CHCH), 1.57-1.80 (8H, m, CH2); 13C NMR: δc (100 MHz, CDCl3); 179.18 (s) 
(C=O), 132.11 (s), 129.22 (2 x d), 128.63 (2 x d), 126.46 (d), 43.88 (d), 26.43 (d), 24.93 (q), 21.57 
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(q); LRMS (EI) m/z 255 (M+, 100%), 175 (80), 119 (20), 80 (65); HRMS (EI) m/z 255.1257 (M+). 
C16H17NO2 Required 225.1259; Δ = -0.8 ppm. 
 
(±)-4-[2-(2-Methylpropoxy)-6-(2-methylpropyl)phenyl]-4-
azatricyclo[5.2.2.02,6]undecane-3,5-dione (238).   
Pd-C (25 mg) was added to a solution of 236 (250 mg, 0.66 mmol) in 
methanol (6.6 mL) before submitting to a hydrogen atmosphere (1 atm.) and 
stirring for 16 h.  The suspension was filtered through Celite® before 
concentrating under reduced pressure to give 238 (242 mg, 99%) as a 
colourless oil. 
Rf = 0.69 (5:1 petroleum ether:ethyl acetate); IR (neat): υmax 2938 (w), 2905 (w), 2848 (w), 1714 (s) 
(C=O), 1488 (m), 1335 (m), 1087 (w), 913 (m), 675 (m) cm–1; 1H NMR: δH (400 MHz, CDCl3); 7.30 
(1H, m, Ar-H), 6.89 (1H, d, J = 7.8 Hz, Ar-H), 6.81 (1H, d, J = 8.3 Hz, Ar-H), 3.71 (2H, d, J = 6.2 Hz, 
OCH2), 3.01 (2H, br s, C(=O)CH), 2.30-3.41 (4H, m, Ar-CH2 and C(=O)CHCH), 2.01 (1H, m, 
OCH2CH), 1.68-1.89 (9H, m), 0.96 (6H, d, J = 6.7 Hz), 0.90 (6H, d, J = 6.5 Hz); 13C NMR: δc (100 
MHz, CDCl3); 179.73 (s), 153.74 (s), 141.35 (s), 129.87 (s), 129.77 (d), 122.29 (d), 109.85 (d), 74.33 
(d), 44.49 (t), 40.99 (d), 29.04 (d), 28.31 (d), 26.23 (t), 25.09 (t), 22.58 (t), 21.73 (q), 19.19 (q); LRMS 
(EI) m/z 383 (M+, 100%), 205 (80), 178 (20), 80 (65); HRMS (EI) m/z 383.2721 (M+). C24H33NO3 
Required 383.2460; Δ = -0.5 ppm. 
 
(±)-5-Hydroxy-4-phenylazatricyclo[5.2.2.02,6]undecan-3-one (241). 
Using the general procedure AC, NaBH4 (30 mg, 0.78 mmol), imide 237 (20 
mg, 0.078 mmol) after 5 min at 0 ºC gave 241 (100% conversion by 1H NMR 
integration) as a colourless oil. 
Rf = 0.5 (2:1 petroleum ether:ethyl acetate); IR (neat): υmax 3430 (br w) (OH), 
2927 (w), 2852 (w), 1680 (s) (C=O), 1431 (m), 1381 (m), 1154 (m), 967 (s), 663 9m) cm–1; 1H NMR: 
δH (400 MHz, CDCl3); 7.57-7.60 (2H, m, Ar-H), 7.39-7.43 (2H, m, Ar-H), 7.26-7.30 (1H, m, Ar-H), 5.33 
(1H, d, J = 7.9 Hz, CHOH), 4.02 (1H, d, J = 8.4 Hz, OH), 2.78 (1H, ddd, J = 10.4, 4.2 and 1.4 Hz, 
C(=O)CH), 2.28 (1H, dd, J = 10.5 and 3.0 Hz, CH(OH)CH), 2.07-2.09 (1H, m, C(=O)CHCH), 1.84 
(1H, m, CH(OH)CHCH), 1.41-1.68 (8H, m, CH2); 13C NMR: δc (100 MHz, CDCl3); 176.73 (s) (C=O), 
137.41 (s) (Ar-C), 129.16 (2 x d), 126.44 (d), 123.82 (2 x d), 89.03 (d) (CHOH), 43.84 (d) (C=OCH), 
43.65 (CH(OH)CH), 26.69 (d), 26.10 (d), 25.10 (t), 24.95 (t), 21.24 (t), 20.92 (t); LRMS (EI) m/z 257 
(M+,100%), 176 (30), 121 (20), 93 (25); HRMS (EI) m/z 257.1418 (M+). C16H19NO2 Required 
257.1416; Δ = 0.8 ppm. 
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Synthesis of (±)-3-(hydroxymethyl)-N-[2-(2-methylpropoxy)-6-(2-methylpropyl)phenyl] 
bicyclo[2.2.2] octane-2-carboxamide (242) and (±)-5-hydroxy-4-[2-(2-methylpropoxy)-6-(2-
methylpropyl)phenyl]-4-azatricyclo[5.2.2.02,6]undecan-3-one (240) (table 22, Entry 11). 
 
Using the general procedure AC, NaBH4 (70 mg, 1.8 mmol), imide 238 (70 mg, 0.18 mmol) in ethanol 
(3 M; 180 µL) after 48 h 80 ºC gave a separable mixture of 240 (42 mg, 72%) and 242 (6 mg, 6%). 
Hemiaminal-240: Rf = 0.25 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.27 
(1H, t, J = 8.1 Hz, Ar-H), 6.95-6.97 (1H, m, Ar-H), 6.81 (1H, dd, J = 8.3 and 1.0 Hz, Ar-H), 5.51 (1H, 
br s, CHOH), 3.76 (2H, d, J = 7.1 Hz, OCH2), 2.90 (1H, m, C(=O)CH), 2.63 (1H, dd, J = 14.8 and 6.2 
Hz, CH(OH)CH), 2.37-2.48 (3H, m), 2.07-2.20 (3H, m), 1.90-1.95 (2H, m), 1.65-1.76 (8H, m, CH2), 
1.05 (6H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.3 Hz), 0.91 (3H, d, J = 6.6 Hz); 13C NMR: δc (100 MHz, 
CDCl3); 128.5 (s), 127.0 (s), 122.9 (s), 121.0 (d), 110.2 (d), 109.3 (d), 89.1 (d), 75.3 (t), 44.1 (d), 43.1 
(d), 27.2, 26.3, 25.9, 24.4, 22.1, 21.1, 20.6, 19.3; LRMS (ESI) m/z 388 (MH+,100%); HRMS (EI) m/z 
388.2775 (MH+). C24H37NO3 Required 388.2223; Δ = 0.5 ppm. 
Acyclic alcohol-242: Rf = 0.13 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 
7.30 (1H, br s, NH), 7.16 (1H, t, J = 8.0 Hz, Ar-H), 6.81 (1H, dd, J = 7.7 and 1.1 Hz, Ar-H), 6.76 (1H, 
dd, J = 8.2 and 1.1 Hz, Ar-H), 3.69-3.74 (3H, m, OCH2 and CH2OH), 3.65 (1H, td, J = 7.5 and 3.6 Hz, 
CH2OH), 2.47 (2H, d, J = 7.3 Hz, Ar-CH2), 2.38-2.41 (2H, m, OH and C(=O)CH), 2.05-2.12 (2H, m), 
1.83-1.95 (2H, m), 1.54-1.69 (9H, m), 1.03 (6H, d, J = 6.3 Hz, OCH2CH(CH3)2), 0.89 (6H, d, J = 6.6 
Hz, Ar-CH2CH(CH3)2); 13C NMR: δc (100 MHz, CDCl3); 174.70 (s) (C=O), 154.06 (s), 140.47 (s), 
127.36 (2 x d), 124.15 (s), 122.33 (d), 109.44 (2 x d), 74.72 (t) (CH2OH), 67.02 (t) (OCH2), 49.05 (t), 
41.47 (d), 41.42 (d), 29.27 (t), 28.48 (t), 28.41 (d), 26.67 (d), 26.58 (t), 26.41 (t), 22.70 (t), 21.90 (t), 
21.00 (q), 19.36 (q); LRMS (ESI) m/z 386 (MH+,100%); HRMS (EI) m/z 386.2622 (MH+). C24H35NO3 
Required 382.2617; Δ = 1.3 ppm. 
 
N-(4-Nitrophenyl)maleimide (144).250  
Using general procedure Z, maleic anhydride (630 mg, 6.4 mmol) and aniline 243 
(885 mg, 6.4 mmol) after 3 h gave 224 (1.51 g, 98%) as a yellow solid. 
1H NMR: δH (400 MHz, CDCl3); 8.37 (2H, d, J = 9.2 Hz), 7.72 (2H, d, J = 9.3 Hz), 6.97 
(2H, s); LRMS (EI) m/z 218 (M+, 100), 122 (80), 96 (20). 
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(±)-4-[4-nitrophenyl]-4-azatricyclo[5.2.2.02,6]undec-8-ene-3,5-dione 
(245).  
1,3 Cyclohexadiene (1.1 mL, 11.5 mmol) and N-aryl maleimide 144 (500 
mg, 2.3 mmol) were dissolved in toluene (2.3 mL) and heated at 80 ºC 
for 2 h.  The suspension was concentrated under reduced pressure and 
purified by FC (1:1 petroleum ether:ethyl acetate) to give 245 (680 mg, 99%) as a pale yellow solid, 
m.p. 234-236 ºC. 
Rf = 0.35 (2:1 petroleum ether:ethyl acetate); IR (neat): υmax max 2927 (w), 2852 (w), 1667 (s) (C=O), 
1540 (s) (N=O) cm–1; 1H NMR: δH (400 MHz, CDCl3); 8.31 (2H, d, J = 9.2 Hz, Ar-H), 7.49 (2H, d, J = 
9.2 Hz, Ar-H), 6.31 (2H, dd, J = 4.6 and 3.1 Hz, CH=CH), 3.29 (2H, ddd, J = 4.3, 2.9 and 1.4 Hz, 
C(=O)CH), 3.07 (2H, t, J = 1.6 Hz, C(=O)CHCH), 1.68-1.72 (2H, m, CH2), 1.48 (2H, dd, J = 7.6 and 
1.5 Hz, CH2); LRMS (EI) m/z 298 (M+, 100%), 176 (95), 122 (50); HRMS (EI) m/z 298.0957 (M+). 
C16H14N2O4 Required 298.0954; Δ = 1.2 ppm. 
 
(±)-3-(Hydroxymethyl)-N-(4-nitrophenyl)bicyclo[2.2.2]oct-5-ene-2-
carboxamide (246).  
Using the general procedure AC, NaBH4 (15 mg, 0.4 mmol), imide 245 
(12 mg, 0.04 mmol) after 5 h at 60 ºC gave 246 (7 mg, 76%) as a yellow 
oil. 
Rf = 0.35 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.24 (2H, d, J = 9.4 Hz, 
Ar-H), 7.86 (2H, d, J = 9.3 Hz, Ar-H), 6.28 (1H, ddd, J = 8.1, 6.5 and 1.5 Hz, CH=CH), 6.21 (1H, ddd, 
J = 8.0, 6.6 and 1.2 Hz, CH=CH), 5.22 (1H, br s, NH), 3.17 (1H, m), 3.01 (2H, dd, J = 9.3 and 3.4 
Hz), 2.92 (1H, br s, OH), 2.44-2.47 (1H, m), 1.61 (2H, m), 1.36-1.39 (2H, m); 13C NMR: δc (100 MHz, 
CDCl3); 175.82 (s) (C=O), 134.21 (d) (C=C), 131.80 (2 x d), 124.56 (d) (C=C), 121.70 (2 x d), 88.53 
(t) (CH2OH), 47.65 (d), 45.76 (d), 32.77 (d), 32.41 (d), 24.02 (t), 23.35 (t); LRMS (ESI) m/z 303 (MH+, 
100%); HRMS (ESI) m/z 303.1280 (MH+). C16H18N2O4 Required 303.1274; Δ = 3.1 ppm. 
 
General procedure AD (alkylation of hemiaminal). 
According to the method of Simpkins,206 the required hemiaminal (0.08 mmol) and anhydrous CuSO4 
(32 mg, 0.2 mmol) were dissolved in CH2Cl2 (300 µL) before adding the required alcohol (0.066 
mmol) and PPTS (2 mg, 0.008 mmol) and stirring overnight.  The reaction was poured onto H2O (1 
mL), extracted with CH2Cl2 (3 x 5 mL) and the combined organic dried over MgSO4 and concentrated 
under reduced pressure to give a crude oil. 
 
(±)-5-(Phenyloxy)-4-phenyl-4-azatricyclo[5.2.2.02,6]undecan-3-one (248).  
Using general procedure AD, hemiaminal 241 (20 mg, 0.08 mmol), anhydrous 
CuSO4 (32 mg, 0.2 mmol), phenol (9 µL, 0.066 mmol) and PPTS (2 mg, 0.008 
mmol) after 16 h purifying by FC (2:1 petroleum ether:ethyl acetate) gave 248 
(18 mg, 67%) as a colourless oil. 
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Rf = 0.91 (2:1 petroleum ether:ethyl acetate); IR (neat): vmax 2975 (w), 2923 (w), 2173 (w), 1675 (w) 
(NCO), 1452 (m), 1253 (s), 1103 (m), 873 (m); 1H NMR: δH (400 MHz, CDCl3); 7.57-7.60 (2H, m, Ar-
H), 7.38-7.42 (2H, m, Ar-H), 7.25-7.34 (5H, m, Ar-H), 6.87 (1H, m, Ar-H), 5.79 (1H, br s, NCH), 2.94 
(1H, ddd, J = 10.2, 4.4 and 1.6 Hz, C(=O)CH), 2.54 (1H, dd, J = 10.3 and 2.4 Hz, NCHCH), 2.23 (1H, 
m, C(=O)CHCH), 2.03 (1H, m), 1.45-1.80 (11H, m); 13C NMR: δc (100 MHz, CDCl3); 155.80 (s), 
137.68 (s), 129.85 (d), 129.13 (d), 126.51 (d), 123.76 (d), 116.59 (d), 115.31 (d), 94.17 (d) (NCH), 
43.66 (d), 40.79 (d), 26.84 (d), 26.32 (d), 25.00 (t), 21.31 (t), 21.18 (t); LRMS (ESI) m/z 334 (MH+, 
100%), 258 (10), 240 (45); HRMS (ESI) m/z 334.1792 (MH+). C22H24NO2 Required 334.1807; Δ = -4.5 
ppm. 
 
(±)-5-(Benzyloxy)-4-phenyl-4-azatricyclo[5.2.2.02,6]undecan-3-one (249).  
Using general procedure AD, hemiaminal 241 (20 mg, 0.08 mmol), anhydrous 
CuSO4 (32 mg, 0.2 mmol), benzyl alcohol (8 mg, 0.066 mmol) and PPTS (2 
mg, 0.008 mmol) after 2 h purifying by FC (2:1 petroleum ether:ethyl acetate) 
gave 249 (29 mg, 87%) as a colourless oil. 
Rf = 0.85 (2:1 petroleum ether:ethyl acetate); IR (neat): vmax 2977 (w), 2913 
(w), 2183 (w), 1702 (w) (NCO), 1450 (m), 1249 (s), 1085 (m), 772 (m); 1H NMR: δH (400 MHz, 
CDCl3); 7.59-7.61 (2H, m, Ar-H), 7.41-7.45 (2H, m, Ar-H), 7.29-7.35 (4H, m, Ar-H), 7.23-7.26 (2H, m, 
Ar-H), 5.35 (1H, br s, CHO), 4.48 (2H, br s, OCH2), 2.91 (1H, ddd, J = 10.4, 4.3 and 1.5 Hz, 
C(=O)CH), 2.48 (1H, m, CH(O)CH), 2.19 (1H, m, C(=O)CHCH), 1.63-1.82 (6H, m), 1.45-1.58 (3H, 
m); 13C NMR: δc (100 MHz, CDCl3); 176.36 (s) (C=O), 137.90 (s) (Ar-C), 129.11 (2 x d), 128.51 (2 x 
d), 127.91 (s), 127.74 (2 x d), 126.38 (2 x d), 123.79 (s), 94.35 (d) (NCH), 67.85 (t) (OCH2Ar), 44.26 
(d), 40.56 (d), 27.36 (d), 26.19 (d), 25.26 (t), 25.09 (t), 21.27 (t), 20.97 (t); LRMS (ESI) m/z 348 (MH+, 
100%), 338 (30), 240 (25); HRMS (ESI) m/z 348.1953 (MH+). C23H26NO2 Required 348.1964; Δ = -3.2 
ppm. 
 
(±)-N-[2-(2-Methylpropoxy)-6-(2-methylpropyl)phenyl]-3-
(phenoxymethyl)bicyclo[2.2.2]octane-2-carboxamide (250). 
PPh3 (10 mg, 0.04 mmol) was added to a solution of alcohol 240 (15 mg, 
0.04 mmol) in toluene (130 µL) and stirred for 10 min before addition of 
phenol (4 mg, 0.04 mmol) followed by DIAD (9 µL, 0.042 mmol).  The 
reaction was heated at 60 ºC under sonication for 1 h before 
concentrating under reduced pressure.  Purification was achieved by FC 
(5:1 petroleum ether:ethyl acetate) to give 250 (13 mg, 74%) as a colourless oil. 
Rf = 0.55 (5:1 petroleum ether:ethyl acetate); IR (neat): vmax 2971 (w), 2923 (w), 2173 (w), 1675 (w) 
(NCO), 1380 (m), 1283 (s), 1086 (m), 675 (m); 1H NMR: δH (400 MHz, CDCl3); 7.29 (2H, t, J = 8.0 Hz, 
Ar-H), 7.16 (1H, t, J = 8.0 Hz, Ar-H), 6.93-6.97 (3H, m, Ar-H), 6.83 (1H, dd, J = 7.8 and 1.1 Hz, Ar-H), 
6.76 (1H, dd, J = 8.2 and 1.2 Hz, Ar-H), 4.02 (2H, d, J = 7.2 Hz, OCH2-bicycle), 3.72 (2H, dd, J = 6.5 
and 0.9 Hz, OCH2), 2.75-2.81 (1H, m, OCH2CH), 2.51 (2H, d, J = 7.2 Hz, Ar-CH2), 2.38 (1H, dt, J = 
6.9 and 1.7 Hz, C(=O)CH), 2.14 (1H, m), 1.97-2.04 (2H, m), 1.84-1.91 (2H, m), 1.50-1.74 (8H, m), 
N
O
O
H
N
O
H
H
O
O
 211 
0.97 (6H, dd, J = 6.7 and 1.0 Hz, CH(CH3)2), 0.88 (6H, dd, J = 6.6 and 1.1 Hz, CH(CH3)2); 13C NMR: 
δc (100 MHz, CDCl3); 140.55 (d), 129.43 (d), 127.12 (d), 122.28 (2 x d), 120.85 (2 x d), 114.65 (d), 
109.37 (d), 76.73 (t), 74.66 (t), 71.43 (d), 48.11 (d), 41.46 (d), 38.49 (d), 29.23 (d), 28.70 (d), 28.37 
(t), 26.61 (t), 22.70 (t), 21.62 (t), 20.87 (2 x q), 19.31 (2 x q); LRMS (ESI) m/z 464 (MH+, 100%); 
HRMS (ESI) m/z 464.3088 (MH+). C30H41NO3 Required 464.3086; Δ = 1.2 ppm. 
 
3-(2-Methylbutyl)pyridine (252).251 
According to the method of Gedig,251 n-BuLi (1.9 M; 13.7 mL, 26 mmol) was 
added to a solution of diisopyopylamine (3.7 mL, 25 mmol) in THF (60 mL) at -78 
ºC.  The reaction was warmed to room temperature over 30 min.  The solution was cooled to -78 ºC 
before dropwise addition of 3-picoline (2.4 mL, 25 mmol).  The solution was allowed to warm to room 
temperature and stirred for 1 h before cooling to -78 ºC and adding 2-bromobutane (2.7 mL, 25 
mmol) dropwise and allowing the reaction to warm to room temperature.  After a further 2 h the 
reaction was quenched with sat. aqueous ammonium chloride (5 mL) and the organic separated.  
The aqueous was extracted with ethyl acetate (3 x 20 mL) and the combined organic washed with 
brine (20 mL), dried over MgSO4 and concentrated in vacuo to give a yellow oil.  Purification was 
achieved by reduced pressure distillation (13 mbar, 83-87 ºC) to give 252 (3.13 g, 85%) as a 
colourless oil. 
1H NMR: δH (400 MHz, CDCl3); 8.44-8.46 (2H, m), 7.51 (1H, ddd, J = 7.8, 2.2 and 1.8 Hz), 7.23-7.26 
(1H, m), 2.66 (1H, dd, J = 13.6 and 6.2 Hz), 2.39 (1H, m), 1.67 (1H, m), 1.41 (1H, m), 1.19 (1H, m), 
0.93 (3H, t, J = 7.4 Hz), 0.87 (3H, d, J = 6.7 Hz); LRMS (ESI) m/z 150 (MH+, 100). 
 
Docking procedure 
All docking calculations were performed using Glide,23 all parameters used were the default settings 
except where otherwise stated. All MM-GB/SA calculations were performed using Prime.252 All results 
were visualised using Maestro.  
 
General procedure AE (condensation of aromatic aldehydes with cyclohexanone). 
According to the method of Singh,253 8 M aqueous NaOH (40 mmol) was added to a solution of 
cyclohexanone (10 mmol) and the required aldehyde (30 mmol) and the reaction stirred until 
complete.  The suspension was then diluted with H2O (50 mL) before extracting with diethyl ether (3 
x 200 mL) and the combined extracts washed with brine (50 mL).  The organic was dried over 
MgSO4 and concentrated under reduced pressure to give the pure bis methylidene cyclohexanone. 
 
(2E,6E)-2,6-bis(furan-2-ylmethylidene)cyclohexan-1-one (281).253 
Using the general procedure AE, 8 M aqueous NaOH (5.1 mL, 40 mmol), 
cyclohexanone (1.06 mL, 10 mmol) and furaldehyde (2.53 mL, 30 mmol) 
after 30 min gave 281 (2.8 g, 99%) as a yellow solid. 
N
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1H NMR: δH (400 MHz, CDCl3); 7.58 (4H, dd, J = 4.8 and 1.9 Hz), 6.69 (2H, d, J = 3.5 Hz), 6.53-6.55 
(2H, m), 3.04 (4H, td, J = 6.4 and 1.7 Hz), 1.91 (2H, quintet, J = 6.4 Hz); LRMS (ESI) m/z 255 (MH+, 
100). 
 
General procedure AF (hydrazine cyclisation and acylation of bis cyclohexanone analogues). 
According to the method Kablie,254 bis methylidene cyclohexanone (1.2 mmol) was dissolved in 
ethanol before addition of hydrazine hydrate (0.3 mL, 5.9 mmol) and the solution refluxed at 80 ºC for 
1 h.  The solution was then cooled to room temperature before concentrating under reduced pressure 
and redissolving in ethyl aceate (10 mL) and washed with H2O (10 mL).  The organic layer was then 
added slowly to a solution of sat. aqueous NaHCO3 (4 mL) and chloroacetyl chloride (0.5 mL, 5.9 
mmol) was added dropwise and the solution stirred for 30 min.  The solution was then washed with 
H2O (10 mL), brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure to give an 
oil. 
 
(±)-2-chloro-1-[(7E)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-3,3a,4,5,6,7-hexahydro-2H-indazol-
2-yl]ethan-1-one (283). 
 
Using the general procedure AF, 281 (300 mg, 1.2 mmol), hydrazine hydrate (0.3 mL, 5.9 mmol) and 
chloroacetyl chloride (0.5 mL, 5.9 mmol) after 2 h purifying by FC (6:1 petroleum ether:ethyl acetate) 
gave a separable mixture of 2 diastereomers 283a (103 mg, 14%) and 283b (500 mg, 70%) a 
colourless oils. 
IR (neat): vmax 2975 (w), 2934 (w), 1715 (s) (C=O), 1343 (m), 1272 (m), 1211 (m), 1109 (m), 873 (s), 
669 (m). 
(3R, 3aR)-283a: Rf = 0.18 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.52 
(1H, d, J = 1.7 Hz, H-9), 7.34 (1H, dd, J = 1.8 and 0.8 Hz, H-14), 7.20 (1H, d, J = 2.5 Hz, H-8), 6.53 
(1H, d, J = 3.4 Hz, H-10), 6.51 (1H, dd, J = 3.4 and 1.8 Hz, H-11), 6.33 (1H, dd, J = 3.3 and 1.9 Hz, 
H-13), 6.26 (1H, d, J = 3.2 Hz, H-12), 5.70 (1H, d, J = 10.6 Hz, H-3), 4.56 (2H, d, J = 3.3 Hz, H-15), 
3.36 (1H, m, H-3a), 3.29 (1H, m, H-6), 2.34 (1H, ddd, J = 13.4, 5.7 and 3.1 Hz, H-6), 1.89-2.02 (2H, 
m, H-5 and H-4), 1.58 (1H, m, H-5), 1.08 (1H, qd, J = 12.8 and 3.0 Hz, H-4); 13C NMR: δc (100 MHz, 
CDCl3); 163.73 (s), 159.79 (s), 152.29 (s), 149.34 (s), 143.39 (d), 142.32 (d), 126.36 (s), 117.01 (d), 
113.50 (d), 111.98 (d), 110.35 (d), 108.22 (d), 58.07 (d), 49.36 (d), 42.08 (t), 27.85 (t), 24.36 (t), 
23.14 (t); LRMS (ESI) m/z 345 (MH+, 40%), 180 (15); HRMS (ESI) m/z 345.0098 (MH+). 
C18H18N2O3Cl Required 345.1006; Δ = -2.3 ppm. 
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(3R, 3aS)-283b: Rf = 0.24 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.51 
(1H, d, J = 1.7 Hz, H-9), 7.38 (1H, dd, J = 1.8 and 0.8 Hz, H-14), 7.03 (1H, m, H-8), 6.49-6.52 (2H, m, 
H-10 and H-11), 6.43 (1H, dd, J = 3.3 and 0.8 Hz, H-13), 6.38 (1H, dd, J = 3.3 and 1.8 Hz, H-12), 
5.08 (1H, d, J = 9.5 Hz, H-3), 4.56 (2H, d, J = 2.8 Hz, H-15), 3.32-3.41 (2H, m, H-3a and H-6), 2.46 
(1H, m, H-6), 2.22 (1H, m, H-5), 2.04 (1H, dt, J = 3.5 and 1.7 Hz, H-4), 1.66 (1H, m, H-4); 13C NMR: 
δc (100 MHz, CDCl3); 166.13 (s), 160.44 (s), 152.13 (s), 150.04 (s), 143.33 (s), 142.31 (d), 126.43 (s), 
116.64 (d), 113.36 (d), 111.91 (d), 110.72 (d), 108.97 (d), 61.52 (d), 52.26 (d), 42.43 (t), 40.68 (t), 
29.09 (t), 28.43 (t); LRMS (ESI) m/z 345 (MH+, 40%), 180 (15); HRMS (ESI) m/z 345.1006 (MH+). 
C18H18N2O3Cl Required 345.1006; Δ = 0.0 ppm. 
 
General procedure AG (hydroxyl pyridine O-alkylation). 
The required α-chloro amide (0.58 mmol) was dissolved in acetone (5 mL) before addition of KI (10 
mg, 0.058 mmol).  The reaction was heated at 60 ºC for 15 min before batch addition of a solution of 
hydroxy pyridine (0.64 mmol) in acetone (5 mL) and K2CO3 (90 mg, 0.64 mmol) every 30 min for 3 h.  
The reaction was stirred for a further 13 h before allowing to cool and concentrating under reduced 
pressure.  The solid was taken up in ethyl acetate (30 mL) and washed with H2O (5 mL), dried over 
MgSO4 and concentrated under reduced pressure to give a yellow oil. 
 
(±)-(7Z)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-2-{2-[(2-nitropyridin-3-yl)oxy]ethyl}-
3,3a,4,5,6,7-hexahydro-2H-indazole hydrate (265). 
 
Using the general procedure AG, 283 (200 mg, 0.58 mmol), KI (10 mg, 0.058 mmol), 2-nitro-3-
hydroxy pyridine (90 mg, 0.64 mmol) and K2CO3 (90 mg, 0.64 mmol) after 17 h purifying by FC (2:1 
petroleum ether:ethyl acetate) gave a separable mixture of diastereomers 265a (18 mg, 8%) and 
265b (80 mg, 31%) as pale yellow soilds, m.p. 183-185 ºC. 
 
IR (neat): vmax 3257 (w), 2976 (w), 2934 (w), 1717 (s) (C=O), 1630 (N=O) (s), 1343 (s), 1274 (m), 
1135 (w), 1115 (m), 978 (m), 753 (m), 669 (m) cm-1; LRMS (ESI) m/z 448 (MH+, 1000%); HRMS 
(ESI) m/z 448.1386 (MH+). C23H20N4O6 Required 448.1383; Δ = -0.7 ppm. 
(3R, 3aR)-265a: Rf = 0.18 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.11 
(1H, dd, J = 3.3 and 2.5 Hz, H-21), 7.53 (1H, d, J = 1.7 Hz, H-9), 7.45 (2H, br s, H-19 and H-20), 7.35 
(1H, dd, J = 1.8 and 0.8 Hz, H-6), 7.20 (1H, d, J = 2.4 Hz, H-8), 6.56 (1H, d, J = 3.4 Hz, H-10), 6.52 
(1H, dd, J = 3.4 and 1.9 Hz, H-11), 6.34 (1H, dd, J = 3.3 and 1.9 Hz, H-13), 6.27 (1H, dd, J = 3.3 and 
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0.7 Hz, H-12), 5.67 (1H, d, J = 10.7 Hz, H-3), 5.30 (2H, d, J = 11.2 Hz, H-15), 3.29-3.40 (2H, m, H-3a 
and H-6), 2.37 (1H, ddt, J = 13.4, 10.4 and 3.1 Hz, H-6), 2.01 (1H, m, H-5), 1.90 (1H, m, H-4), 1.60 
(1H, m, H-5), 1.11 (1H, qd, J = 12.9 and 3.1 Hz, H-4); 13C NMR: δc (100 MHz, CDCl3); 163.54 (s), 
160.06 (s), 152.23 (d), 149.31 (s), 147.17 (s), 143.50 (d), 142.24 (d), 139.76 (s), 128.34 (d), 126.22 
(d), 124.72 (d), 117.14 (d), 113.68 (d), 112.04 (d), 110.53 (d), 108.58 (d), 67.30 (d), 58.00 (d), 49.03 
(t), 27.86 (t), 24.34 (t), 23.15 (t).  
(3R, 3aS)-265b: Rf = 0.24 (5:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.11 
(1H, dd, J = 3.1 and 2.7 Hz, H-21), 7.53 (1H, d, J = 1.7 Hz, H-9), 7.47 (2H, d, J = 3.1 Hz, H-19 and H-
20), 7.38 (1H, dd, J = 1.8 and 0.8 Hz, H-6), 7.05 (1H, d, J = 2.4 Hz, H-8), 6.54 (1H, d, J = 3.4 Hz, H-
10), 6.52 (1H, dd, J = 3.4 and 1.8 Hz, H-11), 6.41 (1H, dd, J = 3.3 and 0.7 Hz, H-13), 6.37 (1H, dd, J 
= 3.3 and 1.8 Hz, H-12), 5.26 (2H, s, H-15), 5.06 (1H, d, J = 9.8 Hz, H-3), 3.34-3.41 (2H, m, H-3a and 
H-6), 2.47 (1H, m, H-6), 2.24 (1H, ddd, J = 5.5, 3.7 and 1.8 Hz, H-4), 2.06 (1H, m, H-5); 13C NMR: δc 
(100 MHz, CDCl3); 160.02 (s), 152.13 (s), 150.12 (s), 147.17 (s), 143.36 (s), 142.30 (d), 139.72 (s), 
128.37 (d), 126.38 (d), 124.64 (d), 116.62 (d), 113.42 (d), 111.95 (d), 110.80 (d), 108.94 (d), 77.26 
(d), 77.06 (d), 67.40 (d), 61.47 (t), 51.90 (t), 29.74 (t), 29.08 (t), 28.46 (t), 23.60 (t). 
 
(±)-(7Z)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-2-{2-[(2-nitrophenyl)oxy]ethyl}-3,3a,4,5,6,7-
hexahydro-2H-indazole hydrate (269). 
 
Using the general procedure AG, 283 (80 mg, 0.23 mmol), KI (4 mg, 0.023 mmol), 2-nitrophenol (24 
mg, 0.26 mmol) and K2CO3 (35 mg, 0.26 mmol) after 17 h purifying by FC (2:1 petroleum ether:ethyl 
acetate) gave a separable mixture of diastereomers 269a (17 mg, 18%) and 265b (25 mg, 24%) as 
pale yellow green soilds, m.p. 172-179 ºC. 
IR (neat): vmax 3260 (w), 2972 (w), 2934 (w), 1716 (s) (C=O), 1630 (N=O) (s), 1341 (s), 1194 (m), 
1142 (w), 1105 (m), 868 (m), 753 (m), 665 (m) cm-1; LRMS (EI) m/z 447 (M+, 100%), 368 (25), 268 
(40), 173 (40), 81 (40); HRMS (EI) m/z 447.1430 (MH+). C24H21N3O6 Required 447.1430; Δ = -0.1 
ppm. 
(3R, 3aR)-269a: Rf = 0.51 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.87 
(1H, dd, J = 8.3 and 1.7 Hz, H-16), 7.52 (1H, d, J = 1.7 Hz, H-9), 7.48 (1H, ddd, J = 8.5, 7.4 and 1.7 
Hz, H-21), 7.38 (1H, dd, J = 1.8 and 0.8 Hz, H-14), 7.02-7.06 (3H, m, Ar-H), 6.51-6.54 (2H, m), 6.41 
(1H, dd, J = 3.3 and 0.8 Hz), 6.36 (1H, dd, J = 3.3 and 1.8 Hz), 5.25 (2H, s, H-15), 5.08 (1H, d, J = 
9.7 Hz, H-3), 3.35-3.40 (2H, m, H-3a and H-6), 2.48 (1H, m, H-6), 2.23 (1H, m, H-5), 2.06 (1H, m, H-
5), 1.63-1.68 (2H, m, H-4); 13C NMR: δc (100 MHz, CDCl3); 152.22 (s), 150.36 (s), 143.26 (s), 142.19 
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(s), 141.47 (d), 133.89 (s), 126.60 (d), 125.77 (d), 120.90 (d), 116.44 (d), 115.37 (d), 113.25 (d), 
111.90 (d), 110.77 (d), 108.84 (d), 67.49 (d), 61.43 (d), 51.85 (t), 29.17 (t), 28.50 (t), 23.64 (t).  
 
(±)-(7Z)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-2-{2-
[(pyridin3-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-indazole 
hydrate (284).  
Using the general procedure AG, 283 (200 mg, 0.58 mmol), KI 
(10 mg, 0.058 mmol), 3-hydroxy pyridine (80 mg, 0.64 mmol) 
and K2CO3 (90 mg, 0.64 mmol)  after 17 h purifying by FC (2:1 
petroleum ether:ethyl acetate) gave 284 (5 mg, 5%) as pale 
yellow oil. 
Rf = 0.43 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.51 (1H, d, J = 1.4 Hz, 
H-9), 7.38 (1H, dd, J = 1.8 and 0.8 Hz, H-14), 7.34 (1H, m, H-17), 7.02 (1H, d, J = 2.3 Hz, H-21), 
6.45-6.52 (3H, m, Ar-H), 6.37-6.41 (3H, m, Ar-H), 5.29 (2H, m, H-15), 5.02 (1H, d, J = 9.8 Hz, H-3), 
3.32-3.38 (3H, m, H-3a and H-6), 2.43-2.48 (2H, m, H-5), 2.23-2.26 (2H, m, H-4). HRMS (ESI) m/z 
404.1534 (MH+). C23H21N3O4 Required 404.1532; Δ = -0.4 ppm. 
 
(±)-(7Z)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-2-{2-
[(pyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-
indazole hydrate (286).  
Using the general procedure AG, 283 (80 mg, 0.23 mmol), KI 
(4 mg, 0.023 mmol), 2-hydroxy pyridine (25 mg, 0.26 mmol) 
and K2CO3 (35 mg, 0.26 mmol) after 17 h purifying by FC (2:1 
petroleum ether:ethyl acetate) gave 286 (6 mg, 7%) as pale 
yellow oil. 
Rf = 0.35 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.51 (1H, d, J = 1.5 Hz, 
H-9), 7.39 (1H, dd, J = 1.8 and 0.8 Hz, H-14), 7.02 (1H, d, J = 2.4 Hz, H-16), 6.51 (2H, dt, J = 3.5 and 
1.8 Hz, Ar-H), 6.37-6.41 (2H, m, Ar-H), 5.29 (1H, m, H-8), 5.07 (2H, m, H-15), 4.81-4.86 (3H, m), 
3.31-3.38 (2H, m, H-6), 2.47 (1H, m, H-5), 2.18-2.24 (2H, m, H-5), 2.06 (1H, m, H-4), 1.65 (1H, m, H-
4). HRMS (EI) m/z 403.1526 (M+). C23H21N3O4 Required 404.1532; Δ = -1.5 ppm. 
 
(±)-(7Z)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-2-{2-[(4-
methylpyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-
indazole hydrate (287).  
Using the general procedure AG, 283 (80 mg, 0.23 mmol), KI 
(4 mg, 0.023 mmol), 2-hydroxy-5-methyl pyridine (30 mg, 0.26 
mmol) and K2CO3 (35 mg, 0.26 mmol) after 17 h purifying by 
FC (2:1 petroleum ether:ethyl acetate) gave 287 (2.6 mg, 3%) 
as pale yellow oil. 
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Rf = 0.42 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 7.51 (1H, d, J = 0.5 Hz, 
H-9), 7.35-7.43 (2H, m, H-14 and H-10), 7.01 (1H, m, H-11), 6.47-6.54 (3H, m, H-11 and H-13), 6.36-
6.41 (4H, m, Ar-H), 5.20 (1H, d, J = 16.0 Hz, H-3), 4.96 (2H, m, H-15), 3.32-3.37 (3H, m, H-6 and H-
3a), 2.42-2.49 (5H, m, H-5 and Ar-CH3), 2.19-2.24 (2H, m, H-4). HRMS (EI) m/z 417.1689 (M+). 
C24H23N3O4 Required 417.1689; Δ = -0.2 ppm. 
 
(±)-(7Z)-3-(furan-2-yl)-7-(furan-2-ylmethylidene)-2-{2-[(3-
nitro-4-methylpyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-
hexahydro-2H-indazole hydrate (288).  
Using the general procedure AG, 283 (80 mg, 0.23 mmol), KI 
(4 mg, 0.023 mmol), 2-hydroxy-5-methyl-6-nitro pyridine (40 
mg, 0.26 mmol) and K2CO3 (35 mg, 0.26 mmol) after 17 h 
purifying by FC (2:1 petroleum ether:ethyl acetate) gave 288 
(3.2 mg, 4%) as pale yellow oil. 
Rf = 0.32 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.04 (1H, d, J = 5.2 Hz, 
H-19), 7.51 (1H, d, J = 1.2 Hz, H-9), 7.36 (1H, m, H-14), 7.03 (1H, m, H-10), 6.50-6.51 (2H, m, Ar-H), 
6.34-6.41 (3H, m, Ar-H), 4.87 (2H, s, H-15), 4.81 (1H, d, J = 5.5 Hz, H-3), 3.30-3.37 (2H, m), 2.43 
(1H, m), 2.18-2.24 (2H, m), 2.04-2.07 (2H, m), 1.65 (3H, m, Ar-CH3), 1.28 (3 H, d, J = 2.5 Hz). HRMS 
(EI) m/z 462.1541 (M+). C24H22N4O6 Required 462.1539; Δ = -1.3 ppm. 
 
(2E,6E)-2,6-bis(furan-3-ylmethylidene]-cyclohexan-1-one (290).253  
Using the general procedure AE, 8 M aqueous NaOH (0.5 mL, 4.0 
mmol), cyclohexanone (100 mg, 1.02 mmol) and furaldehyde (255 µL, 
3 mmol) after 30 min gave 290 (200 mg, 85%) as a yellow solid. 
1H NMR: δH (400 MHz, CDCl3); 7.73 (2H, d, J = 0.6 Hz), 7.63 (2H, s), 7.50 (2H, dd, J = 2.4 and 1.0 
Hz), 6.66 (2H, d, J = 1.8 Hz), 2.84 (4H, td, J = 6.3 and 1.9 Hz), 1.92 (2H, quintet, J = 6.3 Hz); LRMS 
(ESI) m/z 255 (MH+, 100). 
 
(2E,6E)-2,6-bis(thiophen-2-ylmethylidene]-cyclohexan-1-one 
(291).255  
Using the general procedure AE, 8 M aqueous NaOH (0.5 mL, 4.0 
mmol), cyclohexanone (100 mg, 1.02 mmol) and thiophene aldehyde 
(300 µL, 3 mmol) after 30 min gave 291 (270 mg, 95%) as a yellow solid. 
1H NMR: δH (400 MHz, CDCl3); 8.02 (2H, s), 7.56 (2H, m), 7.41 (2H, m), 7.18 (2H, dd, J = 5.1 and 3.7 
Hz), 2.97 (4H, td, J = 6.3 and 1.8 Hz), 2.01 (2H, quintet, J = 6.3 Hz); LRMS (ESI) m/z 287 (MH+, 
100). 
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(2E,6E)-2,6-bis(phenylmethylidene]-cyclohexan-1-one (292).255  
Using the general procedure AE, 8 M aqueous NaOH (0.5 mL, 4.0 
mmol), cyclohexanone (100 mg, 1.02 mmol) and benzaldehyde (310 
µL, 3 mmol) after 30 min gave 292 (270 mg, 95%) as a yellow solid. 
1H NMR: δH (400 MHz, CDCl3); 7.84 (2H, s), 7.50 (4H, m), 7.44 (4H, m), 7.37 (2H, m), 2.97 (4H, td, J 
= 6.2 and 1.9 Hz), 1.83 (2H, m); LRMS (ESI) m/z 275 (MH+, 100). 
 
(2E,)-2-(furan-2-ylmethylidene]-cyclohexan-1-one (293).256  
1M aqueous NaOH (1 mL, 1.0 mmol) was added to a solution of cyclohexanone 
(160 µL, 1.56 mmol) and furaldehyde (86 µL, 1.04 mmol) in ethanol (300 µL).  
After 30 min the precipitate was filtered to give 293 (80 mg, 62%) as a yellow solid. 
1H NMR: δH (400 MHz, CDCl3); 7.57 (1H, d, J = 1.6 Hz), 7.41 (1H, t, J = 2.3 Hz), 6.65 (1H, dd, J = 3.5 
and 0.6 Hz, C), 6.53 (1H, m), 2.94 (2H, td, J = 6.5 and 2.3 Hz), 2.53 (2H, t, J = 6.6 Hz), 1.92 (2H, m), 
1.85 (2H, m); LRMS (ESI) m/z 177 (MH+, 100). 
 
General procedure AH (TMS iodide mediated condensation of alkyl aldehydes with 
cyclohexanone). 
According to the method of Yadav,208 NaI (153 mg, 1.02 mmol) was added to a solution of 
cyclohexanone (100 µL, 1.02 mmol) and aldehyde (2.04 mmol) in acetonitrile (2 mL).  TMS chloride 
(130 µL, 1.02 mmol) was then added and the solution stirred until complete.  The mixture was then 
diluted in diethyl ether (10 mL) and washed with sodium thiosulfate (10 mL), brine (10 mL), dried over 
Na2SO4 and concentrated under reduced pressure to give an oil. 
 
(2E,6E)-2,6-diheptylidenecyclohexan-1-one 
(295).208 
Using the general procedure AH, NaI (153 mg, 1.02 
mmol), cyclohexanone (100 µL, 1.02 mmol), 
heptaldehyde (285 µL, 2.04 mmol) and TMS chloride (130 µL, 1.02 mmol) after 16 h gave 295 (70 
mg, 61%) as a pale yellow oil. 
1H NMR: δH (400 MHz, CDCl3); 6.47 (2H, t, J = 7.4 Hz), 2.37 (4H, q, J = 7.4 Hz), 2.25 (4H, t, J = 7.5 
Hz), 1.52 (2H, m), 1.28-1.38 (16H, m), 0.91 (6H, dd, J = 12.3 and 10.0 Hz); LRMS (ESI) m/z 291 
(MH+, 100). 
 
(2E,6E)-2,6-bid(2-methylpropylidine)cyclohexan-1-one (296).208 
Using the general procedure AH, NaI (153 mg, 1.02 mmol), cyclohexanone 
(100 µL, 1.02 mmol), isopropanal (200 µL, 2.04 mmol) and TMS chloride 
(130 µL, 1.02 mmol) after 16 h gave 296 (62 mg, 53%) as a pale yellow oil. 
1H NMR: δH (400 MHz, CDCl3); 6.66 (2H, dt, J = 9.9 and 1.8 Hz), 2.60 (2H, m), 2.55 (4H, m), 1.77 
(2H, m), 1.05 (12H, d, J = 6.6 Hz); LRMS (ESI) m/z 207 (MH+, 100). 
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(2E,6E)-2,6-dipropylidenecyclohexan-1-one (297).208 
Using the general procedure AH, NaI (153 mg, 1.02 mmol), cyclohexanone 
(100 µL, 1.02 mmol), propanal (160 µL, 2.04 mmol) and TMS chloride (130 
µL, 1.02 mmol) after 16 h gave 295 (47 mg, 46%) as a pale yellow oil. 
1H NMR: δH (400 MHz, CDCl3); 6.47 (2H, t, J = 7.4 Hz), 2.37 (4H, q, J = 7.4 Hz), 2.25 (4H, t, J = 7.5 
Hz), 1.52 (2H, m), 1.28-1.38 (16H, m), 0.91 (6H, dd, J = 12.3 and 10.0 Hz); LRMS (ESI) m/z 179 
(MH+, 100). 
 
(±)-(7Z)-3-(furan-3-yl)-7-(furan-3-ylmethylidene)-2-{2-[(3-nitro-4-
methylpyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-
indazole hydrate (298).  
Using the general procedure AG, the required α-chloro ketone (62 
mg, 0.18 mmol), KI (15 mg, 0.09 mmol), 3-hydroxy-2-nitro pyridine 
(30 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol) after 17 h 
purifying by FC (2:1 petroleum ether:ethyl acetate) gave 298 (32.6 
mg, 36%) as pale yellow oil. 
Rf = 0.43 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.12 (1H, dd, J = 3.5 
and 2.3 Hz), 7.63 (1H, s), 7.48 (4H, m), 7.42 (1H, t, J = 1.7 Hz), 7.03 (1H, m), 6.57 (1H, d, J = 1.6 
Hz), 6.37 (1H, t, J = 0.9 Hz), 5.25 (2H, d, J = 2.2 Hz), 4.97 (1H, d, J = 9.1 Hz), 3.01-3.08 (2H, m), 
2.38 (1H, m), 2.23 (1H, m), 1.62-1.67 (3H, m). HRMS (ESI) m/z 449.1454 (MH+). C23H21N4O6 
Required 449.1461; Δ = -1.6 ppm. 
 
(±)-(7Z)-3-(thiophen-2-yl)-7-(thiophen-2-ylmethylidene)-2-{2-[(3-
nitro-4-methylpyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-
indazole hydrate (299).  
Using the general procedure AG, the required α-chloro ketone (70 
mg, 0.18 mmol), KI (15 mg, 0.09 mmol), 3-hydroxy-2-nitro pyridine (30 
mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol) after 17 h purifying by 
FC (2:1 petroleum ether:ethyl acetate) gave 298 (47.5 mg, 43%) as 
pale yellow oil. 
Rf = 0.46 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.10 (1H, dd, J = 2.2 
and 1.3 Hz), 7.44-7.49 (3H, m), 7.21-7.28 (2H, m), 7.14 (1H, dd, J = 5.1 and 3.7 Hz), 7.10 (1H, m), 
6.98 (1H, m), 5.34 (1H, m), 5.27 (2H, d, J = 11.6 Hz), 3.15-3.27 (2H, m), 2.67 (1H, dd, J = 1.4 and 0.7 
Hz), 2.27-2.36 (2H, m), 2.06-2.13 (2H, m). HRMS (ESI) m/z 481.0097 (MH+). C23H21N4O4S4 Required 
481.1004; Δ = -1.5 ppm. 
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(±)-(7Z)-3-(phenyl)-7-(phenylmethylidene)-2-{2-[(3-nitro-4-
methylpyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-
indazole hydrate (300).  
Using the general procedure AG, the required α-chloro ketone (70 
mg, 0.18 mmol), KI (15 mg, 0.09 mmol), 3-hydroxy-2-nitro pyridine 
(30 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol) after 17 h 
purifying by FC (2:1 petroleum ether:ethyl acetate) gave 298 (24.4 
mg, 57%) as pale yellow oil. 
Rf = 0.51 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.08 (1H, m), 7.22-7.49 
(13H, m), 5.32 (2H, m), 4.95 (1H, m), 3.03-3.14 (2H, m), 2.48 (1H, dddd, J = 15.7, 12.8, 5.4 and 2.9 
Hz), 2.23-2.29 (1H, m), 1.99 (1H, m), 1.69-1.79 (2H, m). HRMS (ESI) m/z 469.1867 (MH+). 
C27H25N4O4 Required 469.1876; Δ = -1.9 ppm. 
 
(±)-(7Z)-3-(phenyl)-2-{2-[(3-nitro-4-methylpyridine-2-yl)oxy]ethyl}-
3,3a,4,5,6,7-octahydro-2H-indazole hydrate (301).  
Using the general procedure AG, the required α-chloro ketone (50 mg, 
0.18 mmol), KI (15 mg, 0.09 mmol), 3-hydroxy-2-nitro pyridine (30 mg, 
0.22 mmol) and K2CO3 (30 mg, 0.22 mmol) after 17 h purifying by FC 
(2:1 petroleum ether:ethyl acetate) gave 301 (15.2 mg, 63%) as pale 
yellow oil. 
Rf = 0.39 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.10 (1H, dd, J = 3.5 
and 2.3 Hz), 7.45-7.46 (2H, m), 7.34 (1H, t, J = 1.4 Hz), 6.33 (2H, d, J = 1.4 Hz), 5.18 (2H, d, J = 2.4 
Hz), 5.01 (1H, d, J = 6.1 Hz), 3.19 (1H, m), 2.72 (1H, dt, J = 14.1 and 1.8 Hz), 2.35 (1H, m), 2.25 (1H, 
m), 2.17 (1H, m), 1.93 (1H, m), 1.45-1.57 (3H, m). HRMS (ESI) m/z 371.1355 (MH+). C18H19N4O5 
Required 371.1355; Δ = 0.0 ppm. 
 
(±)-(7Z)-3-(tetrahydrohuran-2-yl)-7-(tetrahydrofuran-2-
ylmethylidene)-2-{2-[(3-nitro-4-methylpyridine-2-yl)oxy]ethyl}-
3,3a,4,5,6,7-hexahydro-2H-indazole hydrate (302).  
Using the general procedure AG, the required α-chloro ketone (40 
mg, 0.1 mmol), KI (17 mg, 0.12 mmol), 3-hydroxy-2-nitro pyridine 
(18 mg, 0.13 mmol) and K2CO3 (16 mg, 0.12 mmol) after 17 h 
purifying by FC (2:1 petroleum ether:ethyl acetate) gave 302 (19.3 
mg, 23%) as pale yellow oil. 
Rf = 0.51 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.13 (1H, ddd, J = 3.3, 
2.4 and 0.9 Hz), 7.51-7.53 (2H, m), 5.22 (1H, m), 5.11 (1H, m), 4.46 (1H, m), 4.29 (1H, q, J = 4.7 Hz), 
4.03 (1H, m), 3.72-3.92 (5H, m), 2.81 (1H, dt, J = 12.3 and 6.0 Hz), 2.64 (1H, m), 2.28 (1H, m), 2.09-
2.13 (4H, m), 1.48-1.57 (5H, m). HRMS (ESI) m/z 457.2008 (MH+). C23H28N4O6 Required 457.2009; 
Δ = 0.3 ppm. 
N
N
O
O
N
H
O2N
N
N
O
O
N
H
O2N
O
N
N
O
O
N
H
O2N
O
O
 220 
(±)-(7Z)-3-(propan-2-yl)-7-(2-methylpropylidene)-2-{2-[(3-nitro-4-
methylpyridine-2-yl)oxy]ethyl}-3,3a,4,5,6,7-hexahydro-2H-
indazole hydrate (304).  
Using the general procedure AG, the required α-chloro ketone (40 
mg, 0.1 mmol), KI (17 mg, 0.12 mmol), 3-hydroxy-2-nitro pyridine (18 
mg, 0.13 mmol) and K2CO3 (16 mg, 0.12 mmol) after 17 h purifying by 
FC (2:1 petroleum ether:ethyl acetate) gave 304 (26 mg, 23%) as pale 
yellow oil. 
Rf = 0.46 (2:1 petroleum ether:ethyl acetate); 1H NMR: δH (400 MHz, CDCl3); 8.12 (1H, dd, J = 4.1 
and 1.7 Hz), 7.48-7.54 (2H, m), 5.22 (2H, quintet, J = 12.7 Hz), 3.95 (1H, t, J = 4.7 Hz), 2.79-2.83 
(1H, m), 2.61-2.68 (2H, m), 2.40 (1H, dd, J = 12.0 and 5.5 Hz), 2.13 (1H, ddt, J = 11.7, 4.1 and 2.1 
Hz), 1.99 (1H, m), 1.86 (1H, s), 1.67-1.78 (3H, m), 1.52-1.60 (2H, m), 0.89-0.93 (9H, m), 0.73 (3H, d, 
J = 6.8 Hz). HRMS (ESI) m/z 401.2177 (MH+). C21H29N4O4 Required 401.2189; Δ = -3.0 ppm. 
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Appendix 
X Ray Data 
(±)-(2R*, 3S*,4S*)-4-Bromo-3-methyl-2-(4-chlorophenyl)tetrahydro-2H-pyran. 
 
Identification code   AS1006 
Formula    C12 H14 Br Cl O 
Formula weight    289.59 
Temperature    173(2) K 
Diffractometer, wavelength  OD Xcalibur 3, 0.71073 Å 
Crystal system, space group  Orthorhombic, Pna2(1) 
Unit cell dimensions   a = 9.4138(2) Å a = 90° 
     b = 8.9053(2) Å b = 90° 
     c = 14.7138(4) Å g = 90° 
Volume, Z    1233.50(5) Å3, 4 
Density (calculated)   1.559 Mg/m3 
Absorption coefficient   3.521 mm-1 
F(000)     584 
Crystal colour / morphology  Colourless platy needles 
Crystal size    0.41 x 0.35 x 0.06 mm3 
q range for data collection  3.44 to 32.79° 
Index ranges    -13<=h<=14, -10<=k<=13, -21<=l<=21 
Reflns collected / unique  12936 / 3931 [R(int) = 0.0323] 
Reflns observed [F>4s(F)]  2485 
Absorption correction   Analytical 
Max. and min. transmission  0.830 and 0.329 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3931 / 1 / 137 
Goodness-of-fit on F2   0.840 
Final R indices [F>4s(F)]  R1 = 0.0298, wR2 = 0.0475 
     R1+ = 0.0313, wR2+ = 0.0513 
     R1- = 0.0606, wR2- = 0.1355 
R indices (all data)   R1 = 0.0658, wR2 = 0.0515 
Absolute structure parameter  x+ = 0.131(6), x- = 0.869(6) 
     partial racemic twin 
Largest diff. peak, hole   0.617, -0.433 eÅ-3 
Mean and maximum shift/error  0.000 and 0.001 
O
Br
Cl
 232 
 
Bond lengths [Å] and angles [°] for AS1006. 
 
O(1)-C(6)  1.427(2) 
O(1)-C(2)  1.429(3) 
C(2)-C(7)  1.508(3) 
C(2)-C(3)  1.543(2) 
C(3)-C(4)  1.515(2) 
C(3)-C(13)  1.528(3) 
C(4)-C(5)  1.503(3) 
C(4)-Br(1)  1.9869(19) 
C(5)-C(6)  1.523(3) 
C(7)-C(8)  1.373(3) 
C(7)-C(12)  1.396(3) 
C(8)-C(9)  1.390(3) 
C(9)-C(10)  1.371(3) 
C(10)-C(11)  1.373(3) 
C(10)-Cl(1)  1.749(2) 
C(11)-C(12)  1.383(3) 
 
C(6)-O(1)-C(2)  111.99(14) 
O(1)-C(2)-C(7)  107.26(14) 
O(1)-C(2)-C(3)  111.32(15) 
C(7)-C(2)-C(3)  111.93(15) 
C(4)-C(3)-C(13)  112.91(15) 
C(4)-C(3)-C(2)  107.83(15) 
C(13)-C(3)-C(2)  110.14(16) 
C(5)-C(4)-C(3)  113.39(16) 
C(5)-C(4)-Br(1)  108.03(13) 
C(3)-C(4)-Br(1)  109.80(12) 
C(4)-C(5)-C(6)  108.66(18) 
O(1)-C(6)-C(5)  110.53(16) 
C(8)-C(7)-C(12)  119.18(19) 
C(8)-C(7)-C(2)  120.92(18) 
C(12)-C(7)-C(2)  119.87(19) 
C(7)-C(8)-C(9)  121.0(2) 
C(10)-C(9)-C(8)  118.7(2) 
C(9)-C(10)-C(11) 121.71(19) 
C(9)-C(10)-Cl(1) 118.47(18) 
C(11)-C(10)-Cl(1) 119.81(17) 
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C(10)-C(11)-C(12) 119.22(18) 
C(11)-C(12)-C(7) 120.2(2) 
 
(±)-(2R*, 3S*,4S*)-4-Iodo-3-methyl-2-(4-chlorophenyl)tetrahydro-2H-pyran. 
 
Identification code   AS1005 
Formula    C12 H14 Cl I O 
Formula weight    336.58 
Temperature    173(2) K 
Diffractometer, wavelength  OD Xcalibur 3, 0.71073 Å 
Crystal system, space group  Monoclinic, Cc 
Unit cell dimensions   a = 11.1135(2) Å a = 90° 
     b = 14.7231(3) Å b = 102.873(2)° 
     c = 16.2500(4) Å g = 90° 
Volume, Z    2592.08(10) Å3, 8 
Density (calculated)   1.725 Mg/m3 
Absorption coefficient   2.650 mm-1 
F(000)     1312 
Crystal colour / morphology  Colourless blocks 
Crystal size    0.54 x 0.48 x 0.36 mm3 
q range for data collection  3.76 to 32.86° 
Index ranges    -15<=h<=16, -22<=k<=21, -13<=l<=24 
Reflns collected / unique  13733 / 6057 [R(int) = 0.0188] 
Reflns observed [F>4s(F)]  4518 
Absorption correction   Analytical 
Max. and min. transmission  0.572 and 0.424 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  6057 / 2 / 271 
Goodness-of-fit on F2   0.902 
Final R indices [F>4s(F)]  R1 = 0.0285, wR2 = 0.0631 
     R1+ = 0.0285, wR2+ = 0.0631 
     R1- = 0.0343, wR2- = 0.0805 
R indices (all data)   R1 = 0.0424, wR2 = 0.0656 
Absolute structure parameter  x+ = 0.011(17), x+ = 0.989(17) 
Largest diff. peak, hole   0.919, -0.767 eÅ-3 
Mean and maximum shift/error  0.000 and 0.001 
O
I
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Bond lengths [Å] and angles [°] for AS1005. 
 
O(1A)-C(6A)  1.420(4) 
O(1A)-C(2A)  1.435(4) 
C(2A)-C(7A)  1.512(4) 
C(2A)-C(3A)  1.549(5) 
C(3A)-C(4A)  1.505(5) 
C(3A)-C(13A)  1.532(5) 
C(4A)-C(5A)  1.528(5) 
C(4A)-I(1A)  2.167(3) 
C(5A)-C(6A)  1.512(6) 
C(7A)-C(8A)  1.373(5) 
C(7A)-C(12A)  1.394(5) 
C(8A)-C(9A)  1.389(5) 
C(9A)-C(10A)  1.373(5) 
C(10A)-C(11A)  1.383(5) 
C(10A)-Cl(1A)  1.740(3) 
C(11A)-C(12A)  1.387(5) 
O(1B)-C(6B)  1.422(5) 
O(1B)-C(2B)  1.427(4) 
C(2B)-C(7B)  1.500(5) 
C(2B)-C(3B)  1.544(4) 
C(3B)-C(13B)  1.515(5) 
C(3B)-C(4B)  1.522(5) 
C(4B)-C(5B)  1.509(6) 
C(4B)-I(1B)  2.172(3) 
C(5B)-C(6B)  1.525(6) 
C(7B)-C(8B)  1.392(5) 
C(7B)-C(12B)  1.402(5) 
C(8B)-C(9B)  1.392(5) 
C(9B)-C(10B)  1.352(5) 
C(10B)-C(11B)  1.382(6) 
C(10B)-Cl(1B)  1.745(4) 
C(11B)-C(12B)  1.372(5) 
 
C(6A)-O(1A)-C(2A) 111.0(3) 
O(1A)-C(2A)-C(7A) 107.1(3) 
O(1A)-C(2A)-C(3A) 110.5(3) 
C(7A)-C(2A)-C(3A) 112.6(2) 
C(4A)-C(3A)-C(13A) 113.8(3) 
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C(4A)-C(3A)-C(2A) 107.5(3) 
C(13A)-C(3A)-C(2A) 109.5(3) 
C(3A)-C(4A)-C(5A) 112.8(3) 
C(3A)-C(4A)-I(1A) 111.3(2) 
C(5A)-C(4A)-I(1A) 108.0(2) 
C(6A)-C(5A)-C(4A) 108.8(3) 
O(1A)-C(6A)-C(5A) 111.1(3) 
C(8A)-C(7A)-C(12A) 119.3(3) 
C(8A)-C(7A)-C(2A) 120.0(3) 
C(12A)-C(7A)-C(2A) 120.6(3) 
C(7A)-C(8A)-C(9A) 120.8(3) 
C(10A)-C(9A)-C(8A) 119.2(3) 
C(9A)-C(10A)-C(11A) 121.4(3) 
C(9A)-C(10A)-Cl(1A) 119.6(3) 
C(11A)-C(10A)-Cl(1A) 119.1(3) 
C(10A)-C(11A)-C(12A) 118.8(3) 
C(11A)-C(12A)-C(7A) 120.5(3) 
C(6B)-O(1B)-C(2B) 111.4(3) 
O(1B)-C(2B)-C(7B) 106.7(3) 
O(1B)-C(2B)-C(3B) 112.2(3) 
C(7B)-C(2B)-C(3B) 112.6(3) 
C(13B)-C(3B)-C(4B) 113.7(3) 
C(13B)-C(3B)-C(2B) 110.1(3) 
C(4B)-C(3B)-C(2B) 107.3(3) 
C(5B)-C(4B)-C(3B) 113.6(3) 
C(5B)-C(4B)-I(1B) 108.3(2) 
C(3B)-C(4B)-I(1B) 111.1(2) 
C(4B)-C(5B)-C(6B) 108.9(3) 
O(1B)-C(6B)-C(5B) 110.4(3) 
C(8B)-C(7B)-C(12B) 117.9(3) 
C(8B)-C(7B)-C(2B) 121.1(3) 
C(12B)-C(7B)-C(2B) 121.0(3) 
C(7B)-C(8B)-C(9B) 120.5(3) 
C(10B)-C(9B)-C(8B) 119.6(3) 
C(9B)-C(10B)-C(11B) 121.8(3) 
C(9B)-C(10B)-Cl(1B) 119.6(3) 
C(11B)-C(10B)-Cl(1B) 118.7(3) 
C(12B)-C(11B)-C(10B) 118.7(3) 
C(11B)-C(12B)-C(7B) 121.5(3) 
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(±)-(2R*, 3R*,4S*)-3-Methyl-2-phenyl-N-phenyltetrahydro-2H-pyran-4-amine (95) 
THP_002.  
 
Identification code   AS1007 
Formula    C18 H21 N O 
Formula weight    267.36 
Temperature    173(2) K 
Diffractometer, wavelength  OD Xcalibur 3, 0.71073 Å 
Crystal system, space group  Monoclinic, P2(1)/c 
Unit cell dimensions   a = 10.0838(3) Å a = 90° 
     b = 23.4901(6) Å b = 107.398(3)° 
     c = 13.2726(4) Å g = 90° 
Volume, Z    3000.04(16) Å3, 8 
Density (calculated)   1.184 Mg/m3 
Absorption coefficient   0.073 mm-1 
F(000)     1152 
Crystal colour / morphology  Colourless blocky needles 
Crystal size    0.29 x 0.12 x 0.08 mm3 
q range for data collection  3.06 to 28.71° 
Index ranges    -13<=h<=13, -30<=k<=30, -17<=l<=16 
Reflns collected / unique  14086 / 6504 [R(int) = 0.0269] 
Reflns observed [F>4s(F)]  4661 
Absorption correction   Analytical 
Max. and min. transmission  0.995 and 0.986 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  6504 / 2 / 370 
Goodness-of-fit on F2   1.045 
Final R indices [F>4s(F)]  R1 = 0.0462, wR2 = 0.0935 
R indices (all data)   R1 = 0.0733, wR2 = 0.1039 
Extinction coefficient   0.0037(5) 
Largest diff. peak, hole   0.200, -0.157 eÅ-3 
Mean and maximum shift/error  0.000 and 0.001 
 
 
 
O
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Bond lengths [Å] and angles [°] for AS1007. 
 
O(1A)-C(6A)  1.4303(16) 
O(1A)-C(2A)  1.4373(14) 
C(2A)-C(7A)  1.5090(18) 
C(2A)-C(3A)  1.5309(17) 
C(3A)-C(13A)  1.5243(18) 
C(3A)-C(4A)  1.5311(18) 
C(4A)-N(14A)  1.4508(17) 
C(4A)-C(5A)  1.5194(19) 
C(5A)-C(6A)  1.505(2) 
C(7A)-C(8A)  1.3810(18) 
C(7A)-C(12A)  1.3860(18) 
C(8A)-C(9A)  1.385(2) 
C(9A)-C(10A)  1.376(2) 
C(10A)-C(11A)  1.374(2) 
C(11A)-C(12A)  1.384(2) 
N(14A)-C(15A)  1.3746(17) 
C(15A)-C(20A)  1.3917(18) 
C(15A)-C(16A)  1.3977(18) 
C(16A)-C(17A)  1.375(2) 
C(17A)-C(18A)  1.383(2) 
C(18A)-C(19A)  1.372(2) 
C(19A)-C(20A)  1.3822(19) 
O(1B)-C(6B)  1.4333(15) 
O(1B)-C(2B)  1.4360(14) 
C(2B)-C(7B)  1.5070(18) 
C(2B)-C(3B)  1.5247(17) 
C(3B)-C(13B)  1.5223(18) 
C(3B)-C(4B)  1.5289(17) 
C(4B)-N(14B)  1.4533(16) 
C(4B)-C(5B)  1.5270(18) 
C(5B)-C(6B)  1.5095(18) 
C(7B)-C(8B)  1.3851(19) 
C(7B)-C(12B)  1.3879(19) 
C(8B)-C(9B)  1.391(2) 
C(9B)-C(10B)  1.370(2) 
C(10B)-C(11B)  1.372(2) 
C(11B)-C(12B)  1.382(2) 
N(14B)-C(15B)  1.3831(16) 
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C(15B)-C(20B)  1.3926(18) 
C(15B)-C(16B)  1.4014(18) 
C(16B)-C(17B)  1.376(2) 
C(17B)-C(18B)  1.381(2) 
C(18B)-C(19B)  1.374(2) 
C(19B)-C(20B)  1.3817(18) 
 
C(6A)-O(1A)-C(2A) 111.30(9) 
O(1A)-C(2A)-C(7A) 106.27(10) 
O(1A)-C(2A)-C(3A) 111.10(10) 
C(7A)-C(2A)-C(3A) 115.13(10) 
C(13A)-C(3A)-C(2A) 110.59(11) 
C(13A)-C(3A)-C(4A) 110.84(11) 
C(2A)-C(3A)-C(4A) 110.21(10) 
N(14A)-C(4A)-C(5A) 111.60(12) 
N(14A)-C(4A)-C(3A) 110.53(11) 
C(5A)-C(4A)-C(3A) 111.26(10) 
C(6A)-C(5A)-C(4A) 111.63(12) 
O(1A)-C(6A)-C(5A) 111.58(11) 
C(8A)-C(7A)-C(12A) 118.10(13) 
C(8A)-C(7A)-C(2A) 120.63(12) 
C(12A)-C(7A)-C(2A) 121.25(12) 
C(7A)-C(8A)-C(9A) 120.93(14) 
C(10A)-C(9A)-C(8A) 120.29(15) 
C(11A)-C(10A)-C(9A) 119.45(14) 
C(10A)-C(11A)-C(12A) 120.21(15) 
C(11A)-C(12A)-C(7A) 121.00(14) 
C(15A)-N(14A)-C(4A) 126.33(11) 
N(14A)-C(15A)-C(20A) 123.69(12) 
N(14A)-C(15A)-C(16A) 118.81(12) 
C(20A)-C(15A)-C(16A) 117.48(12) 
C(17A)-C(16A)-C(15A) 121.05(13) 
C(16A)-C(17A)-C(18A) 120.99(14) 
C(19A)-C(18A)-C(17A) 118.35(13) 
C(18A)-C(19A)-C(20A) 121.42(14) 
C(19A)-C(20A)-C(15A) 120.70(13) 
C(6B)-O(1B)-C(2B) 111.34(10) 
O(1B)-C(2B)-C(7B) 106.66(10) 
O(1B)-C(2B)-C(3B) 111.74(10) 
C(7B)-C(2B)-C(3B) 113.81(10) 
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C(13B)-C(3B)-C(2B) 110.61(11) 
C(13B)-C(3B)-C(4B) 111.58(11) 
C(2B)-C(3B)-C(4B) 110.03(10) 
N(14B)-C(4B)-C(5B) 113.40(11) 
N(14B)-C(4B)-C(3B) 108.83(10) 
C(5B)-C(4B)-C(3B) 110.28(10) 
C(6B)-C(5B)-C(4B) 110.61(11) 
O(1B)-C(6B)-C(5B) 111.48(10) 
C(8B)-C(7B)-C(12B) 118.41(13) 
C(8B)-C(7B)-C(2B) 120.70(12) 
C(12B)-C(7B)-C(2B) 120.90(12) 
C(7B)-C(8B)-C(9B) 120.34(15) 
C(10B)-C(9B)-C(8B) 120.27(15) 
C(9B)-C(10B)-C(11B) 120.03(15) 
C(10B)-C(11B)-C(12B) 120.00(15) 
C(11B)-C(12B)-C(7B) 120.95(14) 
C(15B)-N(14B)-C(4B) 123.33(10) 
N(14B)-C(15B)-C(20B) 123.62(12) 
N(14B)-C(15B)-C(16B) 118.62(12) 
C(20B)-C(15B)-C(16B) 117.72(13) 
C(17B)-C(16B)-C(15B) 120.94(14) 
C(16B)-C(17B)-C(18B) 120.73(14) 
C(19B)-C(18B)-C(17B) 118.82(14) 
C(18B)-C(19B)-C(20B) 121.28(14) 
C(19B)-C(20B)-C(15B) 120.51(13) 
 
(±)-(1R,4S,5S,6R)-6-[(2,5-dimethylphenyl)carbamoyl]-2,5,8-tiimethyl-2-azabicyclo[2.2.2] 
octane (148). 
 
Identification code   AS0907 
Empirical formula   C19 H28 N2 O 
Formula weight    300.43 
Temperature    173(2) K 
Diffractometer, wavelength  OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group  Monoclinic, P2(1)/c 
Unit cell dimensions   a = 10.52935(10) Å a = 90° 
     b = 19.9834(2) Å b = 93.4266(9)° 
N
O
N
H
endo-148
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     c = 8.07470(8) Å g = 90° 
Volume, Z    1695.98(3) Å3, 4 
Density (calculated)   1.177 Mg/m3 
Absorption coefficient   0.560 mm-1 
F(000)     656 
Crystal colour / morphology  Colourless needles 
Crystal size    0.26 x 0.06 x 0.02 mm3 
q range for data collection  4.43 to 72.27° 
Index ranges    -12<=h<=11, -20<=k<=24, -8<=l<=9 
Reflns collected / unique  11361 / 3313 [R(int) = 0.0269] 
Reflns observed [F>4s(F)]  2795 
Absorption correction   Analytical 
Max. and min. transmission  0.988 and 0.917 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3313 / 1 / 205 
Goodness-of-fit on F2   1.086 
Final R indices [F>4s(F)]  R1 = 0.0372, wR2 = 0.0964 
R indices (all data)   R1 = 0.0450, wR2 = 0.0994 
Largest diff. peak, hole   0.194, -0.184 eÅ-3 
Mean and maximum shift/error  0.000 and 0.001 
 
Bond lengths [Å] and angles [°] for AS0907. 
 
N(1)-C(9)  1.4506(17) 
N(1)-C(2)  1.4740(14) 
N(1)-C(6)  1.4779(15) 
C(2)-C(8)  1.5276(18) 
C(2)-C(3)  1.5597(16) 
C(3)-C(10)  1.5197(14) 
C(3)-C(4)  1.5447(15) 
C(4)-C(20)  1.5243(16) 
C(4)-C(5)  1.5429(15) 
C(5)-C(6)  1.5268(17) 
C(5)-C(7)  1.5414(16) 
C(7)-C(21)  1.5226(19) 
C(7)-C(8)  1.5469(17) 
C(10)-O(10)  1.2288(14) 
C(10)-N(11)  1.3522(15) 
N(11)-C(12)  1.4286(14) 
C(12)-C(17)  1.3867(16) 
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C(12)-C(13)  1.3979(16) 
C(13)-C(14)  1.3929(16) 
C(13)-C(18)  1.5043(17) 
C(14)-C(15)  1.3849(18) 
C(15)-C(16)  1.3894(17) 
C(16)-C(17)  1.3939(16) 
C(16)-C(19)  1.5049(17) 
 
C(9)-N(1)-C(2)  114.59(9) 
C(9)-N(1)-C(6)  111.72(9) 
C(2)-N(1)-C(6)  109.70(9) 
N(1)-C(2)-C(8)  107.16(9) 
N(1)-C(2)-C(3)  109.76(9) 
C(8)-C(2)-C(3)  110.01(10) 
C(10)-C(3)-C(4)  112.74(9) 
C(10)-C(3)-C(2)  111.68(9) 
C(4)-C(3)-C(2)  107.47(9) 
C(20)-C(4)-C(5)  113.40(9) 
C(20)-C(4)-C(3)  111.36(9) 
C(5)-C(4)-C(3)  107.32(9) 
C(6)-C(5)-C(7)  107.83(9) 
C(6)-C(5)-C(4)  109.12(9) 
C(7)-C(5)-C(4)  109.77(9) 
N(1)-C(6)-C(5)  108.93(9) 
C(21)-C(7)-C(5)  113.55(11) 
C(21)-C(7)-C(8)  113.16(10) 
C(5)-C(7)-C(8)  106.75(9) 
C(2)-C(8)-C(7)  108.84(9) 
O(10)-C(10)-N(11) 122.22(10) 
O(10)-C(10)-C(3) 122.83(10) 
N(11)-C(10)-C(3) 114.89(9) 
C(10)-N(11)-C(12) 122.65(9) 
C(17)-C(12)-C(13) 121.19(10) 
C(17)-C(12)-N(11) 118.54(10) 
C(13)-C(12)-N(11) 120.24(10) 
C(14)-C(13)-C(12) 117.17(11) 
C(14)-C(13)-C(18) 120.62(10) 
C(12)-C(13)-C(18) 122.19(10) 
C(15)-C(14)-C(13) 121.61(11) 
C(14)-C(15)-C(16) 121.13(10) 
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C(15)-C(16)-C(17) 117.66(11) 
C(15)-C(16)-C(19) 121.35(11) 
C(17)-C(16)-C(19) 120.99(11) 
C(12)-C(17)-C(16) 121.22(10) 
 
